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Chapter 1
Rheumatoid ArthriƟ s 
Rheumatoid arthriƟ s (RA) is an autoimmune disease characterized by chronic infl am-
maƟ on of the joints aﬀ ecƟ ng the world populaƟ on with an esƟ mated prevalence 
of 1 to 2% (1, 2). The chronic infl ammaƟ on will lead to destrucƟ on of carƟ lage and 
bone causing deformity, disability and even increased mortality (3, 4). The cause of 
the disease is largely unknown; however, mulƟ ple factors like geneƟ c background, 
sex and environment have found to play an important role. Given  the relaƟ vely high 
prevalence of RA, the chronic burden of the disease, and current costs of biological, 
RA is associated with major health care costs (5). Nowadays, cumulaƟ ve knowledge 
in our understanding of the mulƟ ple factors involved in the onset and progression of 
RA, has resulted in major improvements in disease management and treatment that 
will be further discussed below. 
Pathological features of rheumatoid arthriƟ s
The pathophysiology of RA is very complex. In general it is thought that a combina-
Ɵ on of several geneƟ c risk factors and external events could induce an autoimmune 
response, which eventually leads to a persistent infl ammaƟ on of the joints (Figure 
1). Especially geneƟ c factors have been linked to suscepƟ bility and severity of RA 
from which human leukocyte anƟ gen DR4 (HLA-DR4) is the most important. Approxi-
mately 60% of RA paƟ ents carry the so-called shared epitope of the HLA-DRB1*04 
cluster (6, 7) which is believed to present arthriƟ s-related pepƟ des leading to the 
sƟ mulaƟ on and expansion of autoanƟ gen-specifi c cells in the joints and lymph nodes 
(8-11). Other, but less stronger, associated geneƟ c factors are protein tyrosine phos-
phatase non-receptor type 22 (PTPN22), pepƟ dyl arginine deiminase type IV (PADI4), 
cytotoxic T-lymphocyte anƟ gen 4 (CTLA4), Fc receptors for IgG and several cytokine 
and cytokine-receptor genes (12, 13). It is worthwhile to note that also protecƟ ve 
genes have been described (14). For many years RA has been recognized as an au-
toimmune disorder in which rheumatoid factor (RF) is the classic IgG autoanƟ body 
(IgM rheumatoid factor [IgM-RF]). Notably, these autoanƟ bodies are not exclusively 
related to RA as they are also present in paƟ ents with other autoimmune diseases. 
However, in the last decade auto-anƟ bodies against citrullinated proteins (anƟ -CCP) 
also have been associated with the onset and the severity of RA (15-19). These anƟ -
CCP anƟ bodies are highly specifi c and predicƟ ve for RA; they are present in two-third 
of the RA paƟ ents and rare in other infl ammatory diseases or healthy individuals 
(20-22) and are detectable years before the fi rst symptoms of RA emerge (pre clini-
cal phase) (16, 19). The discovery of anƟ -CCP anƟ bodies and the associaƟ on with 
RA strengthens the autoimmune hypothesis (23) and shiŌ  rheumatoid factor to the 
background. Following the autoimmunity phase, biomechanical and neurological 
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events could trigger the transiƟ on to the arƟ cular phase. In this phase the fi rst clini-
cal symptoms become evident, which, when leŌ  untreated, leads to infl ammaƟ on of 
the joints and joint destrucƟ on and ulƟ mately funcƟ onal disabiliƟ es, osteoporosis 
and cardiovascular disease as one of the co-morbidiƟ es (Figure 1).
How exactly the suscepƟ bility for autoimmunity eventually will lead to sustained 
chronic infl ammaƟ on of the joints is sƟ ll unknown although recent studies proposed 
that joint damages provoke primary infl ammaƟ on triggering a cascade of diﬀ erent 
events in the joints that drive infl ammaƟ on (24) (Figure 2). One important process 
Figure 1: A contextual framework for the pathogenesis of rheumatoid arthriƟ s. 
(A) Several geneƟ c risk factors and environmental factors such as smoking are thought to contribute to 
the onset of rheumatoid arthriƟ s (RA) and may contribute to (B) an autoimmune response to factors like 
citrinulated proteins (CCP). This is recognized by the formaƟ on of CCP-specifi c anƟ bodies. These could 
be present years before the onset of clinical symptoms. (C) Biomechanical and neurological events could 
iniƟ ate a transiƟ on to arƟ cular phase. In this phase the fi rst clinical symptoms are manifested. There-
aŌ er infl ammaƟ on-driven pathogenesis occurs, which fi nally leads to (D) infl ammaƟ on of the synovial 
joints and eventually joint destrucƟ on, osteoporosis and a higher suscepƟ bility to cardiovascular disease. 
AbbreviaƟ ons: CCP, cyclic citrullinated pepƟ de; CTLA4, cytotoxic T-lymphocyte anƟ gen 4; GP39, carƟ lage 
glycoprotein 39; PADI4, pepƟ dyl arginine deiminase, type IV; PTPN22, protein tyrosine phosphatase, non-
receptor type 22. From McInnes I and ScheƩ  G, Nat Rev Immunol. 2007; 7:429-42
A
B
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in this cascade is the occurrence of hyperplasƟ c synovium that is accompanied by 
infi ltraƟ on of blood derived infl ammatory cells like macrophages, T lymphocytes, B-
cells, plasma cells, natural killer (NK) cells and NKT cells (5, 8, 25-27). These cells, 
together with synovial fi broblasts (28), are responsible for the producƟ on of many 
pro-infl ammatory cytokines such as TNFα, IL1β, IL6 and IL17. The producƟ on of cy-
tokines will eventually drive angiogenesis and proliferaƟ on of the synovium forming 
an outgrowth, referred to as pannus. In this process matrix-degrading enzymes like 
aggrecanases and matrix metalloproteinases (MMPs) are produced by chondrocytes 
and synovial fi broblasts which will destroy the carƟ lage (29, 30). Eventually the bone 
is also aﬀ ected by the sustained infl ammaƟ on and by RANKL-induced acƟ vaƟ on of 
osteoclasts and synovial fi broblasts (31-36). As indicated in Figure 2, cytokines have 
been recognized as key players in driving the infl ammaƟ on in the pathogenesis of 
RA. Given their strongly regulaƟ on by the transcripƟ on factor nuclear kappa β (NFκβ) 
(37), cytokines and NFκβ are thus important targets in the treatment of RA. 
Table 1: Overview of frequently used DMARD combinaƟ ons and current and upcoming biological 
agents for the treatment of rheumatoid arthriƟ s.
DMARDs Remark Reference
MTX + SSZ (55, 70)
MTX + SSZ + prednisolone COBRA schedule (48, 58)
MTX + HCHQ (59)
MTX + HCHQ + SSZ O’Dell schedule (53)
MTX + lefl unomide (71)
Biological agents 
(oŌ en combined with MTX)
Remark Reference
Infl iximab Chimeric Mab targeƟ ng TNFα (5, 72, 73)
Etanercept Soluble TNF receptor (5, 73, 74)
Adalimumab Humanized Mab targeƟ ng TNFα (5, 73)
Tocilizumab
Humanized IL6 receptor acƟ vaƟ on of T-cells, B-cells, 
macrophages and osteoclasts.
(5, 75)
Rituximab Mab targeƟ ng CD20, eliminaƟ on of B-cells (5, 73, 76) 
Ocrelizumab Mab targeƟ ng CD20, eliminaƟ on of B-cells (77)
Anakinra Interleukin-1 receptor antagonist (27, 78)
Abatacept
Recombinant CTLA4 protein that blocks a cosƟ mula-
tory signal required for T-cell acƟ vaƟ on
(5, 79, 80)
AbbreviaƟ ons: SSZ: sulphasalazine; HCHQ: hydroxychloroquine; MTX: methotrexate; TNF: Tumor 
Necrosis Factor; Mab: Monoclonal anƟ body; IL6: Interleukin 6; CTL4: Cytotoxic T lymphocyte associ-
ated anƟ gen 4; IL-1β: Interleukin 1β.
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Treatment of rheumatoid arthriƟ s 
RA is characterized by chronic infl ammaƟ on of the joints and the presence of au-
to-anƟ bodies against proteins. Clinical symptoms related to infl ammaƟ on and the 
radiographic progression of the disease are the main targets for treatment. Histori-
cally, upon RA diagnosis a mild treatment with non-steroid anƟ -infl ammatory drugs 
(NSAIDs) was iniƟ ated, which partly reduced joint infl ammaƟ on, but had no eﬀ ect 
on radiological disease progression. Nowadays, treatment strategies have a totally 
diﬀ erent design including rapid and aggressive therapy including DMARD (combina-
Figure 2: Pathogenesis of rheumatoid arthriƟ s. 
Rheumatoid arthriƟ s (RA) is characterized by chronic infl ammaƟ on of synovial joints. Derived from the 
bloodstream, T-cells and monocytes will infi ltrate the synovial Ɵ ssue (1). This process is facilitated by adhe-
sion molecules (2). Monocytes will diﬀ erenƟ ate to macrophages and T-cells get acƟ vated (3). The macro-
phages are mainly responsible for the producƟ on of pro-infl ammatory cytokines such as tumor-necrosis 
factor (TNF), interleukin-1 (IL-1) and interleukin-8 (IL-8) (4). Macrophages also produce monocyte chemo-
tacƟ c protein-1 (MCP1) which facilitates the aƩ racƟ on of even more monocytes (5). The cytokines TNFα 
and IL-1 will acƟ vate on their turn synovial fi broblasts (6). In response to this, these cells secrete Matrix 
Metalloproteinases (MMPs), Granulocyte-macrophage colony-sƟ mulaƟ ng factor (GM-CSF), IL-6 and IL-8 
(7). These pro-infl ammatory cytokines and acƟ vated osteoclasts contribute to carƟ lage and bone destruc-
Ɵ on (8). From Pope RM, Nat Rev Immunol. 2002; 2:527-35
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Ɵ ons), glucocorƟ coids and/or biologicals (38-42). In most new treatment strategies, 
the folate antagonist methotrexate (MTX) remains the anchor drug (43). MTX can 
induce apoptosis in acƟ vated T cells(44) and/or provoke an anƟ -infl ammatory eﬀ ect 
(45) by interfering in DNA synthesis via inhibiƟ on of key enzymes in the folate me-
tabolism and purine biosynthesis de novo (46, 47). Therefore potenƟ al target cells 
in RA for MTX are proliferaƟ ng T lymphocytes or synovial fi broblasts although the 
exact mechanism of acƟ on in RA remains largely unknown. Sulphasalazine (SSZ) and 
hydroxychloroquine (hCHQ) are also commonly prescribed DMARDs (48, 49) and are 
oŌ en combined with MTX (Table 1). When diﬀ erent DMARDs have non-overlapping 
mechanisms of acƟ on, it may be aƩ racƟ ve to combine them and anƟ cipate an addi-
Ɵ ve or synergisƟ c eﬀ ect that may improve treatment eﬃ  cacy (50-53). However, not 
every combinaƟ on has proven to be eﬀ ecƟ ve. For example, the combinaƟ on of SSZ 
and MTX does not display a clear addiƟ ve or synergisƟ c eﬀ ect when compared to 
mono-therapy with either of the DMARDs alone (54, 55). Conceivably, this could be 
due to non-compeƟ Ɵ ve inhibiƟ on of the reduced folate carrier (RFC), the main cel-
lular uptake transporter for MTX (56). Whenever the combinaƟ on SSZ/MTX is used, 
usually a third component like CHQ or prednisone is added  to improve clinical ef-
fi cacy compared to using just SSZ and MTX (48, 53, 57-59).
Since the last decade ‘biologicals’ have been introduced for the treatment of RA and 
other infl ammatory related diseases such as Crohn’s disease and arthriƟ s psoriaƟ ca 
Figure 3: Reasons for disconƟ nuaƟ on of tradiƟ onal DMARDs in paƟ ents with RA. 
Blue bars: ineﬃ  cacy, reduced eﬃ  cacy of drug or resistance; red bars: toxicity, intolerance and adverse 
events; green bars: both ineﬃ  cacy and toxicity of the drug; purple bars: total disconƟ nuaƟ ons. IM: intra-
muscular; *study completed in 1994 – no other choices available at that Ɵ me for those with inadequate 
eﬀ ect requiring alternaƟ ve therapy aŌ er MTX. Source: RetrospecƟ ve audit of records of paƟ ents with on-
set of RA between January 1985 and June 1994. References: Galindo-Rodriguez G et al. J Rheumatol 1999; 
26(11):2337-2343 and Fleischmann RM et al. J Rheumatol Suppl 2005; 73:3-7.
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(8, 60, 61). These agents specifi cally target soluble or cell-surface molecules impor-
tant in RA pathogenesis (5, 8). The fi rst biological available for treatment of RA was 
the TNF neutralizing anƟ body infl iximab (62, 63). Infl iximab was soon followed by 
the introducƟ on of other TNFα-blocking agents such as etanercept (soluble TNF re-
ceptor) and adalimumab (humanized TNF anƟ body), which harbor some advantages 
over infl iximab by being less immunogenic (64-67) although also anƟ -adalimumab 
anƟ bodies could be detected in approximately 20% of RA paƟ ents receiving this bio-
logical therapy (68). In addiƟ on to TNFα blockers also antagonists related to other 
pro-infl ammatory cytokines (e.g. IL1-beta and IL-6 receptor)  have been developed 
or are in development (69). Currently used combinaƟ ons of MTX and other DMARDs 
and MTX with biological agents are summarized in Table 1. 
The use of these biologicals has led to a major revoluƟ on in the management of 
RA. Notwithstanding this fact, prescripƟ on of biologicals is currently limited to those 
paƟ ents who failed DMARD therapy, mainly due to signifi cant healthcare costs of 
biological therapies. However, recent studies have shown that early and aggressive 
treatment with a combinaƟ on of biologicals and DMARDs is more eﬀ ecƟ ve and may 
be cost-eﬀ ecƟ ve when taking producƟ vity into account (41, 42, 81, 82). In the fu-
ture biological therapies may become available to a broader group of paƟ ents as 
increased experience will lead to further improvements  of current treatment guide-
lines and generic biologicals will come available around 2015. Notwithstanding this 
fact, DMARDs, given their low price and known eﬃ  cacy, will remain the hallmark in 
RA treatment for the upcoming years. 
Ineﬃ  cacy of DMARD treatment in rheumatoid arthriƟ s
DMARDs or combinaƟ ons of DMARDs remain a common treatment opƟ on for pa-
Ɵ ents with RA (53, 58, 83, 84) although treatment eﬃ  cacy is known to gradually 
decrease over Ɵ me. For some DMARDs, this will require further dose escalaƟ ons 
along with an increased risk of adverse eﬀ ects. With or without dose escalaƟ on, the 
gradually decreasing eﬀ ect over Ɵ me may limit the therapeuƟ c eﬀ ect and eventu-
ally enforces treatment disconƟ nuaƟ on, oŌ en already within two years of therapy 
onset (85, 86). Meta-analyses of treatment eﬃ  cacy demonstrate variable responses 
for individual DMARDs and DMARD combinaƟ ons (86-93) and showed that (hydroxy)
chloroquine and sulphasalazine have a relaƟ ve short duraƟ on of eﬀ ect in the range 
from one to two years, while in contrast methotrexate has an average eﬃ  cacy Ɵ me 
of six to seven years (86, 87, 92, 94). This is further illustrated in Figure 3 depicƟ ng 
the reasons for disconƟ nuaƟ on of tradiƟ onal DMARD use due to either primary (in-
herent) or secondary (acquired) ineﬃ  cacy, toxicity (intolerance/side eﬀ ects) or both. 
Percentages of RA disconƟ nuing therapy varied from 34% for MTX to 70% for oral 
gold (91, 95).
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The issue of drug resistance as a cause of therapy failure has received considerable 
aƩ enƟ on in the treatment of cancer and infecƟ ous diseases(96-100), but has just 
started to be appreciated in RA treatment (101-104). Several DMARDs were iniƟ ally 
developed as anƟ cancer and anƟ microbial drugs, it is conceivable that similar mech-
anisms of resistance could also be applicable in RA treatment. In evoluƟ on organisms 
have developed mulƟ ple defence mechanisms to withstand xenobioƟ c compounds 
which may be (re)acƟ vated aŌ er exposure to chemicals like DMARDs. At a cellular 
level, several mechanisms can confer drug ineﬃ  cacy as illustrated in Figure 4: (1) 
defecƟ ve drug delivery (pharmacokineƟ c interacƟ on), (2) impaired drug uptake, (3) 
increased drug extrusion, (4) impaired drug acƟ vaƟ on, (5) enhanced drug detoxifi ca-
Ɵ on/sequestraƟ on and (6) altered (downstream) eﬀ ects aŌ er drug – target interac-
Ɵ on (101). It is noteworthy that ineﬃ  cacy of biological agents can also occur by the 
formaƟ on of anƟ bodies. In parƟ cular anƟ -infl iximab anƟ body formaƟ on has been 
found in 43% of infl iximab-treated paƟ ents and high anƟ body Ɵ ters were associated 
with decreased clinical response in RA and ankylosing spondyliƟ s (64, 66, 67). Com-
parable fi ndings were observed with the less immunogenic biological adalimumab 
where 17% of the treated paƟ ents developed anƟ bodies in conjuncƟ on with an im-
paired clinical response (105, 106).
Figure 4: Molecular mechanisms of reduced drug eﬃ  cacy. 
(1) Drug resistance due to diminished drug delivery. (2) DefecƟ ve cellular uptake. (3) Cellular extrusion 
by specifi c eﬄ  ux transporters. (4) Impaired drug acƟ vaƟ on. (5) Enhanced drug sequestraƟ on or (6) drug 
detoxifi caƟ on. (7) Drug targeƟ ng. (8) Several modes of other escape mechanisms like, up-regulaƟ on of 
target levels, modifi ed/mutated targets, enhanced repair of damage, impaired capacity for cells to go into 
apoptosis, or salvage of the damage by exogenous compounds. Adapted from Jansen G, Scand J Rheuma-
tol. 2003; 32:325-36
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Aim and outline of the thesis
Eﬃ  cacy of DMARD treatment is reduced or lost over Ɵ me. Although mulƟ ple mecha-
nisms may be responsible for loss of DMARD eﬃ  cacy ( outlined in Figure 4), one key 
mechanism is thought to be due the cellular extrusion of drugs via  selected drug 
transporters. To further address this issue, the aim of this thesis was two-fold; (a) to 
invesƟ gate in more detail the role of drug eﬄ  ux transporters in conferring DMARD 
resistance in in-vitro model systems of immune-competent cells and RA paƟ ents, 
and (b) to explore the eﬃ  cacy of some new targeted drugs which might overcome 
DMARD resistance, but, on the other hand, could also harbor their own mode of 
developing resistance.
Drug eﬄ  ux transporters and DMARD resistance
The increased drug extrusion or eﬄ  ux from target cells has been recognized as an 
important mechanism of drug resistance in cancer (98, 107-109) and is facilitated by 
ATP-binding casseƩ e (ABC) transporters (Figure 5). These cell-membrane proteins 
transport a wide range of structurally and funcƟ onally unrelated drugs causing the 
phenotype denoted as mulƟ drug resistance (MDR). The ABC transporter family is 
Figure 5: Energy-dependent cellular drug extrusions via MDR transporters. 
Following entry of drugs (1 – 2), drugs can be subjected to extrusion (3 – 5) via an energy (ATP)-dependent 
process involving ABC transporters (4). Drugs can be extruded in co-transport with glutathione, or aŌ er 
conversion to glutathione, glucuronide or sulphate conjugates. Adapted from Jansen G, Scand J Rheuma-
tol. 2003; 32:325-36
22
Chapter 1
divided in 7 sub-families named ABCA to ABCG with a total of 49 members and many 
transporters have diverse substrate specifi city. Thus far, only a selected number of 
ABC transporters has been linked to resistance against a variety of anƟ -cancer agents 
and for this reason are referred to MDR transporters: P-glycoprotein (P-gp; ABCB1), 
MulƟ drug Resistance Protein 1 to 5 (MRP1-5; ABCC1-5), MRP7 and 8 (ABCC10 and 
11) and the Breast Cancer Resistance Protein (BCRP; ABCG2). From a physiological/
pharmacological perspecƟ ve, MDR proteins are responsible for protecƟ ng our body 
against a mulƟ tude of environmental toxic substances and for this reason they are 
mainly expressed in Ɵ ssues which are heavily exposed to toxic agents, microbial and 
exogenous compounds; like intesƟ ne, blood-brain-barrier, liver, kidney, breast and 
tesƟ s (110-112). The expression of several MDR transporters on drug-resistant tumor 
cells has been well characterized (107). In contrast, although numerous DMARDs are 
iniƟ ally developed and applied as anƟ cancer agents, the mechanisms involved in re-
sistance to DMARDs have remained elusive. Moreover, it has not been fully docu-
mented whether DMARDs serve as a substrate for the various MDR drug eﬄ  ux trans-
porters. 
In vitro studies already confi rmed that in a human CEM T cell line resistance to SSZ 
was conferred by over expression of BCRP (113, 114). However, it remained un-
known whether this was a specifi c property of the cell line used in these experi-
ments. Therefore it remains important to confi rm these results in other cell lines. 
Beyond in vitro data, early clinically-directed laboratory studies with blood cells from 
RA paƟ ents pointed to a possible involvement of P-gp (ABCB1) in drug resistance as 
the expression and funcƟ onal acƟ vity of this MDR transporter on T cells was shown 
to be increased in paƟ ents who lack response to DMARD treatment (115, 116). In 
addiƟ on, also a number of reports indicated that GCs could induce P-gp expression 
on T-cells (117, 118). These studies prompted us to further explore the role of other 
MDR transporters beyond Pgp for their possible contribuƟ on in conferring DMARD 
resistance. This issue was addressed in the fi rst part of this thesis by providing an 
overview of the current status of MDR transporters and their physiological funcƟ ons 
and implicaƟ ons for autoimmune diseases and cancer. Next, we set out to explore 
in an in-vitro seƫ  ng whether overexpression of MDR transporters could provide a 
mechanisƟ c basis for acquired resistance to sulphasalazine (SSZ) and chloroquine 
(hCHQ), two DMARDs for which resistance in clinical pracƟ ce is most rapidly noted 
(119). Finally, in addiƟ on to the in-vitro studies we also evaluated the expression of 
MDR transporters in relaƟ on to DMARD eﬃ  cacy in peripheral blood lymphocytes 
and monocyte-derived macrophages obtained from healthy controls and RA paƟ ents 
selected by clinical responsiveness and non-responsiveness to DMARDs. 
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New potenƟ al drugs to overcome DMARD resistance
In the second part of the thesis we invesƟ gated the implicaƟ ons of DMARD resist-
ance for the design of therapeuƟ c strategies to overcome resistance. To this end, 
we focussed on two classes of drugs: (a) GlucocorƟ coids (GCs) and (b) proteasome 
inhibitors. GlucocorƟ coids are very eﬀ ecƟ ve in the treatment of RA and frequently 
prescribed in combinaƟ on with the DMARDs MTX and sulphasalazine. This treat-
ment schedule is also known as the COBRA schedule (58, 120-122). Unfortunately, 
toxic eﬀ ects and the onset of primary or acquired resistance can hamper the eﬃ  cacy 
of GCs and therefore careful treatment management is required (123, 124). Several 
mechanisms of resistance to GCs have been described (123, 125-129), including (a) 
enhanced drug eﬄ  ux via the mulƟ drug resistance transporter P-glycoprotein, (b) 
enhanced metabolism by 11b-hydroxysteroiddehydrogenase, (c) down regulaƟ on of 
GlucocorƟ coid Receptor (GR) expression, (d) an increased raƟ o of GRβ over GRα iso-
form expression, (e) posƩ ranscripƟ onal modifi caƟ ons of GR resulƟ ng in reduced GC 
binding aﬃ  nity, or (f) impaired GC-induced apoptosis. To improve the eﬃ  cacy of GCs 
for the treatment of RA, other infl ammatory diseases and cancer, the elucidaƟ on of 
the molecular mechanism of GC resistance is important. Intriguingly, we observed 
opposite eﬀ ects of acquired resistance to chloroquine and sulphasalazine on GC 
Figure 6: AnƟ  infl ammatory properƟ es of bortezomib. 
The transcripƟ on factor NFκβ is a major contributor in the producƟ on of pro-infl ammatory cytokines such 
as TNFα. Upon receptor sƟ mulaƟ on (1), proper NFκβ acƟ vaƟ on (2) requires proteasomal (3) degradaƟ on 
of inhibitor κβ (Iκβ) (4). The NFκβ complex, formed by p50 and p65 subunits (5), can then translocate to 
the nucleus (6) and acƟ vate gene transcripƟ on (7) of pro-infl ammatory cytokines. Proteasome inhibitors 
such as bortezomib are able to prevent proteasomal degradaƟ on of Iκβ and thereby prevenƟ ng acƟ vaƟ on 
of NFκβ, as shown by the red crosses. The use of proteasome inhibitors can provide anƟ -infl ammatory 
properƟ es that could be benefi cial for the treatment of rheumatoid arthriƟ s. Adapted from Paramore A 
and Frantz S. Nat Rev Drug Discov 2003;2:611-612
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sensiƟ vity; CHQ resistance was accompanied by a marked cross-resistance to GCs, 
whereas SSZ-resistance provoked a marked increase in GC sensiƟ vity. The molecular 
basis for these eﬀ ects was invesƟ gated and revealed (38, 113, 130, 131). 
Proteasome inhibitors represent a novel class of therapeuƟ c drugs with a unique 
mode of acƟ on, which may facilitate  bypassing of common resistance mechanisms 
to current therapeuƟ c drugs. Proteasome inhibitors target the ubiquiƟ n-proteasome 
system (UPS), which is responsible for the degradaƟ on of more than 80% of normal 
and abnormal intracellular proteins with a central role for the 26S proteasome (132-
134). For this reason the UPS has been recognized as a valid target for the design of 
a new generaƟ on of potenƟ al anƟ -cancer and anƟ -infl ammatory drugs (135-137). 
IniƟ al studies in haematological and solid tumor models showed that proteasome 
inhibitors induce apoptosis, suppress proliferaƟ on and enhance the acƟ vity of chem-
otherapy and radiaƟ on. Most proteasome inhibitors are small pepƟ de-based struc-
tures being capable of forming a reversible or irreversible bond within one or more 
of the three subunits (β5, β2 and β1) of the proteasome that harbor catalyƟ c acƟ vity, 
thereby blocking proteasome funcƟ on (135). As such, diﬀ erences between protea-
some inhibitors are mainly found in their specifi city for the three catalyƟ c subunits 
and their selecƟ vity for the proteasome itself. Currently, the boronic dipepƟ de bort-
ezomib (PS341, Velcade®) is the fi rst proteasome inhibitor that has been clinically 
approved for the treatment of therapy-refractory mulƟ ple myeloma (138, 139) and 
mantle cell lymphoma (140). Bortezomib has disƟ nct specifi city for the chymotrypsin-
like acƟ vity of the proteasome (residing in the 5 subunit), although at higher con-
centraƟ ons also the caspase-like acƟ vity (residing in the β1 subunit) is inhibited (139, 
141-143). The therapeuƟ c eﬀ ect of proteasome inhibiƟ on in mulƟ ple myeloma is 
dominantly facilitated by the inhibiƟ on of NF-κβ acƟ vaƟ on, a process that is criƟ cally 
dependent on proteasomal degradaƟ on; in its inacƟ ve state, NF-κβ forms a complex 
with the inhibitor κβ (Iκβ) which prevents NF-κβ to enter the nucleus. Proteasomal 
degradaƟ on of the Iκβ complex is required to release NF-κβ and entering the nucleus 
were it serves as a transcripƟ on factor for pro-survival genes and for several pro-
infl ammatory cytokines, including TNFα (144) as shown in Figure 6. Consequently, 
in immune-disorders like RA, where NF-κβ plays an important role in mediaƟ ng the 
release of pro-infl ammatory cytokines, proteasome inhibiƟ on could be an aƩ racƟ ve 
therapeuƟ c approach that warrants further exploraƟ on. Although proteasome in-
hibitors are currently not used for the treatment of RA in a clinical seƫ  ng due to 
their toxic properƟ es, we provided a proof of concept that bortezomib can elicit a po-
tenƟ al anƟ -infl ammatory response by suppressing the release of pro-infl ammatory 
cytokines by acƟ vated T cells from RA paƟ ents. Beyond we invesƟ gated and report 
on a molecular mechanism of acquired resistance to bortezomib, indicaƟ ng that also 
for these types of novel drugs, drug resistance phenomena should be considered. 
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IntroducƟ on into the chapters
Chapter 2 reviews the literature about ABC transporters and their funcƟ on in cells 
from the immune system. Although some ABC transporters are well-known for the 
involvement in drug resistance, they also fulfi l important physiological funcƟ ons. 
Some MDR transporters have been idenƟ fi ed on T-cells, macrophages and dendriƟ c 
cells in which cells they play an important role in regulaƟ ng the immune response. 
This chapter provides an overview of the funcƟ ons of these transporters in immune-
competent system and discuss how blocking of these funcƟ ons could be benefi cial 
for cancer but problemaƟ c for autoimmune diseases. 
In Chapter 3 we describe the development and characterizaƟ on of a chloroquine 
(CHQ) resistant human CEM (T) cell line. Long-term exposure of CEM cells to CHQ 
provoked overexpression of the mulƟ drug resistance eﬄ  ux transporter MRP1, which 
conferred resistance not only to CHQ but, concomitantly, also to the glucocorƟ coids 
(GCs) dexamethasone and prednisone. The molecular basis for this is revealed. 
In Chapter 4 we invesƟ gated the mechanism of  acquired resistance to sulphasala-
zine (SSZ) in two human monocyƟ c cell lines. Resistance to SSZ was conferred by 
overexpression of the mulƟ drug eﬄ  ux transporter BCRP. Intriguingly, SSZ-resistant 
cells displayed a markedly increased sensiƟ vity to GCs for which the molecular mech-
anism was disclosed.
In Chapter 5 we report on a mechanism of adverse interacƟ on of two DMARDs oŌ en 
used in the clinic in combinaƟ on regimens; MTX and SSZ. It is demonstrated that SSZ 
is a potent, non-compeƟ Ɵ ve, inhibitor of the Reduced Folate Carrier the primary cel-
lular MTX importer. Consequently, SSZ-mediated blockade of MTX uptake reduced 
the eﬃ  cacy of MTX.
As a follow-up on in-vitro model systems showing that MDR proteins could be in-
volved in generaƟ ng DMARD resistance, these type of studies were extended to 
blood cells from RA paƟ ents. In Chapter 6 we invesƟ gated the expression of diﬀ erent 
MDR transporters (P-gp, BCRP and MRP1 to 6) in peripheral blood lymphocytes and 
monocyte-derived macrophages obtained from RA paƟ ents and healthy controls. Ex-
pression profi ling of MDR transporters was performed by real-Ɵ me PCR, funcƟ onal 
acƟ vity assays and by immunohistochemistry. Correlates were made between MDR 
expression levels and disease acƟ vity and DMARD responsiveness.  
In Chapter 7, Immunohistochemical analysis of MDR transporter expression levels 
were invesƟ gated in synovial Ɵ ssue from RA paƟ ents before and aŌ er treatment with 
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the DMARDs MTX and lefl unomide. In parƟ cular synovial macrophages displayed a 
marked expression of the MDR transporter BCRP, which was also correlated with an 
aƩ enuated response to MTX and lefl unomide, consistent with the noƟ on that these 
DMARDs are substrates for BCRP.
Chapter 8 we explored whether MDR transporters could (in)directly play a role in the 
cellular release of pro-infl ammatory cytokines and/or chemokines. To this end, cel-
lular release of TNF, IL-8, MCP1 and CCL20 was evaluated in human cell lines over-
expressing various MDR transporters either in the absence or presence of specifi c 
blockers of these transporters 
Proteasome inhibiƟ on could provide a conceptually new experimental treatment 
modality for diﬀ erent immunological disorders, including rheumatoid arthriƟ s. In 
Chapter 9 we evaluated whether the proteasome inhibitor bortezomib was capable 
of suppressing the release of the pro-infl ammatory cytokine TNF by acƟ vated T 
cells from RA paƟ ents who either responded or were clinically non-responsive to 
DMARD therapy.
Despite potenƟ al (pre)clinical acƟ vity of proteasome inhibitors like bortezomib, it is 
unclear whether chronic exposure of immune-eﬀ ector type of cells to bortezomib 
could evoke the acquisiƟ on of resistance to this drug. To explore this issue, and evalu-
ate the possible involvement of MDR transporters, we set out to chronically expose a 
human monocyƟ c-macrophage cell line to bortezomib, which eventually lead to the 
isolaƟ on of a subline that was 200-fold resistant to bortezomib. Chapter 10 describes 
the detailed characterizaƟ on of the bortezomib-resistant cell line and reveals the 
molecular basis for this phenotype being associated with an increased expression of 
the β5 subunit of the proteasome along with a specifi c mutaƟ on in the gene encod-
ing this subunit. 
Chapter 11 describes the characterizaƟ on of a novel proteasome inhibitor, the hexa-
meric pepƟ de 4A6, which was discovered by serendipity during characterizaƟ on of 
the bortezomib-resistant monocyƟ c macrophage cells (described in chapter 10). 4A6 
appeared to be a potent and specifi c inhibitor of the β5 subunit of the proteasome. 
The results are discussed and put in perspecƟ ve in Chapter 12, followed by a Sum-
mary in Chapter 13.
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Summary
 ATP binding casseƩ e (ABC) transporters were originally idenƟ fi ed for their contribu-
Ɵ on to clinical mulƟ drug resistance (MDR) due to their capacity to extrude various 
unrelated cytotoxic drugs. More recent reports have shown that ABC transporters 
can play important roles in the development, diﬀ erenƟ aƟ on and maturaƟ on of im-
mune cells and are involved in migraƟ on of immune eﬀ ector cells to sites of infl am-
maƟ on. Many of the currently idenƟ fi ed endogenous ABC transporter substrates 
have immunosƟ mulaƟ ng eﬀ ects. Increasing the expression of ABC transporters on 
immune cells, and thereby enhancing immune cell development or funcƟ onality, 
may be benefi cial to immunotherapy in the fi eld of oncology. On the contrary, in 
the treatment of auto-immune diseases, blockade of these transporters may prove 
benefi cial, as it could dampen disease acƟ vity by compromising immune eﬀ ector cell 
funcƟ ons. This review will focus on the expression, regulaƟ on and substrate specifi -
city of ABC transporters in relaƟ on to funcƟ onal acƟ viƟ es of immune eﬀ ector cells, 
and discusses implicaƟ ons for the treatment of cancer on the one hand and autoim-
mune diseases on the other hand.
Figure 1:   ABC transporter stochiometry.
Most physiological ABC transporter substrates are synthesized intracellular and are then transported to 
the extracellular environment. Drug substrates enter cells either through passive diﬀ usion or through in-
fl ux transporters. In order to transport substrates from the intracellular to the extracellular compartment, 
ABC transporters require the energy that becomes available upon ATP hydrolysis into ADP. This occurs 
upon dimerizaƟ on of the nucleoƟ de binding domains (NBD). Some ABC transporters require glutathione 
co-transport or conversion of substrates into glutathione, glucuronide or sulphate conjugates in order to 
transport their drug- or physiological substrates. Figure adapted from Jansen et al. (3)
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IntroducƟ on
Resistance to anƟ -cancer drugs is a common problem faced in the treatment of can-
cer. Over the last decades research has shown that some ATP Binding CasseƩ e (ABC) 
transporters play an important role in the resistance to anƟ -cancer, anƟ -infl amma-
tory and anƟ -viral drugs (1-4). ABC-transporters represent a large family of around 
50 trans-membrane proteins, which acƟ vely transport structurally related and unre-
lated compounds across membranes. Some ABC transporters require the co-trans-
port of glutathione or glutathione-conjugates (Figure 1).  Due to acƟ ve transport 
of structurally related and unrelated drug compounds across membranes, members 
of the ABCB, -C, and –G families have been recognized for their roles in the onset 
and maintenance of mulƟ drug resistance (MDR) (1, 4, 5). Many Ɵ mely reviews have 
discussed the role of ABC transporter family members in MDR, their typical drug 
substrates, transporter antagonists, general Ɵ ssue distribuƟ on and their associaƟ on 
with diseases [overview in Table 1] (1, 3, 4, 6-9). The typical membrane topology of 
several relevant transporters is shown in Figure 2. Less aƩ enƟ on has been given to 
the expression of these transporters on immune cells and their putaƟ ve involvement 
in immune processes due to the acƟ ve secreƟ on of infl ammatory mediators such 
as prostaglandins (i.e. S-PGA1-glutathione, PGE1, PGE2, PGF2), leukotrienes (i.e. LTB4, 
LTC4, LTD4), sphingosine-1-phosphate (S1P), sulfaƟ des and cyclic nucleoƟ des (cAMP, 
cGMP) (10, 11). A detailed overview of the physiological substrates and substrate af-
fi niƟ es (Km) for various ABC transporters is provided in Table 2. The relevance of ABC 
transporters for immune funcƟ ons immediately raises the issue how the combined 
administraƟ on of therapeuƟ c drugs and ABC transporter antagonists would infl u-
ence both the survival and physiological funcƟ ons of immune cells during treatment. 
This is parƟ cularly of importance in cancer treatment, since these paƟ ents oŌ en 
already are immunosuppressed due to the cancer environment and chemotherapy 
treatment. On the other hand, the presence of these transporters on immune ef-
fector cells could be involved in the onset or refractoriness of autoimmune diseases 
either by the secreƟ on of pro-infl ammatory mediators or by negaƟ vely infl uencing 
the (long-term) treatment of autoimmune diseases like rheumatoid arthriƟ s (RA) 
with immunosuppressing drugs like non-steroid anƟ -infl ammatory d rugs (NSAID) or 
corƟ costeroids, since these have also been described to be substrates of ABC trans-
porters (3).
An immune reacƟ on can be divided in an anƟ gen-independent innate response (12) 
and an anƟ gen-specifi c adapƟ ve response (13). Immune eﬀ ector cells that belong to 
the innate response are natural killer (NK) cells, granulocytes and anƟ gen presenƟ ng 
cells like macrophages (Mφ) and dendriƟ c cells (DC). These cells are responsible for 
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Table 1: Pharmacological substrates and therapeuƟ c eﬀ ects of ABC transporters.
ABC
Transporter
Tissue 
distribuƟ on
Pharmacological substrates
(Km value*)
Disease 
associaƟ on
Antagonists
(Km value*)
References
P-gp
(ABCB1)
Many Ɵ ssues, 
liver, BBB, 
kidney, 
intesƟ ne, 
placenta
Doxurubucin, daunorubicin 
(0.3 μM), vinblasƟ n (1.3 μM), 
docetaxel, irinotecan, topotecan, 
paclitaxel, chloroquine (2.5 μM), 
glucocorƟ coids
IvermecƟ n 
suscepƟ bility, 
ulceraƟ ve coliƟ s
Verapamil, 
PSC833 (50 nM), 
LY335979 (59 
nM), CsA (200 
nM), CBT-1
(1,3,11,147)
MRP1
(ABCC1)
Ubiquitous
Methotrexate (2.2 mM), 
doxorubicin, daunorubicin, 
vincrisƟ ne, etoposide, 
chloroquine
MK571, 
probenecid, 
NSAIDs, 
fl avonoids, CHQ, 
CBT-1, Sulindac
(1,3,11,147)
MRP2
(ABCC2)
Liver, intesƟ ne, 
kidney
Methotrexate (3 mM), vinblasƟ n, 
etoposide, vincrisƟ n, cisplaƟ n, 
epirubicin, taxanes, doxorubicin,
Dubin-Johnson 
Syndrome
Sulphinpyrazone,
MK571
(1,3,11,147)
MRP3
(ABCC3)
Lung, intesƟ ne, 
liver, kidney
Methotrexate (776 μM), 
etoposide, (vincrisƟ ne)
Probenecid (1,3,11,147,148)
MRP4
(ABCC4)
Many Ɵ ssues 
(kidney)
Methotrexate (0.22 – 1.3 mM), 
mercaptopurine, thioguanine, 
campotothecins, azidothymidine, 
azathioprine, topotecan
Probenecid, 
MK571, 
Sildenafi l, 
fl avonoids, 
NSAIDs (Sulindac)
(1,3,11,147,148)
MRP5
(ABCC5)
Many Ɵ ssues
Methotrexate (1.3 mM), 
fl uorouracil, mercaptopurine, 
thioguanine, azathioprine
Nitroprusside,
Sildenafi l, 
fl avonoids
(1,3,11,147,148)
MRP6
(ABCC6)
Kidney, liver Anthracyclines, etoposide
Pseudoxanthoma 
elasƟ cum
(1,3,11,147)
MRP7
(ABCC10)
Low in all 
Ɵ ssues except 
pancreas
Docetaxel, paclitaxel, 
vincrisƟ ne,vinblasƟ n,  Docetaxel, 
paclitaxel, vincrisƟ ne,vinblasƟ n, 
nucleoside analogues and 
epothilone B
CsA (3,11,147,149,150)
MRP8
(ABCC11)
Low in all 
Ɵ ssues except 
kidney, spleen, 
colon, brain
Methotrexate (0.96 mM), 
5-FdUMP, PMEA, ddC
(3,11,147,149)
MRP9
(ABCC12)
Breast, 
testes (4.5 kb 
transcript); 
brain, skeletal, 
and ovary (1.3 
kb transcript
Not known (11,147,149)
BCRP
(ABCG2)
Liver, breast, 
placenta
Methotrexate (0.7 – 1.3 
mM), sulfasalazine (0.7 
μM), methotrexate-
glu2, methotrexate-glu3, 
mitoxantrone, topotecan, sn-38, 
camptothecin, doxorubicin, 
irinotecan, tyrosine kinase 
inhibitors (e.g. ImaƟ nib, 
Gefi Ɵ nib), diclofenac
Protoporphyria IX
GF120918, 
Ko-143, 
Fumitremorgin C, 
PZ-39
(1,3,11,147,151,152)
* If reported in the literature. AcquisiƟ on from original references or from selected reviews (136,147-149)
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neutralizaƟ on of pathogens or direct killing of pathogen-infected cells and the pro-
ducƟ on of chemokines and cytokines to aƩ ract cells of the adapƟ ve immune res-
ponse like T- and B-cells, which can eliminate infected cells via cell-cell contact or 
secreted anƟ bodies. In this review we evaluate the possible physiological roles of 
MDR-related ABC transporters on immune eﬀ ector cells based on reports on their 
expression paƩ erns and immune-related substrates. In addiƟ on, possible therapeu-
Ɵ c consequences and applicaƟ ons for on the one hand auto-immune diseases, like 
RA, and on the other hand cancer will be discussed. Figure 3 gives a schemaƟ c over-
view of the expression of ABC transporters on diﬀ erent (subsets) of immune eﬀ ector 
cells, which will be discussed in further detail in the paragraphs below. 
ABC transporters and immune cells
Physiological ABC transporter substrates related to the immune 
response 
Next to bile acids, folates and porphyrins, several small pro-infl ammatory molecules 
have been described to be substrates for ABC transporters. Groups of such molecules 
are eicosanoid lipid mediators like prostaglandins and leukotrienes (14) and sphin-
golipids as menƟ oned above (Table 2 and Figure 4), but also steroids or tripepƟ des 
Figure 2: ABC transporter topology.
Typical topology of P-gp, MRP1-9 and BCRP. MSD: membrane spanning domain, NBD: nucleoƟ de binding 
domain.
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like glutathione (GSH) (15). The cysteinyl leukotriene C4 (LTC4), which is derived from 
arachidonic acid, exerts a pro-infl ammatory eﬀ ect on infl ammatory cells (16) by fa-
cilitaƟ ng the migraƟ on of immune cells to lymph nodes (17, 18). LTC4 is the gluta-
thione-conjugated form of LTA4 and has been reported to be transported by MRP1 
(19), MRP2 (20), MRP3 (21), MRP4 (22), MRP6 (23), MRP7 (24) and MRP8 (25) with 
substrate aﬃ  niƟ es in the nanomolar-submicromolar range (Table 2). MRP1 has also 
been implicated in the transport of LTD4 and LTE4, which are extracellular metabolized 
Table 2: Physiological substrates and funcƟ onal (immunological) eﬀ ects of ABC transporters. 
ABC
Transporter
Physiological substrates 
(Km value*)
Immunological 
processes
References
P-gp
(ABCB1)
PAF, S1P, estrone, estriol, estradiol-17b-glucuronide, corƟ sol, 
aldosterone
PAF: acƟ vaƟ on of 
infl ammatory cells, 
angiogenesis 
S1P: T cell homing 
to LN
IL-12: Th1 skewing
(17,30,37,153-156)
TAP 1/2
(ABCB2/3)
pepƟ des AnƟ gen presentaƟ on (48,77)
MRP1
(ABCC1)
LTC4 (105 nM)/LTD4/LTE4, estradiol-17b-glucuronide (2.5 
μM), sulfaƟ des, lipid analogues, estrone-3-sulfate (0.73 μM), 
GSH (1-5 mM), GSSG (43-93 μM), gluthathione conjugate 
of 4-hydoxynonenal (1.4 μM), bilirubin (0.01 μM), bilirubin 
conjugates, DHEAS (5 μM), DNP-SG (3.6 μM), S1P
LTC4/LTD4: 
DC migraƟ on, 
infl ammaƟ on
(19,29,34,36,80,157-
163)
MRP2
(ABCC2)
LTC4 (1.1 μM), estradiol-17b-glucuronide (7.2 μM), GSH, bilirubin 
glucuronides (0.8 μM), DNP-SG (6.5 μM), PGA2
LTC4: DC migraƟ on, 
infl ammaƟ on
(20,27,161,164)
MRP3
(ABCC3)
LTC4 (5 μM), estradiol-17b-glucuronide (18-67 μM), bilirubin 
glucuronides, DNP-SG (6 μM), glycocholate
LTC4: DC migraƟ on, 
infl ammaƟ on
(21,165)
MRP4
(ABCC4)
Prostaglandins PGE1 (2.4 μM), PGE2 (3.4 μM), PGF2a (12.6 
μM), cAMP (44.5-100 μM)/cGMP (9.7-180) μM), estradiol-
17b-glucuronide (30 μM), DHEAS (2 μM), glycocholate (6 μM), 
taurocholate (3.8-7.7 μM), cholate (8.5 μM), folate (170 μM), 
urate (1550 μM), TXB2 (9.9 μM), p-Aminohippurate (160 μM), 
LTB4 (5.2-5.6 μM), LTC4  (0.13-0.32 μM)
PGE2 : DC migraƟ on/
maturaƟ on, immune 
suppression
cAMP/cGMP : cell 
migraƟ on
LTB4/LTC4: 
DC migraƟ on, 
infl ammaƟ on
(22,26,31,36,84,166-
168)
MRP5
(ABCC5)
cAMP (379 μM), cGMP (2.1 μM), DNP-SG, folic acid (10 mM)
cAMP /cGMP: 
migraƟ on
(84,169,170)
MRP6
(ABCC6)
LTC4, DNP-SG
LTC4: DC migraƟ on, 
infl ammaƟ on
(23)
MRP7
(ABCC10)
LTC4, estradiol-17b-glucuronide (58 μM)
LTC4: DC migraƟ on, 
infl ammaƟ on
(24)
MRP8
(ABCC11)
cAMP/cGMP, LTC4, estradiol-17b-glucuronide (63 μM), DHEAS 
(13 μM), glycocholate, taurocholate, folic acid
LTC4: DC migraƟ on, 
infl ammaƟ on
(25,33)
MRP9
(ABCC12)
Not known
BCRP
(ABCG2)
Flavonoids, pheophorbide a, porphyrins (protoporphyrin 
IX), sulfated estrogens, PhIP (2-amino-1-mehtyl-1-6-phenyl-
imidazol[4,5-b]pyridine), estradiol-17b-glucuronide (44 μM), 
DHEAS (13 μM), DNP-SG, phosphaƟ dylserine, folic acid
(38,61,171-174)
* If reported in the literature. AcquisiƟ on from original references or from selected reviews(136,147-149).
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forms of LTC4(19) and MRP4 was shown to transport LTB4(22) which is the hydrolyzed 
form of the precursor LTA4. The other group of eicosanoids, the prostaglandins, are 
de novo synthesized upon stress, cytokine- or growth factor-mediated sƟ mulaƟ on 
or other sƟ muli (14). Diﬀ erent ABC transporters can transport prostaglandins: MRP4 
can export PGE1, PGE2 and PGF2a (26) while MRP2 can export S-PGA1-glutathione (27). 
The tripepƟ de GSH (L-y-glutamyl-L-cysteinyl-glycine) is uƟ lized for various cellular 
detoxifi caƟ on pathways and several ABC transporters transport GSH or GSH S-conju-
gates or require co-transport of GSH to transport specifi c drug substrates like alkyla-
Ɵ ng agents (Table 1) (15, 28, 29). Other key infl ammatory components transported 
by MDR transporters are platelet acƟ vaƟ ng factor (PAF), which is secreted by P-gp 
(30), the cyclic nucleoƟ des cGMP and cAMP, transported by MRP4, MRP5 and MRP8 
(31-33), sphingosine 1-phosphate (S1P) transported by P-gp(17) or MRP1(34) (Figure 
4) and steroids, which are potenƟ al substrates for P-gp, MRP4 and BCRP (1, 35-38). 
A controversial issue remains whether MDR transporters are involved in the secreƟ on 
of (pro)-infl ammatory cytokines and chemokines of relaƟ vely low molecular mass for 
such molecules (5-17kD). PotenƟ al protein substrates for MDR transporters could be 
proteins that are not secreted through the classical exocyƟ c pathway and lack a hy-
drophobic leader pepƟ de. These proteins, also referred to as leaderless proteins, are 
secreted through a disƟ nct secreƟ on pathway in which ABC family A members play a 
role, rather than the ABCB/C/G (MDR-related) family members (39, 40). Over the last 
decade several studies have postulated that MDR proteins like P-gp could funcƟ on 
as eﬄ  ux transporters of cytokines such as TNFα, interleukins (IL-2, IL-4, IL-12) (41, 
42) and IFNγ (43, 44) and that P-gp inhibiƟ on could reduce the secreƟ on of several 
cytokines (44-46). However, in-vivo models of Abcb1 a/b knockout mice revealed no 
diﬀ erences in cytokine profi les compared to their wild type counterparts (47). These 
confl icƟ ng data and the fact that ABC transporters like the transporter-associated 
with anƟ gen processing (TAP) (ABCB2/3) are only able to transport small (oligo) pep-
Ɵ des of up to 40-mer residues (48, 49), do not seem compaƟ ble with a direct role 
in the transport of cytokines with molecular masses of up to 17kD. Nonetheless, it 
may be possible that by extruding some relevant physiological substrates, alteraƟ -
ons in cytokine secreƟ on may result as secondary eﬀ ects. Zhang et al. showed that 
MRP1 expression is induced upon T cell acƟ vaƟ on and that inhibiƟ on of MRP1 acƟ -
vity with the antagonist MK-571 resulted in reduced secreƟ on of IFN. Since MRP1 
inhibiƟ on was accompanied by suppression of genes involved in IFN secreƟ on, it 
was suggested that MRP1 inhibiƟ on only indirectly infl uences IFN secreƟ on i.e. due 
to increase intracellular retenƟ on of a nuclear hormone receptor agonist (50). A dif-
ferent link between ABC transporters and cytokines comes from studies showing that 
certain cytokines can induce ABC transporter expression (51, 52). 
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Figure 3: Expression of MDR transporters on immune cells.
The haematopoieƟ c lineage ontogeny is shown in relaƟ on to reported mRNA or protein expression of 
MDR-related ABC transporters. CLP: common lymphoid precursor, CMP: common myeloid precursor, DC: 
dendriƟ c cell, GMP: granulocyte/monocyte precursor, HSC: haematopoieƟ c stem cell, LC: Langerhans cell, 
MEP: megakaryocyte/erythroid precursor, MF: macrophage, NK: natural killer cell. In part adapted from 
Kock et al. (11). (* van de Ven et al., submiƩ ed, ** van de Ven et al., unpublished results, # Oerlemans et 
al., unpublished results)
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HaematopoieƟ c stem cells 
HaematopoieƟ c stem cells (HSC) are the precursors from which all immune cells de-
rive (53). ABC transporters are believed to have a protecƟ ve role in HSC, thus poten-
Ɵ ally presenƟ ng a problem in the treatment of (haematological) malignancies, since 
cancer stem cells expressing these transporters can escape chemotherapy treatment 
(54). While HSC were described to express P-gp, MRP1 and MRP4 (55-58), the ex-
pression of BCRP was most pronounced and has received the most aƩ enƟ on (59). 
No funcƟ onal studies have been reported to shed light on the relaƟ ve diﬀ erenƟ al 
importance of P-gp, MRP1 and MRP4 in protecƟ ng HSC against toxic components. 
Within HSC, BCRP was idenƟ fi ed as the transporter responsible for the so-called side-
populaƟ on (SP) phenotype by extrusion of the dye Hoechst 33342 (60). Despite its 
presence on stem cells, BCRP knockout mice displayed no alteraƟ on in haematopoi-
esis nor was haematopoiesis or stem cell funcƟ onality altered through inhibiƟ on of 
BCRP with antagonists (59, 61, 62). As the expression of BCRP was found to decrease 
upon lineage commitment, the transporter was hypothesized to play a selecƟ ve role 
in uncommiƩ ed, pluripotent stem cells (63). Notwithstanding this fact, more recent 
studies described BCRP expression in disƟ nct commiƩ ed cells, like erythrocytes (60), 
plasma cells (64) and human skin dendriƟ c cells (van de Ven et al., unpublished ob-
servaƟ on). Therefore, the currently prevailing concept is that BCRP primarily protects 
the HSC, as well as some specifi c other cell types, against endogenous and exoge-
nous toxins like porphyrins under low oxygen condiƟ ons (61, 65, 66). Future studies 
may possibly reveal other disƟ nct physiological funcƟ ons of BCRP.
Monocytes and macrophages 
Macrophages originate from monocytes and are known for their phagocyƟ c capa-
biliƟ es and their important role in the innate immune response (67). Thus far liƩ le 
is known about the physiological funcƟ ons of ABC transporters on human macro-
phages. Only the role of ABCA1 and ABCG1 in cholesterol eﬄ  ux and homeostasis 
has been fully characterized in macrophages (68). The involvement of MDR trans-
porters in immunological funcƟ ons of macrophages has primarily been studied in 
mice, where the MRP inhibitors MK571 and probenecid reduced zymosan-induced 
peritoniƟ s (69). It has been suggested that MRP1 and other MDR transporters are 
involved in pro-infl ammatory reacƟ ons, possibly through the secreƟ on of pro-in-
fl ammatory mediators like LTC4 by macrophages. SupporƟ ve data are available from 
Mrp1 knockout mice that exhibited a decreased response to an infl ammatory sƟ mu-
lus (70, 71). Primary human monocytes were found to express low, but disƟ nct levels 
of MRP1-7 mRNA and upon macrophage diﬀ erenƟ aƟ on the mRNA expression levels 
of these transporters were increased together with de novo mRNA synthesis of P-gp 
and BCRP (72-74). Furthermore, it was shown that inhibiƟ on of MRP1 acƟ vity did 
not interfere with human monocyte-to-macrophage diﬀ erenƟ aƟ on (74). Finally, high 
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expression of BCRP and moderate expression of MRP1 was found on macrophages in 
synovial Ɵ ssue of RA paƟ ents (75). Notably, high BCRP expression on macrophages in 
the synovial sublining was associated with diminished response to the anƟ -rheuma-
Ɵ c drugs methotrexate and lefl unomide (75).
DendriƟ c cells 
The most potent anƟ gen presenƟ ng cells are DC, which are oŌ en considered as the 
bridge between the innate and adapƟ ve response (76). DC can eﬃ  ciently process 
and present both exogenous and endogenous proteins on both MHC-I and –II mole-
cules. For MHC-I mediated anƟ gen presentaƟ on, the ABC transporter family mem-
bers TAP1/2 are essenƟ al (77). Within the DC subsets, ABC transporter expression 
has been analyzed on intersƟ Ɵ al DC and Langerhans cells, but informaƟ on is lacking 
for plasmacytoid DC. In vitro-cultured DC and human skin DC can express P-gp (43, 
46, 78), but expression levels can be rather low (79, 80). P-gp acƟ vity seems impor-
tant for the migraƟ on of human skin DC to the lymphaƟ c vessels, as P-gp neutra-
lizing anƟ bodies and the P-gp antagonist Verapamil reduced migraƟ on of DC and 
retained the DC within the epidermis (43). It remains unclear which physiologic P-gp 
substrate(s) actually drives this DC migraƟ on. Two candidates are PAF (30) or the 
sphingolipid metabolite S1P, which was reported to play a role in T lymphocyte mi-
graƟ on (17). Conceptually, a model for T cell homing to the lymph node might in-
volve S1P transport by P-gp and LTC4 transport by MRP1. As MRP1 is expressed by 
DC (78-80) and is involved in DC migraƟ on through the transport of LTC4 (18, 19), a 
similar model could apply for lymph node migraƟ on of DC (81). A direct contribuƟ on 
of MRP1 in DC migraƟ on was confi rmed in Mrp1 knockout mice, which required the 
exogenous addiƟ on of LTC4 or its derivaƟ ve LTD4 to restore DC migraƟ on (18). In the 
human seƫ  ng, also other ABC transporters like MRP4 or MRP5 (82) could play a role 
in DC migraƟ on. MRP4, recently reported to be expressed in epidermal and dermal 
skin DC (83), can also transport PGE2, LTB4 , LTC4 and cyclic nucleoƟ des like cAMP 
and cGMP (26, 84). A funcƟ onal associaƟ on was revealed by the observaƟ on that 
inhibiƟ on of MRP4, or MRP4 expression down-regulaƟ on by RNAi, reduced human 
skin DC migraƟ on (83). However, addiƟ on of PGE2, LTB4, LTD4 or a cGMP-analog could 
not restore migraƟ on (83), as was shown for LTC4 in the Mrp1 knockout mice (18). So 
conceivably a diﬀ erent substrate is involved. In mice, the absence of Mrp4 did not 
interfere with DC migraƟ on from skin or the generaƟ on of a proper anƟ gen-specifi c 
immune response (85), suggesƟ ng interspecies diﬀ erences for the funcƟ ons of ABC 
transporters on immune cells. 
On top of a role in DC migraƟ on, MRP1 also appeared of relevance in DC diﬀ eren-
Ɵ aƟ on (80). IniƟ al studies by Laupeze et al., using a low-aﬃ  nity MRP1 antagonist 
(indomethacin), showed a signifi cant reducƟ on in CD40 expression on DC (79). More 
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powerful inhibiƟ on of MRP1 acƟ vity by MK-571 or probenecid during DC diﬀ erenƟ -
aƟ on from monocytes (MoDC) or from the acute myeloid leukemia-derived cell line 
MUTZ3 (86, 87), resulted in a markedly impaired diﬀ erenƟ aƟ on towards intersƟ Ɵ al 
DC and Langerhans cells (74, 80). FuncƟ onally these MRP1-blocked DC secreted less 
IL-12 and were impaired in their capacity to sƟ mulate T cell proliferaƟ on (80). Ho-
wever, since these eﬀ ects appeared to be LTC4-independent, it is sƟ ll unclear which 
other MRP1 substrate could play a role in this process. Eﬀ ects of P-gp inhibiƟ on on 
DC diﬀ erenƟ aƟ on remain unclear, as Pendse et al. (46) reported an inhibitory eﬀ ect, 
while studies from our laboratory showed no eﬀ ect of P-gp inhibiƟ on on the diﬀ e-
renƟ aƟ on of MoDC (80). Discrepancies between these studies might be explained 
by the diﬀ erent concentraƟ ons of P-gp inhibitor used and diﬀ erent expression levels 
of P-gp on the donor-derived MoDC. Also, Pendse et al. reported that inhibiƟ on of 
P-gp in MoDC or during monocyte acƟ vaƟ on with LPS resulted in reduced secre-
Ɵ on of IL-12 (46). Recently we found that BCRP is expressed by human skin DC and 
that over-expression of BCRP on CD34+ DC precursor cells resulted in accelerated 
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Figure 4: Synthesis of lipid mediators of infl ammatory responses and ABC transporters facilitaƟ ng their 
transport.
Gal-Cer: galactosyl-ceramide, LPC: lysophosphaƟ dylcholine, LT: leukotriene, MRP: mulƟ drug resistance 
protein, PAF: platelet acƟ vaƟ ng factor, PG: prostaglandin, PGH2: prostaglandin2, HPETE: hydraxyperoxy-
elcosateraenolc acid, P-gp: P-glycoprotein, S1P: sphingosine-1-phosphate, SMase: sphingomyelinase.
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LC diﬀ erenƟ aƟ on and endogenous TGF-dependent LC-specifi c CD1ahi and Langerin 
expression on intersƟ Ɵ al DC cultures (Van de Ven et al., unpublished observaƟ ons). 
Which endogenous BCRP substrate is responsible for these observaƟ ons remains to 
be established. 
T cells 
The expression of ABC transporters on T-cells has been studied, revealing acƟ ve P-gp 
and MRP1 (88-91). Moreover, a correlaƟ on was found between high P-gp expres-
sion on T cells of RA paƟ ents and the lack of response to steroid treatment (92-94). 
Diﬀ erent T-cell subsets or acƟ vaƟ on states are associated with disƟ ncƟ ve paƩ erns 
of P-gp expression and acƟ vity, which could be relevant for their funcƟ ons. CD8+ T 
cells were found to have high P-gp acƟ vity whereas low P-gp acƟ vity was detected in 
CD4+ T-cells (55, 90). Ludescher et al. showed that naive CD8+ T-cells exhibited higher 
P-gp acƟ vity than CD8+ memory T-cells. As menƟ oned, P-gp expression was shown 
to be important for S1P transport in T lymphocyte homing (17). In T regulatory cells 
(Tregs), expression of ABC transporters has not yet been reported, but it is known 
that Tregs are extremely sensiƟ ve to chemotherapy (95), suggesƟ ng that these cells 
probably express minimal or low levels of drug eﬄ  ux transporters. As the immune-
regulatory ABC transporter substrates idenƟ fi ed thus far generally promote a pro-
infl ammatory environment, the hypothesis that Tregs express only low levels of ABC 
transporters should be tested.
Although P-gp has been widely studied in T-cells, some apparent discrepancies were 
reported regarding its expression and funcƟ on. For example, some studies report 
an increase in P-gp expression upon T cell acƟ vaƟ on (90, 96) whereas other studies 
reported a decrease (97-99). Other apparent inconsistencies relate to the funcƟ on 
of P-gp in the process of aging; some studies indicated that P-gp acƟ vity is decreased 
upon aging (100-102) and may thereby contribute to a decrease in T cell cytolyƟ c 
acƟ vity, while others showed either an increase in P-gp acƟ vity (103) or no eﬀ ect 
at all (104). A similar controversy was found with respect to Mrp1 expression on 
acƟ vated murine Th1 cells; Mrp1 was iniƟ ally idenƟ fi ed as a specifi c Th1 acƟ vaƟ on 
marker since treatment with MK-571 could block acƟ vaƟ on (105), but a later study 
in Mrp1 KO mice showed normal Th1 acƟ vaƟ on (106), suggesƟ ng that the MK-571 
eﬀ ect was Mrp1 unrelated. Given normal in vivo anƟ gen-specifi c responses in mice 
lacking Mrp4 expression (85), it seems unlikely that MK-571 inhibiƟ on of Mrp4 acƟ -
vity is involved in Th1 acƟ vaƟ on.
B cells 
OriginaƟ ng from the bone marrow, B-cells can develop into plasma cells or memory 
B-cells, which are key regulators of the humoral immune response. Limited data is 
available regarding the expression and funcƟ on of ABC transporters on B cells. In 
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cancerous plasma cells, i.e. mulƟ ple myeloma, P-gp acƟ vity was linked to therapy 
resistance to vincrisƟ ne, doxorubicin and glucocorƟ coids (107). In healthy individuals 
P-gp acƟ vity was shown to be reduced upon B-cell acƟ vaƟ on and diﬀ erenƟ aƟ on into 
memory B-cells (101, 108-111). In addiƟ on to P-gp, funcƟ onally acƟ ve BCRP was re-
cently found to be present on normal human plasma cells (64) and BCRP acƟ vity was 
associated with unfavorable therapy outcome in mulƟ ple myeloma (112). 
NK cells play a central role in the host defense against viral infecƟ ons. NK cells have 
been described to possess the highest level of funcƟ onal P-gp compared to other leu-
kocyte populaƟ ons (113). Ludescher et al. reported that inhibiƟ on of P-gp acƟ vity in 
NK cells resulted in reduced cytotoxicity, suggesƟ ng that P-gp is involved in the secre-
Ɵ on of cytotoxic compounds by NK cells (90). The authors discussed that P-gp might 
have a role in the secreƟ on of perforins, also because previous reports had found a 
relaƟ on between P-gp acƟ vity and cytotoxicity of CD8
+ T cells (96, 114). However, the 
molecular weight of perforins (~50kD) by far exceeds size-limits for most common 
substrates transported by these transporters (MW: 1-2kD). Studies by N’cho et al. 
(115) and Takahashi et al. (116) also supported a role for P-gp in NK cell cytotoxicity. 
The laƩ er study proposed a role for P-gp in regulaƟ ng the pH in lysosomes in NK 
cells. Beside P-gp protein expression, also mRNA expression of MRP1 and MRP2 was 
described in NK cells (117). Protein expression levels and the funcƟ onal relevance of 
these transporters for NK cells remains to be established. 
ABC transporter expression regulaƟ on and links to 
immune acƟ vaƟ on
Signal transducƟ on pathways involved in DC and immune acƟ vaƟ on can be linked 
to expression regulaƟ on of ABC transporters, e.g. P-gp, MRP1 and BCRP. AcƟ vaƟ on 
of the p38 MAPK pathway by infl ammatory cytokines has been linked to human DC 
maturaƟ on and enhanced anƟ -tumor responses in mice (118, 119). InhibiƟ on of p38 
MAPK resulted in reduced IL12p70 secreƟ on and reduced expression of co-sƟ mulato-
ry molecules and chemokine receptors by DC resulƟ ng in poor T cell sƟ mulatory and 
migratory capaciƟ es (119, 120). In tumor cells, inhibiƟ on of p38 MAPK was shown to 
decrease the acƟ vaƟ on of the transcripƟ on factor AP-1 (acƟ vaƟ ng protein-1), with 
subsequent down regulaƟ on of P-gp expression (121, 122). AP-1 also has binding 
moƟ fs on several other transporters e.g. MRP1 (123) and BCRP (124). Beside the p38 
MAPK pathway, the PI3K/Akt pathway has also been linked to DC acƟ vaƟ on, IL-12 
secreƟ on by DC and DC survival (125). InhibiƟ on of Akt acƟ vaƟ on has been shown to 
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reduce both P-gp and MRP1 expression (126, 127) and Akt phosphorylaƟ on has been 
reported to be required for translocaƟ on of BCRP from the cytoplasm to the plasma 
membrane (62, 128). These reports suggest a funcƟ onal role for ABC transporters 
during an infl ammatory response. 
TherapeuƟ c applicaƟ ons for ABC transporter modulaƟ on
Autoimmune diseases 
In auto-immune diseases there is a loss of negaƟ ve selecƟ on towards self-anƟ gens, 
resulƟ ng in proliferaƟ on of auto-reacƟ ve T-cells and producƟ on of auto-anƟ bodies 
by plasma-cells. These processes are accompanied by a permanent pro-infl amma-
tory state of the immune system, refl ected by producƟ on of pro-infl ammatory cy-
tokines like TNF, IL1β and IL6. Although some anƟ body-driven auto-immune dis-
eases like myasthenia gravis, idiopathic and thromboƟ c thrombocytopenic purpura 
can be self limiƟ ng or potenƟ ally treated with riƟ xumab targeƟ ng CD20 on B cells 
(129, 130), other auto-immune diseases such as rheumatoid arthriƟ s mostly require 
life-long immunosuppressive therapy, targeƟ ng diﬀ erent infl ammatory cells (131). 
Unfortunately, chronic exposure of paƟ ents to immunosuppressive agents oŌ en 
leads to the inducƟ on of drug-resistance. From this viewpoint, diﬀ erent roles for 
MDR transporters in the pathophysiology of autoimmune diseases can be hypoth-
esized. First, as described in the previous secƟ on, MDR transporters can transport 
pro-infl ammatory substrates that may trigger the immune system and facilitate at-
tracƟ on of immune-competent cells to the site of infl ammaƟ on. Second, infl amma-
tory cytokines can induce expression of ABC transporters, thereby possibly caus-
ing persistence of the response due to enhanced secreƟ on of other infl ammatory 
mediators by the ABC transporters. Third, the MDR transporters which are present 
on acƟ vated immune eﬀ ector cells might be associated with base-line resistance to 
treatment in auto-immune diseases, since it is known that MDR transporters have 
anƟ -infl ammatory drugs among their substrates. Several lines of evidence are avail-
able which support this laƩ er role, parƟ cular in the treatment of rheumatoid arthriƟ s 
(RA) with disease modifying anƟ -rheumaƟ c drugs (DMARDs) (3): in vitro studies have 
shown that several DMARDs, e.g. MTX, chloroquine and sulfasalazine, are substrates 
of MDR transporters. Therefore the therapeuƟ c eﬃ  cacy of DMARDs can be impaired 
by the presence of ABC transporters on immune eﬀ ector cells, leading to persistent 
infl ammaƟ on. Furthermore, the use of DMARDs might itself induce the expression 
of MDR-transporters on infl ammatory cells (3, 132, 133). In accordance with these 
observaƟ ons, Van der Heijden et al. (134) showed that the onset of sulfasalazine re-
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sistance in human CEM T-cells aŌ er prolonged exposure is accompanied by a marked 
inducƟ on of BCRP expression. Sulfasalazine sensiƟ vity could be largely restored in 
these cells by adding the specifi c BCRP blocking agent Ko-143 to the culture medium, 
proving the funcƟ onal relaƟ on of BCRP expression and sulfasalazine resistance. In 
sulfasalazine resistant T-cells, basal levels of TNFα producƟ on aŌ er sƟ mulaƟ on were 
markedly increased compared to parental T-cells, poinƟ ng to an enhanced infl amma-
tory state of these cells. Concurrently, TNFα producƟ on was less eﬃ  ciently blocked 
by sulfasalazine, consistent with BCRP-mediated eﬄ  ux of this drug (134). Later also 
in-vivo data confi rmed BCRP-mediated transport of SSZ, as BCRP showed to be a ma-
jor determinant in SSZ absorpƟ on and eliminaƟ on in mice (135). In addiƟ on, certain 
ABC transporters, such as MRP1 to 5 and BCRP, can transport diﬀ erent conjugates of 
folates and anƟ -folates (Table 2). It has been well recognized that these transporters 
may impact the intracellular folate pool size and folate homeostasis under physi-
ological condiƟ ons (136). Also, overexpression of these transporters conferred mod-
erate to marked levels of resistance to various anƟ folates such as methotrexate, the 
cornerstone in the treatment of rheumatoid arthriƟ s (133). However, it is important 
to note that to date no reports are available in which anƟ folate-selected cell lines 
overexpress relevant ABC transporters.
Several clinical studies have been undertaken to invesƟ gate the role of ABC trans-
porters in conferring resistance in auto-immune diseases. Some of these studies 
have shown increased P-gp expression in peripheral blood lymphocytes and T-cells 
from RA paƟ ents aŌ er DMARD treatment (137) or from therapy non-responsive pa-
Ɵ ents (138, 139)(R. Oerlemans et al, unpublished results). Studies by Jorgensen et al. 
revealed high levels of P-gp protein expression in rheumatoid synovium in 5 out of 16 
paƟ ents (140). In our laboratory we found expression and funcƟ onal acƟ vity of P-gp 
in peripheral blood lymphocytes of both healthy controls (n=10) and RA paƟ ents 
(n=21). P-gp acƟ vity was signifi cantly higher in DMARD treated paƟ ents compared to 
DMARD naïve paƟ ents, in line with previous observaƟ ons (137-139). Also increased 
mRNA expression for MRP1 and MRP4 was found in peripheral blood lymphocytes 
of RA paƟ ents compared to controls, the laƩ er being related to poor response to 
DMARD therapy. Moreover, BCRP was shown to be a dominant transporter in mono-
cyte-derived macrophages, its expression being signifi cantly higher in RA-paƟ ents 
compared to controls (141). In accordance with this fi nding, we also showed that 
BCRP is expressed on macrophages in infl amed synovial Ɵ ssue from RA paƟ ents (75). 
High BCRP expression was posiƟ vely correlated with disease acƟ vity and unrespon-
siveness to the anƟ -arthriƟ c drugs MTX and lefl unomide (both being known BCRP 
substrates). In the same study, MRP1 expression was observed on T-cells organized 
in aggregates in synovial Ɵ ssue of one third of the studied RA paƟ ents. Expression of 
P-gp was below limits of detecƟ on in RA synovial Ɵ ssue, consistent with the fi ndings 
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of Jorgensen et al. (140). 
Expression of MDR transporters in auto-immune diseases is not only restricted to 
RA. In other auto-immune diseases such as myasthenia gravis, thrombocytopenic 
purpura and systemic lupus erythematosus, expression of P-gp was associated with 
diminished eﬃ  cacy of steroids (94, 142-144). These data are indicaƟ ve for a role 
of P-gp and other MDR transporters in conferring resistance to immunosuppressive 
agents in auto-immunity. On the other hand, increased expression of these trans-
porters may also play a causaƟ ve role in persistent infl ammaƟ on as described earlier, 
due to enhanced transport of pro-infl ammatory substrates such as LTC4, PAF and S1P. 
Currently no clinical studies have been iniƟ ated to explore potenƟ al benefi cial ef-
fects of MDR antagonists in treatment protocols for auto-immune diseases. In theo-
ry, auto-immune diseases would benefi t opƟ mally from the use of MDR transporter 
antagonists, as they would block the secreƟ on of pro-infl ammatory ABC transporter 
substrates and in parallel prevent resistance against anƟ -infl ammatory drugs. From 
this perspecƟ ve the concomitant use of the non steroidal anƟ -infl ammatory (NSAID) 
drug sulindac might enhance therapy with immunosuppressive agents, since it is 
known to block MRP1 (145) and MRP4 (22) acƟ vity. It is of interest to note that be-
yond sulindac, several other NSAIDs also harbored MRP1 antagonisƟ c acƟ vity (145). 
Clearly, the role of MDR transporters other than P-gp, and immune-eﬀ ector cells 
other than T-lymphocytes warrants further exploraƟ on.
Cancer 
In the treatment of cancer, chemotherapy is the third most used opƟ on next to sur-
gery and radiotherapy. It is recognized that chemotherapy regimens are oŌ en ham-
pered by the acquisiƟ on of chemo-resistance during treatment. Over the past deca-
des, the discovery of the involvement of ABC transporters in the resistant phenotype 
iniƟ ated extensive research for potent ABC transporter antagonist in order to over-
come drug resistance. However, at that Ɵ me liƩ le was known about the putaƟ ve phy-
siological funcƟ ons of these transporters. Nowadays several of these transporters 
have been linked to physiologically important processes, e.g. funcƟ ons in the kidneys 
and the liver, protecƟ on of the blood-brain-barrier and placenta against endogenous 
(and exogenous) toxic compounds and the involvement of the secreƟ on of substrates 
important for the opƟ mal funcƟ oning of immune cells. It therefore seems obvious 
that clinicians and researchers should be cauƟ ous with inhibiƟ ng the acƟ vity of these 
transporters, as this could evoke unwanted side eﬀ ects. Since inhibiƟ on of ABC trans-
porters in combinaƟ on with systemic chemotherapy has proven ineﬃ  cient and seve-
rely toxic, novel strategies should be considered such as local applicaƟ on of MDR an-
tagonists at the site of the tumor (which of course might not be helpful in metastaƟ c 
disease) or specifi c targeƟ ng of MDR transporters in tumor cells. With respect to the 
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immune system and cancer, it is established that treatment with chemotherapeu-
Ɵ c agents dramaƟ cally dampens the immune response, as many immune eﬀ ector 
cells are collaterally targeted by this treatment(81). PaƟ ents receiving chemotherapy 
are therefore suscepƟ ble to viral and bacterial infecƟ ons. InhibiƟ on of MDR-related 
ABC transporters on top of chemotherapy treatment to bypass MDR could then even 
further enhance this immune-suppression and increase the risk of infecƟ ons. It is 
also appreciated that the immune system is important for anƟ -tumor eﬀ ects. Within 
the innate immune system, NK cells are known to recognize MHC I down regulaƟ on 
on tumor cells (146), which is a trigger for these cells to eradicate the tumor cell. For 
this, NK cells need funcƟ onal cytotoxic granules (lysosomes) which may require P-gp 
acƟ vity for funcƟ onality (90, 115, 116). In the adapƟ ve response, APC (and DC in 
parƟ cular) are needed to take up tumor cells and present tumor associated anƟ gens 
(TAA) to T cells. In order for APC precursors to fully diﬀ erenƟ ate into DC they require 
acƟ ve MRP1 (74, 80) and perhaps P-gp (46). Subsequently the DC need to migrate 
to the draining lymph nodes to present the TAA and acƟ vate T cells. For this migra-
Ɵ on the funcƟ onal acƟ vity of P-gp (43), MRP1 (18) and MRP4 (83) is criƟ cal. For the 
homing of T-cells within the lymph nodes, both MRP1 and P-gp are required (17). 
AcƟ vated T cells subsequently leave the lymph nodes, in order to home to the site 
of the tumor where they uƟ lize P-gp acƟ vity to secrete cytotoxic compounds from 
granules (96, 114). InhibiƟ on of ABC transporters, in conjuncƟ on with suppressive cy-
tokines produced by tumor cells, might therefore completely block the development 
of DC and stop the presentaƟ on of TAA to T cells. Our ever increasing knowledge on 
the role of ABC-transporters in immune eﬀ ector cells should be exploited to improve 
anƟ -cancer therapies through enhancement of the expression of ABC transporters 
on immune cells, whether by drugs, specifi c targeƟ ng by ABC transporter-encoding 
adenoviruses or other means. Certainly, more research is warranted in order to com-
prehend the full involvement of ABC transporters in the generaƟ on of an immune 
response.
Concluding remarks
Over the last decade accumulaƟ ng evidence has emerged emphasizing criƟ cal func-
Ɵ onal roles for MDR-related ABC transporters in immune eﬀ ector cells. This knowl-
edge should be considered and exploited for the development of new strategies for 
the treatment of autoimmune diseases and cancer. When increased expression of 
a transporter leads to improvement of an immune response, this could be an in-
teresƟ ng tool for combined chemo-immunotherapies in cancer paƟ ents, as the af-
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fected immune eﬀ ector cells will gain in funcƟ onality and at the same Ɵ me will be 
less prone to toxic side eﬀ ects of chemotherapy treatment. Conversely, from the 
perspecƟ ve of treatment of auto-immune diseases, it may be benefi cial to decrease 
the expression or funcƟ onality of specifi c transporters on specifi c subsets of immune 
eﬀ ector cells, as this could aƩ enuate the generaƟ on of an auto-immune response by 
hampering immune eﬀ ector cell diﬀ erenƟ aƟ on and funcƟ onality. 
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Summary
ObjecƟ ve. To explore the onset and molecular mechanism of resistance to the anƟ -
malarial diseasemodifying anƟ rheumaƟ c drug (DMARD) chloroquine (CQ) in human 
CEM T cells. 
Methods. Human CEM cells were used as an in vitro model system to study the de-
velopment of CQ resistance by growing cells in stepwise increasing concentraƟ ons 
of CQ.
Results. Over a period of 6 months, CEM cell lines developed 4–5-fold resistance 
to CQ. CQ resistance was associated with the specifi c overexpression of mulƟ drug 
resistance–associated protein 1 (MRP-1), an ATP-driven drug eﬄ  ux pump. This was 
illustrated by 1) overexpression of MRP-1 by Western bloƫ  ng and 2) the complete 
reversal of CQ resistance by the MRP-1 transport inhibitors MK571 and probenecid. 
Importantly, CQ-resistant CEM cells retained full sensiƟ vity to other DMARDs, in-
cluding methotrexate, lefl unomide, cyclosporin A, and sulfasalazine, but exhibited 
a high level of cross-resistance (>1,000- fold) to the glucocorƟ coid dexamethasone. 
The mechanisƟ c basis for the laƩ er was associated with aberrant signaling via the 
cAMP–protein kinase A pathway, since the cAMP-inducing agent forskolin reversed 
dexamethasone resistance. Finally, CQ-resistant CEM cells displayed a markedly re-
duced capacity to release proinfl ammatory cytokines (tumor necrosis factor α) and 
chemokines (interleukin-8).
Conclusion. InducƟ on of overexpression of the mulƟ drug resistance eﬄ  ux transport-
er MRP-1 can emerge aŌ er long-term exposure to CQ and results in CQ resistance 
and collateral resistance to dexamethasone. These fi ndings warrant further detailed 
invesƟ gaƟ ons into the possible role of MRP-1 and other members of the superfamily 
of drug eﬄ  ux pumps in diminishing the eﬃ  cacy of DMARDs in rheumatoid arthriƟ s 
treatment.
IntroducƟ on
Rheumatoid arthriƟ s (RA) is a chronic disease with a variable degree of infl amma-
Ɵ on. RA therapy is insƟ tuted with established disease-modifying anƟ rheumaƟ c drugs 
(DMARDs) administered either as sequenƟ al monotherapy or in a variety of combi-
naƟ ons (1–3). Monotherapy with a DMARD is iniƟ ally successful in about 70–80% of 
paƟ ents, depending on the specifi c anƟ rheumaƟ c drug (4). However, reacƟ vaƟ on of 
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infl ammaƟ on oŌ en occurs during conƟ nuous drug therapy, indicaƟ ng that DMARD 
eﬃ  cacy becomes compromised with long-term treatment (5,6). On average, RA pa-
Ɵ ents conƟ nue to take the anchor drug methotrexate (MTX) for around 5–6 years, 
while for drugs such as sulfasalazine (SSZ), gold compounds, and anƟ malarial agents 
such as chloroquine (CQ), this period is much shorter (only 1–2 years) (5). Generally, 
there are 2 reasons for drug disconƟ nuaƟ on—adverse eﬀ ects and lack of eﬃ  cacy. 
The issue of whether the lack of DMARD eﬃ  cacy is mechanisƟ cally associated with 
the development of cellular drug resistance is sƟ ll unresolved. Apart from neoplasƟ c 
diseases or infecƟ ous diseases (e.g., malaria), in which development of drug resis-
tance is a major obstacle to eﬀ ecƟ ve treatment (7,8), it is remarkable that liƩ le is 
known about the mechanisms underlying cellular resistance to DMARDs.
One important mode of drug resistance can be due to enhanced cellular extrusion 
of drugs, a process that can be mediated by specifi c members of a superfamily of 
ATP-binding casseƩ e (ABC) proteins (9). Since these proteins can mediate the eﬄ  ux 
of a wide range of structurally unrelated drugs, they are also referred to as mulƟ drug 
resistance (MDR) proteins. Specifi c MDR proteins known to be involved in resistance 
to anƟ cancer drugs, and possibly also to DMARDs, include P-glycoprotein (P-GP, 
or ABCB1), mulƟ drug resistance–associated proteins (MRPs) 1–9 (ABCC1–12), and 
breast cancer resistance protein (BCRP, or ABCG2) (9,10).
In this study, we focused on the elucidaƟ on of the molecular mechanisms of resis-
tance to CQ. CQ itself is a weak anƟ rheumaƟ c drug, but it is aƩ racƟ ve in combina-
Ɵ on treatment because of its modest toxicity paƩ ern (11). In RA treatment, CQ or 
hydroxychloroquine (HCQ) is oŌ en successfully combined with the anchor drug MTX 
as well as with other drugs (12,13). 
Resistance to CQ was generated in CEM T cells, an in vitro model system for human T 
cells, the cell lineage that plays a central role in the pathogenesis of RA. Two human 
CEM cell lines were used, one of which was sensiƟ ve to MTX (the drug with which CQ 
is frequently combined in clinical pracƟ ce) and the other of which exhibited acquired 
resistance to MTX, in order to determine whether prior exposure to MTX could have 
altered the sensiƟ vity to CQ. In both CEM lines with acquired resistance to CQ, this 
resistance was mediated by the inducƟ on of a cell membrane-associated drug eﬄ  ux 
transporter, MRP-1 (9). Consistently, CQ resistance in CEM cells could be reversed by 
blockers of MRP-1 transport. Importantly, CQ-resistant CEM cells retained their sen-
siƟ vity to other DMARDs, including SSZ, MTX, cyclosporin A (CSA), and lefl unomide, 
but were highly cross-resistant to glucocorƟ coids. 
70
Chapter 3
Materials and methods
Reagents
MTX was provided by Pharmachemie (Haarlem, The Netherlands). CSA was a giŌ  
from NovarƟ s (Arnhem, The Netherlands). CQ, quinacrine, lefl unomide, verapamil, 
SSZ, pyrimethamine, doxorubicin, daunorubicin, probenecid, forskolin, phorbol 
12-myristate 13-acetate (PMA), ionomycin, prednisolone, and dexamethasone were 
purchased from Sigma (St. Louis, MO). Protease inhibitor cocktail (PIC) and Triton 
X-100 were from Boehringer Mannheim (Ingelheim, Germany). MK571 was kindly 
provided by Merck Frosst Canada (Kirkland, Quebec, Canada). RPMI 1640 Ɵ ssue 
culture medium and fetal calf serum (FCS) were obtained from Gibco (Grand Island, 
NY). 3H-dexamethasone (TRK417; 41 Ci/mmole) was purchased from Amersham Life 
Sciences (Buckinghamshire, UK). 
Cell lines
Wild-type (WT) human CCRF-CEM T cells and CEM sublines, previously selected for 
MTX resistance (14), were used in this study. MTX-resistant cell lines were included 
in order to determine whether MTX resistance resulƟ ng from long-term drug expo-
sure altered the sensiƟ vity to CQ. For this purpose, 1 MTX-resistant CEM line (CEM/
MTXRFC↓), exhibiƟ ng MTX resistance due to defecƟ ve cellular uptake via the reduced 
folate carrier (RFC), was characterized in greater detail. In addiƟ on, for selected ex-
periments, we used 2 other MTX-resistant CEM cell lines with diﬀ erent molecular 
mechanisms of resistance to MTX; one had an overexpression of the target enzyme 
dihydrofolate reductase (DHFR), while the other had a decreased acƟ vity of folylpoly-
glutamate synthetase (14). 
All cell lines were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM 
L-glutamine, and 100 units/ml penicillin and streptomycin as previously described. 
Control cell lines overexpressing specifi c MDR proteins (P GP, MRPs 1–5, and BCRP) 
included the P-GP-overexpressing CEM/VLB100 cell line (kindly provided by Dr. H. 
J. Broxterman, Department of Medical Oncology, VU University Medical Center, 
Amsterdam, The Netherlands), 2008 and HEK 293 cells transfected with MRPs 1-5 
(generously provided by Prof. P. Borst, Netherlands Cancer InsƟ tute, Amsterdam, The 
Netherlands), and the BCRP-overexpressing cell line MCF7/MR (15). Expression of 
the various MDR proteins in series of CEM cell lines was determined with specifi c 
monoclonal anƟ bodies to these MDR proteins as described previously (16). 
Drug sensiƟ vity was evaluated by plaƟ ng 1.25 X 105 cells/ml in individual wells of a 
24-well plate containing up to 50 μl of drug soluƟ ons. InhibiƟ on of cell growth (anƟ -
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proliferaƟ ve eﬀ ect) was determined aŌ er 72 hours of incubaƟ on at 37oC by counƟ ng 
viable cells on the basis of trypan blue exclusion. The drug concentraƟ on required to 
inhibit cell growth by 50% compared with untreated controls is defi ned as the IC50. 
Development of CQ resistance
CEM cells and CEM/MTXRFC↓ cells were suspended at a density of 3 X 105/ml in 10 ml 
RPMI 1640 medium containing 10% FCS. CQ was added to the cell suspension of CEM 
cells and CEM/MTXRFC↓ cells at iniƟ al concentraƟ ons of 40 μM and 25 μM, respecƟ ve-
ly, corresponding to the IC50 values for these cell lines. Cell cultures were refreshed 
twice a week with CQ-containing medium. When cell growth in CQ-containing me-
dium approximated growth of control cells, CQ concentraƟ ons in the medium were 
gradually increased by 10 μM. AŌ er a period of 6 months in CQ-containing medium, 
CQ-resistant CEM and CEM/MTXRFC↓cells, hereinaŌ er designated CEM/CQ and CEM/ 
MTXRFC↓/CQ cells, respecƟ vely, were used for further characterizaƟ on. 
Western bloƫ  ng analysis
For analysis of expression of P-GP, MRPs 1–5, BCRP/ABCG2, and glucocorƟ coid recep-
tor α (GRα), cells were harvested in the mid-log phase of growth and washed 3 Ɵ mes 
with ice-cold HEPES buﬀ ered saline at pH 7.4. Total cell lysates of 107 cells were pre-
pared by suspending in 500 μl of lysis buﬀ er containing 50 mM Tris HCl (pH 7.6), 5mM 
dithiothreitol, 20 μl PIC (1 tablet/ml H2O), 20% glycerol, and 0.5% Nonidet P40. The 
suspension was sonicated (amplitude 6, for 3 X 5 seconds with 30-second Ɵ me inter-
vals at 4oC) (MSE sonicator; Wolf Laboratories, Pocklington, UK) and centrifuged at 
14,000 revoluƟ ons per minute for 10 minutes at 4oC in a microcentrifuge (Eppendorf, 
Madison, WI). Protein content of the supernatant was determined by the Bio-Rad 
protein assay (Bio-Rad, Richmond, CA). FiŌ y micrograms of total cell lysate was frac-
Ɵ onated on a 7.5% polyacryl amide gel containing sodium dodecyl sulfate (SDS) and 
transferred onto a nitrocellulose membrane. The nitrocellulose membranes were 
preincubated overnight at 4oC in blocking buﬀ er (5% Bio-Rad Blocker in Tris buﬀ ered 
saline–Tween [TBST] consisƟ ng of 10 mM Tris HCl [pH 8.0], 0.15M NaCl, 0.1% Tween 
20) to prevent nonspecifi c anƟ body binding. 
AŌ er blocking, the membranes were incubated for 1 hour at room temperature with 
the primary anƟ bodies against P-GP (JSB1; 1:500), MRP-1 (MRPr1; 1:500), MRP-2 
(M2I-4; 1:500), MRP-3 (M3II-21; 1:500), MRP-4 (M4I-10; 1:10), MRP-5 (M5I-1; 1:500), or 
BCRP/ABCG2 (BXP21; 1:400) as described by Scheﬀ er et al (16). For GRα, the primary 
anƟ body was sc-1003 (1:500; from Santa Cruz Biotechnology [Santa Cruz, CA] via 
Tebu-bio [Heerhugowaard, The Nether lands]). An anƟ body to β-acƟ n (MAB1501R, 
1:3,000; Chemicon, Temecula, CA) was used to normalize for any loading diﬀ erences. 
AŌ er 3 washing steps with TBST, the membrane was incubated for 1 hour with horse-
radish peroxidase–labeled anƟ -rat or anƟ -mouse anƟ body (1:2,000; Dako, Carpinte-
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ria, CA) as the secondary anƟ body. DetecƟ on of anƟ body binding was followed by 
enhanced chemiluminescence (ECL) using ECL reagent (RPN 2106; Amersham Phar-
macia Biotech, Buckinghamshire, UK) according to the manufacturer’s instrucƟ ons. 
Signal intensity was determined densitometrically (QuanƟ ty One soŌ ware; Bio-Rad) 
and was expressed relaƟ ve to the intensity of the β-acƟ n signal.
Enzyme-linked immunosorbent assay (ELISA)
Tumor necrosis factor α (TNFα) and interleukin-8 (IL-8) producƟ on was analyzed aŌ er 
sƟ mulaƟ on of CEM and CQ-resistant cells (3 X 105/ml) for 24 hours with PMA (10 ng/
ml) and ionomycin (1 μM). Supernatants were then collected by centrifugaƟ on at 
3,000 rpm for 5 minutes and analyzed for TNFα and IL-8 by ELISA (Central Laboratory 
of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Nether-
lands) according to the instrucƟ ons of the manufacturer. The lower limit of detecƟ on 
for TNFα and IL-8 was 5 pg/ml. 
3H-dexamethasone binding studies
The number of cellular glucocorƟ coid receptors was assayed essenƟ ally as described 
by Haarman et al (17). 
StaƟ sƟ cal analysis
StaƟ sƟ cal evaluaƟ on of data was performed with Student’s t-test. P values less than 
0.05 were considered signifi cant.
RESULTS
Development of CQ resistance in CEM cells
In order to gain insight into the development of CQ resistance over Ɵ me, resistance 
to CQ was provoked by culturing CEM cells in the conƟ nuous presence of gradually 
increasing concentraƟ ons of CQ in the culture medium (Figure 1A). At the end of 
a 6-month period, CEM cells were able to grow in the presence of 4–5-fold high-
er concentraƟ ons of CQ compared with the starƟ ng concentraƟ on of 40 μM. The 
growth-inhibitory potenƟ al of CQ for WT CEM cells and the CEM cells with acquired 
resistance to CQ (CEM/CQ cells) is shown in Figure 1B. CEM/CQ cells were markedly 
resistant to CQ as illustrated by the 3.2-fold higher IC50 value for CQ compared with 
WT CEM cells (P < 0.001) (Table 1). Likewise, a similar level of cross-resistance (2.9-
fold) was observed for quinacrine (18), a structural analog of CQ. 
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CQ resistance could also be provoked in CEM cells with acquired resistance to MTX 
(i.e., CEM/MTXRFC↓ cells, a CEM line resistant to MTX due to defecƟ ve cellular uptake 
via the RFC). At the end of a 6-month period, MTXRFC↓ cells also developed resistance 
to CQ and were able to grow in the presence of 5-fold higher concentraƟ ons of CQ 
compared with the iniƟ al concentraƟ on of 25 μM CQ (P < 0.001) (results not shown). 
CQ-resistant CEM/MTXRFC↓ cells were therefore termed CEM/MTXRFC↓/CQ cells. 
Days CQ?(?M)?
CQ?(?M)? CQ?(?M)?
[C
Q
]?r
el
at
iv
e?
to
?st
ar
tin
g?
do
se
?
Ce
ll?
gr
ow
th
?(%
?o
f?c
on
tr
ol
)?
Ce
ll?
gr
ow
th
?(%
?o
f?c
on
tr
ol
)?
Ce
ll?
gr
ow
th
?(%
?o
f?c
on
tr
ol
)?
A
C
B
D
Figure 1: (A) Onset of chloroquine (CQ) resistance in human CEM cells. Resistance to CQ was acquired by 
culturing CEM cells in gradually increasing concentraƟ ons of CQ over Ɵ me. (B) CQ sensiƟ vity of CEM cells 
(open circles) and CQ-resistant CEM cells (CEM/CQ cells; solid circles) selected aŌ er 6 months of culture 
in the presence of CQ. AnƟ proliferaƟ ve eﬀ ects (inhibiƟ on of cell growth) were assessed aŌ er 72 hours of 
exposure to CQ. Results are the mean of at least 4 separate experiments (SD <18%). (C) Stability of the CQ-
resistant phenotype of CEM/CQ cells. CEM/CQ cells (solid circles) were transferred in medium without CQ 
for periods of 3 weeks (squares), 3 months (triangles), and 7 months (diamonds). At these stages, CEM/
CQ cells were evaluated for CQ sensiƟ vity as described in B. CEM cells (open circles) are also shown as a 
reference. Results are the mean of 2 experiments performed in duplicate. (D) Reversal of CQ resistance by 
transport inhibitors of mulƟ drug resistance–associated protein 1 (MRP-1) but not of P-glycoprotein (P-GP). 
CEM/CQ cells (solid circles) were incubated in medium containing nontoxic concentraƟ ons of the MRP-1 
blockers MK571 (20 μM; squares) or probenecid (0.5 mM; triangles) or of the P-GP blocker verapamil (10 
μM; diamonds) and evaluated for CQ sensiƟ vity as described in B. CEM cells (open circles) are also shown 
as a reference. Results are the mean of at least 4 separate experiments (SD <20%). 
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Table 1: AnƟ proliferaƟ ve eﬀ ects of DMARDs and MDR-related and lysosomotropic drugs 
against CQ-and MTX-resistant CEM cells*.
Cell line
CEM/WT CEM/CQ CEM/MTXRFC↓ CEM/MTXRFC↓/CQ 
DMARD
CQ, μM 40.9 ± 6.0 (1) 131 ± 22 (3.2)† 25.0 ± 6.2 (0.6) 100 ± 25 (2.5)† 
MTX, nM 10.4 ± 2.5 (1) 8.4 ± 1.7 (0.8) 1,776 ± 309 (171) 1,471 ± 79 (141) 
SSZ, mM 0.43 ± 0.01 (1) 0.25 ± 0.06 (0.6)‡ 0.45 ± 0.05 (1) 0.28 ± 0.04 (0.6)‡ 
CSA, μM 4.4 ± 0.3 (1) 3.7 ± 0.3 (0.8) 5.4 ± 0.2 (1.2) 4.8 ± 1.0 (1.1) 
Lefl unomide, μM 22.2 ± 1.2 (1) 22.7 ± 2.2 (1) 23.7 ± 5.0 (1.1) 23.5 ± 4.9 (1.1) 
GlucocorƟ coids 
Dexamethasone, μM 0.038 ± 0.013 (1) 70.8 ± 9.8 (1,863)† 0.014 ± 0.003 (0.4) 81.8 ± 35.1 (5,842)† 
MDR drugs 
Doxorubicin, nM 12.7 ± 2.6 (1) 23.6 ± 9.3 (1.9)‡ 20.3 ± 6.9 (1.6) 44.9 ± 4.2 (3.5)‡ 
Daunorubicin, nM 9.9 ± 1.9 (1) 16.9 ± 2.9 (1.7)‡ 9.6 ± 0.2 (1) 19.5 ± 1.1 (2.0)† 
Miscellaneous 
Quinacrine, μM 1.8 ± 0.3 (1) 5.2 ± 1.0 (2.9)† 2.6 ± 0.4 (1.4) 5.7 ± 0.5 (3.2)† 
NH4Cl, mM 14.3 ± 2.7 (1) 15.8 ± 0.5 (1.1) 14.9 ± 2.1 (1) 14.8 ± 0.6 (1) 
Pyrimethamine, μM 2.0 ± 0.1 (1) 2.3 ± 0.3 (1.1) 0.6 ± 0.2 (0.3) 0.6 ± 0.2 (0.3) 
* Values are the mean ± SD drug concentraƟ on required to inhibit cell growth by 50% com-
pared with control (the IC50 value); values in parentheses are the resistance factor (the raƟ o of 
the IC50 value of the modifi ed CEM line to the IC50 value of the wild-type [WT] CEM line [CEM/
WT]). Results represent at least 3–7 separate experiments. DMARD = disease-modifying an-
Ɵ rheumaƟ c drug; MDR = mulƟ drug resistance; CQ = chloroquine; MTX = methotrexate; CEM/
CQ cells = CQ-resistant CEM cells; CEM/MTXRFC↓ cells = CEM cell line exhibiƟ ng MTX resistance 
due to defecƟ ve cellular uptake via the reduced folate carrier (RFC); CEM/MTXRFC↓/CQ cells = 
CQ-resistant CEM/MTXRFC↓ cells; SSZ = sulfasalazine; CSA = cyclosporin A. † P < 0.001 versus 
corresponding CEM/WT or non–CQ-resistant CEM/MTXRFC↓ cell line. ‡ P < 0.05 versus corre-
sponding CEM/WT or non–CQ-resistant CEM/MTXRFC↓ cell line. 
Stability of the CQ resistance phenotype in CEM/CQ cells
In order to assess whether the CQ resis tance phenotype was stable, CEM/CQ cells 
were grown in the absence of CQ for a period of up to 7 months. At intermediate 
Ɵ me points, CQ sensiƟ vity of the CEM/CQ cells was determined (Figure 1C). When 
CEM/CQ cells were grown in the absence of CQ for 3 weeks, the resistance pheno-
type was unchanged. AŌ er 3 months of growth in the absence of CQ, CEM/CQ cells 
sƟ ll retained CQ resistance, although the IC50 value decreased by approximately 50% 
compared with the starƟ ng value. AŌ er 7 months of CQ absence, sensiƟ vity of CEM/
CQ cells to CQ conƟ nued to shiŌ  toward the CQ sensiƟ vity of WT CEM cells, but did 
not fully reach this level. 
DMARD sensiƟ vity of CQ-resistant CEM cell lines 
To invesƟ gate whether the development of CQ resistance also had an impact on the 
cellular sensiƟ vity to other DMARDs, we analyzed the sensiƟ vity of CEM/CQ cells and 
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CEM/MTXRFC↓/CQ cells (anƟ proliferaƟ ve eﬀ ect) to MTX, lefl unomide, CSA, and SSZ 
(Table 1). Both CQ-resistant cell lines retained full sensiƟ vity to lefl unomide and CSA. 
CEM/CQ cells also displayed full sensiƟ vity to MTX, while inducƟ on of CQ resistance 
in CEM/MTXRFC↓ cells did not alter their MTX resistance phenotype. InteresƟ ngly, 
both CEM/CQ and CEM/MTXRFC↓/CQ cells displayed increased sensiƟ vity (1.7-fold; 
P < 0.01) to SSZ. Most strikingly, both CEM/CQ and CEM/MTXRFC↓/CQ cells displayed 
a high level of cross-resistance (1,863-fold and 5,842-fold, respecƟ vely; P < 0.001) 
to the glucocorƟ coid dexamethasone (Table 1). Resistance to dexamethasone was 
stable and was retained even aŌ er 6 months of growth in the absence of CQ (data 
not shown). 
DelineaƟ on of the mechanisƟ c basis of CQ resis tance in CEM/CQ cells. 
CQ has been shown to interact with drug eﬄ  ux proteins, including P-GP and MRP-
1, that can confer mulƟ drug resistance to structurally diverse agents (19,20). When 
mulƟ drug resistance-associated drug eﬄ  ux pumps are involved in CQ resistance, 
cross-resistance to potenƟ al P-GP/MRP-1 substrates (daunorubicin/doxorubicin) 
may be anƟ cipated. Indeed, CEM/CQ and CEM/MTXRFC↓/CQ cells displayed cross-
resistance to doxorubicin and daunorubicin (Table 1).
Based on its chemical property as a weak base, CQ is known for its lysosomotrop-
ic properƟ es leading to sequestraƟ on in acidic/lysosomal compartments (21). For 
this reason, we analyzed the sensiƟ vity of CEM/CQ and CEM/MTXRFC↓/CQ cells to 
pyrimethamine, a weak base anƟ folate inhibitor of DHFR, that can also be seques-
tered in lysosomes (22). In the event that CEM/CQ cells had an increased number 
of lysosomes, one could also expect resistance to compounds that alkalinize acidic 
compartments, including NH4Cl (21). The data shown in Table 1 do not indicate that 
lysoso motropic alkalinizaƟ on eﬀ ects played any role in CQ resistance, because no 
cross-resistance of CEM/CQ cells to pyrimethamine and NH4Cl was observed. 
Reversal of CQ resistance in CEM/CQ cells
If MRP-1 plays a role in conferring CQ resistance in CEM/CQ cells, we would ex-
pect that MRP-1 transport blockers, including probenecid (23) or the leukotriene D4 
analog MK571 (9), could reverse CQ resistance. Indeed, probenecid (0.5 mM) and 
MK571 (20 μM) reversed the CQ resistance phenotype in CEM/CQ cells (Figure 1D) 
and in CEM/MTXRFC↓/CQ cells (results not shown). In contrast, blocking of P-GP ef-
fl ux acƟ vity by verapamil (7.5 μM) (7) did not reverse CQ resistance in CEM/CQ cells 
(Figure 1D). This was also observed in CEM/MTXRFC↓/CQ cells (data not shown). In 
contrast, verapamil reversed vinblasƟ ne resistance 65-fold in P-GP–overexpressing 
CEM/VLB100 cells (data not shown). 
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Figure 2: (A) Expression of mulƟ drug resistance (MDR) proteins in CQ-resistant CEM/CQ cells compared 
with that in wild-type CEM cells (CEM/WT cells). Cell lysates were prepared as described in Materials and 
Methods. For both cell lines, equal loadings of cell lysate protein (50 μg) and MDR control cell line lysate 
(10 μg) were applied onto the sodium dodecyl sulfate (SDS) polyacrylamide gel. An indicaƟ on of the rela-
Ɵ ve level of expression of the various MDR proteins within each cell line can be obtained from the indicated 
Ɵ me of enhanced chemiluminescence exposure for each of the MDR protein immunoblots (1 minute for 
MRP-1, also called ATP-binding casseƩ e protein C1 [ABCC1]; 5 minutes for MRP-4, also called ABCC4; and 
10 minutes for MRP-5, P-GP, and breast cancer resistance protein [BCRP], also called ABCC5, ABCB1, and 
ABCG2, respecƟ vely). Reprobing with β-acƟ n was performed in order to normalize for any protein loading 
diﬀ erences. (B) MRP-1 expression in total cell lysates of CEM cells (lane C), CEM/CQ cells (lane D), a CEM 
cell line exhibiƟ ng methotrexate (MTX) resistance due to defecƟ ve cellular uptake via the reduced folate 
carrier (RFC) (CEM/MTXRFC↓ cells) (lane E), CQ-resistant CEM/MTXRFC↓ cells (CEM/MTXRFC↓/CQ cells) (lane F), 
a CEM cell line with resistance to MTX via an overexpression of the target enzyme dihydrofolate reductase 
(DHFR) (CEM/MTXDHFR↑ cells) (lane G), and a CEM cell line with resistance to MTX via a decreased acƟ vity of 
folylpolyglutamate synthetase (FPGS) (CEM/MTXFPGS↓ cells) (lane H). Cell lysates of 2008 cells (lane A) and 
2008 cells transfected with MRP-1 (2008/MRP-1 cells) (lane B) served as controls. For all cell lines, equal 
quanƟ Ɵ es of cell lysates (50 μg) were applied onto the SDS polyacrylamide gel, except for the 2008/MRP-1 
cell line, for which 10 μg of cell lysate was used. MRP-1 was detected with the monoclonal anƟ body MRPr1 
(16). AddiƟ onal details are provided in Materials and Methods. (C) CorrelaƟ on between MRP-1 expression 
in the panel of CQ-and MTX-resistant CEM cells (relaƟ ve to MRP-1 expression in CEM/WT cells) and the 
anƟ proliferaƟ ve eﬀ ect of CQ, measured as the drug concentraƟ on required to inhibit cell growth by 50% 
compared with untreated controls (IC50). See Figure 1 for other defi niƟ ons. 
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MDR protein expression in CEM, CEM/CQ, and MTX-resistant CEM 
cells
Western bloƫ  ng analysis was performed to demonstrate that MRP-1 protein expres-
sion was indeed markedly increased in CEM/CQ cells compared with parental CEM 
cells (Figure 2A). Furthermore, we analyzed whether CEM/CQ cells displayed altered 
protein expression of other MDR-associated drug eﬄ  ux pumps, including MRP-2 (re-
sults not shown), MRP-3 (results not shown), P-GP, and BCRP; however, expression 
levels of these MDR transporters were below the limit of detecƟ on, as in WT CEM 
cells (Figure 2A). InteresƟ ngly, unlike up-regulaƟ on of MRP-1, expression of MRP-4 
and MRP-5 appeared to be down-regulated in CQ-resistant CEM cells (Figure 2A). 
MRP-1 protein expression by Western bloƫ  ng was also evaluated in a broader panel 
of MTX-and CQ-resistant CEM lines (Figure 2B). Variable expres sion of MRP-1 (190 
kd) was noted in the panel of CEM lines; the basal level of expression of MRP-1 in 
WT CEM cells (lane C) was 6-fold lower than in the reference cell line 2008 cells (lane 
A). CEM/CQ cells (lane D) displayed a marked overexpression of MRP-1 (4.6-fold), 
whereas CEM/MTXRFC↓ cells (lane E) had a lower expression (0.7-fold) than WT CEM 
cells. AcquisiƟ on of CQ resistance in CEM/MTXRFC↓ cells induced MRP-1 expression 
almost 4-fold (lane F). InteresƟ ngly, 2 addiƟ onal CEM cell lines previously selected 
for MTX resistance (see Materials and Methods) due to increased DHFR levels (lane 
G) or decreased polyglutamylaƟ on capacity (lane H) also had elevated expression of 
MRP-1 (5.2-fold and 3.5-fold, respecƟ vely, compared with WT CEM cells), and this 
was accompanied by a 2.4-fold (P < 0.001) and 2.6-fold (P < 0.001) lower sensiƟ vity 
to CQ, respecƟ vely, compared with WT CEM cells. Overexpression of MRP-1 in the 
panel of CQ- and MTX-resistant CEM lines correlated posiƟ vely (R2 = 0.89, P = 0.004) 
with the anƟ proliferaƟ ve eﬀ ects (IC50) of CQ (Figure 2C). 
Mechanism of cross-resistance to glucocorƟ coids in CQ-resistant cells 
To further explore the mechanism of glucocorƟ coid resistance in CQ-resistant CEM 
cells (Table 1), we invesƟ gated the possible contribuƟ ons of MDR proteins (10), nota-
bly P-GP and MRP-1, but neither of them appeared to be involved based on observa-
Ɵ ons that blockers of these MDR proteins (verapamil and MK571, respecƟ vely) failed 
to reverse dexamethasone resistance (not shown). We next determined whether 
down-regulaƟ on of GRα could account for dexamethasone resistance (24). Western 
bloƫ  ng analysis (Figure 3A) and 3H-dexamethasone binding studies (Figure 3B) re-
vealed that GRα levels were indeed decreased (2–3-fold) in CQ-resistant CEM and 
CEM/MTXRFC↓ cells. However, this eﬀ ect is not likely to fully explain the glucocorƟ -
coid resistance phenotype, since CQ-resistant CEM and CEM/MTXRFC↓ cells that were 
grown in the absence of CQ for >6 months (lanes C and F, respecƟ vely, in Figure 3A) 
sƟ ll retained glucocorƟ coid resistance and had comparable levels of GRα compared 
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with parental cells (lanes A and D, respecƟ vely, in Figure 3A). 
Since impaired acƟ vity of glucocorƟ coids has also been described in relaƟ on to de-
fecƟ ve crosstalk with specifi c signaling pathways (e.g., protein kinase A [PKA], cAMP, 
and phosphaƟ dylinositol 3-kinase) (25), we invesƟ gated whether acƟ vaƟ on of these 
pathways had an eﬀ ect on dexamethasone resistance. InteresƟ ngly, when CQ-re-
sistant cells were incubated in the presence of the cAMP-inducing agent forskolin, 
dexamethasone sensiƟ vity was fully restored, both in CEM/CQ cells (Figure 4A) and 
in CEM/MTXRFC↓/CQ cells (Figure 4B), as well as in cells that were grown in the ab-
sence of CQ for 6 months. Of note, when CQ-resistant cells were preincubated with 
forskolin for 72 hours, washed, and then analyzed for dexamethasone sensiƟ vity for 
72 hours in forskolin-free medium, no restoraƟ on of dexamethasone sensiƟ vity was 
observed (data not shown). These results indicate that when cAMP levels drop upon 
removal of forskolin, the dexamethasone cross-resistant phenotype of CQ-resistant 
cells remains unaltered. 
A       B      C           
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CEM/WT
?-Actin ? CEM/Dexa
D      E       F CEM/CQ
CEM/WT
GR-? ?
CEM/MTXRFC?/CQ
CEM/MTXRFC?
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Glucocorticoid receptor number/cell (x 103)   
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Figure 3: (A) Expression of glucocorƟ coid receptor α (GRα) in total cell lysates of CEM/WT cells (lane A), 
chloroquine (CQ)–resistant CEM cells (CEM/CQ cells) (lane B), CEM/CQ cells grown in the absence of CQ 
for 6 months (lane C), CEM/MTXRFC↓ cells (lane D), CEM/MTXRFC↓/CQ cells (lane E), and CEM/MTXRFC↓/CQ 
cells grown in the absence of CQ for 6 months (lane F). (B) 3H-dexamethasone–GR binding (expressed as GR 
number per cell) for CEM/WT cells, CEM/CQ cells, CEM/MTXRFC↓ cells, and CEM/MTXRFC↓/CQ cells. A subline 
of CEM cells (CEM/Dexa cells) with acquired resistance to dexamethasone (>1,000-fold) that exhibited <7% 
of 3H-dexamethasone–GR binding capacity served as a control. Results are the mean of 2 experiments 
performed in duplicate. See Figure 2 for other defi niƟ ons. 
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Eﬀ ect of CQ resistance on TNFα and IL-8 secreƟ on
The eﬀ ect of CQ resistance on the release of proinfl ammatory cytokines (TNFα) and 
chemokines (IL-8) was invesƟ gated following 24 hours of cellular sƟ mulaƟ on with 
PMA and ionomycin. TNFα secreƟ on from CEM/MTXRFC↓/CQ cells was markedly 
reduced compared with that in their WT counterparts (94%; P < 0.001), and IL-8 
secreƟ on was markedly reduced both in CEM/CQ cells and in CEM/MTXRFC↓/CQ cells 
compared with that in their WT counterparts (>95%; P < 0.001 for both) (Figure 5). 
DISCUSSION 
The present study shows that in an in vitro model of immune eﬀ ector cells (CEM 
cells), the development of CQ resistance is conferred by overexpression of MRP-1, a 
mulƟ drug eﬄ  ux pump. Furthermore, other CEM cells, previously selected for resis-
tance to MTX, also displayed cross-resistance to CQ via MRP-1 over-expression. Both 
CQ-resistant cell types were characterized by a marked cross-resistance to the glu-
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Figure 4: Eﬀ ect of forskolin on reversal of dexamethasone cross-resistance in chloroquine (CQ)–resistant 
CEM cells (A) and in CQ-resistant CEM/MTXRFC↓ cells (B). Circles represent CEM/WT cells and non–CQ-
resistant CEM/MTXRFC↓ cells. Open squares represent CQ-resistant sublines. Solid squares represent CQ-
resistant sublines coincubated for 72 hours with 20 μM forskolin. Open triangles represent CQ-resistant 
cells cultured for 6 months in the absence of CQ. Solid triangles represent CQ-resistant cells cultured for 6 
months in the absence of CQ and coincubated for 72 hours with 20 μM forskolin. InhibiƟ on of cell prolifera-
Ɵ on was assayed aŌ er 72 hours of exposure to dexamethasone in the presence or absence of forskolin. 
Results are the mean of 3 experiments (SD <29%). See Figure 2 for other defi niƟ ons. 
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cocorƟ coid dexamethasone, and they exhibited impaired secreƟ on of TNFα and IL-8. 
MRP-1 is a well-established member of the superfamily of transporters and has an 
important role in mediaƟ ng resistance to several anƟ cancer drugs and toxic com-
pounds (7,9). Whether mulƟ drug resistance transporters can also contribute to the 
lack of eﬃ  cacy of anƟ rheumaƟ c drugs is an understudied issue (10,26,27), although 
the results of a large meta-analysis of 110 studies indicated that the majority of dis-
conƟ nuaƟ ons of the DMARDs CQ and SSZ resulted from lack of eﬃ  cacy (6,28). 
The DMARD CQ has been studied in depth for its anƟ malarial mode of acƟ on and re-
sistance (8). In Plasmodium falciparum malaria, CQ resistance is mediated in part by 
mutaƟ ons in the pfmdr1 gene, which encodes for a lysosomal membrane protein in 
the parasite that shares homology with the ABC transporter P-GP (8). In mammalian 
cells, CQ has been idenƟ fi ed as a substrate/modulator of P-GP (19,29). InteracƟ ons of 
CQ with MRP-1 were inferred from observaƟ ons that MRP-1–overexpressing mam-
malian cells displayed resistance to CQ (20). Along these lines, we demonstrated in 
the present study that inducƟ on of MRP-1 overex pression was the mechanisƟ c basis 
for CQ resistance in CEM cells when these cells were exposed to clinically achievable 
TNF?? IL?8
CEM/WT
CEM/CQ
CEM/MTXRFC?
CEM/MTXRFC?/CQ
(%?of?CEM/WT) (%?of?CEM/WT)
Figure 5: Release of tumor necrosis factor α (TNFα) and interleukin-8 (IL-8) from CEM/WT cells and CEM/
MTXRFC↓ cells and their chloroquine (CQ)–resistant counterparts aŌ er 24 hours of sƟ mulaƟ on with phorbol 
12-myristate 13-acetate and ionomycin. TNFα and IL-8 release was measured in supernatants by enzyme-
linked immunosorbent assay. Results are the mean and SD of 3–5 separate experiments. CEM/CQ cells = 
CQ-resistant CEM cells (see Figure 2 for other defi niƟ ons).
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concentraƟ ons of CQ (30) for a period of up to 6 months. Evidence for a direct role 
of MRP-1 in CQ resistance was based on 1) independent up-regulaƟ on of MRP-1 ex-
pression during acquisiƟ on of CQ resistance both in CEM cells and in CEM/MTXRFC↓ 
cells, 2) reversal of CQ resistance by the MRP-1 transport blockers probenecid and 
MK571, and 3) a correlaƟ on of MRP-1 expression with CQ sensiƟ vity for CQ-selected 
and non–CQ-selected (MTX-resistant) CEM cells. 
It is important to note that acquisiƟ on of CQ resistance did not result in a concomi-
tant loss of sensiƟ vity to a series of other DMARDs, including MTX, CSA, lefl unomide, 
and SSZ. InteresƟ ngly, CQ-resistant cells were even more sensiƟ ve to SSZ than were 
CEM and CEM/MTXRFC↓ cells. Based on observaƟ ons that mammalian cells displaying 
MRP-1 overexpression were resistant to short-term exposures to MTX (23), CEM/CQ 
cells could have exhibited resistance to MTX. However, this was not observed, which 
could have been due to the fact that in contrast to MRP-1, expression of 2 other 
potenƟ al MTX eﬄ  ux proteins, MRP-4 and MRP-5 (10), was down-regulated in CEM/
CQ cells. 
Most interesƟ ng was the marked cross-resistance to glucocorƟ coids in CQ-resistant 
cells. Although the issue of glucocorƟ coid resistance in RA treatment is less well stud-
ied than in cancer treatment (24,31), it has been recognized to be of clinical impor-
tance in RA treatment as well (32,33). In the treatment of paƟ ents with systemic 
lupus erythematosus, drug combinaƟ ons of CQ and prednisone have also been used 
without apparent signs of drug resistance (34). However, the possibility cannot be 
excluded that other Ɵ me and dosing schedules of CQ in a clinical seƫ  ng may confer a 
less pronounced level of glucocorƟ coid cross-resistance than reported here for CEM 
cells in vitro. To date, no systemaƟ c clinical studies that address this point have been 
reported. 
It is of interest that chronic exposure to CQ appeared to confer a phenotype of a 
non–GRα expression–dependent glucocorƟ coid resistance similar to that previously 
observed with prolonged dexamethasone treatment, which could be restored by 
PKA acƟ vaƟ on by forskolin (35). MechanisƟ cally, it is also possible that one of the 
nonlysosomotropic modes of acƟ on of CQ (i.e., inhibiƟ on of the MAP kinase signaling 
pathway [36,37]) has down-regulated signaling and interacƟ ons with GRα (25,33). 
SƟ mulaƟ on of PKA acƟ vity by forskolin could then, temporarily, restore GR-glucocor-
Ɵ coid–induced apoptosis and anƟ proliferaƟ ve eﬀ ects. Taken together, these results 
indicate that long-term exposure to CQ can convey secondary eﬀ ects of markedly 
diminished acƟ vity of glucocorƟ coids, via a mechanism that has thus far only been 
described to occur aŌ er long-term glucocorƟ coid exposure. 
The issue of drug resistance as the molecular basis of failure of DMARD therapy 
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(10,26,27) has been addressed in a limited number of small-scale clinical studies. 
Moreover, these studies focused mainly on the MDR transporter P-GP rather than 
on MRPs. An increased expression of P-GP was noted in lymphocytes of RA paƟ ents, 
which could have contributed to failure of treatment with SSZ and bucillamine (38), 
prednisolone (39,40), and possibly MTX (41). These clinical studies, however, did not 
resolve the issue of whether up-regulaƟ on of P-GP was due either to a drug-induced 
process and/or to an infl ammaƟ on-induced process. In this respect, P-GP expres-
sion is controlled by acƟ vaƟ on and transcripƟ onal regulaƟ on of NF-κβ (42), the key 
regulator of transcripƟ on of various infl ammatory genes such as TNFα. Moreover, 
TNFα itself was able to induce MRP-1 expression in mammalian cells (43). There is 
evidence of crosstalk between mulƟ drug resistance transporters, proinfl ammatory 
cytokines, and DMARDs. From this perspecƟ ve, further insight will be required to 
establish a direct or indirect relaƟ onship between MDR protein expression profi le 
and the aberrant profi le of TNFα and IL-8 release, or vice versa, in CQ-resistant cells. 
MRP-1 and P-GP belong to the superfamily of 48 ABC transporter proteins (9). The 
physiologic funcƟ on of most of these ABC transporters and their possible role in drug 
resistance remain to be elucidated. ABC transporter proteins currently idenƟ fi ed to 
play a role in resistance to anƟ cancer drugs include the subfamily of MRPs (MRPs 
1–6), P-GP, and BCRP (9,29). With respect to DMARDs, MRPs 1–5 and BCRP were im-
plicated in conferring resistance to MTX, and MRP-5 has been involved in resistance 
to azathioprine, while BCRP was shown to be involved in resistance to SSZ (10,15,44). 
Finally, resistance to gold compounds does not seem to be mediated by MDR pro-
teins (10). 
In addiƟ on to a pharmacologic role of MDR transporters in cellular extrusion of 
drugs/toxic compounds, there is cumulaƟ ve evidence that MDR transporters may 
play an important physiologic role in infl ammatory/immunologic processes (10). Me-
diators of infl ammaƟ on such as platelet-acƟ vaƟ ng factor and (cysteinyl) leukotrienes 
(e.g., leukotriene C4) are physiologic substrates of P-GP and MRP-1, respecƟ vely (45). 
In fact, funcƟ onal P-GP and MRP-1 acƟ vity is necessary to trigger chemokine-depen-
dent mobilizaƟ on of dendriƟ c cells to lymph nodes aimed at enhancing the immune 
response (45,46). Conversely, MRP-1-knockout mice displayed a markedly impaired 
response to an infl ammatory sƟ mulus (47). 
Hence, MRP-1 overexpression upon acquisiƟ on of either CQ or MTX resistance could 
have a dual eﬀ ect. On the one hand, MRP-1 may diminish the anƟ proliferaƟ ve/im-
munosuppressive eﬀ ect of CQ by increased drug eﬄ  ux. On the other hand, increased 
MRP-1 expression may result in enhanced transport of natural substrates that can 
promote an immune response. Given the fact that MRP-1 is consƟ tuƟ vely expressed 
on human blood lymphocytes (48) and dendriƟ c cells (46), this may imply that CQ-
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or other DMARD-induced alteraƟ ons in MRP-1 expression could infl uence the func-
Ɵ onal infl ammatory/immunologic properƟ es of these cells. However, it should be 
menƟ oned that with the onset of CQ resistance, other (signaling) pathways may also 
be compromised as shown in the present study for TNFα and IL-8, in altered secre-
Ɵ on of proinfl ammatory cytokines and chemokines. The reduced producƟ on of TNFα 
in conjuncƟ on with resistance to CQ should be a desirable eﬀ ect, but it sƟ ll needs to 
be confi rmed in a clinical seƫ  ng. 
In conclusion, although the issue of drug resistance has received much aƩ enƟ on 
from the perspecƟ ve of neoplasƟ c and infecƟ ous diseases, it is not exclusively rel-
evant to these diseases. The expanding knowledge of the physiologic substrates and 
funcƟ ons of an increasing number of mulƟ drug resistance transporters, along with 
their tentaƟ ve role in infl ammatory and immunologic processes (10,45), deserves 
further aƩ enƟ on, parƟ cularly in diseases such as RA, in which paƟ ents receive long-
term treatment with DMARDs. The present study also indicates potenƟ al types of 
drug interacƟ ons or secondary eﬀ ects of DMARD combinaƟ ons in RA treatment, as 
we have previously demonstrated for a combinaƟ on of MTX and SSZ (49). HCQ has 
proven to be an aƩ racƟ ve drug in DMARD combinaƟ on treatment for RA (4,13), but 
its long-term use may compromise the acƟ vity of other anƟ -infl ammatory drugs, par-
Ɵ cularly glucocorƟ coids. In vitro models like the one described in the present study 
can be of further assistance in addressing quesƟ ons concerning the onset of DMARD 
resistance, molecular mechanisms and stability of resistance, evasion/circumvenƟ on 
of resistance, and implicaƟ ons for cytokine producƟ on. UlƟ mately, this informaƟ on 
should be further exploited in a clinical seƫ  ng (50).
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Summary
Background: GlucocorƟ coids (GCs) are commonly used in the treatment of (chro-
nic) infl ammatory diseases and cancer, but inherent or acquired resistance to these 
drugs limits their opƟ mal eﬃ  cacy. The availability of drugs that could modulate GC 
resistance is therefore of potenƟ al clinical interest. 
ObjecƟ ve: To explore the molecular basis of GC sensiƟ saƟ on of GC resistant monocy-
Ɵ c/macrophage cells aŌ er chronic exposure to sulfasalazine.
Methods: Human monocyƟ c/macrophage THP1 and U937 cells represent a cell line 
model system characterized by inherent resistance to the GCs dexamethasone and 
prednisolone. Both cell lines were chronically exposed in vitro to 0.3-0.6mM sulfasa-
lazine (SSZ) for approximately 3 months, aŌ er which they were characterized for GC 
sensiƟ vity, expression levels of GC-receptor and components of the nuclear factor 
Kappa-β (NFβ) signaling pathway, and their ability to undergo GC induced apopto-
sis.
Results: Chronic exposure to SSZ markedly sensiƟ sed both U937 and THP1 cells to 
dexamethasone (781- and 1389-fold, respecƟ vely) and prednisolone (562- and 1,220-
fold, respecƟ vely). RestoraƟ on of GC sensiƟ vity in cells exposed to SSZ was provoked 
via GC induced apoptosis, coinciding with inhibiƟ on of NFβ acƟ vaƟ on. Moreover, 
western blot analysis revealed a markedly increased expression of glucocorƟ coid re-
ceptor  (GR) in cells exposed to SSZ. Since GR mRNA levels were only marginally 
increased, these results suggest that an altered post-transcripƟ onal mechanism was 
operable which conferred a stable GRprotein on SSZe exposed cells.
Conclusion: These results suggest that chronic targeƟ ng of the NFB signaling path-
way by SSZ may be exploited as a novel strategy to stabilize GR expression and 
thereby sensiƟ se primary resistant cells to GCs.
IntroducƟ on
The anƟ -infl ammatory and anƟ proliferaƟ ve properƟ es of glucocorƟ coids (GCs) in-
cluding prednisolone and dexamethasone have led to their widespread use in the 
treatment of (chronic) infl ammatory diseases such as rheumatoid arthriƟ s (RA) as 
well as several human cancers (eg, acute lymphoblasƟ c leukemia) (1-3). The mecha-
nisƟ c basis for the anƟ -infl ammatory and anƟ cancer eﬀ ects of GCs involves an inter-
acƟ on with cytosolic glucocorƟ coid receptor (GR) (4, 5). Upon nuclear translocaƟ on, 
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the GC-GR complex can bind to GC responsive elements in the promoter region of 
several genes which control expression of both cell death/apoptosis proteins and 
pro-infl ammatory cytokines such as tumour necrosis factor  (TNF) (2, 6, 7). More-
over, GR can physically interact and antagonise transcripƟ on factors, including AP-1 
and nuclear factor Kappa β (NFβ), which facilitate transcripƟ on of pro-infl ammatory 
and anƟ apoptoƟ c genes (4, 5, 8). At least three isoforms of GR have been reported 
- GR, GR and GR (9-12) of which only the -isoform is capable of high aﬃ  nity GC 
binding. The -isoform lacks the high aﬃ  nity GC binding capacity and is known as a 
dominant negaƟ ve regulator of GR. The funcƟ onal and biological signifi cance of 
GR is not yet clear (13). 
The eﬃ  cacy of GCs can be limited by primary or acquired resistance (9, 14-19). Sev-
eral modes of resistance to GC induced apoptosis have been described (2, 9, 17, 
18, 20) including (1) enhanced drug eﬄ  ux via the mulƟ drug resistance transporter 
P-glycoprotein, (2) enhanced metabolism by 11-hydroxysteroid-dehydrogenase, (3) 
downregulaƟ on of GR expression, (4) an increased raƟ o of GR over GR expression, 
(5) post-transcripƟ onal modifi caƟ ons of GR resulƟ ng in reduced GC binding aﬃ  nity, 
or (6) impaired GC induced apoptosis. Several of these mechanisms have been found 
responsible for inherent clinical resistance to GCs (14, 15, 21). ElucidaƟ on of the mo-
lecular basis underlying GC sensiƟ vity and resistance is therefore of key importance 
in improving the eﬃ  cacy of GCs for treatment of infl ammatory and malignant dis-
eases. 
In clinical rheumatology, the addiƟ on of prednisolone to a drug combinaƟ on of 
methotrexate (MTX) and sulfasalazine (SSZ), also known as the COBRA combinaƟ on, 
appeared to be markedly more eﬀ ecƟ ve than SSZ+MTX alone (22-24). These obser-
vaƟ ons suggested that SSZ, which inhibits the acƟ vaƟ on of the transcripƟ on factor 
NFB (25-27), and MTX are capable of condiƟ oning cells for enhanced prednisolone 
acƟ vity. Recent studies from our laboratory showed that chronic exposure of the 
human (T lymphocyƟ c) cell line CCRF-CEM to SSZ markedly enhanced its primary 
sensiƟ vity to dexamethasone (by 10-20 fold) (28, 29). This observaƟ on prompted us 
to invesƟ gate whether chronic exposure to SSZ would also provoke restoraƟ on of GC 
sensiƟ vity in myeloid cells with inherent resistance to GCs.
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Materials and Methods
Materials
Dexamethasone, prednisolone, sulfasalazine, RU486 and etoposide (VP-16) were ob-
tained from Sigma Chem Co, St Louis, Co, U.S.A. 
Cell culture
Human THP1 and U937 (monocyƟ c/macrophage) and CCRF-CEM (T lymphocy-
Ɵ c) cell lines (ATCC,  Manassas, Virginia, USA) were cultured in RPMI-1640 medi-
um supplemented with 10% fetal calf serum, 2mM L-glutamine and 100 μg/ml 
penicillin+streptomycin. Cell cultures were seeded at an iniƟ al density of 3 x 105 cells/
ml and refreshed bi-weekly. 
Exposure of parental/wild type (WT) U937 and THP1 cells to SSZ was performed es-
senƟ ally as described in detail by De Bruin et al (30). Briefl y, THP1 and U937 cells 
were iniƟ ally incubated with a concentraƟ on of SSZ (0.4 mM and 0.3 mM, respecƟ ve-
ly) that conveyed a 50% growth inhibitory eﬀ ect. Following 2-3 weeks of adaptaƟ on 
to these SSZ levels, SSZ concentraƟ ons were gradually increased to 0.6 mM for both 
cell lines over a period of another 2.5 months. At this stage, cells had unchanged 
doubling Ɵ mes and unchanged phenotypic properƟ es compared with parental cells 
(30). Cells kept at 0.6 mM SSZ (further designated as THP1/SSZ and U937/SSZ) were 
used for further characterizaƟ on of GC sensiƟ vity.
Cell growth inhibiƟ on assays
Growth inhibiƟ on by dexamethasone and prednisolone was assessed by plaƟ ng 1.25 
x 105 cells/ml in individual wells of a 24-well plate (Costar) containing 1 ml of medium 
per well and up to 50 μl of drug soluƟ on. InhibiƟ on of cell growth was determined 
aŌ er 72 hours drug exposure followed by viable cell counƟ ng using a hemocytometer 
and trypan blue exclusion. The drug concentraƟ on required to inhibit cell growth by 
50% compared with control growth is defi ned as IC50. 
Western blot analysis
Cells were harvested in the mid-log phase of growth and washed 3 Ɵ mes with ice-
cold HEPES buﬀ ered saline pH 7.4. Total cell lysates of were prepared by suspending 
107 cells in 500 μl of lysis buﬀ er containing: 50 mM Tris-HCl (pH 7.6), 5 mM dithi-
otreitol, 20 μl PIC (Protease Inhibitor Cocktail (Boehringer Mannheim, Germany), 1 
tablet/ml H2O), 20% glycerol and 0.5% NP-40). The suspension was sonicated (MSE 
sonicator, amplitude 6, for 3 x 5 seconds with 30 seconds Ɵ me intervals at 4oC) and 
centrifuged in an Eppendorf microcentrifuge (10 min, 14,000 rpm, 4oC). Protein con-
tent of the supernatant was determined by the Bio-Rad Protein Assay Dye Reagent 
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(Bio-Rad 500-0006). FiŌ y microgram of total cell lysates were fracƟ onated on a 7.5% 
polyacrylamide gel containing SDS and transferred onto a nitrocellulose membrane. 
The nitrocellulose membranes were pre-incubated overnight at 4oC in blocking buﬀ er 
[5% Bio-Rad Blocker in TBS-T (10 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% Tween-20] 
to prevent non-specifi c anƟ body binding. The membranes were then incubated for 1 
hour at room temperature with the primary anƟ bodies (Santa Cruz Biotechnology via 
Tebu-bio, Heerhugowaard, The Netherlands) for GR (sc-1003, 1: 500), NFB p65 (sc-
8008, 1: 1000), NFβ p50 (sc-8414, 1:1000) or IkB (sc-1643, 1: 500). As a control for 
protein loading, -acƟ n (1:3,000, MAB1501R anƟ body from Chemicon InternaƟ onal, 
Ca, U.S.A.) was used. AŌ er 3 washing steps with TBS-T, membranes were incubated 
for 1 hour with HRP-labeled anƟ -rat/mouse (1:2000 for GR, NFβ p65, NFβ p50 
and IkB, and 1:3000 for -acƟ n) as a secondary anƟ body (DAKO, p0447). AnƟ body 
reacƟ vity was followed by enhanced chemiluminescence (ECL, Amersham Pharmacia 
Biotech RPN 2106) according to the manufacturer’s instrucƟ ons. Signal intensity was 
determined densitometrically (soŌ ware QuanƟ ty One, Bio-Rad) and expressed rela-
Ɵ ve to the intensity of the -acƟ n signal. 
RT-PCR
Real-Time PCR (RT-PCR) was performed using a Taqman 7000 apparatus (Applied 
Biosystems, Foster City, CA, USA). Primers and probes were designed using Primer 
Express soŌ ware (Applied Biosystems). All probes were labeled with 5’-FAM as a 
reporter. GR and GR probes were labeled with 3’-TAMRA as a quencher, while 
NFβp65 was labeled with 3’-Dabsyl. The following primers and probe combinaƟ ons 
were used: 
GR FW 5’-tgacaaaactcƩ ggaƩ ctatgca-3’ (500 nM); 
GR probe 5’-aagtggƩ gaaaatctccƩ aactaƩ gcƩ ccaaac-3’ (275 nM); 
GR RV 5’-Ʃ caatactcatggtcƩ atccaaaa-3’ (700 nM); 
GR FW 5’-gcagcggƩ Ʃ atcaactgaca-3’ (500 nM); 
GR probe 5’-aactcƩ ggaƩ ctatgcatgaaaatgƩ atgtggƩ a-3’ (100 nM); 
GR RV 5’-tgtgtgagatgtgcƩ tctggƩ -3’ (900 nM); 
NFβp65 FW 5’-gaccƩ caagagcatcatgaagaa-3’ (900 nM); 
NFβp65 probe 5’-agtccƩ tcagcggacccaccga-3’ (200 nM); 
NFβp65 RV 5’-cgaggtggaggccgg-3’ (700 nM). 
All samples were normalized against 2-microglobulin (2M) levels: 
β2M FW 5’-agatagƩ aagtgggatcgagacatgt (500 nM)-3’; 
β2M probe 5’-agcagcatcatggaggƩ tgaagatgcc-3’ (125 nM); 
β2M RV 5’-agcagaaƩ tggaaƩ catccaa-3’ (700 nM). 
The PCR reacƟ on was as follows: 2min at 500C, 10min at 950C, 50 cycles of 15 sec at 
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950C – 1min at 600C. All PCRs were performed with comparable eﬃ  ciencies (>95%).
Assay of Apoptosis 
THP-1 and U937 cells (1.5 x 105/well) were incubated (24-well plates; 1ml medium) 
with dexamethasone for 24-96 hours. At selected Ɵ me intervals, 2 x 104 cells were 
harvested and analyzed by fl ow cytometry (FACS Calibur, Beckton Dickinson, USA) 
for early apoptosis by Annexin-V-FITC staining (APOPTESTTM-FITC A-700, VPS Diagnos-
Ɵ cs, Hoeven, The Netherlands) and late apoptosis by 7-amino-acƟ nomycin D (7-AAD) 
staining (BD PharMingen, BD Biocsciences, Alphen aan de Rijn, The Netherlands) ac-
cording to manufacturer’s protocol. Human CCRF-CEM leukemia T- cells were used as 
a posiƟ ve control for GC induced apoptosis. In addiƟ on, VP-16 (etoposide) was used 
as a control drug for inducƟ on of apoptosis. Finally, ZVAD-fmk (10-50 μM; Alexis Bio-
chemicals, Breda, The Netherlands) was used as a broad spectrum caspase inhibitor 
and added to cells 1 hour prior to exposure to GC or VP-16. 
NFkβ binding acƟ vity assay
NFβ binding acƟ vity was measured using the EZ-Detect NFκβ p65 TranscripƟ on 
Factor Kit (Pierce, Rockford, IL, USA). Briefl y, nuclear extracts of all samples were 
prepared according to manufacturer’s instrucƟ ons (NE-PER Nuclear and Cytoplasmic 
ExtracƟ on Reagents, Pierce). Nuclear extracts were incubated for 1 hour in an ELISA 
plate coated with NFβ bioƟ nylated-consensus DNA sequence to which only acƟ ve 
NFκβ p65 protein can bind. As a posiƟ ve control, 2 μl of TNF-acƟ vated HeLa cell nu-
clear extract was used. AŌ er binding, primary anƟ body against NFβ p65 was added 
and incubated for 1 hour, followed by secondary HRP-conjugated anƟ body for 1 hour. 
AŌ erwards, luminol/enhancer soluƟ on and stable peroxide soluƟ on were added and 
chemoluminescence was detected using a luminometer.
StaƟ sƟ cal analysis
StaƟ sƟ cal signifi cance of diﬀ erences was analyzed by ANOVA using SPSS 9.0 compu-
ter soŌ ware. A p-value ≤ 0.05 was considered to be staƟ sƟ cally diﬀ erent.
Results
SensiƟ saƟ on of myeloid cells to GCs by chronic exposure to SSZ
Human THP1 and U937 cells are refractory to growth inhibiƟ on by the GCs dexame-
thasone  (IC50 > 25μM) and prednisolone (IC50 > 500μM) (Figure 1). In order to mimic 
the clinical situaƟ on of cellular exposure to dose-escalaƟ ons of SSZ, THP1 and U937 
cells were grown in gradually increasing, clinically achievable (31-33) concentraƟ ons 
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of SSZ (0.3-0.6mM) over a period of 3 months (30). The cells were then analyzed 
again for GC sensiƟ vity (Figure 1), revealing a three orders of magnitude sensiƟ sa-
Ɵ on of both THP1/SSZ and U937/SSZ cells for dexamethasone (IC50 0.018 ± 0.007 M 
and 0.032 ± 0.012M, respecƟ vely) and prednisolone (IC50 0.41 ± 0.23 M and 0.89 
± 0.07 M, respecƟ vely). For U937/SSZ, GC sensiƟ vity was retained for more than 
one year when cells were grown in the absence of SSZ (data not shown). For THP1/
SSZ cells, GC sensiƟ vity was retained for 4 months of cell growth in the absence of 
SSZ, aŌ er which the cells gradually regained their original GC resistance (Figure 2A). 
InteresƟ ngly, when these cells were challenged again with SSZ, they rapidly regained 
their GC-sensiƟ ve phenotype in < 2 weeks (Figure 2B).  
Figure 1: Reversal of inherent glucocorƟ coid resistance in THP1 and U937 monocyƟ c/macrophage cells 
induced by chronic exposure to sulfasalazine (SSZ).
AnƟ proliferaƟ ve eﬀ ect aŌ er 72 h exposure of (A, B) dexamethasone and (C, D) prednisolone against THP1/
WT (open circles), U937/WT cells (open triangles) and their counterparts chronically exposed to SSZ for 3 
months (closed symbols). Results of fi ve independent experiments (SD ,25%).
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GC induced apoptosis in cells exposed to SSZ
GCs can exert their anƟ proliferaƟ ve eﬀ ect by inducing apoptosis. Flow cytometric 
analysis of Annexin-V/7AAD posiƟ ve cells was performed to determine whether the 
GC sensiƟ sing eﬀ ect in THP1/SSZ and U937/SSZ cells is due to inducƟ on of apoptosis. 
Since data were largely similar for THP1 and U937 cells, only those for THP1 cells and 
its THP1/SSZ subline are shown. Exposure of THP1/WT cells to 10 μM dexamethaso-
ne for 24-72 h revealed low numbers (10±4%) of apoptoƟ c cells (Figures 3A and 4A). 
This was not due to a lack of apoptoƟ c potenƟ al of these cells as treatment of THP1/
WT cells for 24 h with 25 μM etoposide (VP-16) resulted in 88±5% apoptoƟ c cells 
(Figures 3B and 4A). Dexamethasone induced apoptosis was observed in U937/SSZ 
and THP1/SSZ cells (44±7% apoptoƟ c cells) aŌ er exposure to 1 M dexamethasone 
for 72h, but not as much at earlier Ɵ me points (Figures 3C and 4B). For comparison, 
GC-sensiƟ ve human CEM (T-lymphocyƟ c) cells showed 22% and 55% apoptoƟ c cells 
aŌ er 48h and 72h exposure to 1 M dexamethasone, respecƟ vely (Figures 3D and 
4C). In all cases apoptosis induced by VP-16 and dexamethasone was inhibited by the 
pan-caspase inhibitor ZVAD-fmk. Altogether, these results indicate that chronic ex-
posure to SSZ induces the ability of iniƟ ally GC resistant cells to undergo GC induced 
apoptosis.
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Figure 2: Gradual loss of dexamethasone sensiƟ vity in sulfasalazine (SSZ) exposed THP1 cells following 
withdrawal of SSZ and restoraƟ on of dexamethasone sensiƟ vity aŌ er repeat challenge with SSZ.
(A) Dexamethasone sensiƟ vity aŌ er 72 h incubaƟ on for SSZ-exposed THP1 cells (solid circles) was assessed 
aŌ er withdrawal of SSZ from the cell cultures for a period of 120 days (solid squares), 220 days (solid 
triangles) and 270 days (solid diamonds). THP1/WT cells acted as reference (open circles). (B) Dexametha-
sone sensiƟ vity restored aŌ er repeat challenge of SSZ exposed THP1 cells following 270 days of withdrawal 
of SSZ (fi g 2A) (solid diamonds) with 0.6 mM SSZ for a period of 3 days (open squares) and 12 days (open 
diamonds). Other symbols as in fi g 2A. All results shown represent the mean of two experiments performed 
in duplicate.
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Eﬀ ect of GR expression and changes in the NFkβ signalling pathway 
on GC sensiƟ vity in SSZ exposed cells
To invesƟ gate whether the mechanisƟ c basis for the restoraƟ on of GC sensiƟ vity 
in cells exposed to SSZ is associated with changes in the expression and/or acƟ vity 
of GR, we fi rst determined whether the GR-antagonist RU486 could abrogate this 
GC-sensiƟ saƟ on. RU486 (1 μM) fully antagonized the growth inhibitory eﬀ ects of 
dexamethasone for THP1/SSZ cells (data not shown), supporƟ ng a funcƟ onal role 
for GR in the observed GC sensiƟ saƟ on eﬀ ect. Next, mRNA levels of GR were de-
termined in U937/WT and THP1/WT cells and cells exposed to SSZ. Figure 5A shows 
that mRNA levels for GRin U937/SSZ and THP1/SSZ cells were only increased 1.5-
fold (p<0.01) and 1.6-fold (p=0.02), respecƟ vely, compared with parental cells. Nota-
bly, GR mRNA levels in THP1 and U937 cells were at least 200-fold lower than GR 
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Figure 3: GlucocorƟ coid (GC) induced apoptosis in THP1 cells exposed to sulfasalazine (SSZ). 
Eﬀ ects of dexamethasone (72 h exposure) and VP-16 (24 h exposure) on inducƟ on of early apoptosis (An-
nexin V-FITC staining) and late apoptosis (7-AAD staining) as measured by fl ow cytometry: (A) THP1/WT 
cells + dexamethasone; (B) THP1/WT cells + VP-16; (C) THP1/SSZ cells + dexamethasone; (D) CEM cells + 
dexamethasone. A representaƟ ve example of three separate experiments is shown.
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mRNA levels and were unchanged aŌ er chronic exposure to SSZ (data not shown). 
Since NFβ is a main target of SSZ, we also assessed whether SSZ had a specifi c ef-
fects on components of this signaling pathway. mRNA levels of NFβp65, the main 
component of NFβ, were increased 1.9-fold (p<0.001) and 2.3-fold (p<0.001) in 
U937/SSZ and THP1/SSZ cells, respecƟ vely, compared with parental cells (Figure 5B).
Although GR mRNA levels were only minimally increased, western blot analysis re-
vealed markedly raised levels (5-6 fold) of GR protein in U937/SSZ and THP1/SSZ 
cells compared with parental cells, in which GR protein was barely detectable (Figure 
6). Consistent with the GC sensiƟ vity profi le and stability of the GC sensiƟ vity phe-
notype was the fi nding that increased GR protein expression was retained in U937/
SSZ cells grown without SSZ for 12 months. Moreover, loss of GC sensiƟ vity in THP1/
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Figure 4: Time course of glucocorƟ coid (GC) induced apoptosis in parental and sulfasalazine (SSZ) ex-
posed THP1 cells.
Apoptosis inducƟ on (% Annexin-V posiƟ vity) following 24–72 h exposure to dexamethasone (1–10 μM) or 
VP-16 (25 μM) with or without the apoptosis inhibitor ZVADfmk (50 μM). (A) THP1/WT cells; (B) THP1/SSZ 
cells; (C) CCRF-CEM cells. Mean (SD) results of three separate experiments.
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SSZ cells 12 months aŌ er SSZ withdrawal (Figure 2) correlated with the barely detect-
able levels of GR protein in these cells. However, SSZ repeat challenge of these cells 
upregulated GR protein expression in parallel with an increase in GC sensiƟ vity. 
Together these results show that upregulaƟ on of GR protein contributes to the SSZ-
induced enhancement of GC sensiƟ vity. 
Western blot analysis also revealed alteraƟ ons in the protein expression of NFβp65, 
its precursor NFβp105, and the NFβ inhibitory component IkB, but not of 
NFβp50 (Figure 6). Increases in NFβ-p65 and IkB protein levels were super-im-
posable with the increases in GR expression and concomitant GC sensiƟ vity in pa-
rental cells, SSZ exposed cells and cells grown in the absence of SSZ. 
Finally, to assess whether the imbalance in protein expression of the NFβ subunits 
p65 and p50 in cells exposed to SSZ is associated with an inacƟ ve state of NFβ, 
nuclear extracts of SSZ exposed cells and THP1/WT and U937/WT cells were assayed 
for NFβ DNA binding acƟ vity. Residual NFβp65 DNA binding acƟ vity in THP1/SSZ 
cells was 15 (±8)% compared with THP1/WT cells. Basal levels of NFβ binding in 
U937/WT cells were four Ɵ mes lower than in THP1/WT cells and in U937/SSZ cells 
NFβp65 DNA binding was further reduced three fold (not shown). 
CollecƟ vely, these data indicate that the upregulaƟ on of GR protein together with 
diminished NFβ binding acƟ vity contribute to the enhanced GC sensiƟ vity seen with 
exposure to SSZ.
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Figure 5: GlucocorƟ coid receptor (GR)α and nuclear factor kappa β (NFκβ)p65 mRNA levels in parental 
and sulfasalazine (SSZ) exposed THP1 and U937 cells.
mRNA levels of (A) GRα and (B) NFκβp65 relaƟ ve to β2-microglobulin (β2-M) in parental (WT), THP1/SSZ 
and U937/SSZ cells determined by real-Ɵ me PCR. Mean (SD) results of three separate experiments.
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Discussion
This study has shown that chronic exposure to the anƟ -infl ammatory drug SSZ results 
in restoraƟ on of GC sensiƟ vity in two inherently GC resistant monocyƟ c/macrophage 
cell lines THP1 and U937 by upregulaƟ on of GR levels and consequent GC induced 
apoptosis.
SSZ is commonly prescribed in the USA and Europe as a disease modifying anƟ -rheu-
maƟ c drug used as second line treatment of RA paƟ ents (34-36). It is considered 
to be a relaƟ vely slow acƟ ng drug, with opƟ mal clinical acƟ vity which usually oc-
curs aŌ er 4-8 weeks of treatment (36, 37). The anƟ -infl ammatory properƟ es of SSZ 
are conveyed via inhibiƟ on of the enzyme Inhibitor β kinase (IKK)- (25, 26, 33). 
InhibiƟ on of IKK-mediated phosphorylaƟ on of Iβ, the natural inhibitor of NFβ, 
prevents dissociaƟ on of the Iβ/NFβ complex, thereby abrogaƟ ng nuclear trans-
locaƟ on of NFβ where it facilitates transcripƟ onal acƟ vaƟ on of proinfl ammatory 
cytokines such as TNF. Our study indicates that the GC sensiƟ sing eﬀ ects of SSZ 
in U937 and THP1 cells were not rapidly induced but were only fully apparent aŌ er 
2-3 months of chronic exposure to SSZ. InteresƟ ngly, however, the eﬀ ects were long 
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Figure 6: Expression of glucorƟ coid receptor (GR)α, nuclear factor kappa β (NFκβ)p65 and inhibitor ka-
ppa β (Ikβ)a protein expression in THP1 and U937 cells exposed to sulfasalazine (SSZ). 
Western blot analysis of GRα, NFkβp65, NFkβp105, NFkβp50 and Ikβa protein expression was evaluated 
relaƟ ve to β-acƟ n in parental and SSZ exposed THP1 and U937 cells, SSZ exposed cells (THP1/SSZ) aŌ er 
withdrawal of SSZ and (for THP1 cells) aŌ er repeat challenge with SSZ. Lane A: THP1/WT cells; lane B: 
THP1/SSZ cells; lane C: THP1/SSZ cells (-SSZ 270 days); lane D: THP1/SSZ (-SSZ 270 days + 12 days 0.6 mM 
SSZ); lane E: THP1/SSZ cells (-SSZ 270 days + 30 days 0.6 mM SSZ); lane F: U937/WT cells; lane G: U937/SSZ 
cells; lane H: U937/SSZ (-SSZ 270 days). Lanes I and J represent control samples for GRa expression in GC 
sensiƟ ve CEM cells and leukaemic blast cells, respecƟ vely. Dexamethasone sensiƟ vity profi le (+, sensiƟ ve; 
-, resistant) for each cell line is depicted for comparison. #Protein loading per lane 22.5 mg; for lanes I and 
J: 7.5 mg. A representaƟ ve picture of two separate experiments is shown.
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lasƟ ng in the absence of SSZ and rapidly reinduced when recurrence of GC resistance 
occurred (Figure 2). Thus, direct inhibiƟ on of IKK- by SSZ per se does not seem to 
be the sole mechanism by which GC sensiƟ vity is provoked and sustained in U937 
and THP1 cells. 
It is possible that the mechanism of GC resistance in parental U937 and THP1 cells 
may be related to a low level of GC expression (Figure 6) being  insuﬃ  cient to iniƟ ate 
a GC induced apoptoƟ c cascade, in contrast to GC sensiƟ ve T lymphocyƟ c CEM cells 
that express ample levels of GR (18, 28). Chronic exposure to SSZ apparently sets 
condiƟ ons under which the GR protein is upregulated or stabilised beyond a thresh-
old level that is suﬃ  cient for GC induced apoptosis. Some underlying mechanisms 
could be instrumental in conferring this SSZ induced GC sensiƟ sing eﬀ ect: (1) TNF is 
a known inducer of the dominant negaƟ ve -isoform of GR (12). Consequently, the 
downregulatory eﬀ ects on TNF producƟ on induced by SSZ (30, 33) could counteract 
GR inducƟ on and enhance transcripƟ on of GR. The GR mRNA levels consistently 
outweighed those of GR mRNA in THP1/SSZ and U937/SSZ cells by at least two or-
ders of magnitude. (2) Studies with myelomonocyƟ c cell line models (38) and leuke-
mic blast cells from paƟ ents (39) indicated that, post-transcripƟ onally, the stability of 
GR, NFβp65 and IB was suscepƟ ble to intracellular proteolyƟ c acƟ vity of granu-
lar serine proteases and the 26S-proteasome/ubiquitaƟ on system (38, 40-42). Al-
though a direct inhibitory eﬀ ect of SSZ on serine proteases could not be established 
(43), our observaƟ ons that GR, NFβp65 and IB followed the same paƩ ern of 
protein up/downregulaƟ on aŌ er SSZ exposure and withdrawal (Figure 6) could be 
compaƟ ble with a common eﬀ ect on protein stability by reduced 26S-proteasome/
ubiquiƟ naƟ on acƟ vity. (3) Beyond protein levels of GR and NFβp65, it is conceiv-
able that transcripƟ onal acƟ vity of NFβ will be impaired in SSZ exposed cells by the 
direct physical and antagonisƟ c interacƟ on of GR and NFβ-p65, as well as by the 
imbalanced expression of NFβp65 and NFβp50 (Figure 6) which require stochio-
metric interacƟ ons for opƟ mal transcripƟ onal acƟ vity (44). Consequently, expression 
of NFβ controlled survival genes will therefore be impaired, with the result that cells 
exposed to SSZ will be more prone to GC induced apoptosis (Figures 3 and 4).
Although the issue of GC resistance may be less well explored in RA than in haema-
tological cancers, they share common mechanisms of resistance (1, 2, 17, 18) and 
strategies to overcome resistance aŌ er disease treatment will be of interest to both 
diseases. Data from our in vitro studies showed that chronic exposure of SSZ can 
evoke enhancement of GC sensiƟ vity in primary sensiƟ ve cells (T cells) (28) and in-
dependently in two primary GC resistant myeloid cell lines (this study). These results 
are in line with empirical clinical observaƟ ons ot enhanced anƟ -infl ammatory eﬃ  ca-
cy for an SSZ+MTX+prednisolone combinaƟ on in the treatment of RA (22-24, 36) and 
102
Chapter 4
supports further evaluaƟ on of SSZ + GC or other NFβ inhibitors + GCs for the treat-
ment of leukemia. Such combinaƟ ons would parƟ cularly apply to condiƟ ons where 
low levels of GR expression are considered to be limiƟ ng factors in conferring GC 
sensiƟ vity, but may also be of interest from a GC sparing perspecƟ ve when targeƟ ng 
primary GC sensiƟ ve cells (28). As such, SSZ deserves further exploraƟ on in GC based 
drug combinaƟ ons in chronic infl ammatory diseases such as RA, polymyalgia rheu-
maƟ ca and arthriƟ s temporalis (45), as well as the leukemias (3).
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Summary
One successful therapy for the treatment of rheumatoid arthriƟ s (RA) is the combi-
naƟ on of the two disease modifying anƟ  rheumaƟ c drugs (DMARDs) methotrexate 
(MTX), sulfasalazine (SSZ) with the glucocorƟ coid prednisolone. However, the combi-
naƟ on of MTX and SSZ alone is not addiƟ vely/synergisƟ cally acƟ ve, which may point 
to drug interacƟ on. 
Using human monocyƟ c/macrophage THP1 and U937 cells as a model system for 
infl ammatory cells, we reveal two types of interacƟ ons of SSZ with MTX/folate me-
tabolism: (1) SSZ was shown to be a non-compeƟ Ɵ ve inhibitor of reduced folate car-
rier (RFC) mediated uptake of MTX, and (2) long term SSZ exposure induced the up-
regulaƟ on of the mulƟ drug resistance transporter ABCG2.
IntroducƟ on
Rheumatoid ArthriƟ s (RA) is a common autoimmune disease which is characterized 
by a chronic infl ammaƟ on of the synovial joints and infi ltraƟ on by blood-derived cells 
(T cells and macrophages) (1). Disease Modifying AnƟ -rheumaƟ c Drugs (DMARDs) 
are used to reduce to infl ammaƟ on or modify the course of RA and can be used as 
single drugs or in combinaƟ on-with other DMARDs (2-5).
Sulfasalazine (SSZ) is a commonly prescribed DMARD for the treatment of paƟ ents 
with RA (6, 7) and those with infl ammatory bowel disease (8). For the treatment of 
RA, SSZ (2–3 g/day) is oŌ en combined with the anchor drug methotrexate (MTX) 
(7.5–15 mg/week), although this combinaƟ on therapy does not display addiƟ ve/
synergisƟ c eﬀ ects compared to monotherapy with either SSZ or MTX (9, 10). In fact, 
addiƟ on of a third component such as hydroxychloroquine (3, 11) or prednisone (12) 
is usually required to signifi cantly improve clinical eﬃ  cacy. Furthermore, one notable 
adverse eﬀ ect observed was a persistent increase in plasma homocysteine levels in 
paƟ ents with RA who were receiving the combinaƟ on of MTX and SSZ, compared 
with those receiving single-drug therapy (13, 14). Elevated plasma homocysteine lev-
els are associated with cellular folate depleƟ on (15-18), which has been ascribed to 
the inhibitory eﬀ ects of SSZ on several intracellular enzymes involved in folate me-
tabolism (19, 20) and/or inhibiƟ on of intesƟ nal folate uptake (21, 22). 
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In a recent study from our laboratory (23), data were presented revealing a mecha-
nism where SSZ act as a non-compeƟ Ɵ ve inhibitor of the reduced folate carrier (RFC) 
in a human (CEM) T-cell line. RFC is the dominant cell membrane transport protein 
for natural folates as well as structurally related drugs such as MTX and is responsible 
for the cellular transport of these compounds. This model of interacƟ on could not 
only explain the lack of addiƟ vity/synergism of SSZ when combined with MTX, but 
also the side eﬀ ect of folate defi ciency (23).
The objecƟ ve of this study was to assess whether drug interacƟ on(s) of methotrex-
ate (MTX) and sulfasalazine (SSZ) found in CEM(T) were also observed in other im-
munological cell types implicated in the pathophysiology of RA, notably monocyƟ c/
macrophage cells represented by 2 cell-line models: THP1 and U937 cells.
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Figure 1: (A) ABCG2 over-expression in THP1 cells aŌ er 3 months exposure to sulphasalazine (0.6 mM) 
compared to parental THP1 cells. β-AcƟ n was used as loading control. (B)  Microarray analysis of ABC 
transporters revealing a selecƟ ve 9-fold increase of ABCG2 mRNA (encircled in red) in THP1/0.6SSZ cells 
compared to THP1/WT cells. (C) AnƟ proliferaƟ ve eﬀ ect of methotrexate (MTX) in THP1/WT and THP1/SSZ 
cells with increased ABCG2 protein expression. 
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Materials and methods
Materials
SSZ and folic acid were purchased from Sigma (St. Louis, MO). MTX was a generous 
giŌ  from Pharmachemie (Haarlem, The Netherlands). Trimetrexate was a giŌ  from 
Dr. D. Fry (Park-Davis, Ann Arbor, MI). Stock soluƟ ons of 25 mM SSZ were prepared by 
dissolving SSZ in 50 mM NaHCO3 at 37°C. Following fi lter sterilizaƟ on (through a 0.22 
m fi lter), stock soluƟ ons of SSZ were stored at –20 oC. [3H]-MTX (specifi c acƟ vity 
20–25 Ci/mmole) was obtained from Moravek Biochemicals (Brea, CA) and purifi ed 
prior to use by thin layer chromatography as described previously (24). RPMI 1640 
Ɵ ssue culture medium (with 2.2 moles/liter folic acid) and whole fetal calf serum 
(FCS) were purchased from Gibco BRL (Grand Island, NY).
Cell lines
Cell cultures of the human monocyƟ c-macrophage cell lines THP1 and U937 were 
maintained in RPMI 1640 medium with 2.2 moles/liter folic acid supplemented with 
10% FCS, 2 mM L-glutamine, and 100-units/ml penicillin/streptomycin. Cells were 
cultured at an iniƟ al density of 3×105/ml in a 5% CO2 incubator. THP1 and U937 cells 
with acquired resistance to SSZ were obtained by growing cells in stepwise increas-
ing concentraƟ ons of SSZ (0.3 – 0.6 mM) over a period of 3 months resulƟ ng in THP1 
and U937 cells selected to grow in the presence of 0.6 mM of SSZ (THP1/SSZ0.6 and 
U937/SSZ0.6).
Microarray analysis of ABC transporters and ATP Binding CasseƩ e 
Transporter G2 (ABCG2) protein detecƟ on 
Microarray analysis was used to determine mRNA expression levels of ABC transport-
ers in SSZ-resistant THP1 cells and was performed essenƟ ally as described before 
(25). ATP Binding CasseƩ e Transporter G2 (ABCG2) protein was detected by Western 
Blot as described before (26). AŌ er blocking, the membranes were incubated for 
one hour at room temperature with the primary anƟ bodies for ABCG2/BCRP (BXP21, 
1:400) as described by Maliepaard et al (27). β-AcƟ n was used (MAB1501R, 1:3000, 
Chemicon InternaƟ onal, CA, USA) as loading control. 
Cell growth inhibiƟ on studies 
The anƟ proliferaƟ ve eﬀ ects of MTX was assessed by seeding cells into individual 
wells of 24-well plates (1.25×105/ml; 1 ml/well). Eight concentraƟ ons covering 2–3 
logs were added to the individual wells. Cells were then exposed conƟ nuously to the 
drugs for 72 hours, aŌ er which viable cell numbers were determined by a hemocy-
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tometer and trypan blue exclusion. The drug concentraƟ on required to inhibit cell 
proliferaƟ on by 50% is depicted as IC50 value. 
Transport studies 
RFC-mediated uptake of [3H]-MTX was analyzed for THP1/U937 wild type cells and 
THP1/U937 SSZ0.6 cells in the mid-log phase of growth., essenƟ ally as described by 
Jansen et al (23). In short, cells were harvested and washed with transport buﬀ er 
(140 mM NaCl, 20 mM HEPES, 6 mM KCl, 2 mM MgCl2, and 6.0 mM D-glucose [pH 
7.4]). Cells were suspended to a fi nal density of 1.5x107/ml cells for THP1/U937 par-
ent cells or THP1/U937 SSZ cells. IncubaƟ ons with 0.05–5 M of [3H]-MTX in the 
absence or presence of inhibitors, were made for 3 minutes (for THP1/U937 parent 
cells and THP1/U937 SSZ cells) at 37 oC in a shaking water bath. Transport was termi-
nated by the addiƟ on of 10 ml of ice-cold transport buﬀ er, aŌ er which the cell sus-
pension was centrifuged (500g for 5 minutes at 4 oC), and the cell pellet was washed 
once more with 10 ml of ice-cold transport buﬀ er. The fi nal pellet was suspended in 
water and processed for radioacƟ vity counƟ ng. 
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Figure 2: AnƟ proliferaƟ ve eﬀ ect of methotrexate (MTX) in combinaƟ on with sulfasalazine (SSZ) against 
THP1 parent and THP1/SSZ cells. Cells were incubated in the absence (,  ) and presence of 0.6 mM SSZ 
(○) or 1.5 mM SSZ (◊). Cell viability was determined aŌ er 72 hrs exposure to MTX. Results are expressed 
as the percentage of the growth of cells incubated in the absence of drugs. Results are the mean of 3 
independent experiments. 
112
Chapter 5
Results and discussion
InducƟ on of ABCG2 aŌ er SSZ incubaƟ on has minor eﬀ ect on MTX 
sensiƟ vity
In human CEM(T) cells, SSZ exposure induced the expression of the MDR protein 
ABCG2 (Breast Cancer Resistant Protein, BCRP) (26, 28). InducƟ on of this protein was 
also found in THP1 cells (Figure 1A) and U937 cells (data not shown) aŌ er 3 months 
Figure 3: (A) Eﬀ ect of SSZ on RFC-mediated uptake uptake of 3H-MTX was determined in THP1/SSZ cells 
as described before(23) with extra cellular concentraƟ ons of 0.05 M () and  2 M () [3H]MTX in the 
absence or presence of a concentraƟ on range (0-1000 M) SSZ. Results are the mean of 3 separate experi-
ments and are expressed as a percentage of [3H]-MTX uptake compared with controls without addiƟ ons. 
(B) Dixon plot represenƟ ng reciprocal uptake rates of [3H]-MTX uptake over a 3 min. period at extracellular 
concentraƟ ons of 1.0 M (), 2.5 M () and 5.0 M () [3H]MTX in the presence of 0-100 M SSZ. Ki 
value as calculated from the x-axis intercept.
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of exposure to SSZ at a maximum concentraƟ on of 0.6 mM (Figure 1A). These ob-
servaƟ ons were also confi rmed by microarray analysis in which THP1/SSZ0.6 cells 
showed a selecƟ ve 9-fold increase of ABCG2 mRNA compared to THP1/WT cells (Fig-
ure 1B). Although MTX is described as a substrate for ABCG2 (29-31), only minor dif-
ferences in the anƟ proliferaƟ ve eﬀ ect of MTX were observed between the THP1/WT 
cells and the ABCG2 over-expressing cell line THP1/SSZ0.6 (Figure 1C) when the as-
says were performed in the absence of SSZ and MTX exposure for 72 hrs. Comparable 
results were found for U937/WT and U937/SSZ0.6 cells (data not shown). AddiƟ on 
of the ABCG2 antagonist Ko143 had no eﬀ ect on the MTX sensiƟ vity in THP1/SSZ0.6 
and U937/SSZ0.6 cells (data not shown). Based on these results we can conclude 
that upregulaƟ on of ABCG2, even though it is an eﬄ  ux transporter of MTX, has just a 
minor eﬀ ect on MTX sensiƟ vity in THP1/SSZ and U937/SSZ cells following long-term 
exposures to MTX. This does not rule out the possibility that ABCG2 upregulaƟ on 
could confer resistance to MTX aŌ er short-term (<4hr) exposures to MTX as was re-
cently described by Shafran et al (31). 
SSZ inhibits RFC-mediated MTX uptake
In the absence of SSZ , THP1/SSZ, U937/SSZ cells and parental THP1 , U937 cells were 
equally sensiƟ ve to MTX (Fig 1A and data not shown). However, in the presence of 
SSZ a markedly concentraƟ on-dependent loss of MTX eﬃ  cacy (i.e., increase in the 
IC50 value) was observed: 16-25-fold at 0.6 mM SSZ and >200-fold at 1.5 mM SSZ 
(Figure 2). Under these condiƟ ons no cross-resistance, even a 6-fold collateral sen-
siƟ vity, was observed to a lipophilic anƟ folate trimethrexate. These results indicate 
that RFC-mediated MTX uptake could be inhibited by SSZ.
In order to test this, transport studies using two concentraƟ ons of [3H]-MTX (0.05 M 
and 2 M) in combinaƟ on with increasing doses of SSZ showed that SSZ was able to 
inhibit RFC-mediated MTX uptake in a concentraƟ on dependent maƩ er (Figure 3a). 
Since the potency of SSZ to inhibit [3H]-MTX transport by 50% was similar at both 
0.05 M and 2 M [3H]-MTX concentraƟ ons, this suggests that SSZ acts as a non-
compeƟ Ɵ ve inhibitor of RFC in THP1 and U937 cells. The non-compeƟ Ɵ ve nature of 
RFC inhibiƟ on by SSZ was confi rmed by Dixon plot analysis (Figure 3B), revealing a Ki 
value of around 40 μM, well within clinically achievable concentraƟ ons of SSZ. 
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Conclusion
DMARD combinaƟ ons of SSZ and MTX can, when given simultaneously, provoke loss 
of MTX eﬃ  cacy due to potent inhibiƟ on of RFC-mediated uptake by SSZ in THP1 and 
U937 cells. InteracƟ ons of SSZ with RFC may also impair cellular uptake of natural 
folate cofactors, leading to inducing folate defi ciency. Under specifi ed condiƟ ons (i.e. 
short term drug exposures) the SSZ-induced upregulaƟ on of the drug eﬄ  ux protein 
ABCG2 may also contribute to loss of MTX eﬃ  cacy and folate defi ciency. All of these 
eﬀ ects are summarized in a mode presented in Figure 4. 
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eﬄ  ux by ABCG2. 
SSZ acts as a non-compeƟ Ɵ ve inhibitor of the RFC by interacƟ ng at an RFC domain that is disƟ nct form 
the binding/transport site for MTX and natural folates. This leads to diminished cellular uptake of these 
compounds confering loss of MTX eﬃ  cacy and intracellular defi ciency. In addiƟ on, SSZ induces ABCG2 
expression, a drug eﬄ  ux protein that can extrude MTX.
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Summary
IntroducƟ on. Disease modifying anƟ rheumaƟ c drugs (DMARDs) have a well estab-
lished role in the treatment of rheumatoid arthriƟ s (RA) but either inherent primary 
resistance or acquired resistance may limit long-term eﬃ  cacy of these DMARDs. 
Overexpression of specifi c mulƟ drug eﬄ  ux transporters, members of the ATP-Bind-
ing CasseƩ e (ABC) superfamily confer MulƟ drug Resistance (MDR). Apart from the 
MDR transporter P-glycoprotein (P-gp), expression profi ling of other MDR eﬄ  ux 
transporters that could contribute to DMARD resistance has received liƩ le aƩ enƟ on. 
ObjecƟ ve. Herein, we undertook expression profi ling and funcƟ onal acƟ viƟ es of 
selected MDR transporters in immune-eﬀ ector cells of RA paƟ ents in relaƟ on to 
DMARD treatment and drug resistance. 
Methods. Assessment of the expression profi le and funcƟ onal acƟ viƟ es of selected 
MDR eﬄ  ux transporters including P-gp, mulƟ drug resistance related proteins 1 to 
9 (MRP1 to MRP9) and Breast Cancer Resistance Protein (BCRP), were analyzed in 
peripheral blood lymphocytes (PBLs) and monocyte-derived macrophages (MDM) 
obtained from 52 RA paƟ ents (including DMARD-naïve and DMARD-(non) responsive 
paƟ ents) and healthy individuals (n=19) using real-Ɵ me PCR, immunohistochemistry 
and fl ow cytometry.
Results. A wide range of mRNA and protein levels of MDR transporters was observed 
in PBLs and MDM from RA paƟ ents as well as healthy controls. RelaƟ ve to healthy 
individuals, peripheral blood lymphocytes from RA paƟ ents displayed signifi cantly 
higher mRNA levels of MRP1 (2.5-fold), MRP4 (1.6-fold) and MRP7 (1.9-fold). Fur-
thermore, signifi cantly increased levels of BCRP mRNA (2.8-fold) and BCRP protein 
(2.4-fold) were observed in monocyte-derived macrophages from RA paƟ ents com-
pared to controls. AddiƟ onal analyses revealed that a 1.8-fold increased funcƟ on-
al acƟ vity of P-gp in CD3+ cells in RA paƟ ents receiving DMARD treatment versus 
DMARD-naïve paƟ ents was exclusively contributed by DMARD non-responders ( p = 
0.019).In line with this observaƟ on, P-gp mRNA levels were found to be signifi cantly 
increased (2-fold) in PBLs of DMARD responders compared to DMARD-naive paƟ ents 
(p = 0.050). Finally, P-gp protein levels in MDM correlated with DAS28 scores (r = 
0.775, p = 0.011).
Conclusion. This is the fi rst study that invesƟ gated the potenƟ al involvement of a 
broad panel of MDR transporters in immune cells in relaƟ on to DMARD and clini-
cal response parameters. The study reveals that upregulaƟ on of specifi c MDR eﬄ  ux 
transporters in immune-competent cells may contribute to an aƩ enuated DMARD 
response in RA paƟ ents.
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INTRODUCTION
Rheumatoid arthriƟ s (RA) is a common autoimmune disease characterized by 
chronic infl ammaƟ on of the synovial joints and infi ltraƟ on by blood-derived infl am-
matory cells (T cells and macrophages) (1). From a therapeuƟ c perspecƟ ve, Disease 
Modifying AnƟ -RheumaƟ c Drugs (DMARDs), either as single drug or in combina-
Ɵ on, fi nd widespread applicaƟ on as fi rst line treatment opƟ on (2-5). In addiƟ on, the 
DMARD methotrexate (MTX) is commonly used in combinaƟ on schedules with other 
DMARDs and biological agents (6-9). Monotherapy with a DMARD is iniƟ ally success-
ful in about 50-60% of RA paƟ ents, depending on the specifi c anƟ -rheumaƟ c drug 
used (10). However, despite chronic treatment with DMARDs, reacƟ vaƟ on of infl am-
maƟ on oŌ en occurs, indicaƟ ng that these drugs lose their eﬃ  cacy over Ɵ me (11-15). 
In this respect, it has been recognized that RA paƟ ents remain on the anchor drug 
MTX for a median period of 5-6 years, whereas for the DMARDs chloroquine (CHQ) 
or sulfasalazine (SSZ) this period is much shorter being typically one to two years 
(12, 13). Apart from loss of eﬃ  cacy, adverse eﬀ ects are another common reason for 
switching to other DMARDs or biological agents (16, 17). Currently, it is sƟ ll an unre-
solved issue whether tapering of DMARD eﬃ  cacy is mechanisƟ cally associated with 
the development of cellular drug resistance. 
One important mechanism of drug resistance is based on cellular extrusion of drugs, 
an eﬄ  ux process that is mediated by specifi c members of the family of ATP-Binding 
CasseƩ e (ABC) proteins (18). These extrusion proteins mediate drug eﬄ  ux thereby 
conferring mulƟ drug resistance (MDR) to a wide range of structurally and mechanis-
Ɵ cally unrelated drugs. Resistance to several anƟ cancer drugs has been associated 
with overexpression of specifi c MDR proteins, including P-glycoprotein (P-gp), MulƟ -
drug Resistance Proteins (MRP) 1-9 and Breast Cancer Resistance Protein (BCRP) (18-
23). Next to anƟ cancer drugs, there is also cumulaƟ ve evidence, mostly based on in 
vitro data, that several DMARDs are also potenƟ al transport substrates of MDR eﬄ  ux 
transporters and, upon chronic drug treatment they induce upregulaƟ on of selected 
MDR transporters (24). Specifi cally, MTX is known to be transported by several MDR 
transporters, including MRP1-5 and BCRP, while CHQ was idenƟ fi ed as a transport 
substrate for MRP1 whereas both SSZ and lefl unomide were BCRP substrates (25-
29). Moreover, studies with T-cell subsets from RA paƟ ents revealed that eﬄ  ux and 
resistance to glucocorƟ coids can be mediated by enhanced acƟ vity of Pgp (30-34). 
A putaƟ ve role for Pgp was also suggested in conferring drug resistance to MTX (34, 
35); however, due to its anionic nature, MTX is apparently not a substrate for P-gp 
(24), although this issue remains controversial to some extent. Recently, we showed 
that the MDR transporters BCRP and to a minor extent MRP1 were expressed on 
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synovial Ɵ ssue macrophages from RA paƟ ents; this correlated with an aƩ enuated 
response to MTX and lefl unomide (36). It is now being appreciated that various MDR 
transporters can be diﬀ erenƟ ally expressed in immune-eﬀ ector cells where they may 
have dual funcƟ ons; on the one hand they may neutralize potenƟ al toxic eﬀ ects of 
xenobioƟ c environmental compounds (37), while on the other hand they may facili-
tate the extrusion of intracellular substrates that serve as mediators of immunologi-
cal and infl ammatory processes (38). 
Taken together, there is consensus that MDR eﬄ  ux transporters could play a role in 
DMARD resistance. Since thus far most studies on this topic either focussed on one 
specifi c MDR transporter or specifi c cell types, there is a need to extend these stud-
ies to mulƟ ple MDR/ABC transporters on immune cells derived from RA paƟ ents in 
relaƟ on to clinical status of DMARD (non)responsiveness. For this purpose, we here 
determined the expression levels of key MDR transporters (P-gp, MRP1-9 and BCRP) 
on peripheral blood lymphocytes (PBLs) and monocyte-derived macrophages (MΦ) 
from healthy controls and RA paƟ ents and assessed whether or not these param-
eters correlated with the clinical response to DMARDs. 
MATERIALS AND METHODS
Reagents 
Iscove’s modifi ed Dulbecco’s medium (IMDM) and fetal calf serum (FCS) were ob-
tained from Gibco Chemical Co, Grand Island NY, USA. The ABCG2 inhibitor Ko143 
was kindly provided by Prof. G J Koomen (University of Amsterdam, Amsterdam, The 
Netherlands) and the MRP1 inhibitor MK571 and the P-gp inhibitor Reversin-121 
(P121) were obtained from Alexis Benelux, Breda, The Netherlands. The BCRP sub-
strate bodipy-prazosin, the P-gp substrate Syto16 and the MRP1 substrate Calcein-
AM were obtained from Invitrogen, Breda, The Netherlands. Fluorescein isothiocy-
anate (FITC)-conjugated CD8 and phycoerythrin (PE)-conjugated CD3, CD4, CD20 and 
CD25 were obtained from Becton-Dickinson, Alphen aan den Rijn, The Netherlands. 
Macrophage colony sƟ mulaƟ ng factor (M-CSF) was obtained from R&D systems, 
Minneapolis, USA. 
Subjects
In this study, blood samples were obtained from 52 paƟ ents fulfi lling the ACR criteria 
for RA and 19 healthy individuals. The clinical disease acƟ vity of the RA paƟ ents was 
determined by using the disease acƟ vity score evaluaƟ ng 28 joints (DAS28)(39). Sub-
123
MDR transporters in immune cells from RA paƟ ents
jects were categorized into four sub-groups: (1) Healthy controls, (2) DMARD-naïve 
RA paƟ ents (defi ned as not receiving any DMARD therapy in the present and past), (3) 
DMARD-responders (defi ned as having a DAS28 score ≤3.2 under DMARD therapy) 
and (4) DMARD non-responders (defi ned as having a DAS28 of > 3.2 under DMARD 
therapy as described before (40)). PaƟ ents taking DMARDs were on a stable dose for 
at least 3 months. PaƟ ents taking glucocorƟ coids within 3 months before entering 
the study were excluded. The study protocol was approved by the local Medical Eth-
ics CommiƩ ee of the VU University Medical Centre (Amsterdam, The Netherlands) 
and all subjects gave wriƩ en informed consent before entering the study.
IsolaƟ on of blood mononuclear cells and culture condiƟ ons
Peripheral blood mononuclear cells (PBMCs) were isolated from freshly obtained 
blood samples by gradient centrifugaƟ on (35 min at 400xg) on Ficoll-Paque Plus (Am-
ersham Biosciences, Amersham, UK) according to the manufacturer’s instrucƟ ons. 
AŌ er centrifugaƟ on, the interphase was carefully collected and washed 3 Ɵ mes using 
phosphate-buﬀ ered saline (PBS) supplemented with 1% BSA. The lymphocyte frac-
Ɵ on was counted and resuspended in IMDM culture medium supplemented with 
10% FCS, 2 mM L-glutamine and 100 g/ml penicillin and streptomycin. Monocytes 
were isolated by adherence aŌ er 2 hours incubaƟ on at 37oC in culture fl asks followed 
by RNA extracƟ on. A porƟ on of the adhered monocytes were used for macrophage 
(Mφ) diﬀ erenƟ aƟ on by culturing the monocytes for 7 days in the presence of 50 ng/
ml M-CSF and RNA was extracted. Peripheral blood lymphocytes (PBLs) remaining in 
the suspension aŌ er monocyte adherence, were collected for analysis of MDR mRNA 
expression and funcƟ onal acƟ vity of MDR eﬄ  ux transporters.
Assessment of P-gp, MRP1 and BCRP acƟ vity by fl ow cytometry
Measurement of P-gp, MRP1 and BCRP transport acƟ vity was performed essenƟ ally 
as previously described (41, 42). Assays were validated using human cell lines over-
expressing either MRP1 (GLC4/ADR (43)), P-gp (CEM/VBL, (44)) or BCRP (MCF7/MR, 
(45)). In short, cells were incubated in a total volume of 500 μL at a cell density of 
3 x 105 cells/ml for 60 minutes in a 37oC water bath in the presence of a fl uorescent 
substrate; Calcein-AM (4 nM), Syto16 (1 nM) and Bodipy-prazosin (25 nM) for the de-
tecƟ on of MRP1, P-gp and BCRP acƟ viƟ es, respecƟ vely. To measure funcƟ onal MDR 
acƟ vity cells were also incubated with specifi c transport inhibitors; MK571 (50 μM), 
P121 (10 μM) and Ko143 (200 nM) for the inhibiƟ on of MRP1, P-gp and BCRP, respec-
Ɵ vely. AŌ er incubaƟ on with the chromophoric substrates alone or in the presence of 
the specifi c transport inhibitor, cells were washed twice using ice-cold PBS supple-
mented with 0.1% bovine serum albumin (BSA) and kept on ice protected from light 
for 30 minutes. Flow cytometric analysis was performed using a FACS Scan (Becton 
Dickinson) equipped with a 488-nm argon laser with 530 nm (FL1), 585 nm (FL2) and 
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a 670 nm (FL3) band pass fi lter. Cell Quest soŌ ware (Becton Dickinson) was used for 
data acquisiƟ on and analysis. MDR transporter acƟ vity was expressed as an AcƟ vity 
Index (AI) described by the following formula:
 Mean Fluorescence level in the presence of antagonist - non loaded cells
 Mean Fluorescence level in the abscence of antagonist - non loaded cells
An index of ≥1.10 is representaƟ ve for funcƟ onal MDR acƟ vity.
IsolaƟ on of RNA and real-Ɵ me PCR analysis
RNA from PBLs and Mφ was isolated using the Qiagen RNeasy Plus isolaƟ on kit 
(Qiagen, Hilden, Germany) according to the instrucƟ ons of the manufacturer. Total 
RNA concentraƟ ons were determined using a Nanodrop ND-1000 spectrophotom-
eter (Nanodrop Technologies, Wilmington, USA). RNA was reverse-transcribed to 
copy DNA (cDNA) using random hexamers as described previously (46) using 1 μg of 
RNA. Real Ɵ me PCR analysis was performed using the LightCycler 2.0 (LC) instrument 
(Roche DiagnosƟ cs, Penzberg, Germany) and HybridizaƟ on Probes, essenƟ ally as de-
scribed earlier (47). All samples were tested by using the LightCycler FastStart DNA 
MasterPLUS HybProbe kit (Roche DiagnosƟ cs) according to manufacturer’s recom-
mendaƟ ons. PCR reacƟ ons were performed in duplicates using 5 μL cDNA, equiva-
lent to 20ng RNA, which was added to 15 μL of reacƟ on mixture in a fi nal volume of 
20 μL. The primers and probes were as previously published (48, 49). The primer/
probe sequences and their concentraƟ ons are depicted in the Supplementary Table 
S1. The PCR program for all targets consisted of an iniƟ al denaturaƟ on step at 95ºC 
for 10 min and 45 cycles of warming up to 95ºC, immediately followed by 15 s at 
60ºC. AŌ er the fi nal cycle, capillaries were cooled for 30 s at 40ºC. Fluorescence 
curves were analyzed with the LC soŌ ware (version LCS4 4.0.5.415). This soŌ ware 
uses the second derivaƟ ve maximum method to calculate the fracƟ onal cycle num-
bers where the fl uorescence signals are above background (crossing point, CP), being 
the point at which the rate of change of fl uorescence is greatest. The relaƟ ve mRNA 
expression levels of the target genes were calculated using Qbase analysis soŌ ware 
(50) in which β-glucuronidase (GUS) and GAPDH were used as control housekeeping 
genes. For correcƟ on of inter-run variaƟ on, a calibrator sample based on a cDNA pool 
derived from various MDR-overexpressing human cell lines, including 2008/MRP1-3, 
HEK/MRP4-7, MCF7/MR (BCRP), CEM/VBL (P-gp), was used in every PCR run. The cal-
ibrator sample was also used as a reference sample, to calculate the relaƟ ve mRNA 
expression levels in all tested samples. 
Immunohistochemistry
Immunohistochemistry was performed as previously described (51, 52) and all an-
Ɵ body diluƟ ons were prepared in PBS supplemented with 1% (w/v) BSA. In short, 
125
MDR transporters in immune cells from RA paƟ ents
cytocentrifuge preparaƟ ons with 20,000 cells/spot were air-dried overnight and 
fi xed with 100% acetone for 10 minutes. Non-specifi c binding sites were blocked for 
30 minutes at room temperature with PBS containing 5% normal rabbit serum (Da-
koCytomaƟ on). Next, cells were incubated for one hour at room temperature with 
primary monoclonal anƟ bodies against BCRP (BXP-21, 1:50 and BXP-53, 1:25) (51), 
P-gp (JSB-1, 1:25) (53), MRP1 (MRPr1, 1:50) (52), MRP2 (M2III6, 1:50) (52), MRP4 
(M4I10, 1:50) (52), MRP5 (M5I1, 1:50) (52) and MRP6 (M6II3, 1:25) (52) together 
with the appropriate negaƟ ve controls, IgG subclass with appropriate secondary an-
Ɵ body. The slides were then washed 3 Ɵ mes in PBS and incubated with bioƟ nylated 
rabbit-anƟ -mouse (1:150, DakoCytomaƟ on) or bioƟ nylated rabbit-anƟ -rat (1:100, 
DakoCytomaƟ on) as secondary anƟ body. AŌ er one hour incubaƟ on at room tem-
perature, the slides were washed 3 Ɵ mes in PBS and incubated with streptavidin 
conjugated to horseradish peroxidase (1:500; Zymed, San Francisco, CA) for 30 min-
utes. AŌ er washing 5 Ɵ mes with PBS, bound peroxidase was developed with 0.02% 
(w/v) 3-amino-9-ethylcarbazole and 0.02% (v/v) H2O2 in 0.1 M sodium acetate (pH 
5.0) and nuclei were stained with hematoxylin. The staining results were scored by 
determining staining intensity of 100 cells uƟ lizing the following scores: 0 (negaƟ ve 
cells), 1 (weakly posiƟ ve cells), 2 (posiƟ ve cells) and 3 (strongly posiƟ ve cells). The 
total scores ranged from 0 (100% x 0) to 3.0 (100% x 3). 
StaƟ sƟ cal analysis
To evaluate the signifi cance of observed diﬀ erences between groups all samples were 
analyzed using the Mann-Whitney test. Spearman correlaƟ ons were performed to 
evaluate the associaƟ on of MDR transporter expression/acƟ vity with DAS28 scores, 
erythrocyte sedimentaƟ on rate (ESR) values and other relevant disease acƟ vity pa-
rameters for RA. All analyses were performed in SPSS version 14.0. A two-tailed P-
value ≤ 0.05 was considered to be staƟ sƟ cally signifi cant.
RESULTS
PaƟ ent demographics
Blood was obtained from 52 RA paƟ ents and 19 healthy controls and their baseline 
characterisƟ cs are summarized in Table 1. Nine RA paƟ ents were DMARD-naive with 
an average DAS28 score of 5.2 (SD ± 1.2). DMARD responder and non-responder 
groups included 15 and 28 paƟ ents with an average DAS28 score of 2.2 (SD ± 0.7) 
and 4.8 (SD ± 0.6) respecƟ vely. Among the majority of the RA paƟ ents, 36 out of 43, 
MTX was included in the treatment schedule. Mean age was not signifi cantly diﬀ er-
ent between the selected groups. 
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MDR transporter expression and eﬄ  ux acƟ viƟ es in peripheral blood 
lymphocytes from RA paƟ ents
Flow cytometry with fl uorescent substrates was used to determine the funcƟ onal 
acƟ viƟ es of P-gp, MRP1 and BCRP in PBLs (Figure 1A) and in CD3+ cells (Figure 1B) 
from RA paƟ ents and healthy controls. P-gp and MRP1 acƟ viƟ es were readily detect-
able in all tested samples of both PBL and CD3+ fracƟ ons of peripheral blood cells, 
while BCRP acƟ vity was below the preset threshold indicaƟ ve for funcƟ onal acƟ v-
ity; acƟ vity index (AI) ≥ 1.1. Mean values for the transport acƟ vity index (AI) of P-gp 
acƟ vity were slightly higher, but not signifi cantly diﬀ erent, in PBLs and CD3+ cells of 
RA paƟ ents vs controls (AI: 2.6 vs 2.0, p=0.48 and AI: 2.4 vs 1.7, p=0.16; Table S2). 
Consistently, the mean Pgp levels relaƟ ve to GUS were higher in RA paƟ ents vs con-
trols (raƟ o: 2.5 vs 1.9), however, this diﬀ erence did not reach staƟ sƟ cal signifi cance 
(p=0.10; (Figure 1C, Table S2)). Regarding MRP1, no diﬀ erences in acƟ viƟ es were 
found between PBLs and the CD3+ fracƟ on from RA paƟ ents and healthy controls 
(AI: 1.3, Figure 1A/B). 
EvaluaƟ on of mRNA expression levels of Pgp, MRP1-9 and BCRP in PBLs from RA pa-
Ɵ ents over controls showed signifi cantly higher values for MRP1 (2.1-fold, p=0.02), 
Table 1: PaƟ ent characterisƟ cs.
RA paƟ ents (n = 52)
Controls
DMARD
Naïve
DMARD
Responders
DMARD 
Non-responders
Total (n) 19 9 15 28
male/female 10/9 4/5 5/10 8/20
Age (year) 54.3 (±16.3) 58.9 (±19.8) 56.1 (±20.3) 55.5 (±13.2)
DAS28 NA 5.22 (±1.23) 2.20 (±0.72) 4.79 (±0.57)
ESR (mm/hr) NA 46±30 13 (±13) 28 (±22)
DMARD treatment
Methotrexate (n) NA NA 13 24
Sulphasalazine (n) 3 5
Hydroxychloroquine (n) 1 10
CombinaƟ on therapy (n) NA NA 2 8
Overview of subjects who parƟ cipated in the study. 19 Healthy controls, 9 DMARD-naive (paƟ ents who had 
not received DMARD treatment in the past or present), 15 DMARD responders (defi ned as having a DAS28 
score ≤ 3.2 under DMARD therapy) and 28 DMARD non-responders (defi ned as having a DAS28 of ≥ 3.2 
under DMARD therapy) were included in the study. For each group the average age, DAS28 and ESR are 
depicted. PaƟ ents used methotrexate, sulphasalazine or hydroxychloroquine either as mono-therapy or in 
combinaƟ on regimens. AbbreviaƟ ons: NA: Not Applicable; DMARD: Disease Modifying AnƟ  RheumaƟ c 
Drug; DAS: Disease AcƟ vity score; ESR: Erythrocyte SedimentaƟ on Rate.
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MRP4 (1.6-fold, p=0.019) and MRP7 (1.9-fold, p=0.015) (Figure 1C/D, Table S2). No 
signifi cant diﬀ erences were observed for P-gp, BCRP, MRP2, MRP3 and MRP5-7, while 
expression levels for MRP8 and MRP9 mRNA were below the limits of detecƟ on. Col-
lecƟ vely, these results indicate that mRNA levels of three MDR eﬄ  ux transporters 
(MRP1, MRP4 and MRP7) are diﬀ erenƟ ally expressed in PBLs from RA paƟ ents rela-
Ɵ ve to healthy controls, but funcƟ onal acƟ viƟ es of 3 central MDR transporters (Pgp, 
MRP1 and BCRP) are not signifi cantly diﬀ erent.
Figure 1: MDR funcƟ onal acƟ vity and relaƟ ve mRNA expression in peripheral blood lymphocytes and 
CD3+ cells from RA paƟ ents and healthy controls.
(A) FuncƟ onal acƟ vity of P-gp, BCRP and MRP1 in peripheral blood lymphocytes and (B) CD3+ cells in RA 
paƟ ents and controls. (C) RelaƟ ve mRNA expression of P-gp, BCRP and MRP1 in peripheral blood lym-
phocytes from RA paƟ ents and controls, and (D) RelaƟ ve mRNA expression of MRP2-7 in peripheral blood 
lymphocytes from RA paƟ ents and controls. MRP8 and MRP9 mRNA levels were below the limits of detec-
Ɵ on accuracy.Horizontal and verƟ cal bars depict the median and maximum/minimum value, respecƟ vely. 
StaƟ sƟ cally signifi cant diﬀ erences between RA paƟ ents and healthy controls, analyzed by Mann-Whitney 
test, are indicated with an asterisk when p≤0.05. MDR transporter acƟ vity was expressed as an AcƟ vity 
Index (AI) by comparing the mean fl uorescence level in the presence of the appropriate inhibitor with the 
fl uorescence level in the absence of the inhibitor.
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MDR protein and mRNA expression in monocyte-derived macrophages 
from RA paƟ ents
Macrophages represent a cell type of key relevance in driving RA disease and thus 
serve as a target for DMARD therapy. To invesƟ gate expression levels of MDR eﬄ  ux 
transporters in human monocyte-derived macrophages (MDM), protein and mRNA 
levels were analyzed by immunohistochemistry and RT-PCR, respecƟ vely. A large 
variaƟ on in BCRP, P-gp and MRP1 protein expression levels was observed both in the 
MDM of the control group and in the RA paƟ ents group (Figure 2A/B). Of note, BCRP 
expression was signifi cantly higher (2.4-fold, p=0.025) in the RA group (median: 1.27) 
compared to controls (median 0.53) (Figure 2B, Table S2). Consistently, relaƟ ve BCRP 
mRNA expression (Figure 2C) was also signifi cantly increased (2.8-fold, p=0.034) in 
Figure 2: MDR protein and mRNA expression in monocyte-derived macrophages (MDM) from RA pa-
Ɵ ents and healthy controls.
(A) RepresentaƟ ve immunohistochemical staining of Pgp, BCRP and MRP1 on monocyte-derived macro-
phages from RA paƟ ents, together with the appropriate macrophage marker 3A5 and negaƟ ve control 
(isotype anƟ body). (B) Mean staining intensity for Pgp, BCRP and MRP1 on MDM from RA paƟ ents as de-
termined by scoring the staining intensity of 100 cells, range: 0 (negaƟ ve) to 3 (strongly posiƟ ve). (C) MDR 
mRNA expression of P-gp, BCRP and MRP1-7 relaƟ ve to the mRNA expression levels from a MDR cell-line 
pool. mRNA of MRP8 and MRP9 were below the detecƟ on level. Horizontal and verƟ cal bars depict the 
median and maximum/minimum value, respecƟ vely. StaƟ sƟ cally signifi cant diﬀ erences between RA pa-
Ɵ ents and healthy controls, analyzed by Mann-Whitney test, are indicated with an asterisk when p≤0.05.
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RA paƟ ents (median: 0.074) compared to healthy controls (median: 0.026). In addi-
Ɵ on, relaƟ ve mRNA expression of MRP3 was 1.4-fold higher (p=0.053) in MDM from 
RA paƟ ents (median: 1.427) compared to controls (median 1.016). As to the remain-
ing MDR transporters tested, Pgp, MRP1-2, MRP4-7 and MRP8,9 (data not shown), 
no signifi cant diﬀ erences in relaƟ ve mRNA levels were revealed between RA paƟ ents 
and controls (Figure 2C, Table S2). CollecƟ vely, these results demonstrate that BRCP 
expression (both mRNA and protein) is diﬀ erenƟ ally upregulated in MDM from RA 
paƟ ents. 
Figure 3: FuncƟ onal acƟ vity and mRNA expression of Pgp and MRP1 in relaƟ on to DMARD treatment.
(A) AcƟ vity levels of P-gp and MRP1 in peripheral blood lymphocytes and (B) CD3+ cells from DMARD-
treated and DMARD-naive RA paƟ ents. (C) Diﬀ erenƟ al MDR mRNA expression of P-gp and MRP1 in PBLs 
of DMARD-treated vs DMARD-naive paƟ ents, relaƟ ve to the mRNA expression levels from a MDR cell-line 
pool. Horizontal and verƟ cal bars depict the median and maximum/minimum value, respecƟ vely. StaƟ sƟ -
cally signifi cant diﬀ erences between RA paƟ ents and healthy controls, analyzed by Mann-Whitney test, are 
indicated with an asterisk when p≤0.05. MDR transporter acƟ vity was expressed as an AcƟ vity Index (AI) by 
comparing the mean fl uorescence level in the presence of the appropriate inhibitor with the fl uorescence 
level in the absence of the inhibitor.
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MDR transporter mRNA expression and funcƟ onal acƟ vity in 
peripheral blood lymphocytes and CD3+ cells from DMARD-treated 
RA paƟ ents
To analyze whether expression of MDR transporters in RA paƟ ents is aﬀ ected by 
DMARD treatment per se, MDR eﬄ  ux transporter expression levels in PBL and CD3+ 
cells of DMARD-naïve RA paƟ ents were iniƟ ally compared with those of DMARD-
treated RA paƟ ents (regardless of their clinical DMARD response). It is noteworthy 
that the funcƟ onal acƟ vity of P-gp was 2-fold higher in PBLs of DMARD-treated pa-
Ɵ ents versus DMARD- naïve paƟ ents (median AI: 2.9 vs 1.5, respecƟ vely, p=0.08) 
(Figure 3A, Table S3). In CD3+ cells from DMARD-treated paƟ ents a signifi cant 
(p=0.02) 1.5-fold increase in P-gp acƟ vity was also observed in DMARD-treated ver-
sus DMARD-naive RA paƟ ents (median AI: 2.4 vs 1.6) (Figure 3B, Table S3). In line 
with the funcƟ onal acƟ vity of P-gp in PBLs, median relaƟ ve P-gp mRNA levels were 
also increased (1.7-fold) in DMARD-treated over DMARD- naïve RA paƟ ents, even 
though this diﬀ erence was not staƟ sƟ cally signifi cant (Figure 3C, Table S3). For all 
other MDR transporters tested (BCRP, MRP1-7) no signifi cant diﬀ erences in relaƟ ve 
mRNA expression levels were observed between DMARD-naive and DMARD-treat-
ed RA paƟ ents (Table S3). Finally, no marked diﬀ erences in relaƟ ve mRNA levels of 
P-gp, BCRP and MRP1-7 were observed with monocyte-derived macrophages from 
DMARD-naïve and DMARD-treated RA paƟ ents (Table S3). These results indicate that 
DMARD treatment markedly aﬀ ects the funcƟ onal acƟ vity of P-gp in PBLs from RA 
paƟ ents, while those of MRP1 and BCRP are just marginally infl uenced. 
AssociaƟ ons of MDR transporter expression levels with clinical 
parameters and DMARD responsiveness  
Next, the expression of MDR eﬄ  ux transporters in DMARD non-responders (DAS28 > 
3.2 under therapy) was compared with DMARD-responding paƟ ents (DAS28 ≤ 3.2 un-
der therapy). No signifi cant diﬀ erences could be observed between DMARD respond-
ers and DMARD non-responders (Table S4). Similar levels of P-gp funcƟ onal acƟ vity 
were noted in both PBLs and CD3+ cells of DMARD-responders vs non-responders 
(Figure 4A). In concordance with the funcƟ onal acƟ vity of P-gp, no staƟ sƟ cally signifi -
cant diﬀ erence in relaƟ ve mRNA levels was observed for this transporter in PBLs (Fig-
ure 4B), even though mRNA levels of P-gp tended to be slightly increased (1.5-fold) in 
DMARD non-responders (Table S4). Modest MRP1 and neglible BCRP funcƟ onal acƟ v-
ity was measured in PBL samples from DMARD non-responders, but insuﬃ  cient sam-
ples sizes in the group of DMARD-responders did not allow an assessment of signifi -
cant diﬀ erences between these two groups (Table S4). For all other MDR transporters 
tested, no signifi cant diﬀ erences in mRNA levels were observed between DMARD-re-
sponders and non-responders, even though mRNA levels in the non-responder group 
were up to 1.7-fold higher (Figure 4C, Table S4). Moreover, also levels in MDM from 
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DMARD-responders versus DMARD non-responders (Figure 4D, Table S4). 
When comparing DMARD non-responders with DMARD naive paƟ ents (Table S5), 
increased P-gp funcƟ onal acƟ vity was observed in PBLs (1.5 fold, p = 0.076) and CD3+ 
cells (1.8 fold, p = 0.019 respecƟ vely) of DMARD non-responders (Figure 5A/B). In 
line with this observaƟ on, a 2-fold (p = 0.050) increase of P-gp mRNA was found 
in PBLs of DMARD non-responders (Figure 5C). No addiƟ onal signifi cant diﬀ erences 
were observed in mRNA levels of the other MDR transporters in PBLs (Figure 5C) and 
MDM (Figure 5B).
Lastly, we assessed by linear regression analysis whether MDR transporter expres-
sion is correlated with clinical parameters of DMARD response, including DAS28 and 
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Figure 4: DMARD response related to MDR funcƟ onal acƟ vity and mRNA expression in peripheral blood 
lymphocytes and monocyte-derived macrophages from RA paƟ ents with diﬀ erent response to DMARD 
treatment.
(A) FuncƟ onal acƟ vity of P-gp in peripheral blood lymphocytes and CD3+ cells derived from RA paƟ ents 
which were indicated as DMARD non-responders or responders, (B) RelaƟ ve mRNA expression of P-gp, 
BCRP and MRP1 in peripheral blood lymphocytes, (C) RelaƟ ve mRNA expression of MDR transporters 
MRP2-7 in peripheral blood lymphocytes, and (D) RelaƟ ve mRNA expression of MDR transporters Pgp, 
BCRP and MRP1-7 in monocyte-derived macrophages. Horizontal and verƟ cal bars depict the median 
and maximum/minimum value, respecƟ vely. StaƟ sƟ cally signifi cant diﬀ erences between RA paƟ ents and 
healthy controls, analyzed by Mann-Whitney test, are indicated with an asterisk when p≤0.05. MDR trans-
porter acƟ vity was expressed as an AcƟ vity Index (AI) by comparing the mean fl uorescence level in the 
presence of the appropriate inhibitor with the fl uorescence level in the absence of the inhibitor.
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Figure 5: MDR funcƟ onal acƟ vity and mRNA expression in peripheral blood lymphocytes and monocyte-
derived macrophages from DMARD non-responders compared to DMARD-naive paƟ ents.
FuncƟ onal acƟ vity of P-gp, BCRP and MRP1 in (A) peripheral blood lymphocytes and (B) CD3+ cells derived 
from RA paƟ ents which were indicated as DMARD non-responders or DMARD-naive, (C) RelaƟ ve mRNA ex-
pression of P-gp, BCRP and MRP1 in peripheral blood lymphocytes, (D) RelaƟ ve mRNA expression of MDR 
transporters MRP2-7 in peripheral blood lymphocytes, and (E) RelaƟ ve mRNA expression of MDR trans-
porters Pgp, BCRP and MRP1-7 in monocyte-derived macrophages. Horizontal and verƟ cal bars depict the 
median and maximum/minimum value, respecƟ vely. StaƟ sƟ cally signifi cant diﬀ erences between RA pa-
Ɵ ents and healthy controls, analyzed by Mann-Whitney test, are indicated with an asterisk when p≤0.05. 
MDR transporter acƟ vity was expressed as an AcƟ vity Index (AI) by comparing the mean fl uorescence 
level in the presence of the appropriate inhibitor with the fl uorescence level in the absence of the inhibitor.
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ESR. The results of the correlaƟ on and regression analysis are summarized in Supple-
mentary Table S6. With respect to MDR mRNA levels in PBLs, a signifi cant correlaƟ on 
was observed between MRP4 mRNA expression and ESR values (Spearman r=0.536, 
p = 0.032, β = 0.001) along with a near signifi cant correlaƟ on with the DAS28 score 
(Spearman r = 0.450, p = 0.080, β = 0.012) (Figure S1, Table S6). Overall, no correla-
Ɵ on was found between the funcƟ onal acƟ vity of any of the tested MDR transporters 
and the DAS28 score or ESR from DMARD responders and DMARD non-responders. 
In contrast, for MDM signifi cant correlaƟ ons were observed for P-gp protein expres-
sion levels and DAS28 values (Spearman R = 0.775, p = 0.011, β = 0.221) as well as 
MRP6 protein expression and ESR (Spearman R = 0.654, p = 0.034, β = 0.002) (Figure 
S1, Table S6). Taken collecƟ vely, these results demonstrate that selecƟ ve MDR trans-
porters including MRP2, 4 and 6 are apparently diﬀ erenƟ ally upregulated in either 
PBLs or MDM following DMARD treatment or in conjuncƟ on with disease acƟ vity or 
ESR. 
DISCUSSION
This study demonstrates that selected members of the ABC superfamily of MDR ef-
fl ux transporters are diﬀ erenƟ ally upregulated in immune-eﬀ ector cells from RA pa-
Ɵ ents as compared to healthy volunteers. In parƟ cular, mRNA levels of MRP1, MRP4 
and MRP7 are upregulated in PBLs from RA paƟ ents, whereas BCRP mRNA and pro-
tein levels were markedly upregulated in MDM from RA paƟ ents. Furthermore, P-gp 
acƟ vity and mRNA levels were increased in PBLs from RA paƟ ents that had an at-
tenuated clinical response to DMARDs. Finally, Pgp protein expression in MDM was 
correlated with DAS28 disease acƟ vity score, while MRP4 mRNA (in PBL) and MRP4 
protein (in MDM) were correlated with ESR.
Although the current treatment of RA with DMARDs has proven its eﬀ ecƟ veness, 
paƟ ents are sƟ ll confronted either with inherent or acquired resistance phenom-
ena to DMARD therapy (11-13, 18, 24, 32, 54) for which the underlying molecular 
mechanisms remain sƟ ll unclear. It has been recognized that enhanced cellular drug 
extrusion, facilitated by MDR eﬄ  ux pumps of the ABC superfamily, could contribute 
to an aƩ enuated response/resistance to DMARDs (18, 24, 36). Moreover, there is 
cumulaƟ ve evidence that beyond a pharmacological funcƟ on of ABC transporters, 
some of them may also elicit a physiological funcƟ on by mediaƟ ng the eﬄ  ux of pro-
infl ammatory factors, thereby promoƟ ng (anƟ )infl ammatory responses (18, 37, 55-
62). The objecƟ ves of the current study were to focus on a selected group of 11 MDR 
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eﬄ  ux transporters (Pgp, BCRP and MRP1-9) and invesƟ gate whether: (a) the expres-
sion and acƟ vity of MDR transporters was diﬀ erenƟ ally upregulated in RA paƟ ents 
compared to healthy controls, (b) MDR transporter expression is provoked following 
DMARD treatment, and/or (c) is implicated in DMARD responsiveness. These ques-
Ɵ ons were addressed in two populaƟ ons of immune cells, PBLs and MDMs, implicat-
ed in the pathophysiology of RA (1), obtained from healthy donors and DMARD-naive 
and DMARD-(non) responding RA paƟ ents.
Previously other groups also demonstrated that P-gp expression (mRNA levels and 
funcƟ onal eﬄ  ux acƟ vity) can be increased in PBLs/CD3+ cells of RA paƟ ents (30, 34) 
and for other auto-immune diseases (57, 63, 64). On top of this, the present study 
also revealed that MRP1, MRP4 and MRP7 mRNA expression were signifi cantly in-
creased (Fig. 1, Table S2). InteresƟ ngly, important immuno-regulatory funcƟ ons of 
MRP1 and MRP4 have been demonstrated in dendriƟ c cells (65-68) as well as for 
P-gp in T-cells (69). The presence of these ATP-driven eﬄ  ux transporters could also 
be involved in conferring resistance to anƟ -rheumaƟ c drugs, e.g. glucocorƟ coids by 
P-gp (31, 33), chloroquine by MRP1, (26) and MTX by MRP1 and MRP4, (24, 70). For 
MRP7, no DMARD substrates are presently known, and also its physiological funcƟ on 
is as yet unclear (71). 
The present study has its limitaƟ ons due to its cross-secƟ onal design and the small 
sample size of DMARD-naïve paƟ ents, which underpowered staƟ sƟ cal analyses. 
Thus, cauƟ on should be made in jumping to conclusive statements what propor-
Ɵ on of the upregulated expression of mulƟ ple MDR transporters is aƩ ributable to 
the infl ammatory process and/or disease acƟ vity and what proporƟ on is a DMARD 
treatment-induced phenomenon. The noƟ on, however, that MRP4 mRNA expression 
in PBLs of RA paƟ ents is correlated with disease acƟ vity and ESR (Table S5) supports 
the concept that disease acƟ vity is a contribuƟ ng factor in the upregulaƟ on of spe-
cifi c MDR eﬄ  ux transporters. Consistently, Hider et al (72) showed that treatment of 
primary RA paƟ ents with a constant low dose of MTX reduced disease acƟ vity as well 
as MRP1 expression in PBLs. In addiƟ on, Agarwal et al showed that with refractori-
ness to MTX therapy, P-gp protein expression on PBLs was increased and associated 
with disease acƟ vity, but P-gp was not a common cause of methotrexate resistance 
(73). Notwithstanding this fact, DMARD non-responsiveness aŌ er dose escalaƟ ons 
can apparently also contribute to MDR transporter upregulaƟ on as illustrated by ob-
servaƟ ons that increased P-gp mRNA expression and funcƟ onal acƟ vity is  correlated 
with a lower DMARD response. The present study also revealed that the profi le of 
MDR transporter expression in MDM diﬀ ers considerably from that of PBLs/CD3+ 
cells from RA paƟ ents and controls. In parƟ cular, BCRP mRNA and protein as well 
as MRP3 mRNA levels were diﬀ erenƟ ally and signifi cantly increased in MDMs ob-
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tained from RA paƟ ents as compared to those from controls. A funcƟ onal role for 
MRP3 in macrophages has not yet been reported. Intriguingely, the data for BCRP 
expression on MDM is very much reminiscent of the marked expression of BCRP on 
macrophages in the synovial lining and sublining in infl amed synovial Ɵ ssue from 
RA paƟ ents (36). In fact, BCRP expression on macrophages residing in the synovial 
sublining correlated with a diminished response to two DMARD substrates of BCRP, 
MTX and lefl unomide (36). However, in the current study, BCRP expression on MDMs 
was not signifi cantly correlated with DMARD-responsiveness, neither were expres-
sion levels of the other MDR transporters tested (Table S4). It is conceivable that a 7 
day ex vivo/in vitro culture period of MDMs could have deranged possible correla-
Ɵ ve eﬀ ects as opposed to macrophages directly stained for BCRP within the synovial 
architecture of RA paƟ ents (36). Furthermore, it should also be considered that BCRP 
expression on synovial macrophages was observed already prior to the iniƟ aƟ on of 
treatment with the DMARDs MTX and lefl unomide (36), while in the present study 
BCRP expression was noted on MDMs from paƟ ents of whom the majority received 
MTX treatment. Hence, when BCRP expression would be dominantly infl uenced by 
micro-environmental factors (e.g. hypoxia (74)) in synovial Ɵ ssue rather than being 
DMARD therapy induced, this may also account for an apparent lack of correlaƟ on 
of BCRP expression on MDMs with MTX response. Whether this also holds for other 
DMARDs or combinaƟ ons of DMARDs, remains to be established. 
In conclusion, this is the fi rst study that invesƟ gated the potenƟ al involvement of a 
broad panel of MDR transporters in immune cells in relaƟ on to DMARD treatment 
and clinical response parameters. The study confi rms P-gp as relevant determinant 
in resistance to DMARDs but reveals a possible role BCRP in DMARD resistance in 
MDMs. The knowledge of the preferred DMARD substrates for MDR transporters 
(24, 36), combined with the analysis of expression levels of MDR transporters on 
various immune-competent cells, may help to select treatment of RA paƟ ents with 
those DMARDs or experimental drugs that are no or poor substrates for either one of 
the upregulated drug eﬄ  ux transporters. The present study has its limitaƟ ons due to 
its cross-secƟ onal design and the small sample size of DMARD-naive paƟ ents, which 
underpowered staƟ sƟ cal analyses. However, the encouraging results obtained war-
rant further evaluaƟ on in studies with a longitudinal design to monitor alteraƟ ons in 
expression/funcƟ onal acƟ vity of MDR transporters during the course of treatment of 
individual RA paƟ ents.
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Supplementary data
Table S1: Primer and probe concentraƟ on and sequences of the selected MDR transporters and 
housekeeping genes
Gene Primer ConcentraƟ on
Ct Value of reference 
standard*
GUS
Forward GAAAATATGTGGTTGGAGAGCTCATT 300 nM 32.04 (0.71)
Reverse CCGAGTGAAGATCCCCTTTTTA 300 nM
Probe CCAGCACTCTCGTCGGTGACTGTTCA 200 nM
GAPDH
Forward GTCGGAGTCAAGGGATT 300 nM 24.34 (0.41)
Reverse AAGCTTCCCGTTCTCAG 300 nM
Probe TCAACTACATGGTTTACATGTTCCAA 200 nM
MRP1
Forward TACCTCCTGTGGCTGAATCTGG 300 nM 29.63 (0.34)
Reverse CCGATTGTCTTTGCTCTTCATG 300 nM
Probe CCGTCAATGCTGTGATGGCGATGAT 200 nM
MRP2
Forward AGCGAGACCGTATCAGGTT 300 nM 35.12 (0.73)
Reverse TTCTGGTTGGTGTCAATCCTCA 300 nM
Probe TGCCTTTGAGCACCAGCAGCGATTT 200 nM
MRP3
Forward GCACCATTGTCGTGGCTACA 300 nM 32.11 (0.40)
Reverse GCAGGACACCCAGGACCAT 300 nM
Probe CATCCTCTCCCACCTGTCCAAGCTCA 200 nM
MRP4
Forward TGGATTCTGTGGCTTTGAACAC 900 nM 27.72 (0.68)
Reverse AGCCAAAATGAGCGTGCAA 900 nM
Probe CGTACGCCTATGCCACGGTGCTG 300 nM
MRP5
Forward CCCAGGCAACAGAGTCTAACC 300 nM 30.28 (0.55)
Reverse CGGTAATTCAATGCCCAAGTC 300 nM
Probe TGACGGAAATCGTGCGGTCTTGGT 200 nM
MRP6
Forward AGACACGGTTGACGTGGACAT 900 nM 29.15 (0.29)
Reverse GCTGACCTCCAGGAGTCCAA 900 nM
Probe CCAGACAAACTCCGGTCCCTGCTGAT 250 nM
MRP7
Forward GCGGGTTAAGTCTGTGACAGA 900 nM 32.88 (0.77)
Reverse CCCACCCGCAGAACTTGA 900 nM
Probe CTGCTGAGTGGCATTCGGGTC 250 nM
MRP8
Forward AGGGTCTACCACCACTACATCCA 900 nM 29.36 (0.34)
Reverse CGATCAGCACCACGAAGAAG 900 nM
Probe CAGCTGGAGGTTACATGGTCTCTTGCATAATT 250 nM
MRP9
Forward TTCATCCAAAGGCCTGTCATT 900 nM 32.50 (0.16)
Reverse CCGTTCGCACACACACTT 900 nM
Probe CATACATCATCCAGCTGAGCGGACTGCT 250 nM
BCRP
Forward AGATGGGTTTCCAAGCGTTCAT 400 nM 32.21 (0.63) 
Reverse CCAGTCCCAGTACGACTGTGACA 400 nM
Probe TGCTGGGTAATCCCCAGGCCTCTATAGC 200 nM
P-gp
Forward GTCCCAGGAGCCCATCCT 500 nM 32.74 (1.09)
Reverse CCCGGCTGTTGTCTCCATA 500 nM
Probe TTGACTGCAGCATTGCTGAGAACATTGC 200 nM
*Average Ct values from a 10 Ɵ me diluƟ on of the used reference standard based on a cDNA pool 
derived from various MDR overexpressing human cell lines, including 2008/MRP1-3, HEK/MRP4-7, 
MCF/MR (BCRP) and CEM/VBL (P-gp). This standard was used to calculate relaƟ ve expression levels 
in all tested samples.
137
MDR transporters in immune cells from RA paƟ ents
Table S2: MDR mRNA and protein expression/acƟ vity in controls and RA paƟ ents
Controls RA Total
mRNA expression in PBLs N mean +/- SD median N mean +/- SD median p* Index**
P-gp 10 1.774± 0.745 1.903 21 3.233 ± 2.109 2.533 0.104 1.822
BCRP 8 0.150±0.115 0.1100 12 0.133±0.105 0.114 0.512 0.887
MRP1 10 1.189±0.668 1.028 21 2.456±1.650 2.183 0.024* 2.066
MRP2 10 0.376±0.261 0.331 21 0.628±0.408 0.585 0.134 1.670
MRP3 9 0.223±0.346 0.113 21 0.248±0.319 0.141 0.556 1.112
MRP4 10 0.071±0.019 0.075 21 0.113±0.0500 0.098 0.019* 1.592
MRP5 10 0.262±0.201 0.205 21 0.317±0.175 0.264 0.321 1.210
MRP6 3 0.005 ± 0.005 0.002 6 0.009 ± 0.008 0.006 0.262 1.800
MRP7 10 0.279±0.190 0.243 21 0.535±0.336 0.476 0.015* 1.918
MDR acƟ vity in peripheral blood lymphocytes (AcƟ vity Index)
P-gp 22 2.031±0.630 1.985 26 2.630±1.400 1.800 0.482 1.295
MRP1 10 1.271±0.318 1.195 24 1.234±0.2952 1.215 0.850 0.971
BCRP 8 1.019±0.169 0.985 21 1.003±0.1871 1.010 0.788 0.984
MDR acƟ vity in CD3+ cells (AcƟ vity Index)
P-gp 24 1.743±0.386 1.775 26 2.378±1.149 1.935 0.162 1.364
MRP1 12 1.358±0.334 1.330 24 1.223±0.346 1.225 0.298 0.901
BCRP 8 1.003±0.171 0.950 22 1.000±0.102 0.970 0.313 0.997
mRNA expression in monocyte-derived macrophages
P-gp 5 0.021± 0.013 0.021 11 0.056± 0.117 0.012 0.571 2.667
BCRP 11 0.040± 0.046 0.0260 12 0.112± 0.1015 0.074 0.034* 2.800
MRP1 11 0.282 ± 0.115 0.260 12 0.413±0.221 0.320 0.132 1.465
MRP2 6 0.037± 0.009 0.034 11 0.055± 0.067 0.030 0.880 1.486
MRP3 11 0.956± 0.239 1.016 12 1.345± 0.451 1.427 0.053 1.407
MRP4 11 0.016± 0.006 0.013 12 0.019± 0.008 0.018 0.340 1.188
MRP5 11 0.120± 0.164 0.113 12 0.250± 0.149 0.258 0.340 2.083
MRP6 6 0.001± 0.000 0.001 11 0.002± 0.001 0.002 0.451 2.000
MRP7 6 0.103± 0.071 0.096 11 0.144± 0.090 0.142 0.514 1.398
MDR protein expression in monocyte-derived macrophages
P-gp 6 0.662±0.711 0.312 18 0.952±1.025 0.625 0.920 1.438
BCRP 11 0.532±0.395 0.410 27 1.270±0.987 0.982 0.025* 2.387
MRP1 10 0.632±0.324 0.602 26 0.743±0.526 0.658 0.751 1.176
MRP2 3 0.517±0.448 0.750 9 0.244±0.331 0.000 0.282 0.472
MRP4 7 0.227±0.274 0.063 23 0.179±0.306 0.000 0.603 0.789
MRP5 7 0.501±0.337 0.595 23 0.472±0.435 0.436 0.641 0.942
MRP6 5 0.180±0.247 0.000 17 0.233±0.349 0.100 0.874 1.294
*p based on mean values; **RaƟ o of mean value of RA paƟ ents versus healthy controls. Expression of 
MRP8 and MRP9 were below detecƟ on limit (Ct>40)
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Table S3: MDR mRNA and protein expression/acƟ vity in DMARD naive and DMARD treated RA paƟ ents
DMARD Naive DMARD treated
mRNA expression in PBL’s N mean +/- SD median N mean +/- SD median p* Index**
P-gp 4 2.037± 1.395 1.446 17 3.515± 2.180 3.242 0.194 1.726
BCRP 4 0.100± 0.085 0.090 8 0.150± 0.115 0.131 0.461 1.500
MRP1 4 1.839± 1.190 1.424 17 2.601± 1.738 2.310 0.622 1.414
MRP2 4 0.461± 0.317 0.415 17 0.667± 0.424 0.688 0.502 1.447
MRP3 4 0.284± 0.170 0.330 17 0.239± 0.348 0.127 0.303 0.842
MRP4 4 0.078± 0.0423 0.076 17 0.121± 0.049 0.098 0.194 1.551
MRP5 4 0.242± 0.098 0.251 17 0.334± 0.186 0.264 0.561 1.380
MRP6
MRP7 4 0.578± 0.220 0.502 17 0.525± 0.362 0.451 0.447 0.908
MDR acƟ vity in peripheral blood lymphocytes (AcƟ vity Index)
P-gp 8 1.966± 1.199 1.490 18 2.925± 1.411 2.945 0.0802 1.488
MRP1 8 1.146± 0.149 1.170 16 1.278± 0.342 1.265 0.1336 1.115
BCRP 7 0.964± 0.103 0.980 15 1.015± 0.208 1.015 0.2829 1.053
MDR acƟ vity in CD3+ cells (AcƟ vity Index)
P-gp 7 1.556± 0.412 1.610 19 2.681± 1.190 2.430 0.022* 1.723
MRP1 7 1.109± 0.206 1.210 17 1.269± 0.385 1.260 0.227 1.144
BCRP 7 0.986± 0.047 0.970 15 1.001± 0.121 0.970 0.916 1.015
mRNA expression in monocyte-derived macrophages
P-gp 6 0.017± 0.013 0.010 7 0.083± 0.142 0.018 0.234 4.882
BCRP 4 0.086± 0.115 0.041 8 0.125± 0.100 0.085 0.283 1.453
MRP1 4 0.324± 0.078 0.346 8 0.458± 0.259 0.3179 0.933 1.414
MRP2 4 0.030± 0.018 0.026 7 0.069± 0.082 0.056 0.315 2.300
MRP3 4 1.057± 0.255 0.959 8 1.489± 0.470 1.652 0.109 1.409
MRP4 4 0.022± 0.007 0.023 8 0.017± 0.008 0.017 0.368 0.773
MRP5 4 0.360± 0.195 0.382 8 0.196± 0.092 0.197 0.154 0.544
MRP6 4 0.001± 0.001 0.000 7 0.002± 0.002 0.003 0.164 2.000
MRP7 4 0.135± 0.042 0.144 7 0.149± 0.112 0.099 0.927 1.104
*p based on mean values; **RaƟ o of mean value of DMARD treated versus DMARD naive paƟ ents; Expres-
sion of MRP8 and MRP9 were below detecƟ on limit (Ct>40).
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Table S4: MDR mRNA and protein expression/acƟ vity in DMARD responders and non-responders
DMARD responders DMARD non-responders
mRNA expression in PBL’s N mean +/- SD median N mean +/- SD median p* Index**
P-gp 8 2.722 ± 2.056 2.109 9 4.219 ± 2.150 3.810 0.167 1.550
BCRP 4 0.138 ± 0.150 0.075 4 0.162 ± 0.091 0.194 0.886 1.174
MRP1 8 2.095 ± 1.911 1.102 9 3.050 ± 1.536 2.610 0.114 1.456
MRP2 8 0.525 ± 0.425 0.405 9 0.796 ± 0.405 0.736 0.139 1.516
MRP3 8 0.178 ± 0.167 0.104 9 0.294 ± 0.459 0.142 0.888 1.652
MRP4 8 0.101 ± 0.044 0.080 9 0.138 ± 0.049 0.127 0.092 1.366
MRP5 8 0.251 ± 0.114 0.225 9 0.408 ± 0.212 0.297 0.114 1.625
MRP6 2 0.019 ± 0.004 0.019 1 0.009 0.009 - 0.474
MRP7 8 0.382 ± 0.257 0.302 9 0.651 ± 0.408 0.476 0.167 1.704
MDR acƟ vity in peripheral blood lymphocytes (AcƟ vity Index)
P-gp 3 2.703 ± 2.128 1.510 15 2.969 ± 1.326 3.150 0.722 1.098
MRP1 1 1.610 1.610 15 1.255 ± 0.342 1.250 - 0.780
BCRP 1 1.450 1.450 15 0.986 ± 0.178 1.010 - 0.680
MDR acƟ vity in CD3+ cells (AcƟ vity Index)
P-gp 3 1.556 ± 0.412 1.810 15 2.737 ± 2.090 2.540 0.955 1.759
MRP1 1 1.240 1.240 15 1.271 ± 0.398 1.270 - 1.025
BCRP 1 0.940 0.940 15 0.964 ± 0.200 0.970 - 1.026
mRNA expression in monocyte-derived macrophages
P-gp 3 0.050± 0.058 0.024 4 0.108± 0.191 0.015 0.857 2.160
BCRP 3 0.096±0.040 0.075 5 0.141±0.125 0.095 1.000 1.469
MRP1 3 0.430 ± 0.278 0.331 5 0.475± 0.280 0.305 1.000 1.105
MRP2 3 0.050±0.024 0.057 4 0.083±0.112 0.040 0.629 1.660
MRP3 3 1.739±0.362 1.661 5 1.339±0.495 1.643 0.571 0.770
MRP4 3 0.012±0.006 0.009 5 0.019±0.010 0.019 0.250 1.583
MRP5 3 0.152±0.097 0.116 5 0.222±0.088 0.255 0.250 1.461
MRP6 3 0.003±0.0001 0.003 4 0.002±0.002 0,001 0.400 0.667
MRP7 3 0.188±0.096 0.174 4 0.120±0.128 0.068 0.400 0.638
MDR protein expression in monocyte-derived macrophages
P-gp 10 1.113 ± 1.228 0.615 11 0.968 ± 0.863 0.900 0.698 0.870
BCRP 13 1.343 ± 1.188 0.750 14 1.191 ± 0.699 0.966 0.827 0.887
MRP1 11 0.933 ± 0.571 1.045 13 0.633 ± 0.486 0.445 0.259 0.678
MRP2 4 0.313 ± 0.375 0.250 4 0.238 ± 0.354 0.100 0.886 0.760
MRP4 8 0.201 ± 0.358 0.000 13 0.193 ± 0.301 0.115 0.633 0.960
MRP5 10 0.133 ± 0.589 0.334 11 0.549 ± 0.273 0.493 0.916 4.128
MRP6 8 0.253 ± 0.454 0.000 8 0.241 ± 0.254 0.187 0.328 0.953
*p based on mean values; **RaƟ o of mean value of DMARD non-responders versus DMARD responders; 
Expression of MRP8 and MRP9 were below detecƟ on limit (Ct>40).
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Table S5: MDR mRNA and protein expression/acƟ vity in DMARD naive and DMARD non-responders
DMARD Naive DMARD non-responders
mRNA expression in PBL’s N mean +/- SD median N mean +/- SD median p* Index**
P-gp 4 2.037± 1.395 1.446 9 4.219 ± 2.150 3.810 0.050 2.071
BCRP 4 0.100± 0.085 0.090 4 0.162 ± 0.091 0.194 0.343 1.620
MRP1 4 1.839± 1.190 1.424 9 3.050 ± 1.536 2.610 0.200 1.659
MRP2 4 0.461± 0.317 0.415 9 0.796 ± 0.405 0.736 0.200 1.727
MRP3 4 0.284± 0.170 0.330 9 0.294 ± 0.459 0.142 0.330 1.035
MRP4 4 0.078± 0.0423 0.076 9 0.138 ± 0.049 0.127 0.106 1.769
MRP5 4 0.242± 0.098 0.251 9 0.408 ± 0.212 0.297 0.330 1.686
MRP6 1 0.009 0.009 -
MRP7 4 0.578± 0.220 0.502 9 0.651 ± 0.408 0.476 0.825 1.126
MDR acƟ vity in peripheral blood lymphocytes (AcƟ vity Index)
P-gp 8 1.966± 1.199 1.490 15 2.969 ± 1.326 3.150 0.076 1.510
MRP1 8 1.146± 0.149 1.170 15 1.255 ± 0.342 1.250 0.186 1.095
BCRP 5 0.964± 0.103 0.980 15 0.986 ± 0.178 1.010 0.359 1.023
MDR acƟ vity in CD3+ cells (AcƟ vity Index)
P-gp 7 1.556± 0.412 1.610 15 2.737 ± 2.090 2.540 0.019 1.759
MRP1 7 1.109± 0.206 1.210 15 1.271 ± 0.398 1.270 0.256 1.146
BCRP 5 0.986± 0.047 0.970 15 0.964 ± 0.200 0.970 0.916 0.978
mRNA expression in monocyte-derived macrophages
P-gp 6 0.017± 0.013 0.010 4 0.108± 0.191 0.015 0.057 6.353
BCRP 4 0.086± 0.115 0.041 5 0.141±0.125 0.095 0.413 1.640
MRP1 4 0.324± 0.078 0.346 5 0.475± 0.280 0.305 0.905 1.466
MRP2 4 0.030± 0.018 0.026 4 0.083±0.112 0.040 0.686 2.767
MRP3 4 1.057± 0.255 0.959 5 1.339±0.495 1.643 0.286 1.267
MRP4 4 0.022± 0.007 0.023 5 0.019±0.010 0.019 0.730 0.864
MRP5 4 0.360± 0.195 0.382 5 0.222±0.088 0.255 0.286 0.617
MRP6 4 0.001± 0.001 0.000 4 0.002±0.002 0,001 0.686 2.000
MRP7 4 0.135± 0.042 0.144 4 0.120±0.128 0.068 0.486 0.889
*p based on mean values; **RaƟ o of mean value of DMARD non-responders versus DMARD naive pa-
Ɵ ents; Expression of MRP8 and MRP9 were below detecƟ on limit (Ct>40).
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Table S6: CorrelaƟ on of funcƟ onal acƟ vity, protein expression and mRNA expression of MDR trans-
porters in peripheral blood lymphocytes and monocyte-derived macrophages with DAS28 and ESR
DAS28 ESR
n r β P r β P
PBL acƟ vity
P-gp 18 -0.161 -0.217 ± 0.232 0.523 -0.047 -0.018 ± 0.018 0.854
MRP1 16 0.001 -0.009 ± 0.070 0.996 -0.127 -0.000 ± 0.005 0.640
BCRP 16 -0.216 -0.041 ± 0.041 0.423 -0.155 0.003 ± 0.003 0.568
CD3+ acƟ vity
P-gp 19 -0.152 -0.142 ± 0.195 0.535 0.064 -0.005 ± 0.015 0.794
MRP1 17 0.173 0.048 ± 0.075 0.507 0.230 0.002 ± 0.005 0.375
BCRP 17 -0.038 -0.023 ± 0.064 0.885 -0.028 0.000 ± 0.004 0.916
PBL mRNA
P-gp 16 0.394 0.584 ± 0.324 0.131 0.249 0.024 ± 0.021 0.353
BCRP 7 0.250 0.046 ± 0.036 0.595 0.523 0.002 ± 0.002 0.236
MRP1 16 0.238 0.202 ± 0.273 0.374 0.0457 0.012 ± 0.017 0.867
MRP2 16 0.171 0.065 ± 0.067 0.528 0.102 0.006 ± 0.004 0.708
MRP3 16 -0.288 -0.034 ± 0.057 0.279 -0.277 -0.003 ± 0.003 0.299
MRP4 16 0.450 0.012 ± 0.007 0.080 0.536 0.001 ± 0.000 0.032*
MRP5 16 0.221 0.025 ± 0.031 0.412 0.004 -0.001 ± 0.002 0.987
Macrophages mRNA
P-gp 4 0.600 0.002 ± 0.003 0.417 -0.200 -0.000 ± 0.000 0.917
BCRP 5 -0.300 -0.017 ± 0.072 0.683 0.500 0.002 ± 0.004 0.450
MRP1 5 -0.600 -0.246 ± 0.096 0.350 -0.100 -0.007 ± 0.009 0.950
MRP2 4 -0.400 0.002 ± 0.001 0.750 0.800 0.002± 0.001 0.333
MRP3 5 -0.400 -0.281 ± 0.325 0.517 0.600 0.012± 0.0190 0.350
MRP4 5 0.800 0.004 ± 0.002 0.133 -0.200 0.000± 0.000 0.783
MRP5 5 0.400 0.047 ± 0.042 0.517 0.900 0.004± 0.002 0.083
Macrophages 
protein
P-gp 10 0.775 0.221 ± 0.077 0.011* 0.582 0.010 ± 0.005 0.081
BCRP 16 0.349 0.084 ± 0.095 0.186 0.448 0.008 ± 0.005 0.082
MRP1 17 0.153 0.038 ± 0.076 0.557 0.234 0.004 ± 0.004 0.366
MRP2 8 -0.230 -0.050 ± 0.066 0.582 -0.103 -0.000 ± 0.004 0.793
MRP4 16 0.338 0.017 ± 0.014 0.200 0.2778 0.001 ± 0.001 0.298
MRP5 16 0.068 -0.011 ± 0.063 0.802 0.014 -0.001 ± 0.004 0.959
MRP6 11 0.548 0.024 ± 0.016 0.088 0.6543 0.002 ± 0.001 0.034*
 Expression of MRP8 and MRP9 were below detecƟ on limit (Ct>40)
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Figure S1: (A) CorrelaƟ on of BSE with relaƟ ve MRP4 mRNA expression in peripheral blood lymphocytes 
obtained from RA paƟ ents. (B) CorrelaƟ on of DAS28 scores with P-gp protein expression in monocyte-
derived macrophages derived from RA paƟ ents. (C) correlaƟ on of BSE with MRP6 protein expression in 
monocyte-derived macrophages derived from RA paƟ ents. 
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Chapter 7
Summary
ObjecƟ ve. To determine whether mulƟ drugresistance eﬄ  ux transporters are ex-
pressed on immune eﬀ ector cells in synovial Ɵ ssue from paƟ ents with rheumatoid 
arthriƟ s (RA) and compromise the eﬃ  cacy of methotrexate (MTX) and lefl unomide 
(LEF). 
Methods. Synovial Ɵ ssue biopsy samples obtained from RA paƟ ents before treat-
ment and 4 months aŌ er starƟ ng treatment with MTX (n = 17) or LEF (n = 13) were 
examined by immunohistochemical staining and digital image analysis for the ex-
pression of the drug eﬄ  ux transporters P-glycoprotein, mulƟ drug resistance–associ-
ated protein 1 (MRP-1) through MRP-5, MRP-8, MRP-9, and breast cancer resistance 
protein (BCRP), and the relaƟ onship to clinical eﬃ  cacy of MTX and LEF was assessed. 
Results. BCRP expression was observed in all RA synovial biopsy samples, both pre-
treatment and posƩ reatment, but not in control noninfl ammatory synovial Ɵ ssue 
samples from orthopedic paƟ ents. BCRP expression was found both in the inƟ mal 
lining layer and on macrophages and endothelial cells in the synovial sublining. Total 
numbers of macrophages in RA paƟ ents decreased upon treatment; in biopsy sam-
ples with persistently high macrophage counts, 2-fold higher BCRP expression was 
observed. Furthermore, median BCRP expression was signifi cantly increased (3-fold) 
in nonresponders to disease-modifying anƟ rheumaƟ c drugs (DMARDs) compared 
with responders to DMARDs (P = 0.048). Low expression of MRP-1 was found on 
synovial macrophages, along with moderate expression in T cell areas of synovial 
biopsy specimens from one-third of the RA paƟ ents. 
Conclusion. These fi ndings show that the drug resistance–related proteins BCRP and 
MRP-1 are expressed on infl ammatory cells in RA synovial Ɵ ssue. Since MTX is a sub-
strate for both BCRP and MRP-1, and LEF is a high-aﬃ  nity substrate for BCRP, these 
transporters may contribute to reduced therapeuƟ c eﬃ  cacy of these DMARDs.
IntroducƟ on
The disease-modifying anƟ rheumaƟ c drugs (DMARDs) methotrexate (MTX), lefl u-
nomide (LEF), sulfasalazine, and (hydroxy)chloroquine have an established place 
in the treatment of paƟ ents with rheumatoid arthriƟ s (RA), either as single agents 
or in combinaƟ on with other DMARDs or biologic agents (1,2). Despite the potent 
disease-modifying eﬀ ects of these DMARDs, it is well recognized that long-term 
treatment is oŌ en accompanied by a gradual loss of eﬃ  cacy, requiring dosage es-
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calaƟ on up to a stage where treatment has to be disconƟ nued for reasons of inef-
fi cacy and/or toxicity (3–5). From oncology research, it has been established that 
specifi c cell membrane–associated drug eﬄ  ux transporters belonging to the family 
of ATP-binding casseƩ e (ABC) proteins, notably P-glycoprotein (ABCB1), mulƟ drug 
resistance–associated protein 1 (MRP-1) through MRP-5 (ABCC1 through ABCC5), 
and breast cancer resistance protein (BCRP; ABCG2), can be induced upon therapy 
with various anƟ cancer drugs to confer a phenomenon known as acquired (mulƟ )
drug resistance (6–9). Studies conducted in our laboratory have shown that acquired 
resistance to the DMARDs sulfasalazine and chloroquine could be mediated by the 
increased expression of the ABC transporters BCRP and MRP-1, respecƟ vely (10–12). 
Furthermore, it was very recently demonstrated that LEF is a high-aﬃ  nity substrate 
for BCRP (13). 
A number of studies have examined the expression of P-glycoprotein and MRP-1 
(messenger RNA levels, protein levels, funcƟ onal acƟ vity) on peripheral blood cells of 
RA paƟ ents. Maillefert et al (14) observed that P-glycoprotein levels were increased 
on peripheral blood cells from paƟ ents with RA who were treated with predniso-
lone compared with untreated healthy individuals, which may be compaƟ ble with 
the known role of steroids as substrates for P-glycoprotein. Likewise, Llorente et al 
(15) showed that RA paƟ ents had funcƟ onally acƟ ve P-glycoprotein on peripheral 
blood lymphocytes, which was markedly higher in RA paƟ ents in whom disease was 
refractory to treatment than in RA paƟ ents with a good clinical response to DMARD 
therapy. 
More recently, 2 studies evaluated the expression of MRP-1 (by funcƟ onal acƟ vity 
and immunohistochemical staining) as a potenƟ al MTX drug eﬄ  ux pump in periph-
eral blood cells of RA paƟ ents. In a crosssecƟ onal study, Wolf et al (16) demonstrated 
that, counterintuiƟ vely, paƟ ents with funcƟ onal MRP-1 expression who were treated 
with MTX had beƩ er response rates based on the European League Against Rheuma-
Ɵ sm response criteria (17) than did paƟ ents with low MRP-1 acƟ vity. Hider et al (18) 
showed that MRP-1 expression on peripheral blood cells declined from baseline to 6 
months with MTX therapy. These results suggest that beyond drug-induced changes 
in MRP-1 expression during dosage escalaƟ ons, basal levels of MRP-1 expression in 
immune eﬀ ector cells may also be induced by disease acƟ vity/infl ammaƟ on status 
(9). In contrast to studies on peripheral blood cells from RA paƟ ents, liƩ le is known 
about expression levels of ABC transporters on infl ammatory cells in RA synovial Ɵ s-
sue. 
In the present study, we assessed the expression of a panel of ABC transporters with 
an established role in drug resistance in RA synovial Ɵ ssue biopsy samples that were 
obtained prior to and aŌ er 4 months of therapy with MTX and LEF. Beyond P-glyco-
152
Chapter 7
protein, we focused on the more recently idenƟ fi ed ABC transporters MRP-1 through 
MRP-5, MRP-8, and MRP-9, which have MTX among their substrates (8), and BCRP, 
for which both MTX and LEF are known substrates (13), thereby allowing correlaƟ on 
analysis with response to these drugs.
PATIENTS AND METHODS
PaƟ ents
We analyzed synovial Ɵ ssue biopsy specimens derived from the same knee joints of 
17 paƟ ents with acƟ ve RA before and aŌ er 4 months of treatment with MTX (start-
ing dosage 7.5 mg/week; increased stepwise to 15 mg/week over 12 weeks) and 13 
paƟ ents with RA before and aŌ er 4 months of treatment with LEF (20 mg/day; load-
ing dose 100 mg/day for the fi rst 3 days). AcƟ ve disease was defi ned as ≥6 swollen 
or tender joints and levels of moderate or worse on the physician’s and paƟ ent’s as-
sessments of disease acƟ vity. All paƟ ents had at least 1 clinically involved knee joint. 
Concomitant treatment with low-dose prednisone (<10 mg/day) and stable doses 
of nonsteroidal anƟ infl ammatory drugs was allowed. None of the paƟ ents had ever 
received MTX or LEF before enrolling in the study. Treatment with other DMARDs 
was terminated following a washout phase of 28 days. Before treatment and aŌ er 4 
months of treatment, the Disease AcƟ vity Score in 28 joints (DAS28) (19) was deter-
mined. Arthroscopies were performed as described previously (20), as part of a joint 
study that was approved by the medical ethics commiƩ ees of the Leiden University 
Medical Center (Leiden, The Netherlands), and the Leeds University Medical Center 
(Leeds, UK) (21). As noninfl ammatory control synovial Ɵ ssue, we included 7 samples 
from paƟ ents with mechanical joint injury (kindly provided by Dr. B. J. van Royen, VU 
University Medical Center). 
For staƟ sƟ cal analysis, RA paƟ ents were divided into a group of paƟ ents who re-
sponded to DMARDs and a group of paƟ ents who did not respond to DMARDs, ac-
cording to the DAS28 response criteria (19). Responders were paƟ ents with a signifi -
cant decrease in DAS28 score (>1.2) aŌ er treatment and paƟ ents with a moderate 
change in DAS28 score (≤1.2 and ≥0.6) and low/moderate disease acƟ vity (DAS28 
score ≤5.1). The remaining paƟ ents were classifi ed as nonresponders. AddiƟ onal 
analysis was performed based on the C-reacƟ ve protein (CRP) level. PaƟ ents who 
had a normal CRP level (≤10 mg/liter) aŌ er 4 months of treatment were considered 
to be responders.
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Immunohistochemical analysis 
Immunohistochemical staining of cryostat secƟ ons (5 μm) of synovial Ɵ ssue from RA 
paƟ ents and controls was performed using a 3-step immunoperoxidase method as 
described previously (22). SecƟ ons were stained with the following monoclonal anƟ -
bodies (5–10 μg/ml): C219 (anƟ –P-glycoprotein; Alexis, Lausen, Switzerland), MRPr1 
(anƟ –MRP-1), M2III6 (anƟ –MRP-2), M3II9 (anƟ –MRP-3), M4I10 (anƟ –MRP-4), M5I-1 
(anƟ –MRP-5), M8II16 (anƟ –MRP-8), M9I-27 (anƟ –MRP-9), and BXP-21 (anƟ -BCRP), 
as previously described (22,23). T cells and macrophages were stained with phyco-
erythrin (PE)–conjugated anƟ -CD3 (Dako, Glostrup, Denmark) and 3A5 (24), respec-
Ɵ vely. Synovial Ɵ ssue fi broblasts were visualized using PE-conjugated anƟ -CD90 (BD 
PharMingen, San Diego, CA).
Analysis of mulƟ drug resistance–associated protein expression
SecƟ ons stained for BCRP and 3A5 (macrophages) (24) were analyzed by digital im-
age analysis, as described previously (25). Briefl y, for each marker representaƟ ve 
regions were used for image acquisiƟ on, using 400x magnifi caƟ on. These regions 
were divided into 6 high-power fi elds (hpf) with a 3-pixel overlap. PosiƟ ve cells were 
evaluated by analyzing 18 consecuƟ ve hpf and scoring the numbers of posiƟ ve cells 
per square millimeter in the inƟ mal lining layer and synovial sublining.
Double-labeling immunofl uorescence
ABC transporter protein expression was detected with species-specifi c horseradish 
peroxidase (HRP)–labeled secondary reagents, and development was with rhoda-
mine/thyramine (red fl uorescence) according to the instrucƟ ons of the manufac-
turer (Dako). T cells and macrophages (primary anƟ bodies anƟ -CD3 and anƟ -CD68, 
respecƟ vely) were detected with bioƟ n-labeled anƟ -mouse secondary anƟ bodies 
(Dako), with streptavidin–Alexa 488 used as substrate (green fl uorescence; Molecu-
lar Probes, Eugene, OR). Slides were mounted with Vectashield, containing 1 μg/ml 
4’,6-diamidino-2-phenylindole (for staining of nuclei) (Vector, Burlingame, CA). Cells 
were examined using a fl uorescence microscope (Leica, Rijswijk, The Netherlands).
StaƟ sƟ cal analysis
StaƟ sƟ cal analysis was performed using nonparametric tests. CorrelaƟ on of BCRP 
expression in individual paƟ ents before treatment and aŌ er 4 months of treatment 
with MTX or LEF was calculated using Spearman’s rho. The Mann-Whitney U test was 
used to assess signifi cant diﬀ erences in macrophage counts before and aŌ er treat-
ment with MTX and LEF, for BCRP expression between RA paƟ ents compared with 
healthy controls and DMARD responsive paƟ ents compared with paƟ ents whose RA 
was not responsive to DMARDs. P values less than 0.05 were considered signifi cant.
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RESULTS
Expression of drug resistance–related transporters on macrophages, 
T cells, and endothelial cells in RA synovial Ɵ ssue 
Immunohistochemical staining for the drug resistance–related transporters P-glyco-
protein, MRP-1 through MRP-5, MRP-8, MRP-9, and BCRP was performed on synovial 
biopsy specimens obtained from RA paƟ ents prior to and aŌ er 4 months of treat-
ment with MTX (n = 17) or LEF (n = 13). NegaƟ ve staining was observed for all isotype 
controls (Figure 1A). Staining with 3A5 showed that synovial Ɵ ssue samples were 
highly enriched for infi ltrated macrophages in the inƟ mal lining layer and synovial 
sublining (Figure 1B). The most abundantly expressed drug eﬄ  ux transporter in RA 
synovial Ɵ ssue, both in the inƟ mal lining layer and the synovial sublining, appeared 
to be BCRP (Figure 1C). Only a few BCRP-posiƟ ve cells could be idenƟ fi ed in “non-
infl ammatory” synovial Ɵ ssue from orthopedic paƟ ents (Figure 1F), which also dis-
played low levels of infi ltrated macrophages (3A5 staining) (Figure 1E) as compared 
with RA synovium (Figure 1B). More detailed analysis by fl uorescence microscopy 
demonstrated the colocalizaƟ on of BCRP and CD68 in the inƟ mal lining layer and 
Figure 1: Light microscopy images of ATP-binding casseƩ e transporter expression in rheumatoid arthriƟ s 
(RA) and control synovial Ɵ ssue. 
(A) Mouse isotype staining. (B) Macrophage staining with 3A5 in RA synovial Ɵ ssue. (C) Staining for breast 
cancer resistance protein (BCRP) in RA synovial Ɵ ssue. (D) Control synovial Ɵ ssue isotype staining. (E) Ma-
crophage staining with 3A5 in control synovial Ɵ ssue. (F) Staining for BCRP in control synovial Ɵ ssue.
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Figure 2: Immunofl uorescence double staining of RA synovial Ɵ ssue for CD68 and BCRP. 
(A) Macrophage staining with anƟ -CD68. (B) Staining for BCRP with BXP-21. (C) Nuclei staining with 4’,6-di-
amidino-2-phenylindole (DAPI). (D) Merge of A, B, and C. (E-G) More detailed images of macrophage stain-
ing with anƟ -CD68 (E) staining for BCRP with BXP-21 (F) and nuclei staining with DAPI (G) in synovial lining 
cells. (H) Merge of E, F, and G. See Figure 1 for other defi niƟ ons.
Figure 3: Immunofl uorescence double staining of rheumatoid arthriƟ s synovial Ɵ ssue for CD3/mulƟ drug 
resistance–associated protein 1 (MRP-1) and CD68/MRP-1. 
(A) Light microscopy view of T cell aggregate stained with anƟ -CD3. (B) Detailed immunofl uorescence 
picture of CD3 staining in a lymphocyƟ c aggregate (boxed area in A). (C) MRP-1 staining (with MRPr1) of 
the fi eld shown in B. (D) Merge of B and C. (E) Light microscopy view of macrophage staining with anƟ -
CD68. (F) Immunofl uorescence staining for CD68. (G) MRP-1 staining (with MRPr1) of the fi eld shown in F. 
(H) Merge of F and G.
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synovial sublining, confi rming that BCRP is expressed on RA macrophages. BCRP was 
also found to be expressed on endothelial cells (Figures 2A–H), and weak expression 
was observed on perivascular CD3-posiƟ ve T cells (results not shown).
With light microscopy, weak MRP-1 staining was observed in synovial Ɵ ssue biopsy 
specimens from approximately one-third of the RA paƟ ents. With more sensiƟ ve de-
tecƟ on methods (immunofl uorescence; rhodamine/thyramine development), clear 
MRP-1 expression was observed on CD3-posiƟ ve lymphocytes, being most abundant 
in lymphocyƟ c aggregates and less pronounced on neighboring T cells (Figures 3A–
D). With this detecƟ on method we also observed moderate MRP-1 expression on 
CD68-posiƟ ve macrophages in biopsy specimens from the same paƟ ents (Figures 3E 
and F). No colocalizaƟ on of MRP-1 was found with CD90, a marker for synovial Ɵ ssue 
fi broblasts (results not shown). Expression levels of P-glycoprotein, MRP-2 through 
MRP-5, MRP-8, and MRP-9 in synovial Ɵ ssue from RA paƟ ents were below the im-
munohistochemical detecƟ on limit.
BCRP expression and response to MTX and LEF therapy
In synovial Ɵ ssue from 7 healthy controls, consistent with very low macrophage 
counts, only a few BCRP-posiƟ ve cells were idenƟ fi ed. BCRP expression in synovi-
al Ɵ ssue from RA paƟ ents was signifi cantly higher than that in controls (P < 0.001) 
(Figure 4A). BCRP expression in individual paƟ ents appeared to be rather constant 
over Ɵ me, since a signifi cant correlaƟ on was found between BCRP expression before 
treatment and aŌ er 4 months of treatment with MTX or LEF (R = 0.57; P < 0.001) 
(Figure 4B). The median number of 3A5-posiƟ ve macrophages decreased aŌ er treat-
ment with MTX or LEF, from 295 cells/mm2 (range 11–821) before treatment (mean 
DAS28 6.2) to 160 cells/mm2 (range 12–853) aŌ er treatment (mean DAS28 5.0) (P 
= 0.06) (Figure 4C). Within the laƩ er group, those paƟ ents with a persistently high 
macrophage count in the synovial Ɵ ssue aŌ er 4 months of treatment with MTX or LEF 
had a 2-fold higher median number of BRCP-posiƟ ve cells (200 cells/mm2) compared 
with paƟ ents with a low macrophage count (101 cells/mm2) (P = 0.082) (Figure 4D).
Since both MTX and LEF are BCRP substrates (8,13) and thus can be extruded from 
synovial Ɵ ssue macrophages via this transporter, expression levels of BCRP in the 
synovial sublining were correlated with the response to MTX and LEF therapy. In 
paƟ ents whose RA did not respond to therapy, the median number of BCRP-posiƟ ve 
cells aŌ er 4 months of treatment appeared to be signifi cantly higher than in paƟ ents 
who did respond to therapy. The median number of BCRP-posiƟ ve cells in nonre-
sponders was 3-fold higher using the DAS28 response criteria (P = 0.048) (Figure 
5A) and 4-fold higher using CRP level (P = 0.035) (Figure 5B). Analysis of MTX and 
LEF separately also showed higher BCRP expression in nonresponders (using either 
the DAS28 or CRP level) compared with responders, although this diﬀ erence only 
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reached staƟ sƟ cal signifi cance for MTX in the analysis of CRP level (P = 0.023) (Figure 
5B). The low incidence of MRP-1 expression in the synovial samples from RA paƟ ents 
did not allow correlaƟ on analysis with disease acƟ vity or response to MTX therapy.
DISCUSSION
This is the fi rst detailed study invesƟ gaƟ ng RA synovial Ɵ ssue expression of a panel of 
mulƟ drug transporter proteins from the family of ABC transporters, which are known 
to confer resistance to mulƟ ple anƟ cancer drugs as well as DMARDs (9,26). Immuno-
A B
C
Figure 4: (A) BCRP expression in the sublining layer in controls (median 3 posiƟ ve cells/mm2 [range 0–13]) 
and paƟ ents with RA (median 77 posiƟ ve cells/mm2 [range 2–1,617]). (B) CorrelaƟ on between BCRP ex-
pression in the sublining layer before treatment and BCRP expression aŌ er 4 months of treatment with 
methotrexate (MTX) or lefl unomide (LEF) in individual paƟ ents. (C) Number of 3A5-posiƟ ve macrophages 
in the sublining layer and Disease AcƟ vity Score in 28 joints (DAS28) before treatment (median 259 posi-
Ɵ ve cells/mm2 [range 11–821]; mean DAS28 score 6.2) and aŌ er 4 months of treatment with MTX or LEF 
(median 160 posiƟ ve cells/mm2 [range 12–853]; mean DAS28 score 5.0). (D) BCRP expression in the sublin-
ing layer aŌ er 4 months of treatment in paƟ ents with high macrophage counts (## in C) and paƟ ents with 
low macrophage counts (# in C). Values are the number of posiƟ ve cells/mm2. Horizontal bars show the 
median. The median numbers of BCRP-posiƟ ve cells in paƟ ents with high macrophage counts and paƟ ents 
with low macrophage counts were 200 cells/mm2 and 101 cells/mm2, respecƟ vely. ** = P < 0.01. Mɸ = 
macrophage (see Figure 1 for other defi niƟ ons).
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histochemical detecƟ on of P-glycoprotein, MRP-2 through MRP-5, MRP-8, and MRP-
9 in RA synovial Ɵ ssue was not observed, in contrast to the drug transporters MRP-1 
and BCRP, the laƩ er being markedly expressed on RA synovial Ɵ ssue macrophages 
in the inƟ mal lining layer and the synovial sublining and on endothelial cells. Impor-
tantly, BCRP expression was observed in the synovial Ɵ ssue from RA paƟ ents prior to 
therapy. This fi nding suggests that BCRP expression may be intrinsically associated 
with the infl ammatory status of RA synovial Ɵ ssue, rather than being a therapy-in-
duced phenomenon as is commonly observed in anƟ cancer treatment (27–30).
It should, however, be noted that some paƟ ents had received sulfasalazine as iniƟ al 
treatment prior to a washout period and iniƟ aƟ on of MTX or LEF treatment in the 
current study. Previous studies from our laboratory have shown that prolonged in 
vitro exposure of T cells to sulfasalazine may provoke inducƟ on of BCRP (10), but this 
inducƟ on was transient and reversed upon disconƟ nuaƟ on of sulfasalazine exposure 
(11). Thus, it seems unlikely that the marked expression levels of BCRP on synovial 
macrophages observed at the beginning of MTX or LEF treatment may be the result 
of any previous sulfasalazine treatment.
BCRP expression and funcƟ onal acƟ vity in cancer cells is highly variable (27). There 
may be epigeneƟ c reasons for this, since aberrant promoter methylaƟ on inacƟ vates 
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Figure 5: (A) BCRP expression in RA synovial biopsy specimens from responders and nonresponders to 4 
months of treatment with methotrexate (MTX) or lefl unomide (LEF), determined by the Disease AcƟ v-
ity Score in 28 joints. The median number of BCRP-posiƟ ve cells was 75 (range 0–484) in responders to 
MTX and 300 (range 2–1,159) in nonresponders to MTX. The median number of BCRP-posiƟ ve cells was 
127 (range 1–223) in responders to LEF and 297 (range 11–1,007) in nonresponders to LEF. The median 
number of BCRP-posiƟ ve cells was 101 (range 0–484) in all responders and 297 (range 2–1,159) in all non-
responders. (B) BCRP expression in RA synovial biopsy specimens from responders and nonresponders to 4 
months of treatment with MTX or LEF, determined by C-reacƟ ve protein (CRP) level. The median number of 
BCRP-posiƟ ve cells was 40 (range 0–484) in responders to MTX and 224 (range 2–1,159) in nonresponders 
to MTX. The median number of BCRP-posiƟ ve cells was 122 (35–305) in responders to LEF and 169 (1–
1,007) in nonresponders to LEF. The median number of BCRP-posiƟ ve cells was 50 (0–484) in all responders 
and 215 (1–1,159) in all nonresponders. Values are the number of BCRP-posiƟ ve cells in the sublining layer. 
Horizontal bars show the median. * = P < 0.05 by Mann-Whitney U test. See Figure 1 for other defi niƟ ons.
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the BCRP gene (31,32) or alternaƟ vely, some alteraƟ ons in environmental condiƟ ons 
may up-regulate BCRP expression as observed under hypoxic condiƟ ons (30) or af-
ter folate supplementaƟ on to sustain folate homeostasis (33). One pathophysiologic 
condiƟ on in RA synovial Ɵ ssue that could be implicated in BCRP expression is its hy-
poxic environment. It is well recognized that synovial infi ltraƟ ng cells suﬀ er from hy-
poxic stress (34). Given the noƟ on that BCRP transcripƟ on is induced by hypoxia via 
the hypoxia-inducible transcripƟ on factor complex hypoxia-inducible factor 1α (HIF-
1α) (35), and that HIF-1α is parƟ cularly expressed in synovial Ɵ ssue macrophages 
(36,37), this may underlie the expression of BCRP on these cells.
The results of biodistribuƟ on and funcƟ onal studies have indicated that BCRP plays 
important physiologic and pharmacologic roles, parƟ cularly in the clearance of toxic 
agents from the gastrointesƟ nal tract, blood–brain barrier, liver, placenta, and mam-
mary glands (22,38,39). With respect to hematologic cells, BCRP has been idenƟ fi ed 
in hematopoieƟ c stem cells (40) and dendriƟ c cells (41). From a treatment perspec-
Ɵ ve, BCRP has been recognized to mediate the cellular export of several anƟ cancer 
drugs (8,27–29), and its expression has been associated with poor clinical outcome 
in the treatment of acute myeloid leukemia (42). Beyond this, DMARDs, such as MTX, 
sulfasalazine, and LEF, can also be extruded from cells via BCRP (8,10,13,43). Of note, 
BCRP can export MTX as well as its diglutamate and triglutamate metabolites, which 
could thus lead to diminished eﬃ  cacy of MTX (43).
The present study revealed BCRP expression on synovial Ɵ ssue macrophages from all 
tested paƟ ents with RA. High BCRP expression was associated with the persistence 
of infi ltrated synovial Ɵ ssue macrophages aŌ er treatment with MTX or LEF (Figures 
4C and D), which might be related to the BCRP-mediated eﬄ  ux of these drugs in 
macrophages. Accordingly, a staƟ sƟ cally signifi cant associaƟ on was found between 
BCRP expression in RA synovial Ɵ ssue and a diminished clinical response to DMARD 
therapy, assessed by aƩ enuated improvement in DAS28 scores aŌ er 4 months of 
treatment, or persistent high CRP levels.
In addiƟ on to BCRP expression on synovial Ɵ ssue macrophages, moderate expression 
of MRP-1 was found on macrophages in synovial Ɵ ssue from one-third of the RA pa-
Ɵ ents, while more prominent expression of MRP-1 could be noted on CD3-posiƟ ve T 
cells in lymphocyƟ c aggregates from these paƟ ents, by more sensiƟ ve staining meth-
ods. MTX and the anƟ malarial agent chloroquine are among the DMARD substrates 
of MRP-1, and expression of this transporter may thus confer resistance to these 
drugs (6,12,44). However, since MRP-1 levels in synovial T cells are rather moderate, 
a major contribuƟ on to a reduced response to MTX or anƟ malarial drugs remains 
elusive. Apart from its putaƟ ve pharmacologic role in MTX extrusion, MRP-1 has an 
important physiologic funcƟ on; it exports mediators of infl ammaƟ on such as leukot-
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riene C4, which triggers anƟ gen-presenƟ ng dendriƟ c cell migraƟ on to lymph nodes 
via chemoaƩ racƟ on by CCL19 (45,46). Since high levels of CCL19 have been idenƟ fi ed 
in RA synovial Ɵ ssue (47,48), MRP-1 may be instrumental in the homing of infl amma-
tory cells in RA synovial Ɵ ssue.
Current experimental strategies to reverse drug resistance associated with eﬄ  ux 
transporters include the use of specifi c inhibitors of ABC transporters. Small mol-
ecule inhibitors of BCRP have been tested in the laboratory seƫ  ng (27,29). Whether 
such an approach may also be of therapeuƟ c benefi t in RA remains to be established. 
Recently, Zaher et al (49) reported that Iressa, an epidermal growth factor receptor 
antagonist and BCRP transport inhibitor, could markedly enhance the bioavailability 
of the DMARD sulfasalazine (a BCRP substrate [10,11]) by blocking intesƟ nal extru-
sion of sulfasalazine via BCRP. Consistent with these fi ndings, specifi c polymorphisms 
in the BCRP gene were idenƟ fi ed as determining factors in sulfasalazine absorpƟ on 
and disposiƟ on (50). Based on this proof of principle, BCRP expression in RA synovial 
Ɵ ssue may also be an interesƟ ng target for intervenƟ on aimed at increasing MTX, 
LEF, or sulfasalazine levels in RA macrophages. Such an approach, however, should 
also take into account possible negaƟ ve eﬀ ects on potenƟ al physiologic properƟ es of 
BCRP in infl amed RA synovial Ɵ ssue.
In conclusion, along with an established role in the eﬃ  cacy of cancer therapy, this 
study revealed that mulƟ drug resistance–related transporters, notably BCRP and to 
a lesser extent MRP-1, may play a role in the eﬃ  cacy of specifi c DMARDs in treat-
ing RA. DelineaƟ on of their precise pharmacologic and physiologic eﬀ ects warrants 
further evaluaƟ on and should be helpful in improving the eﬃ  cacy of DMARDs such 
as MTX, LEF, sulfasalazine, and (hydroxy)chloroquine, which are substrates for these 
drug eﬄ  ux transporters.
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Summary
Background.  Several members of the ATP-binding casseƩ e protein family are known 
to confer (mulƟ )drug resistance by extruding small molecule therapeuƟ c drugs. How-
ever, there is confl icƟ ng evidence whether mulƟ drug resistance (MDR) transporters 
are either directly/physically or indirectly involved in the secreƟ on of chemokine and 
cytokine polypepƟ des with a molecular mass of 5-17 kD. 
ObjecƟ ve. To invesƟ gate the involvement of the MDR transporters P-glycoprotein 
(P-gp), MulƟ drug Resistance-associated Protein 1-5 (MRP1-5) and Breast Cancer Re-
sistance Protein (BCRP) in the secreƟ on of the chemokines CCL20, MCP1 and IL-8 and 
the cytokine TNF.  
Methods. Panels of human cell lines lacking or overexpressing Pgp, MRP1-5 or BCRP 
were acƟ vated by the phorbol ester PMA and ionomycin for 24 hours aŌ er which 
secreƟ on of chemokines and TNF was analyzed by ELISA. SecreƟ on profi les were 
also evaluated in the absence or presence of blockers of P-gp, MRP1-5 and BCRP in 
the panel of cell lines. 
Results. Overexpression of MDR transporters per se was not associated with en-
hanced secreƟ on of cytokines and chemokines, with the possible excepƟ on of a role 
for MRP1 in CCL-20 secreƟ on. It was noteworthy that cell lines with overexpression 
of MDR transporters due to selecƟ on with anƟ -rheumaƟ c or anƟ -cancer drugs dis-
played markedly decreased secreƟ on of chemokines and cytokines as compared 
to cell lines transfected with MDR transporters. Blockers of MDR transporters only 
displayed an indirect diﬀ erenƟ al eﬀ ect on chemokine/cytokine secreƟ on by either 
promoƟ ng or suppressing the extrusion of molecules that regulate their secreƟ on.   
Conclusion. This study did not reveal compelling evidence for a direct physical role of 
chemok ine/cytokine secreƟ on by P-gp, MRP1-5 or BCRP. However, blocking of these 
transporters can, indirectly, confer alteraƟ ons in chemokine/cytokine secreƟ on pro-
fi les. 
IntroducƟ on
Selected members of the ATP-binding casseƩ e (ABC) transporter family are well rec-
ognized for their role in conferring resistance to therapeuƟ c compounds used for 
the treatment of cancer (1) and auto-immune diseases such as rheumatoid arthriƟ s 
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(2, 3). Since these proteins can mediate the eﬄ  ux of a wide range of structurally 
unrelated drugs, they are also referred to as mulƟ drug resistance (MDR) transporter 
proteins, including P-glycoprotein (P-gp), MulƟ drug Resistance-associated Proteins 
(MRP) 1-9, and Breast Cancer Resistance Protein (BCRP) (4-8). 
Even though MDR transporters have received most aƩ enƟ on for their role in resist-
ance, they also are important for opƟ mal funcƟ oning of the immune system. For 
example, it has been established that the migraƟ on of anƟ gen presenƟ ng dendrit-
ic cells depends on funcƟ onal P-gp, MRP1 and MRP4 acƟ vity (9-11). Furthermore, 
MRP1 knock-out mice are known to exhibit a reduced infl ammatory response (12). 
These observaƟ ons have been connected to the ability of MDR transporters to trans-
port small immuno-regulatory compounds such as bioacƟ ve lipids (prostaglandins 
and leukotrienes), steroid hormones (4, 6, 13-16) and cyclic nucleoƟ des which are 
important factors in immunological/ infl ammatory processes (17, 18).  
In chronic infl ammatory diseases, other key immune-regulatory compounds include 
(pro)-infl ammatory cytokines and chemokines (19, 20). It was originally hypothesized 
by Salmon and Dalton (21) that P-gp could aƩ ribute, either directly or indirectly, in 
the release of the pro-infl ammatory cytokine TNF. In fact, several studies have been 
presented that support a potenƟ al role of MDR transporters in the cellular release 
of some of these infl ammatory mediators and especially those with a relaƟ vely low 
molecular mass (5-17kD) and/or secretory proteins that lack a hydrophobic leader 
pepƟ de signal and thus are not secreted through the classical ER to Golgi exocyƟ c 
pathway. It is now well established that P-gp can facilitate the cellular extrusion of 
small, cyclic pepƟ des up to 10-12 mer (22, 23) Beyond this, it has also been sug-
gested that P-gp could funcƟ on as an eﬄ  ux transporters for cytokines such as TNFα, 
interleukins (IL-2, IL-4, IL-12) (24, 25) and IFNγ (26, 27) and that P-gp inhibiƟ on could 
reduce the secreƟ on of several cytokines (28). Notwithstanding these facts, in-vivo 
models of Pgp/Abcb1a/b knockout mice revealed no diﬀ erences in cytokine profi les 
compared to their wild type counterparts (29).  
Like Pgp, three members of the MRP (ABCC subfamily), including MRP1, MRP2 and 
MRP6 were found to be capable of exporƟ ng small (cyclic) pepƟ des (23, 30). MRP1 
may also play a role in the secreƟ on of two lager proteins, basic fi broblast growth 
factor (MW: 16kD) (31) and Annexin 1 (MW: 38kD) (32), both of which lack a leader 
signal sequence for secreƟ on via the classical ER-Golgi exocyƟ c pathway. Intriguingly, 
results from De Jong et al even suggested that MRP1 could facilitate the extrusion 
of a 52 kD recombinant IL4-toxin (33). Of further noƟ ce, within the A subfamily of 
ABC transporters, ABCA1 was idenƟ fi ed to mediate the secreƟ on of the 17 kD pro-
infl ammatory cytokine IL-1 (34, 35). IL-1 lacks a secretory signal pepƟ de for the 
classical exocyƟ c pathway.                     
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Considering the above data from the perspecƟ ve that the professional pepƟ de trans-
porters involved in anƟ gen presentaƟ on, i.e. TAP1 (ABCB2) and TAP2 (ABCB3), are 
only able to transport small (oligo) pepƟ des of up to 40-mer residues (29, 36, 37), it 
remains an unresolved and intriguiging issue how MDR transporters could mecha-
nisƟ cally transport  chemokines/cytokines with molecular masses of up to 17kD. As 
such, rather than a direct involvement of MDR transporters in chemokine/cytokine 
release, it may also be conceivable that an indirect eﬀ ect of extruding physiological 
substrates by MDR transporters provokes a concomitant release of selected chemok-
ines/cytokines. To explore these issues further, we set out to invesƟ gate in panels of 
cell lines lacking or overexpressing human MDR transporters (Pgp, MRP1-5, BCRP), 
and in human monocyte-derived dendriƟ c cells, whether changes in secreƟ on of se-
lected chemokines (CCL20, CCL2/MCP1 and CXCL8/IL-8) (20) and the cytokine TNF 
could be aƩ ributed to funcƟ onal acƟ vity or funcƟ onal blocking of MDR transporters. 
IL-8 is involved in the acƟ vaƟ on of neutrophils in infl ammatory regions and sƟ mu-
lates vascularisaƟ on (38). CCL-20 aƩ racts mainly memory T lymphocytes and imma-
ture dendriƟ c cells to the infl ammaƟ on area (39). MCP1 mediates the infi ltraƟ on and 
acƟ vaƟ on of monocytes/ macrophages into the sites of infl ammaƟ on (40). TNF is a 
central regulator of infl ammaƟ on and inƟ mately involved in the pathophysiology of 
rheumatoid arthriƟ s (19).
Materials and methods
Reagents
Iscove’s modifi ed Dulbecco’s medium (IMDM) and fetal calf serum (FCS) were ob-
tained from Gibco Chemical Co, Grand Island NY, USA. The ABCG2 inhibitor Ko143 
was kindly provided by Prof. G.J. Koomen (The Netherlands) and the MRP1 inhibitor 
MK571 and the P-gp inhibitor Reversin-121 (P121) were obtained from Alexis Bene-
lux, Breda, The Netherlands. PSC833 was obtained from NovarƟ s, Basel, Switzerland. 
All other materials were obtained from Sigma Chem Co, St Louis, MO, U.S.A.
Cell Lines
MulƟ ple human cell lines were selected based on their known expression of BCRP 
(MCF-7/MR, CEM/SSZ), P-gp (CEM/VBL, SW1573/R160), MRP1 (CEM/CHQ, SW1573/
R120, 2008/MRP1, HL60/ADR), MRP2 (2008/MRP2), MRP3 (2008/MRP3), MRP4 
(HEK293/MRP4) and MRP5 (HEK293/MRP5) (23, 41-47). An overview of the prop-
erƟ es of cell lines is shown in Table 1. Cell lines were cultured at 5% CO2 and 37oC 
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in standard RPMI 1640 or DMEM medium supplemented with 10% FCS, 2 mM L-
glutamine and 100 μg/ml penicillin and streptomycin. Prior to sƟ mulaƟ on the ad-
hesive cell lines were kept in 6 wells plates in a total volume of 2 ml per well at a 
cell concentraƟ on of 1.25 x 105 cells/ml unƟ l 60-70% confl uence was reached and 
suspension cells lines were plated in 24 wells at a density of 3 x 105 cells/ml. 
Cell sƟ mulaƟ on
Prior sƟ mulaƟ on cells were fi rst incubated with or without their appropriate MDR 
inhibitor or a DMSO vehicle control (0.1%) and by adding Verapamil (10 μM, P-gp), 
P121 (5 μM, P-gp), Ko143 (200 nM, BCRP), MK571 (25 μM, MRP1) or probenecid 
(0.5 mM, MRP1-5). AŌ er 1 hour incubaƟ on at 5% CO2 and 37oC cells were sƟ mulated 
with PMA (10 ng/ml) and ionomycin (1 μg/ml) for 24 hours at 5% CO2 and 37oC. AŌ er 
24 hours the supernatants were collected by centrifugaƟ on (5 min, 3.000 rpm, Ep-
pendorf centrifuge) and stored at -80oC. Total cell concentraƟ on was determined by 
Table 1: Overview and characterisƟ c features of cell lines with various MDR transporter proteins.
Cell line Origin Parental 
MDR transporter 
transfected 
MDR transporter 
drug-induced   
MDR-pump 
expression 
CEM/S T-cell leukemia + 
CEM/SSZ + BCRP 
CEM/CHQ  + MRP1 
CEM/VBL + P-gp 
HL60 PromyelocyƟ c leukemia + 
HL60/ADR + MRP1 
2008 Ovarian Carcinoma + 
2008/MRP1 + MRP1 
2008/MRP2 + MRP2 
2008/MRP3 + MRP3 
HEK293 Human embryonic kidney + 
HEK293/MRP4 + MRP4 
HEK293/MRP5 + MRP5 
SW1573 Non-small cell lung carcinoma + 
SW1573/R120  + MRP1
SW1573/R160 + P-gp
MCF-7 Breast carcinoma + 
MCF-7 MR + BCRP 
AbbreviaƟ ons used: CHQ, chloroquine; MR, mitoxantrone; ADR, adriamycin
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counƟ ng viable cells by trypan blue exclusion. If applicable adhesive cell lines were 
detached by adding PBS supplemented with 0.25% trypsin and 0.5 mM EDTA and 
resuspended in a total volume of 1 ml PBS.
ELISA procedure
CCL20, MCP1, IL-8 and TNF-α levels in the supernatants were measured by ELISA. For 
IL-8 and TNF-α commercially available ELISA kits (both from Sanquin, Amsterdam, 
The Netherlands) were used according the instrucƟ ons provided by the manufactur-
er. CCL20 and MCP1 were quanƟ fi ed by ELISA as described previously (48). In brief, 
96-well ELISA plates (Nunc Maxisorp, Life Technologies, Inc., Merelbeke, Belgium) 
were coated overnight with the primary anƟ body: anƟ -human CCL20 (1 μg/ml) or 
MCP1 (1 μg/ml). Subsequently the plates were incubated with a blocking soluƟ on 
(PBS/BSA 0.5%, 1 hour, RT), followed by incubaƟ on with the standards (2.7-1600 pg/
ml for CCL20 and 15.6-2000 pg/ml for MCP-1) and the samples (1 hour, RT). AŌ er in-
cubaƟ on the plates were washed 4 Ɵ mes (PBS/0.05% Tween-20) and incubated with 
the second, bioƟ nylated, anƟ body (CCL20; 100 ng/ml and MCP1; 100 ng/ml, 1 hour, 
RT). Again the plates were washed 4 Ɵ mes with PBS/Tween and incubated (1/2 hour, 
RT) with 1:10.000 diluted streptavidin-HRP (Sanquin, Amsterdam, The Netherlands). 
AŌ er a third wash step (4 Ɵ mes with PBS/Tween), the plates were incubated with 
100 μl peroxidase substrate soluƟ on containing 0.2 mg/ml orthophenylene diamine 
(ICN pharmaceuƟ cals, USA) in 0.1 M (pH 5.5) sodium acetate soluƟ on (Merck, Darm-
stadt, Germany) with 0.03% H2O2. AŌ er color development, the reacƟ on was stopped 
with 50 μl 2M H2SO4 and the absorbance was measured at 490 nm on an ELISA plate 
reader (Tecan Spectra Fluor, Giessen, The Netherlands). The measured chemokines 
or cytokine concentraƟ ons were corrected to pg/ml per one million cells. DetecƟ on 
levels were for all used ELISA’s was 1 pg/ml. 
StaƟ sƟ cal analysis
The mean values of all measurements were calculated including the standard devia-
Ɵ on. To determine if the used blockers had a signifi cant eﬀ ect, one-way ANOVA was 
performed in SPSS 14.0. 
Results
Chemokine and TNFα secreƟ on in drug-resistant/MDR transporter 
over-expressing cell lines
Whenever MDR transporters would play a role in chemokine/cytokine secreƟ on, one 
may anƟ cipate that overexpression of selected MDR transporters, including P-gp, 
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MRP1-5 and BCRP, would result in enhanced secreƟ on of selected cytokines and 
chemokines. To explore this hypothesis, parental and MDR-overexpressing cells were 
sƟ mulated by PMA-ionomycin for 24 hours and analyzed for alteraƟ ons in cytokine 
(TNF) and chemokine (CCL20, MCP1 and IL-8) release. Overall, a large variaƟ on in 
CCL20, MCP1, IL-8 and TNF secreƟ on was observed in the panel of cell lines (Table 
2). Within the panel of MRP1-overexpressing cell lines, 3 out of 4 (HL60/ADR, 2008/
MRP1 and SW1573/R120) showed an increased secreƟ on of CCL-20 compared to 
their parental counterparts, whereas in one MRP-1 overexpressing cell line, CEM/
CHQ, a signifi cant 10-fold decrease in CCL20 secreƟ on was observed. For cell lines 
overexpressing MRP2-5, no signifi cant alteraƟ ons in CCL20 secreƟ on were demon-
strated. In the panel of two Pgp-overexpressing cell lines no consistent profi le of 
an increased CCL20 secreƟ on was observed; one cell line (SW1573/R120) showed 
a 3-fold increase in CCL20 secreƟ on, whereas another (CEM/VBl) showed a 30-fold 
decrease. The same holds for the panel of two BCRP-overexpressing cells; no consist-
ent profi le of an increased CCL20 secreƟ on was observed; one cell line (CEM/SSZ) 
showed unaltered CCL20 secreƟ on, whereas another (MCF7/MR) showed a 6-fold 
decrease compared to their parental counterparts. 
MCP1 is diﬀ erenƟ ally secreted within the panel of cell lines; HL60 and HL60/ADR 
(MRP1+) cells secreted substanƟ al amounts of MCP1, while others (SW1573 and 
2008 cells) do not secrete this chemokine (Table 2). No diﬀ erenƟ al (increases) in 
MCP1 secreƟ on were observed in 3 out of 4 MRP1-overexpressing cells, MRP2-5 
overexpressing cells and BCRP-overexpressing cells compared to parental cells. Of 
note, CEM/CHQ (MRP1+) and CEM/VBl (P-gp+) cells again revealed a markedly re-
duced MCP1 secreƟ on compared to CEM/WT cells. 
IL-8 secreƟ on is not infl uenced in 3 out of 4 MRP1 overexpressing cells, except that 
again in CEM/CHQ cells IL-8 secreƟ on is markedly suppressed (Table 2). Notably, 
IL-8 secreƟ on was also found to be suppressed 2-fold in 2008/MRP3 cells, 8-fold in 
HEK293/MRP4 cells and CEM/Vbl (P-gp+) cells and 6-fold in CEM/SSZ (BCRP+) cells. 
For other cell lines tested, no signifi cant alteraƟ ons in IL-8 secreƟ on were revealed. 
TNF secreƟ on in the panel of MRP-overexpressing cells was only noted for cell lines 
of the CEM and HL60 panel, but no signifi cant diﬀ erences were observed between 
the wild type and MRP1-overexpressing variants (Table 2). A 2-fold increase in TNF 
secreƟ on was observed in CEM/SSZ (BCRP+) cells, whereas in CEM/VBl (P-gp+) cells 
TNF secreƟ on was suppressed almost 100-fold.     
Together, these results indicate that MDR-overexpression per se is not associated 
with an increased secreƟ on of TNFa, MCP1 or IL-8, with the one possible excepƟ on 
for CCL20. Rather, more oŌ en the secreƟ on of these chemokines and cytokines is 
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decreased, notably in cell lines in which MDR-transporter overexpression is a conse-
quence of drug-selecƟ on and to a minor extent due to MDR transfecƟ on. 
Eﬀ ect of MDR transporter blockers on chemokine/TNFα secreƟ on
Whenever MDR transporters would play a role in chemokine/cytokine secreƟ on, it 
may also be anƟ cipated that blockers of these MDR transporters should inhibit their 
secreƟ on.  We tested this hypothesis by evaluaƟ ng the eﬀ ect of blockers of MRP1-5, 
Pgp and BCRP on the secretory profi le of CCL20, MCP-1, IL-8 and TNF.  
CCL20 secreƟ on could be consistently inhibited, up to 70%, in the panel of 4 MRP1-
overexpressing cells either by the specifi c MRP1 blocker MK571 and the broad 
Table 2: Overview of chemokine and cytokine secreƟ on from cell lines with and without MDR over-
expression.
Cell line
MDR 
transporter 
CCL20
SecreƟ on (pg/ml)
MCP1 
SecreƟ on (pg/ml)
IL-8
SecreƟ on (ng/ml)
TNFα
SecreƟ on (pg/ml)
CEM Wt 287 ± 135 32 ± 61 52.7 ± 34.3 998 ± 110
HL60 Wt 127 ± 32 256000 ± 128000 618 ± 424 1208 ± 722
SW1573 Wt 2566 ± 435 < 1 9.9 ± 12.6 < 1
2008 Wt 8742 ± 9375 < 1 719 ±792 < 1
HEK293 Wt 845 ± 269 296 ± 262 41.7 ± 35.2 < 1
MCF7 Wt 1268 ± 58 61 ± 8 < 0.01 < 1
CEM/CHQ MRP1 27 ± 27 (*) ↓↓ < 1 (*) ↓↓ < 0.1 (*) ↓↓ 996 ± 571 =
HL60/ADR MRP1 796 ± 335 (*) ↑↑ 144000 ± 47000 ↓ 630 ± 335 = 726 ± 565 =
SW1573/R120 MRP1 9176 (*) ↑↑ < 1 = 12.6 = < 1 =
2008/MRP1 MRP1 16900 ± 11500 ↑ < 1 = 762 ± 251 = < 1 =
2008/MRP2 MRP2 8410 ± 7615 = < 1 = 610 ± 557 = < 1 =
2008/MRP3 MRP3 8090 ± 4997 = < 1 = 243 ± 156 ↓↓ < 1 =
HEK293/MRP4 MRP4 379 ± 11 ↓↓ 516 ± 141 ↑ 5.2 ± 5.7 ↓↓ < 1 =
HEK293/MRP5 MRP5 1225 ± 206 ↑ 551 ↑ 37.1 ± 42.1 = < 1 =
CEM/SSZ BCRP 264 ± 105 = 23 ± 27 = 8.6 ± 7.6 (*) ↓↓ 1949 ± 799 ↑
MCF7/MR BCRP 199 ± 2 (*) ↓↓ 55  ± 16 = < 0.01 = < 1 =
CEM/VBL Pgp 9 ± 10 (*) ↓↓ < 1 (*) ↓↓ 6.5 ± 4.6 (*) ↓↓ 11 ± 15 (*) ↓↓
SW1573/2R160 Pgp 8509 ↑↑ < 1 = 0.6 ↓↓ < 1 =
Cytokine/chemokine secreƟ on was analyzed by ELISA aŌ er 24 hours sƟ mulaƟ on with PMA/
ionomycin. Results are depicted as the mean ± S.D. of 3-5 experiments or duplicate experiments 
when no S.D. is provided. Symbols: ↑; 1.5 – 2.0 fold increase relaƟ ve to WT cell line. ↑↑; ≥ 2.0 
fold increase relaƟ ve to WT cell line. ↓; 1.5 – 2.0 fold decrease relaƟ ve to WT cell line. ↓↓; ≥ 
2.0 fold decrease relaƟ ve to WT cell line. =; no change relaƟ ve to WT cell line. (*) indicates P < 
0.05. ND: Not determined.
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MRP1-5 inhibitor, probenecid (Table 3). Probenecid also inhibited secreƟ on of 
CCL20 in MRP2-5 overexpressing cells by 40-75%. MRP1-5 blocking by MK571 and/
or probenecid also inhibited MCP1 secreƟ on in HL60/ADR (by 4-fold) and HEK293/
MRP4 cells (by 3-fold) (Table 3). IL-8 secreƟ on was suppressed 2-2.5 fold by probene-
cid in SW1573/2R120 cells and HEK293/MRP4 cells (Table 3). Notably, in the panel 
of 2008 MRP1-3 cell lines, probenecid and MK571 even sƟ mulated IL-8 secreƟ on up 
to 3-fold. Regarding TNF secreƟ on, no signifi cant inhibitory eﬀ ects were observed 
of MRP1 blocking by MK571 or probenecid. It should be noted however that, though 
a somewhat minor extent, also inhibitory and sƟ mulatory eﬀ ects of probenecid and 
MK571 on chemokine secreƟ on by MRP1-5 overexpressing cells were observed for 
parental cells (Table 3), suggesƟ ng that some MRP1-5 unrelated factors are also in-
volved.   
InteresƟ ngly, for P-gp overexpressing CEM/VBl cells, the Pgp blockers verapamil and 
P121 accomplished a 2- to 8.8-fold increase in the secreƟ on of CCL20, IL-8 and TNF 
(Table 3). These Pgp blockers had no signifi cant eﬀ ects on the secreƟ on of these 
chemokines and TNF in parental CEM cells. Intriguingly, the eﬀ ects of verapamil 
and P121 observed for CEM/VBl cells we not corroborated in another Pgp-over ex-
pressing cell line, SW1573/2R160. Here, the blockers had more of an inhibitory eﬀ ect 
on CCL20, and IL-8 release rather than a sƟ mulatory eﬀ ect. 
Finally, blocking of BCRP by Ko143 had no diﬀ erenƟ al eﬀ ect on CCL20, MCP1, IL-8 and 
TNF secreƟ on in the panel of CEM vs CEM/SSZ and MCF7 vs MCF7/MR cells (Table 
3). Percentage-wise, most experimental condiƟ ons showed a modest increase (up to 
1.7-fold) rather than a consistent decrease in cytokine/chemokine secreƟ on. 
Together, blocking of the MDR transporters P-gp, MRP1-5 and BCRP did not reveal ro-
bust or consistent inhibitory eﬀ ects on the secreƟ on of CCL20, MCP1, IL-8 and TNF. 
In fact, in one case of CEM/VBl cells, blocking of Pgp conveyed a marked sƟ mulatory 
eﬀ ect on their secreƟ on. 
Discussion
Data from the current study indicate that overexpression of MDR transporters Pgp, 
MRP1-5 and BCRP per se does not aƩ ribute to enhanced secreƟ on of selected chem-
okines (CCL20, MCP1 and IL-8) and the pro-infl ammatory cytokine TNF. However, 
development of MDR-related resistance to anƟ -rheumaƟ c and anƟ -cancer drugs and 
blocking of MDR funcƟ on can provoke marked diﬀ erenƟ al eﬀ ects on the secreƟ on of 
chemokines and cytokines.  
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Table 3: Eﬀ ect of MDR transporter blockers on chemokine and cytokine secreƟ on from 
cell lines with and without MDR overexpression.
Cell line
MDR 
transporter
CCL20
SecreƟ on
MCP1 
SecreƟ on
IL-8
SecreƟ on
TNFα
SecreƟ on
MK PB MK PB MK PB MK PB
CEM Wt ↓↓* ↓↓ ↑↑ ↓↓ ↓ = = =
HL60 Wt ↓ = ↓↓ ↓↓ = = = ↓
SW1573 Wt ↓ = = = = ↓↓ = =
2008 Wt ↓ ↓ = = ↑ ↑↑ = =
CEM/CHQ MRP1 ↓ = = = = = ↑ =
HL60/ADR MRP1 ↓↓ ↓↓* ↓↓* ↓↓* ↑ = = =
SW1573/R120 MRP1 ↓ ↓↓ = = ↓↓ ↓ = =
2008/MRP1 MRP1 ↓ ↓ = = ↑ ↑ = =
2008/MRP2 MRP2 = ↓ = = ↑ = = =
2008/MRP3 MRP3 = ↓ = = ↑ ↑ = =
HEK293/MRP4 MRP4 N.D ↓↓* N.D ↓↓ N.D ↓↓ = =
HEK293/MRP5 MRP5 N.D ↓↓* N.D ↓↓ N.D ↓↓ = =
VP P121 VP P121 VP P121 VP P121
CEM Wt = ↓↓ = ↓ = ↓ = ↑
SW1573 Wt ↓ ↓ = = ↓↓ ↓↓ = =
CEM/VBL Pgp ↑↑↑* ↑↑↑* = = ↑↑↑* ↑ ↑↑↑* ↑↑
SW1573/2R160 Pgp ↓↓ ↓↓* = = ↓ ↓↓ = =
KO KO KO KO
CEM Wt = ↓ = ↑
MCF7 Wt = ↑ = =
CEM/SSZ BCRP = ↓ = =
MCF7/MR BCRP = = = =
Cytokine/chemokine secreƟ on was analyzed by ELISA aŌ er 24 hours sƟ mulaƟ on with 
PMA/ionomycin. ConcentraƟ ons of blockers (added 1 hour prior to sƟ mulaƟ on): MK571 
(MK) = 25 μM; Probenecid (PB) = 0.5 mM; Verapamil (VP) = 7.5 μM; P121 (reversin) = 5 
μM and Ko143 (KO) = 200 nM. ↑; 1.5 - 2.5 fold increase relaƟ ve to control cell line. ↑↑; 
2.5 – 5.0 fold increase relaƟ ve to control cell line. ↑↑↑; ≥ 5.0 fold increase relaƟ ve to 
control cell line. ↓; 1.5 - 2.0 fold decrease relaƟ ve to control cell line. ↓↓; ≥ 2.0 fold de-
crease relaƟ ve to control cell line. =; no change relaƟ ve to control cell line. (*) indicates 
P ≤ 0.05. ND: Not determined.
175
Indirect  involvement of MDR transporters in chemokine and cytokine secreƟ on
With the possible excepƟ on of a role for MRP1 in CCL20 secreƟ on, observaƟ ons from 
the current study indicated that MDR transporter overexpression had no consistent 
eﬀ ect on CCL20, MCP1, IL-8 and TNF secreƟ on. Together with similar observaƟ ons 
in Pgp-/- knock out mice (29), this would provide further support for the noƟ on that 
MDR transporters do not directly and physically aƩ ribute to the secreƟ on of chem-
okines and cytokines. The current observaƟ ons also illustrated that the profi le of 
chemokine and cytokine secreƟ on can be markedly altered in cells that harbor over-
expression of MDR transporters as a mechanism of acquired resistance to anƟ cancer 
drugs (vinblasƟ n, adriamycin and mitoxantrone) (44, 46, 47) or anƟ -rheumaƟ c drugs 
(chloroquine and sulfasalazine) (42, 43) as compared to MDR-transfected cell lines. 
Concordingly, a study by Duan et al (49) showed that paclitaxel-resistant ovarian car-
cinoma cells secreted markedly higher concentraƟ ons of IL-8, MCP1 and IL-6. In this 
respect it is interesƟ ng to note that selecƟ on of resistance to chloroquine, sulfasala-
zine and vinblasƟ n was accompanied by markedly decreased IL-8, MCP1 and CCL20 
secreƟ on. Regarding CEM/CHQ cells, it remains to be established whether aberrant 
protein kinase A signalling in these cells plays a role in this observaƟ on (43). It was 
also important to explore the possibility that this reduced secreƟ on was due to MDR-
transporter mediated extrusion of the cell acƟ vaƟ on sƟ mulus. Given its hydrophobic 
nature, PMA may serve as a substrate for MDR transporters like Pgp, possibly result-
ing in diminished cell acƟ vaƟ on and chemokine and cytokine secreƟ on. This may be 
exemplifi ed by CEM/VBl (Pgp+) cells, in which secreƟ on of low levels of chemokines 
and cytokines is (parƟ ally) restored aŌ er blocking of Pgp. Hence, it should be taken 
into account that the propensity of a cell sƟ mulus being a substrate for one or more 
of the MDR transporters could indirectly diminish the secretory capacity of cytokines 
and chemokines. 
Several studies demonstrated that inhibiƟ on of MDR transporter capacity could sup-
press the secreƟ on of chemokines and cytokines (24, 25, 27, 28). Conceivably, such an 
inhibitory eﬀ ect may point to a contribuƟ on of MDR-transporters, however, it should 
be taken into account that most inhibitors (verapamil, MK571, probenecid) are not 
fully specifi c and are also toxic compounds by themselves which could aﬀ ect chem-
okine and cytokine secreƟ on. In the present study, we also observed that chemok-
ine/cytokine secreƟ on is diminished in parental cell lines that have no or basal levels 
of specifi c MDR transporters, suggesƟ ng that diﬀ erenƟ al side eﬀ ects of the inhibitors 
could infl uence chemokine/cytokine secreƟ on in various cell types. In this context, 
one reported side eﬀ ect of probenecid above concentraƟ ons of 0.5 mM is that it 
provokes an intracellular ATP depleƟ on, which would indirectly diminish secreƟ on 
(50). AlternaƟ vely, MDR transporters may also operate indirectly by extruding small 
molecules that either block or promote chemokine/cytokine secreƟ on or produc-
Ɵ on. For example, there is preliminary evidence to suggest that blockade of MRP1 by 
176
Chapter 8
MK571 results in the retenƟ on of an agonist for the transcripƟ onal repressor PPAR, 
which has been demonstrated to suppress, among others, the transcripƟ on of TNF, 
IL-1 and IL-6 genes (51). Together, defi niƟ ve proof for a direct involvement of a MDR 
transporter in chemokine/cytokine secreƟ on should not solely depend on intact cell 
based studies, but also include transport studies uƟ lizing reconsƟ tuted vesicles of a 
specifi c MDR transporter in proteoliposomes (52). Nevertheless, interpretaƟ on of 
these types of studies should be done with cauƟ on as steric hindrance by polypep-
Ɵ des of 5-10 kD (chemokines) up to 17 kD (cytokines) may interfere with prototypical 
small molecule substrates for MDR transporters without physical transport of these 
chemokines and cytokines.  The physiological role of several MDR transporters in im-
mune cell funcƟ on is well established. With respect to for example specialized anƟ -
gen presenƟ ng dendriƟ c cells (DC), the MDR transporters Pgp, MRP1 and MRP4 have 
a clear role in DC diﬀ erenƟ aƟ on, maturaƟ on and funcƟ on (10, 11, 16). For Pgp, it is 
thought that extrusion of bioacƟ ve lipids (e.g. platelet acƟ vaƟ ng factor or sphingo-
sine-1-phoshate) may facilitate DC migraƟ on (53). Loss of funcƟ on of Pgp and MRP1 
in knock out mice resulted in impaired migratory capacity of DCs towards lymph 
nodes (9, 26). In this process, MRP1 funcƟ ons by extruding its physiological substrate 
leukotriene C4 which promotes chemotaxis to the chemokines CCL19 and CCL21 (9). 
The present study further illustrated that long-term exposure and development of 
MDR-related resistance to cancer chemotherapeuƟ c and anƟ -rheumaƟ c drugs can 
markedly infl uence secreƟ on profi les of chemokines and cytokines and expression 
profi les of MDR transporters. To what extent this will either compromise or promote 
immune funcƟ on in cancer or arthriƟ c paƟ ents, requires further exploraƟ on.
CollecƟ vely, this study revealed no compelling evidence for a direct physical involve-
ment of the MDR transporters P-gp, MRP1-5 and BCRP in extruding polypepƟ des 
with molecular sizes of chemokines or cytokines. However, a blockade of these trans-
porters can elicit an indirect eﬀ ect of either suppressing or promoƟ ng chemokine/cy-
tokine secreƟ on by immune eﬀ ector cells and as such contribute to their funcƟ onal 
regulaƟ on. 
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Summary
ObjecƟ ve. The proteasome is a mulƟ catalyƟ c proteinase complex regulaƟ ng the 
intracellular breakdown of many proteins, including those mediaƟ ng the acƟ vaƟ on 
of pro-infl ammatory signaling pathways (e.g. NFB), cell proliferaƟ on and survival. 
Conceptually, proteasome inhibitors may therefore elicit potenƟ al anƟ -infl ammatory 
properƟ es by inhibiƟ ng these processes and thereby impair the cellular release of 
pro-infl ammatory cytokines such as Tumor Necrosis Factor  (TNF) in RA paƟ ents. 
Methods. Whole-blood from 19 RA paƟ ents (including methotrexate-responsive and 
non-responsive paƟ ents) and 7 healthy volunteers was incubated ex-vivo with the 
proteasome inhibitor bortezomib aŌ er T-cell sƟ mulaƟ on with CD3/CD28. InhibiƟ on 
of cytokine producƟ on by bortezomib was measured aŌ er 24 and 72 hours by ELI-
SA. Eﬀ ects of bortezomib on apoptosis and T-cell acƟ vaƟ on (CD25 expression) were 
measured by FACS-analysis. 
Results. Bortezomib proved to be a rapid (<24 hour) and potent inhibitor of the re-
lease of several NFB-inducible cytokines (including TNF, IL-1β, IL-6 and IL-10) by 
acƟ vated T-cells from healthy volunteers and RA paƟ ents, regardless of their clinical 
responsiveness to methotrexate. Median concentraƟ ons of bortezomib required to 
inhibit TNF producƟ on by 50% (mIC-50) were 12 nM (range: 8-50 nM) for healthy 
volunteers and 46 nM (range: 18-60 nM) for RA paƟ ents. A reducƟ on of T cell acƟ va-
Ɵ on and a marked inducƟ on of T-cell apoptosis were revealed as late eﬀ ects aŌ er 
bortezomib incubaƟ ons beyond 24 hours.
Conclusion. Proteasome inhibitors represented by bortezomib may elicit potenƟ al 
anƟ -infl ammatory properƟ es that deserve further exploraƟ on in experimental thera-
pies for RA.
IntroducƟ on
The proteasome is a mulƟ meric proteinase complex that facilitates the degradaƟ on 
of approximately 80% of intracellular proteins. The catalyƟ c acƟ viƟ es of the protea-
some not only ensure protein homeostasis; they also provide a fi ned-tuned mecha-
nism of controlled (in)acƟ vaƟ on of proteins involved in cell proliferaƟ on, signaling 
processes and the generaƟ on of anƟ genic pepƟ des to be presented on MHC class I 
molecules (1-3). In this context, for example, acƟ vaƟ on and nuclear translocaƟ on of 
the transcripƟ on factor NFB inƟ mately depends on proteasome-mediated break-
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down of its natural inhibitor protein IB and thereby mediates the transcripƟ onal 
regulaƟ on of several pro-infl ammatory cytokines such as TNF and IL1 (4, 5) as 
well as anƟ -apoptoƟ c genes (6). From this perspecƟ ve, it has been anƟ cipated that 
inhibitors of the proteasome may counteract the NFB acƟ vaƟ on process and elicit a 
potenƟ al anƟ -infl ammatory response (7-11). 
Bortezomib (Velcade®, PS341), a boronic acid dipepƟ de, is the fi rst specifi c pro-
teasome inhibitor that is registered in cancer chemotherapy for therapy-refractory 
mulƟ ple myeloma paƟ ents (12, 13). Bortezomib is used as single agent and in drug 
combinaƟ on regimens where it has displayed addiƟ ve/synergisƟ c anƟ -tumor eﬀ ects 
when combined with glucocorƟ coids (dexamethasone) or TNF-related apoptosis-
inducing ligand (TRAIL) (13, 14). InteresƟ ngly, paƟ ents with relapsed or refractory 
lymphoma who responded to bortezomib had a marked reducƟ on in plasma TNF 
levels as compared to bortezomib non-responders (15). Of addiƟ onal interest from a 
potenƟ al anƟ -infl ammatory perspecƟ ve were preliminary data from animal models 
for arthriƟ s (16, 17) which revealed that bortezomib treatments conveyed clear ther-
apeuƟ c eﬀ ects. In fact, a recent report by Neubert et al showed that bortezomib tar-
gets both short and long-lived plasma cells in mice with lupus-like disease, thereby 
abrogaƟ ng the producƟ on of anƟ bodies to double-stranded DNA and prevenƟ ng the 
onset of nephrites (18). The present study was undertaken to assess the potenƟ al 
anƟ -infl ammatory eﬀ ects of bortezomib on the basis of inhibiƟ ng the producƟ on of 
TNF and other pro-infl ammatory cytokines by acƟ vated T cells from RA paƟ ents.
Materials and methods 
PaƟ ent characterisƟ cs 
All paƟ ents signed an informed consent form, and the study on ‘DMARD-resistance’ 
was approved by the Medical Ethics commiƩ ee of the VU University Medical Center, 
Amsterdam, The Netherlands. CharacterisƟ cs of 19 RA paƟ ents included in this study 
were: male/female: 5/14; mean age: 52.5 years; mean DAS28 score (Disease AcƟ vity 
Score for 28 joints): 4.3 (range 1.3-7.2). Five paƟ ents had no prior treatment with Dis-
ease Modifying AnƟ -RheumaƟ c Drugs (DMARD-naive). Thirteen paƟ ents used meth-
otrexate (MTX) 15-30 mg/week, and 1 paƟ ent used the combinaƟ on of sulfasalazine 
and hydoxychloroquine. PaƟ ents were on DMARDs for at least 3 months (range: 12 
weeks to 9 years). PaƟ ents that were on DMARD therapy were defi ned as DMARD re-
sponders if their DAS28 was ≤3.2 at the Ɵ me of enrollment (n=7); RA paƟ ents with a 
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Table 1: Baseline characterisƟ cs of (subgroup) RA paƟ ents and controls and outcome of TNFa 
inhibiƟ on from acƟ vated T-cells by bortezomib and methotrexate.
Controls 
(n=7)
RA pts 
(n=19)
DMARD naïve 
(n=5)
DMARD 
responders (n=7)
DMARD non-responders 
(n=7)
Mean age (yr) (SD) 38 (13) 53 (17)NS
Mean ESR (mm/
hr) (SD)
27 (27)
Median DAS28 
score (range)
5.5 (4.4-6.9) 2.1 (1.3-2.9) 5.5 (3.9-7.2)
Median IC50 
bortezomib (nM) 
(range)
12 (8-50) 46 (18-60)* 47 (32-59)* 48 (24-60)* 27 (18-59)
Median IC50 MTX 
(nM) (range)
53 (18-85) 59 (16-325) 55 (32-102) 44 (28-260) 60 (16-325)
IC50: drug concentraƟ on required to inhibit TNFa producƟ on by 50%. *p<0.05, NS Not Signifi cant. 
DAS28: Disease AcƟ vity Score (28 joints), ESR: Erythrocyte SedimentaƟ on Rate. 
DAS28 score of >3.2 were defi ned as DMARD non-responders (n=7). Finally, 7 healthy 
volunteers were included (male/female: 4/3; mean age: 38 years). AddiƟ onal paƟ ent 
characterisƟ cs are described in Table 1.
Materials 
Bortezomib was kindly provided by Millennium PharmaceuƟ cals; Cambridge, MA, 
U.S.A. Stock soluƟ ons of 1 mM were prepared in dimethylsulfoxide (DMSO) and 
stored at -20oC. CD3/CD28 anƟ bodies were a generous giŌ  from Prof. L. Aarden 
(Sanquin, Amsterdam, the Netherlands). AnƟ -CD25-PE was obtained from Becton 
Dickinson; San Jose, CA, U.S.A. Cytokine ELISA assays (PeliKine) for TNF, IL-1β, IL-6 
and IL-10 were obtained from Sanquin, Amsterdam, The Netherlands, and uƟ lized 
according to the manufacturers’ instrucƟ ons and as described previously (19).
Procedures and T-cell acƟ vaƟ on
Whole blood (1:10 diluted with heparin-containing DMEM medium, supplemented 
with 0.1% fetal calf serum) of 19 RA paƟ ents and 7 healthy volunteers controls were 
incubated ex vivo with CD3/CD28 anƟ bodies (0.1 μg/ml and 1 μg/ml respecƟ vely) 
as T-cell acƟ vaƟ ng agents as described previously (19). T-cell acƟ vaƟ on was monito-
red by CD25-PE staining by fl ow cytometry. The whole blood incubates were then 
supplemented with a concentraƟ on range (0-100 nM) of bortezomib, and, as a refe-
rence, 33-300 nM MTX, followed by an incubaƟ on period of 24-72 hours. InhibiƟ on 
of TNF producƟ on was measured aŌ er 72 hours drug exposure by ELISA as descri-
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bed before (19). Beyond TNF, producƟ on of other NFB-inducible cytokines (i.e. 
IL-1β, IL-6 and IL-10) was measured in whole blood from 3 separate healthy controls 
and 3 RA paƟ ents aŌ er T-cell sƟ mulaƟ on and 24 hour exposure to bortezomib.
Apoptosis assay
Peripheral blood lymphocytes (PBLs) of RA paƟ ents and healthy volunteers were 
isolated by Ficoll-Paque Plus density centrifugaƟ on and suspended in DMEM-me-
dium supplemented with 10% fetal calf serum. Apoptosis in PBLs was analyzed by 
fl ow cytometry (FACS) aŌ er 24 and 48 hours exposure to bortezomib using Annex-
in-V-FITC/7-aminoacƟ nomycin D (7-AAD) staining (APOPTESTTM-FITC A700, VPS 
DiagnosƟ cs, Hoeven, the Netherlands) according to the manufacturer’s protocol. 
Phycoerythrin labeled T-cell markers (CD4/CD8/CD25) were obtained from Becton 
Dickinson; San Jose, CA, U.S.A.
StaƟ sƟ cal analysis
StaƟ sƟ cal analysis was performed with the Mann-Whitney test to analyze diﬀ erences 
between RA paƟ ents and healthy volunteers.
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Figure 1: Bortezomib-induced inhibiƟ on of TNFα, IL-1β, IL-6 and IL-10 producƟ on in acƟ vated T-cells 
from controls and RA paƟ ents. 
Bortezomib- induced inhibiƟ on of TNF, IL-1β, IL-6, and IL-10 producƟ on from acƟ vated T-cells of (A) healthy 
volunteers (n=3) and (B) DMARD-naïve RA paƟ ents (n=3) was analyzed aŌ er 24 hour sƟ mulaƟ on of T-cells 
in whole blood by αCD3-α/CD28 in the presence of the indicated concentraƟ ons of bortezomib. Results 
are depicted as the mean percentage of cytokine producƟ on relaƟ ve to controls incubated without bort-
ezomib. 
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Results
Bortezomib-induced cytokine release from acƟ vated T-cells
In a pilot seƫ  ng, the ability of bortezomib was assessed to inhibit the release of cyto-
kines from CD3/CD28 acƟ vated T-cells from controls (Figure 1A) and RA paƟ ents 
(Figure 1B). ProducƟ on of TNF, IL-1β, IL-6 and IL-10 producƟ on in controls was half 
maximally inhibited at bortezomib concentraƟ ons between 5-25 nM (Figure 1A). In 
acƟ vated T-cells of RA paƟ ents (Figure 1B), bortezomib also inhibited the producƟ on 
of IL-6, IL-1β and TNF, although for the laƩ er cytokine, slightly higher concentraƟ -
ons of bortezomib were required. ProducƟ on of IL-10 in acƟ vated T-cells of RA pa-
Ɵ ents was less eﬃ  ciently inhibited as compared to controls. 
InhibiƟ on of TNFα release from acƟ vated T-cells by bortezomib and 
methotrexate
The potency of bortezomib to inhibit the producƟ on of TNF was further invesƟ ga-
ted in a larger group of RA paƟ ents (n=19) which could be subcategorized in DMARD-
naïve paƟ ents (n=5), DMARD-responsive paƟ ents (DAS28 < 3.2, n=7) and DMARD 
non-responsive RA paƟ ents (DAS28 > 3.2, n =7). For comparison, inhibiƟ on of TNF 
producƟ on was also analyzed for methotrexate (MTX) as a reference drug. Follow-
ing αCD3/αCD28 sƟ mulaƟ on of T-cells, absolute levels of baseline TNF producƟ on 
were not signifi cantly diﬀ erent in whole blood incubates from 7 healthy volunteers 
(baseline TNF producƟ on: 3208± 2554 pg/ml; range: 623-7361 pg/ml) and 3 groups 
of RA paƟ ents; DMARD-naive (n=5), DMARD-responders (n=7) and DMARD non-re-
sponders (n=7) (Figure 2). Upon co-incubaƟ on with bortezomib, median concentra-
Ɵ ons of this drug required to inhibit TNF producƟ on by 50% (mIC50) were 3.8-fold 
lower (p=0.01) for healthy controls (IC50: 12 nM, range: 8-50 nM) as compared to 
the total group of RA paƟ ents (IC50: 46 nM, range: 18-60 nM) (Table 1, Figure 3). 
Sub-analysis for the DMARD non-responsive RA paƟ ents showed a 1.7-fold greater 
potency of bortezomib to inhibit TNF producƟ on compared to DMARD-naive and 
DMARD-responsive RA paƟ ents, but this diﬀ erence was not signifi cant (p=0.32) (Fig-
ure 4). Median concentraƟ ons of MTX to inhibit TNF producƟ on by 50% were not 
signifi cantly diﬀ erent (p=0.64) between healthy controls (IC50: 53 nM, range 18-85 
nM) and RA paƟ ents (IC50: 59 nM, range: 16-325 nM) (Table 1).
Bortezomib-induced inducƟ on of apoptosis and inhibiƟ on of T-cell 
acƟ vaƟ on 
Along with a rapid reducƟ on in TNF release, a marked inducƟ on of apoptosis was 
observed in peripheral blood lymphocytes (PBLs) of RA paƟ ents at a later stage of 
bortezomib exposure: 10-21 % Annexin-V posiƟ ve cells in control condiƟ ons versus 
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Figure 2: Baseline TNFα producƟ on by acƟ vated T-cells of RA-paƟ ents and healthy volunteers. 
Baseline TNFa  producƟ on by αCD3-α/CD28 acƟ vated T-cells from healthy controls (n=7), total group of 
RA paƟ ents (n=19), and aŌ er sub-classifi caƟ on in DMARD-naïve (n=5), DMARD-responders (n=7) and 
DMARD-non-responding RA paƟ ents (n=7). Data are presented as mean values (pg/ml) ±SD Diﬀ erences in 
baseline TNFα producƟ on in the tested groups were not staƟ sƟ cally diﬀ erent. Note: no TNFa producƟ on 
was observed in unsƟ mulated whole blood cell cultures.
Figure 3: Bortezomib-induced inhibiƟ on of TNFα producƟ on by acƟ vated T-cells from RA paƟ ents and 
healthy volunteers. 
Dose-response curve for bortezomib-induced inhibiƟ on of TNFα producƟ on by αCD3-α/CD28 acƟ vated T-
cells from healthy volunteers (squares, n=7) and RA paƟ ents (triangles, n=19). Results are presented as 
median value and range (bars) for each bortezomib concentraƟ on tested. 
Figure 4: Bortezomib-induced inhibiƟ on of TNFa release by acƟ vated T-cells from (subgroups of) RA 
paƟ ents and healthy volunteers. 
ConcentraƟ ons of bortezomib required for 50% inhibiƟ on (IC50) of TNFα producƟ on in αCD3/αCD28-
sƟ mulated whole blood cell cultures of individual healthy volunteers (n=7; fi lled squares) and RA paƟ ents 
(n=19; triangles) as well as 3 RA subgroups. The horizontal lines depict the median IC-50 value for each 
group. 
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62-77% Annexin-V/7AAD-posiƟ ve cells aŌ er exposure to 10-100 nM bortezomib for 
48 hours, respecƟ vely (Figure 5A). A representaƟ ve FACS analysis of bortezomib-
induced T cell apoptosis in PBLs from a RA paƟ ent is shown in Figure 5B. Without 
bortezomib (control), only 7% of CD4/CD8 posiƟ ve (acƟ vated) T-cells were apoptoƟ c, 
while aŌ er incubaƟ on with 33 nM bortezomib for 48 hours (represenƟ ng IC-50 value 
for inhibiƟ on of TNF producƟ on in RA whole-blood), 60% of CD4/CD8 posiƟ ve T-
cells were apoptoƟ c based on Annexin-V staining. Apoptosis inducƟ on by bortezomib 
could be parƟ ally prevented, in a concentraƟ on dependent manner, by pre-incuba-
Ɵ on with the broad-spectrum-caspase inhibitor ZVAD-fmk (10-50 M), suggesƟ ng 
that cell death was mediated via apoptosis rather than by necrosis (data not shown). 
For comparison, no inducƟ on of apoptosis was observed aŌ er 48 hours exposure to 
300 nM concentraƟ ons of MTX (Figure 5C). EvaluaƟ on of the T-cell acƟ vaƟ on status 
by CD25 expression showed that as oﬀ  48 hours incubaƟ on with bortezomib, CD25 
expression decreased in a concentraƟ on dependent manner (Figure 5D).
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Figure 5: Eﬀ ects of bortezomib on T-cell acƟ vaƟ on and inducƟ on of apoptosis.   
(A) InducƟ on of apoptosis by bortezomib in αCD3-α/CD28-sƟ mulated peripheral blood lymphocytes of RA 
paƟ ents aŌ er 24 hours (white bars) and 48 hours (black bars) drug exposure. (B) RepresentaƟ ve FACS anal-
ysis depicƟ ng inducƟ on of apoptosis (Annexin-V posiƟ ve) in the CD4/CD8 posiƟ ve populaƟ on of (acƟ vated) 
T-cells in control condiƟ ons (without bortezomib) and aŌ er 48 hours exposure to 33nM bortezomib. (C) In-
ducƟ on of apoptosis by MTX in αCD3/αCD28-sƟ mulated peripheral blood lymphocytes of RA paƟ ents aŌ er 
24 hours (white bars) and 48 hours (black bars) drug exposure. (D) Percentage of acƟ vated (CD25 posiƟ ve) 
T-cells in αCD3-α/CD28-sƟ mulated peripheral blood lymphocytes aŌ er incubaƟ on with bortezomib. Results 
presented are the mean ±SD of 3 individual RA paƟ ents.
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Discussion
Nowadays, the ubiquiƟ n-proteasome system is recognized as the major pathway for 
degradaƟ on of intracellular proteins, many of which play a key role in regulaƟ on of 
pro-infl ammatory cytokines (7, 11). Data from the present study further support the 
proof of principle that bortezomib can confer inhibiƟ on of TNF producƟ on in whole 
blood from RA paƟ ents aŌ er T-cell sƟ mulaƟ on. MechanisƟ cally, this eﬀ ect can be 
explained by inhibiƟ on of the NFB signalling pathway as a downstream eﬀ ect of 
proteasome inhibiƟ on in conjuncƟ on with inducƟ on of apoptosis in acƟ vated T-cells 
(12-14, 17). In the whole blood assay employed in this study, it is anƟ cipated that 
beside T-cells, monocytes/macrophages will be the main producers of IL-1, IL-6 and 
TNF, as they get sƟ mulated by cytokines (like IL-17) produced by acƟ vated T-cells 
(20). Since we observed that bortezomib abrogated T-cell acƟ vaƟ on at low concen-
traƟ ons, it can be speculated that the producƟ on of these cytokines by monocytes/
macrophages is inhibited simultaneously.
Consistent with inhibiƟ on of NFB were observaƟ ons (Figures. 1, 3, 4) that besides 
TNF, bortezomib also inhibited other NFB-inducible cytokines (IL-1β, IL-6, IL-10) 
(Figure 1) in a concentraƟ on range (10-50 nM) that was previously shown to abro-
gate NFB acƟ vity (21). Given the central role of the ubiquiƟ n-proteasome system in 
regulaƟ ng signalling pathways (11), it is anƟ cipated that signalling pathways other 
than NFB may be eﬀ ected at higher concentraƟ ons of bortezomib and/or longer 
exposure Ɵ mes. In fact, concentraƟ ons of bortezomib that provoke apoptosis induce 
p38 MAPK acƟ vity along with a release of anƟ -infl ammatory cytokines, such as IL-
10 (22). The incomplete inhibiƟ on of IL-10 producƟ on at higher concentraƟ ons of 
bortezomib (Figure 1) may be consistent with this noƟ on. While bortezomib-induced 
inhibitory eﬀ ects on NFB acƟ vity could be observed rather rapidly (within 24 hour, 
Figure 1), bortezomib-induced apoptosis of acƟ vated T-cells was recognized as a later 
eﬀ ect, emerging between 24 and 48 hours of bortezomib exposure. In this respect, 
our data are consistent with Blanco et al showing that bortezomib was parƟ cularly 
acƟ ve against alloreacƟ ve (CD25+) T-cells and not resƟ ng T-cells (23). Based on the 
profi le of inhibiƟ on of TNF producƟ on, bortezomib exhibited potent ex vivo acƟ vity 
for both DMARD-naive and clinically DMARD-responsive RA paƟ ents, and an even 
slightly greater acƟ vity for DMARD non-responsive paƟ ents. This result may point to 
the fact that proteasome targeƟ ng may bypass or circumvent common mechanisms 
of loss of eﬃ  cacy to DMARDs aŌ er chronic administraƟ on (24). 
Apart from the inter-paƟ ent variability in ex vivo response to bortezomib, one other 
intriguing observaƟ on was that bortezomib displayed a greater potency in blocking 
190
Chapter 9
of TNF producƟ on by acƟ vated T-cells from healthy controls than from RA paƟ ents. 
An explanaƟ on for this is not readily available but could relate to possible diﬀ erences 
between healthy controls and RA paƟ ents with respect to (i) quanƟ taƟ ve and quali-
taƟ ve diﬀ erences in proteasomal catalyƟ c acƟ vity in T-cells from healthy controls 
versus paƟ ents with RA or other autoimmune diseases (25-27), or (ii) higher con-
sƟ tuƟ ve NFB acƟ vity in acƟ vated T-cells from RA paƟ ents (4), which would require 
higher bortezomib dosages for inhibiƟ on. In addiƟ on, a recent study (28) indicated 
that plasma pharmacokineƟ cs and acƟ vity of bortezomib can be infl uenced by up-
take of bortezomib in red blood cells. In our study, we made use of (1:10) diluted 
whole blood cell samples (19) within which variability in erythrocyte concentraƟ ons 
could have infl uenced residual concentraƟ ons of bortezomib to some degree. No-
tably, pharmacokineƟ cs of bortezomib in phase I clinical trials showed peak plasma 
levels of 50-1000 nM and steady state plasma levels of 10-20 nM (29, 30), which 
are within the concentraƟ on range where bortezomib showed inhibiƟ on of TNF 
producƟ on by acƟ vated T-cells from RA paƟ ents (Table 1, Figure 1) and inducƟ on of 
T-cell apoptosis. It remains to be established whether this inducƟ on of apoptosis is 
based solely on the apoptoƟ c eﬀ ects of bortezomib itself or whether it also involves 
previously reported bortezomib-induced sensiƟ zaƟ on of apoptoƟ c eﬀ ects of TRAIL 
or TNF (14). Obviously, any design of a trial for bortezomib in RA treatment should 
address a number of issues: (a) assessment of opƟ mal dosing/therapeuƟ c window 
for RA treatment, (b) it is anƟ cipated that commonly long term drug administraƟ on 
to RA paƟ ents will require special precauƟ ons with respect to drug safety (31), (c) it 
should be considered that proteasome inhibiƟ on may parƟ ally abrogate intracellular 
degradaƟ on of (citrinullated) proteins in RA paƟ ents (32). Finally, (d) it remains to be 
revealed to which extent other pro-infl ammatory cytokine producing cells (mono-
cytes, macrophages) in peripheral blood or in synovial Ɵ ssue are subject to targeƟ ng 
by bortezomib as demonstrated for acƟ vated T cells in this study.
Despite the current success of DMARDs and biologic agents, there is sƟ ll room for 
improvement of RA therapy (33). Given their unique profi le of acƟ on, proteasome 
inhibitors (34, 35) certainly deserve further evaluaƟ on for future clinical applicaƟ on 
in the treatment of chronic infl ammatory diseases. As a proof of concept, this pilot 
study demonstrated that proteasome targeƟ ng by specifi c inhibitors such as bort-
ezomib, can suppress producƟ on of pro-infl ammatory cytokines from acƟ vated T 
cells of RA paƟ ents. Thus, beyond demonstraƟ ons of good clinical acƟ vity against 
certain types of cancer, proteasome inhibitors may represent a new generaƟ on of 
targeted small molecule drugs in the therapeuƟ c armour, in parƟ cular for paƟ ents 
with DMARD-refractory RA.
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Summary
The proteasome inhibitor bortezomib is a novel anƟ cancer drug that has shown 
promise in the treatment of refractory mulƟ ple myeloma. However, its clinical eﬃ  -
cacy has been hampered by the emergence of drug-resistance phenomena, the mo-
lecular basis of which remains elusive. Toward this end, we here developed high lev-
els (45- to 129-fold) of acquired resistance to bortezomib in human myelomonocyƟ c 
THP1 cells by exposure to stepwise increasing (2.5-200 nM) concentraƟ ons of bort-
ezomib. Study of the molecular mechanism of bortezomib resistance in these cells 
revealed (1) an Ala49Thr mutaƟ on residing in a highly conserved bortezomib-binding 
pocket in the proteasome β5-subunit (PSMB5) protein, (2) a dramaƟ c overexpression 
(up to 60-fold) of PSMB5 protein but not of other proteasome subunits including 
PSMB6, PSMB7, and PSMA7, (3) high levels of cross-resistance to β5 subunit-target-
ed cytotoxic pepƟ des 4A6, MG132, MG262, and ALLN, but not to a broad spectrum 
of chemotherapeuƟ c drugs, (4) no marked changes in chymotrypsin-like proteasome 
acƟ vity, and (5) restoraƟ on of bortezomib sensiƟ vity in bortezomib-resistant cells 
by siRNA-mediated silencing of PSMB5 gene expression. CollecƟ vely, these fi ndings 
establish a novel mechanism of bortezomib resistance associated with the selecƟ ve 
overexpression of a mutant PSMB5 protein. 
IntroducƟ on
The ubiquiƟ n proteasome system (UPS) facilitates the degradaƟ on of ubiquiƟ n-
tagged intracellular proteins, many of which play a regulatory role in cell prolifera-
Ɵ on, cell survival, and signaling processes (1-3). As such, proteasome inhibitors have 
been recognized as a new generaƟ on of chemotherapeuƟ c agents and anƟ -infl am-
matory drugs (4-13). The boronic dipepƟ de bortezomib (PS341, Velcade©) is the fi rst 
proteasome inhibitor that has been approved for the treatment of refractory mul-
Ɵ ple myeloma (6,14). Bortezomib is a reversible inhibitor that targets primarily the 
β5-subunit (PSMB5) subunit/chymotrypsin-like acƟ vity of the 26S proteasome and 
to a somewhat lesser extent also caspase-like acƟ vity harbored by the β1 (PSMB6) 
proteasome subunit. At higher concentraƟ ons, bortezomib inhibits trypsin-like pro-
teolyƟ c acƟ vity facilitated by β2 (PSMB7) proteasome subunits (15-17). Despite 
promising clinical acƟ vity, some paƟ ents with mulƟ ple myeloma failed to respond to 
bortezomib therapy (18). Moreover, the eﬃ  cacy for bortezomib may diﬀ er between 
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tumor types (6, 19-21). Whether these observaƟ ons are related to common mech-
anisms of drug resistance frequently seen for anƟ cancer (22) or anƟ -infl ammatory 
drugs23 is largely unknown. However, their characterizaƟ on is of key importance as 
it may pave the way for the overcoming of drug resistance, thereby enhancing the 
eﬃ  cacy of this new class of proteasome-targeted drugs.
One mode of primary resistance to bortezomib is conveyed by consƟ tuƟ vely high 
levels of heat shock protein 27 (24). In the context of acquired resistance, studies 
aimed at delineaƟ ng the mechanism of acquired resistance to the tripepƟ dyl alde-
hyde proteasome inhibitor ALLN (N-acetyl-leucyl-leucyl-norleucinal) revealed 2 pos-
sible molecular mechanisms: (a) enhanced cellular eﬄ  ux via the mulƟ drug resistance 
(MDR) transporter P-glycoprotein (Pgp; ABCC1) (25) or mulƟ drug resistance-related 
protein 1 (MRP1; ABCC1) (26) and (b) increased detoxifi caƟ on via up-regulated acƟ v-
ity of aldo-keto reductase (27). Recent studies showed that Pgp overexpression con-
ferred low levels (3-fold) of bortezomib resistance (28) as well as to the irreversible 
proteasome inhibitor epoxomicin, but cells with 4- to 7-fold acquired resistance to 
epoxomicin did not show Pgp overexpression as a molecular basis of resistance (29). 
Two independent reports analyzing acquired resistance to the irreversible protea-
some inhibitor NLVS (NIP-Leu3-vinyl sulfone) in mouse EL4 thymoma cells showed 
loss of proteasome funcƟ on that was compensated by overexpression of another 
protease acƟ vity, tripepƟ dylpepƟ dase II (30-32). However, a more detailed charac-
terizaƟ on of these NVLS-resistant EL4 cells revealed that residual proteasome acƟ v-
ity was suﬃ  cient to sustain cell funcƟ on and viability (33) so that the actual modality 
of resistance in these cells remains to be elucidated. Altogether, given the lack of a 
profound understanding of the mechanisms of acquired resistance to bortezomib 
in mammalian cells, we set out to characterize human monocyƟ c/macrophage cells 
with high levels of acquired bortezomib resistance aŌ er in vitro selecƟ on using a 
protocol of stepwise increases in bortezomib concentraƟ ons. Our fi ndings establish 
that bortezomib resistance is not conferred by increased expression of MDR eﬄ  ux 
pumps. Rather, qualitaƟ ve and quanƟ taƟ ve alteraƟ ons were observed at the level 
of the β5 proteasome subunit; these included a PSMB5 gene mutaƟ on resulƟ ng in a 
subsƟ tuƟ on of a crucial amino acid (Ala49Thr) in the bortezomib-binding pocket of 
the β5-subunit. These bortezomib-resistant cells highly overexpressed this mutant 
β5-subunit and displayed a marked cross-resistance to β5-targeted cytotoxic pep-
Ɵ des but not to other classes of therapeuƟ c drugs. Hence, these fi ndings establish 
a novel modality or bortezomib resistance associated with the selecƟ ve overexpres-
sion of a structurally altered β5-subunit.
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Materials and methods
Reagents
Bortezomib (BTZ)/Velcade® was kindly provided by Millennium PharmaceuƟ cals 
(Cambridge, USA). The proteasome-inhibitors MG132 (Z-Leu-Leu-Leucinal) and 
MG262 (Z-Leu-Leu-Leu-boronate) were purchased from Calbiochem/ Merck (Noƫ  ng-
ham, UK). The cytotoxic pepƟ de 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-
Gly-Bza) was synthesized as described previously 26. The tripepƟ dylpepƟ dase II in-
hibitor H-Ala-Ala-Phe-chloromethylketone was obtained from Bachem (Germany). 
Chloroquine, mitoxantrone, cisplaƟ n (CDDP), geldanamycin, doxorubicin, sulfasala-
zine, 5-FU, NP-40, trimethylrhodamine-ethyl ester (TMRE), ALLN (N-acetyl-Leu-Leu-
norleucinal) and leupepƟ n (Ac-Leu-Leu-Arg-al) were obtained from Sigma-Aldrich 
(St. Louis, MO, U.S.A.). Bleomycin was obtained from Dagra Pharma (Diemen, The 
Netherlands). Methotrexate was from Pharmachemie (Haarlem, The Netherlands). 
Methylprednison was purchased from Pfi zer (New York, NY, U.S.A.), cyclosporin A 
was kindly provided by NovarƟ s (Arnhem, The Netherlands) and Iressa®/gefi Ɵ nib 
was a giŌ  from AstraZeneca (Zoetermeer, The Netherlands). Protease Inhibitor Cock-
tail (PIC) was obtained from Roche DiagnosƟ cs (Almere, The Netherlands). RPMI-
1640 Ɵ ssue culture medium and fetal calf serum were obtained from Gibco Chem. Co 
(Grand Isl., NY, U.S.A). All fl uorogenic pepƟ de substrates (Suc-Leu-Leu-Val-Tyr-amc, 
Ac-Arg-Leu-Arg-amc and Z-Leu-Leu-Glu-amc), the proteasome inhibitor Ac-APnLD-al 
and proteasome-related anƟ bodies (β1, β2, β5, α7, α/β core were purchased from 
Biomol (Plymouth MeeƟ ng, PA, U.S.A.). AnƟ body 20S X (NB120-3330) was obtained 
from Novus Biologicals, LiƩ leton, USA). AnƟ bodies to Hsp27 (#2402) and Hsp90 
(#4875) were from Cell Signaling Technologies (Danvers, MA, USA), AnƟ bodies to 
XIAP (M044-3) and P21 (OP68) were from MBL, Int. Co (USA) and Calbiochem (Ger-
many), respecƟ vely. AnƟ -ubiquiƟ n anƟ body (sc-8017) was purchased from Santa 
Cruz Biotechnology (Santa Cruz, Ca, USA). 
Cell culture and development of BTZ-resistant cell lines
Human monocyƟ c/macrophage THP1 cells (ATCC, Manassas, VA) were kept as a sus-
pension culture in RPMI-1640 medium supplemented with 5% fetal calf serum, 20 
mM HEPES, 2 mM glutamine, and 100 μg/mL penicillin/streptomycin at 5% CO2 and 
37°C. Cell cultures were seeded at a density of 3 x 105 cells/mL and refreshed twice 
weekly. Bortezomib (BTZ)–resistant THP1 cell lines were obtained by stepwise in-
creasing extracellular concentraƟ ons of bortezomib over a period of 6 months, start-
ing at a concentraƟ on of 2.5 nM (IC50 concentraƟ on: 3.3 nM) up to a concentraƟ on of 
200 nM bortezomib. During this process, cultures were isolated that were grown in 
the presence of 30 nM (THP/BTZ30), 50 nM (THP1/BTZ50), 100 nM (THP1/BTZ100), and 
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200 nM bortezomib (THP1/BTZ200). All bortezomib-resistant cell lines retained paren-
tal doubling Ɵ mes (28 ± 3 hours) and morphology, and also retained their typical ca-
pacity to diﬀ erenƟ ate into adherent macrophage-like cells upon exposure to phorbol 
myristate acetate (PMA). To invesƟ gate the stability of the resistance phenotype, an 
aliquot of THP1/BTZ100 cells was cultured in the absence of bortezomib for a period of 
up to 6 months. These cells will be further designated as THP1/BTZ(-100) cells.
Proteasome acƟ vity in cell lysates
Chymotrypsin-like, trypsin-like, and caspase-like proteolyƟ c acƟ viƟ es of the protea-
some were measured in freshly prepared cell lysates as described previously (34, 35) 
with some minor modifi caƟ ons to the protocol. In brief, a total of 5 x 106 untreated 
or bortezomib-exposed THP1 cells were washed 3 Ɵ mes with ice-cold PBS and spun 
down by centrifugaƟ on (5 minutes, 250g, 4°C). Cell pellets were then resuspended in 
an ATP-containing lysis buﬀ er (10 mM Tris-HCl buﬀ er (pH 7.8) containing 5 mM ATP, 
0.5 mM DTT, and 5 mM MgCl2) and kept on ice for 10 minutes. For complete lysis, cells 
were sonicated (MSE sonicator, amplitude 7, for 3 x 5 seconds with 20-second Ɵ me 
intervals at 4°C) followed by centrifugaƟ on (5 minutes, 16 000g, 4°C) to remove cell 
debris. The supernatant was collected and protein concentraƟ on was determined 
using the Bio-Rad protein assay (Hercules, CA). Fluorogenic pepƟ de substrates to 
measure the chymotrypsinlike, trypsin-like, and caspase-like acƟ vity were Suc-Leu-
Leu-Val-Tyr-amc, Ac-Arg-Leu-Arg-amc, and Z-Leu-Leu-Glu-amc, respecƟ vely, all at 
a 100-μM fi nal concentraƟ on. The substrates were incubated with 20 μg total cell 
protein extract in the presence or absence of specifi c inhibitors in a total assay vol-
ume of 200 μL. Specifi c inhibitors for chymotrypsin-like, caspaselike, and trypsin-like 
acƟ vity included bortezomib (10 nM), Ac-APnLD-al (25 μM), and leupepƟ n (20 μM), 
respecƟ vely. The release of AMC was monitored online over a 2-hour Ɵ me period at 
37°C with 5-minute intervals. Fluorescence was measured on a Tecan Spectra Fluor 
apparatus (Giessen, The Netherlands) using excitaƟ on and emission wavelengths of 
360 and 465 nm, respecƟ vely. ProteolyƟ c acƟ vity was calculated from the slopes of 
the linear porƟ on of the curves. All results were expressed as percentage relaƟ ve to 
untreated THP1/WT cells (100%).
RT-PCR/siRNA proteasome subunits
mRNA expression levels of proteasome subunits PSMB5 (β5), PSMB6 (β1), PSMB7 
(β2) and the endogenous housekeeping gene β-glucuronidase (GUS) as a refer-
ence were quanƟ fi ed using real-Ɵ me PCR analysis (Taqman) on an ABI Prism 7700 
sequence detecƟ on system (PE Applied Biosystems). All probes were labeled with 
5’-FAM and 3’-BHQ1 as a reporter. Primers and probes were designed using Primer 
Express soŌ ware (Applied Biosystems). Primers, probe combinaƟ ons and concentra-
Ɵ ons used for the quanƟ taƟ ve real-Ɵ me PCR were as follows: PSMB5 forward (50 
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nM): CTTCAAGTTCCGCCATGGA; PSMB5 reverse (300 nM): CCGTCTGGGAGGCAA TG-
TAA; PSMB5 probe (200 nM): TTGCAGCTGACTC CAGGGCTACAGC; PSMB6 forward 
(300 nM): AGGCATGACCAAGGAAGAGTGT; PSMB6 reverse (50 nM): GAGCCATC-
CCGCTCCAT; PSMB6 probe (200 nM): TGCAATTCACTGCCAAT GCTCTCGC; PSMB7 for-
ward (300 nM): TCGGTGTA TGCTCCACCAGTT; PSMB7 reverse (50 nM): GCAAAATCG-
GCTTCCAAGAC; PSMB7 probe (200 nM): TTCTCTT TTGATAACTGCCGCAGGAATGC; GUS 
forward (300 nM): GAAAATATGTGGTTG GAGAGCTCATT; GUS reverse (300 nM): CCGA 
GTGAAGATCCCCTTTTTA; GUS probe (200 nM): CCAGCACTCTCGTCGGTGAC TGTTCA. 
Real-Ɵ me PCR was performed in a total reacƟ on volume of 50 μl containing TaqMan 
buﬀ er A (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands), 4mM MgCl2, 
0.25 μM of each dNTP (Amersham Pharmacia Biotech) and 1.25 U AmpliTaq Gold 
DNA polymerase (Applied Biosystems). Samples were heated for 10 min at 95°C to 
acƟ vate the AmpliTaq Gold DNA polymerase and amplifi ed during 40 cycles of 15 s 
at 95°C and 60 s at 60°C. RelaƟ ve mRNA expression levels of the target genes in each 
sample were calculated using the comparaƟ ve cycle Ɵ me (Ct) method (36). Briefl y, 
this PCR Ct value is the cycle number at which emiƩ ed fl uorescence exceeds 10x the 
standard deviaƟ on (S.D.) of baseline emissions as measured from cycles 3–15. The 
Ct of the target gene is normalised to the GUS PCR Ct value by subtracƟ ng the GUS 
Ct value from the target Ct value. The mRNA expression level for each target PCR 
relaƟ ve to GUS was calculated using the following equaƟ on: mRNA expression = 2(Ct 
target-Ct GUS) x 100%.
For RNA interference experiments all targeted and non-targeted siRNA constructs 
were obtained from Dharmacon (LafayeƩ e, USA) and all experiments were per-
formed in 24 well plates or T25 fl asks. THP1/WT, THP1/BTZ(-100) and THP1/BTZ200 cells 
were cultured following the suppliers’ protocol for THP1 cells. Briefl y, prior to trans-
fecƟ on, cells were cultured overnight at a density of 5 x 104 cells/ml in RPMI 1640 
medium supplemented with 7.5% FCS and 20mM HEPES. Cells were transfected us-
ing Dharmafect 2 (DF2) and 100nM of PSMB5 On-Targetplus SmartPool siRNA. As 
negaƟ ve control 100nM On-targetplus siControl non-targeƟ ng and GAPD pool were 
used. To assess transfecƟ on-eﬃ  ciency siGLO was used as a transfecƟ on-indicator. 
AŌ er 24 hours, transfecƟ on-eﬃ  ciency (usually > 85%) was determined by fl ow cy-
tometry using siGlo as transfecƟ on indicator. At this stage diﬀ erent concentraƟ ons 
of bortezomib were added and inducƟ on of apoptosis and cell growth-inhibiƟ on was 
determined aŌ er 24 hours bortezomib exposure. Western blot experiments to assess 
protein knock-down were performed aŌ er 72 hours siRNA incubaƟ ons. 
Sequence analysis 
DNA was isolated from THP1/WT, THP1/BTZ7, THP1/BTZ30, THP1/BTZ100 and THP1/
BTZ(-100) cells using a Qia amp DNA blood mini kit (250) (Qiagen, Valencia, CA, USA). 
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Subsequently, part the second exon of the PSMB5 gene was amplifi ed by PCR. The 
primers were designed using Vector NTI (Invitrogen) soŌ ware (forward: TTCCGCCAT-
GGAGTCATA, reverse: GTTGGCAAGCAGTTTGGA). PCR products were directly se-
quenced by dideoxy chain-terminaƟ on method using a kit ABI PrismTM BigDye Ter-
minator (Perkin Elmer, Foster City, CA, USA) and analyzed by an autosequencer ABI 
Prism GeneƟ c Analyser 3100 automaƟ c DNA sequencer (Perkin Elmer).
Growth inhibiƟ on assays 
EvaluaƟ on of drug sensiƟ vity was carried out as described previously (37). Cells were 
seeded at an iniƟ al density of 1.25 x 105 cells/ml in individual wells of a 24-well plate 
containing up to 50 μl of drug soluƟ ons. InhibiƟ on of cell growth was determined 
aŌ er 72 hour incubaƟ on at 37oC by counƟ ng viable cells based on trypan blue exclu-
sion. The drug concentraƟ on required to inhibit cell growth by 50% compared to 
untreated controls was defi ned as the IC50. 
QuanƟ fi caƟ on of ubiquiƟ nated proteins/proteasome subunits 
Western blot analysis to determine the accumulaƟ on of ubiquiƟ nated proteins upon 
bortezomib exposure was performed essenƟ ally as described previously (37). In 
short, cells were harvested in the mid-log phase of growth and washed 3 Ɵ mes with 
ice-cold buﬀ ered saline pH 7.4. Total cell lysates of 5 x 106 cells were prepared by 
resuspending in 0.5 ml lysis buﬀ er containing: 50 mM Tris-HCl (pH 7.6), 5 mM dithi-
otreitol (DTT), 20 μl PIC (Protease Inhibitor Cocktail; 1 tablet/ml H2O), 20% glycerol 
and 0.5% NP-40. The suspension was sonicated (MSE sonicator, amplitude 7, for 3 
x 5 seconds with 20 seconds Ɵ me intervals at 4oC) and centrifuged in an Eppendorf 
micro-centrifuge (5 min, 12,000 rpm, 4oC). Protein content of the supernatant was 
determined by the Bio-Rad protein assay. Twenty to thirty microgram of total cell 
lysates were fracƟ onated on a 10% polyacrylamide gel containing SDS and trans-
ferred onto a PVDF membrane. The membranes were pre-incubated overnight at 4oC 
in blocking buﬀ er (5% Bio-Rad Blocker in TBS-T; 10 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 
0.1% Tween-20) to prevent non-specifi c anƟ body binding. AŌ er blocking, the mem-
branes were incubated for 1 hour at room temperature with an ubiquiƟ n-specifi c 
anƟ body (1:1000, Santa-Cruz, SC-8017). AŌ er 3 washing steps with TBS-T, the mem-
branes were incubated for 1 hour with HRP-labelled goat-anƟ -mouse (1:6000, Dako, 
Glostrup, Denmark) secondary anƟ body. DetecƟ on of anƟ body binding was followed 
by chemoluminescence using Supersignal (Pierce Biotechnology, Rockford, USA) ac-
cording to the manufacturers’ instrucƟ ons. Digital Image acquisiƟ on was performed 
using the Versadoc Imaging System (Biorad Lab., Veenendaal, The Netherlands). 
Expression of β1, β2, β5, α7 and α/β-core proteasome subunits were determined 
essenƟ ally as described above. Primary anƟ -bodies from Biomol for β1 (1:1000, 
PW8140), β2 (1:1000, PW8145), β5 (1:1000, PW8895 or 1:1000 20S X), α7 (1:1000, 
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PW8110) and α/β (1:1000, PW8155) were incubated for 1 hour at room tempera-
ture. An anƟ body to α-tubulin was used (1:1000, Santa Cruz, sc-8035) to check and 
normalize for any loading diﬀ erences. HRP-labelled Donkey-anƟ -rabbit (1:6000, Am-
ersham, UK) or goat-anƟ -mouse (1:6000, DAKO) secondary anƟ -bodies were used. 
The signal intensity was determined densitometrically using QuanƟ ty One soŌ ware 
(Bio-Rad) and was expressed relaƟ ve to the intensity of the α-tubulin signal.  
NaƟ ve gel electrophoresis/gel fi ltraƟ on chromatography
CharacterizaƟ on of the proteasome (detecƟ on of core/regulatory parƟ cles and suc-
Leu-Leu-Val-Tyr-amc hydrolysis acƟ vity), in wild type and bortezomib-resistant THP1 
cells by naƟ ve gel electrophoresis was performed essenƟ ally as described by Elsasser 
et al (38) using acid washed glass beads (Sigma) for the preparaƟ on of lysates.
Gel fi ltraƟ on chromatography of proteasome complexes and proteasome subunits 
was performed as described by Chondrogianni et al (39) using a Superdex 200 HR 
10/30 column (Amersham Pharmacia Biotech, The Netherlands) connected to an 
Gynkotek Model 300 HPLC system and calibrated with a with a mixture of purifi ed 
proteins in a MW range of 16.6 kD to 669 kD. Briefl y, 1.5 x 107 THP1/WT and THP1/
BTZ100 cells were washed three Ɵ mes in PBS and then lysed in 200 μl ice-cold 20 mM 
Tris-HCl, pH 7.5, 5 mM ATP and 0.2% Nonidet-P40. Cell extracts were then centri-
fuged at 4oC for 15 min at 14,000 rpm in an Eppendorf centrifuge. Hundred microlit-
ers of the supernatant fracƟ on were applied on the Superdex column equilibrated in 
20 mM Tris-HCl, pH7.5, 5 mM ATP and 120 mM NaCl. The column was then eluted 
with the same buﬀ er at a fl ow rate of 0.4ml/min. FracƟ ons of 0.4 ml were collected 
for western blot analysis of proteasome β5 and α7 subunit expression. 
Proteasome subunit aﬃ  nity probing 
Aﬃ  nity labelling of funcƟ onal proteasome subunits in intact cells was performed 
with the BodipyFL-Ahx3L3VS probe essenƟ ally as described by Berkers et al (40). Prior 
to aﬃ  nity labelling experiments THP1/BTZ cells were cultured in the absence of bort-
ezomib for 4 days.
Mitochondrial trans-membrane potenƟ al (∆ψm)  
The eﬀ ect of bortezomib on the mitochondrial trans-membrane potenƟ al (∆ψm) was 
measured as described by Ling et al (41). Briefl y, 1 x 105 cells were resuspended in 
0.5 ml culture-medium and incubated for 15 minutes at 37oC with 25 nM tetram-
ethylrhodamine ethyl ester (TMRE), aŌ er which cells were washed 3 Ɵ mes with ice-
cold PBS supplemented with 0.1% BSA. TMRE accumulaƟ on was measured by fl ow 
cytometry using a B&D FACScalibur apparatus. Data were analyzed with FCS-express 
V3 soŌ ware as described above.
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Microarray analysis 
THP1/WT cells, THP1/BTZ30, THP1/BTZ100 and THP1/BTZ(-100, 6mo) cells were harvested in 
the mid-log phase of growth. The amount and integrity of isolated RNA was meas-
ured using a spectrophotometer (NanoDrop ND100 (Wilmington, DE, USA)) and a 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). 
Microarray expression analysis was carried out as described by Cloos et al (42), using 
the Human Release 2.0 oligonucleoƟ de library (designed by Compugen (San Jose, 
CA, USA) and obtained from Sigma-Genosys (Zwijndrecht, The Netherlands)) for 
prinƟ ng the slides.
The arrays were scanned using an Agilent Microarray Scanner (Agilent Technologies, 
Amstelveen, The Netherlands). Spot analysis and feature extracƟ on were fully au-
tomated using BlueFuse version 3.4 (BlueGnome, Cambridge, UK). Spots were ex-
cluded when the Confi dence value <0.1. Subsequently, Lowess block normalizaƟ on 
was performed within the same program on the non-fl agged spots and exported 
to Excel (MicrosoŌ ©). RaƟ o’s of resistant divided by the untreated reference sample 
were used for further analysis. 
Immunofl uorescence microscopy 
Freshly prepared cytospins from THP1/WT and THP1/BTZ200 cells were used at a den-
sity of 10.000 cells per spin. Cells were fi xed with 3.5% paraformaldehyde for 15 min 
at RT and then washed twice with PBS and permeabilized by saponin (PBS + 2% sa-
ponin, 2 min at RT). Following two successive washes with PBS, slides were incubated 
for 2 hours at RT with either PBS (control), rabbit anƟ -β5 subunit anƟ body (20S X) 
diluted 1:50 and mouse anƟ -α7 subunit anƟ body (Biomol, PW8110) diluted 1:100 
in PBS + 4% BSA. Double staining detecƟ on was performed with a FITC-conjugated 
goat anƟ -mouse anƟ body (Sanquin, Amsterdam, The Netherlands) diluted 1:100 
and TRITC-conjugated swine anƟ -rabbit anƟ body (Dako, Glostrup, Denmark) diluted 
1:100. The slides were mounted with Vectashield (Vector Laboratories, Burlingame, 
CA, USA) and examined using a Leica fl uorescence microscope. 
Apoptosis assay 
Bortezomib-induced apoptosis was analyzed by measuring AnnexinV-FITC/7-ami-
noacƟ nomycin D (7-AAD) staining (APOPTESTTM-FITC A700, VPS DiagnosƟ cs, Hoeven, 
the Netherlands) according to the instrucƟ ons of the manufacturer. Briefl y, inducƟ on 
of apoptosis was determined aŌ er 24 hours exposure by bortezomib. One million 
cells were harvested and washed 3 Ɵ mes with ice-cold PBS. The cell pellet was incu-
bated for 30 minutes with 7-Amino-acƟ nomycin D (7-AAD) on ice followed by incu-
baƟ on with Annexin-V according to the instrucƟ ons of the manufacturer. Annexin-V 
and 7-AAD expression was measured by fl ow cytometry (Beckton & Dickinson, FAC-
204
Chapter 10
Scalibur) and analysed using FCSexpress V3 soŌ ware (Denovo soŌ ware, Thornhill, 
Canada).
StaƟ sƟ cs
StaƟ sƟ cal analysis was performed using Analysis of Variance between groups (ANO-
VA) in Graphpad prism. P values < 0.05 were considered to be staƟ sƟ cally signifi cant.
Table 1: Growth inhibitory eﬀ ects of proteasome inhibitors and various anƟ -cancer/-infl amma-
tory drugs for wild type (WT) and Bortezomib (BTZ)-resistant THP1 cells.
IC50# Resistance Factor##
Proteasome inhibitors THP1/WT THP1/BTZ50 THP1/BTZ100 THP1/BTZ200
Bortezomib (nM) 3.3 ± 0.6 45 79 129
MG132 (nM) 237 ± 54 8.1 11.9 15.8
MG262 (nM) 2.1 ± 0.6 8.3 10.3 10.8
ALLN (μM) 3.7 ± 0.4 5.8 10.0 18.1
4A6 (μM) 0.26 ± 0.06 44 117 287
Miscellaneous drugs
Methotrexate (nM) 8.0 ± 1.4 0.8 1.0
Sulfasalazine (μM) 275 ± 49 1.3 0.8
Chloroquine (μM) 56.3* 1.1 1.1
Cyclosporin A (μM) 3.9* 0.9 0.8
5-Fluorouracil (μM) 2.3* 0.5 0.4
Methylprednison (μM) 0.69* 1.1 1.0
Doxorubicin (nM) 18.9 ± 6.2 1.3 1.5
Mitoxantrone (nM)      2.5 ± 1.3 1.4 1.2
Bleomycin (μM) 4.9 ± 2.9 0.6 0.5
CisplaƟ n (μM) 0.84 ± 0.46 2.1 1.9
Iressa (μM) 10.4 ± 4.6 1.3 1.3
Geldanamycin (nM) 30.6 ± 13.1 1.0 1.1
AAF-cmk (μM) 7.3 ± 1.8 1.4 1.9 1.1
#IC50: Drug concentraƟ on resulƟ ng in 50% growth inhibiƟ on compared to control.
## Resistance factor: raƟ o IC50 BTZ-resistant cell line over IC50 THP1/WT cells.
* Mean of two experiments performed in duplicate.
Results depicted are the mean of at least 3-10 experiments ± S.D.
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Results
Establishment of cells with acquired resistance to bortezomib
To explore the molecular basis of acquired resistance to bortezomib, human mono-
cyƟ c/macrophage THP1 cells were exposed in vitro over a period of 6 months to 
stepwise increasing concentraƟ ons of bortezomib represenƟ ng approximately 1- to 
50-fold the IC50 (2.5 nM to 200 nM). THP1 cells grown in the presence of 50 nM 
(THP1/BTZ50), 100 nM (THP1/BTZ100), and 200 nM (THP1/BTZ200) bortezomib were 
used for further characterizaƟ on. Dose-response curves for bortezomib-induced cell 
growth inhibiƟ on revealed 45-fold (IC50: 148 ± 54 nM), 79-fold (IC50: 261 ± 71 nM), 
and 129-fold (IC50: 426 ± 72 nM) levels of resistance in THP/BTZ50, THP1/BTZ100, and 
THP1/BTZ200 cells, respecƟ vely, compared with wild-type THP/1 cells (IC50: 3.3 ± 0.6 
nM; Figure 1A).
Cross-resistance profi le of bortezomib-resistant cells to proteasome 
inhibitors and various anƟ cancer/anƟ -infl ammatory drugs
Bortezomib-resistant cells displayed appreciable cross-resistance to other known 
small (3-mer) pepƟ de-based proteasome inhibitors (ALLN, MG132, and MG262; Table 
1), although to a lower level (6- to 18-fold) than for bortezomib itself. Strikingly, very 
high levels of cross-resistance (up to 300-fold) were observed for the 6-mer cytotoxic 
pepƟ de 4A6 (26) that exerts a specifi c β5-subunit–related/chymotrypsin-like protea-
some inhibitory acƟ vity (R.O.,Y.G.A., R.J.S., G.J., unpublished results). Of note, no ap-
preciable levels of cross-resistance were observed for a broad spectrum of chemo-
therapeuƟ c drugs with disƟ nct mechanisms of acƟ on, for example, methotrexate 
(folate antagonist), sulfasalazine (inhibitor κB kinase/NFκB inhibitor), 5-fl uorouracil 
(fl uoropyrimidine anƟ metabolite), chloroquine (lysosomotropic drug), bleomycin 
(DNAinteracƟ ng agent), gefi Ɵ nib (epidermal growth factor receptor tyrosine kinase 
inhibitor), cisplaƟ n (DNA interchelator), cyclosporine A (immunosuppressive drug), 
methylprednisolone (corƟ costeroid), geldanamycin (heat shock protein inhibitor), 
doxorubicin (DNA-interacƟ ng drug), and mitoxantrone (topoisomerase inhibitor; 
Table 1). The laƩ er 2 drugs are bona fi de substrates of the ATP-driven drug eﬄ  ux 
transporters P-glycoprotein (Pgp; ABCB1), mulƟ drug resistance-associated proteins 
1-9 (MRP1-9/ABCCs), or breast cancer resistance protein (BCRP; ABCG2) (22). The 
lack of cross-resistance to these drugs in bortezomib-resistant cells argues against a 
mulƟ drug resistance (MDR) phenotype. This noƟ on was further corroborated by the 
observaƟ on that parental mRNA levels of Pgp, MRP1-9, and BCRP were retained in 
bortezomib-resistant cells (data not shown) and Western blot experiments (Figure 
S1) showing no diﬀ erenƟ al expression of Pgp, MRP1-6, and BCRP in bortezomib-re-
sistant cells versus parental THP1/WT cells. Finally, bortezomib-resistant cells lacked 
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cross-resistance to AAF-cmk, an inhibitor of the proteolyƟ c system tripepƟ dylpepƟ -
dase II (33). Together, these results demonstrate that cross-resistance of bortezomib-
resistant cells is restricted to (pepƟ de) drugs that primarily target the proteasome’s 
β5-subunit.
To further characterize the bortezomib-resistant cells, and to gain insight whether 
mulƟ ple mechanisms of resistance may contribute to the bortezomib-resistant phe-
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Figure 1: Emergence of acquired resistance to bortezomib and impaired bortezomib-induced accumula-
Ɵ on of ubiquiƟ nated proteins in bortezomib-resistant cells. 
(A) Dose-response curve for bortezomib-induced growth inhibiƟ on of wild-type (WT) human monocyƟ c/
macrophage THP1 cells and bortezomib (BTZ)–resistant variants THP1/BTZ50, THP1/BTZ100, and THP1/
BTZ200, selected for growth in extracellular concentraƟ ons of 50 nM, 100 nM, and 200 nM bortezomib, 
respecƟ vely. Results depicted are the mean of 7 to 20 experiments (± SD). Drug exposure Ɵ me, 72 hours. 
(B) AccumulaƟ on of ubiquiƟ nated proteins in THP1/WT cells and bortezomib-resistant sublines aŌ er expo-
sure to bortezomib. Bortezomib-resistant cells were allowed a 4-day drug washout period (control) aŌ er 
which they were exposed for 24 hours to their selecƟ ve concentraƟ ons of bortezomib. THP/WT cells were 
exposed to 10 nM BTZ for 24 hours. (C) AccumulaƟ on of ubiquiƟ nated proteins in THP/WT cells aŌ er 24-
hour exposure to 10 to 100 nM bortezomib and for THP1/BTZ200 cells aŌ er 24-hour exposure to bortezomib 
concentraƟ ons beyond selecƟ ve concentraƟ ons (up to 1000 nM). A representaƟ ve picture of 2 separate 
experiments is depicted.
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notype, microarray analysis was performed to assess diﬀ erenƟ al gene expression 
in control THP1/WT cells versus THP1/BTZ30 cells, THP1/BTZ100 cells, and its subline 
THP1/BTZ(-100) grown in the absence of BTZ for 6 months. The enƟ re data set of the 
test series is available at the GEO database, accession number GSE11771 (43). Pre-
liminary evaluaƟ on of expression of genes specifi cally involved in drug metabolism 
and resistance (n = 101), apoptosis (n = 59), and cell cycling (n = 76) showed no 
marked and/or robust alteraƟ ons (< 2- or > 2-fold) that could be associated with 
resistance (Figure S2). Consistently, Western blot analysis for specifi c proteins in 
these gene categories (eg, Hsp27, Hsp90, XIAP, and p21) showed no marked changes 
in bortezomib-resistant cells compared with bortezomib-sensiƟ ve THP1/WT cells 
(Figure S3). Strikingly, however, approximately 40% of genes represenƟ ng the vari-
ous proteasome subunits, in parƟ cular β-subunits, showed a markedly (≥ 2-fold) in-
creased expression level (Figure S2). Only 2 proteasome subunit-related genes were 
down-regulated in expression (≤ 2-fold): the immunoproteasome subunits β5i and 
β1i. Of addiƟ onal interest, no alteraƟ ons were observed in expression levels of genes 
encoding ubiquiƟ n-conjugaƟ ng enzymes, ubiquiƟ nspecifi c proteases, or ubiquiƟ n C-
terminal hydrolases. Finally, up-regulated expression of proteasome subunit genes 
in bortezomib-resistant cells appeared to be transient as gene expression normal-
ized when THP1/BTZ100 cells were grown in the absence of bortezomib for 6 months 
(Figure S2). Together, gene array analyses further support the noƟ on that alteraƟ ons 
in proteasome subunit composiƟ on or funcƟ on may be dominantly involved in the 
bortezomib-resistant phenotype.
Diminished accumulaƟ on of ubiquiƟ nated proteins in bortezomib-
resistant cells
A characterisƟ c feature of proteasome inhibiƟ on is the accumulaƟ on of ubiquiƟ nat-
ed proteins that provokes loss of mitochondrial membrane potenƟ al and apoptosis 
(33,41). Consistently, marked accumulaƟ on of ubiquiƟ nated proteins was observed 
in wild-type cells exposed to bortezomib but not in bortezomib-resistant cells at their 
selecƟ ve concentraƟ on of 30 to 200 nM (Figure 1B). However, the laƩ er cells showed 
clear accumulaƟ on of ubiquiƟ nated proteins if exposed to concentraƟ ons of bortezo-
mib above the selecƟ ve concentraƟ ons (500-1000 nM; Figure 1C). Thus, bortezomib 
resistant cells have retained their capacity to accumulate ubiquiƟ nated proteins, ex-
cept that this process is iniƟ ated at markedly higher concentraƟ ons of bortezomib 
consistent with the resistance factor for bortezomib.
Impaired bortezomib-induced loss of mitochondrial membrane 
potenƟ al and inducƟ on of apoptosis in bortezomib-resistant cells
The shiŌ  in bortezomib-induced accumulaƟ on of ubiquiƟ nated proteins in borte-
zomib-resistant cells paralleled the shiŌ  in bortezomib-induced loss of mitochondrial 
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Figure 2: Diﬀ erenƟ al inducƟ on of apoptosis by bortezomib and VP16 in bortezomib-resistant cells.
(A) Loss of mitochondrial membrane potenƟ al (ΔΨm) aŌ er 24-hour exposure of THP1/WT cells and THP1/
BTZ200 cells to a concentraƟ on range of bortezomib. (B) InducƟ on of apoptosis (annexin V–posiƟ ve cells) in 
THP1/WT cells and THP1/BTZ200 cells aŌ er 24-hour exposure to a concentraƟ on range of bortezomib. (C) 
A representaƟ ve fl ow cytometric picture of apoptosis inducƟ on (annexin V/7-AAD staining) aŌ er 24-hour 
incubaƟ on of THP1/WT cells and THP1/BTZ200 cells with 100 nM BTZ. (D) A representaƟ ve fl ow cytomet-
ric picture of apoptosis inducƟ on (annexin-V/7-AAD staining) aŌ er 48-hour incubaƟ on of THP1/WT cells 
and THP1/BTZ200 cells with 1 μM VP-16/etoposide. All results present the means (± SD) for 3 independent 
experiments.
A B
DC
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membrane potenƟ al (Figure 2A) and inducƟ on of apoptosis (Figure 2B,C). For com-
parison, the anƟ cancer drug and topoisomerase II inhibitor etoposide (VP16) was 
equally eﬀ ecƟ ve in inducing apoptosis in wild-type as well as bortezomib-resistant 
cells (Figure 2D). These results indicate that bortezomib-resistant cells have retained 
their capacity to undergo apoptosis, consistent with the lack of alteraƟ ons in gene 
expression of apoptosis-related genes (Figure S2), but the ability to undergo apopto-
sis is specifi cally impaired for proteasome inhibitor type of drugs.
Marked overexpression of proteasome subunit β5 but not 
chymotrypsin-like proteasomal acƟ vity in bortezomib-resistant cells
Because the cross-resistance data (Table 1) were consistent with specifi c alteraƟ ons 
at the level of proteasome subunit expressionand/or catalyƟ c acƟ vity, the expres-
sion paƩ ern of individual β1-,β2-, and β5-subunits was determined in wild-type and 
drugresistant cells grown at their selecƟ ve bortezomib concentraƟ ons. Furthermore, 
to explore the stability of the bortezomib-resistance phenotype, we also examined 
a subline of THP1/BTZ100 that was grown in the absence of bortezomib for 6 months 
(termed THP1/BTZ(-100)). Proteasome β1 and β2-subunit expression was only slightly 
increased (< 2-fold), whereas proteasome α7-subunit expression was not signifi -
cantly altered in the bortezomib-resistant cells (Figure 3A). In contrast, β5 protein 
levels, relaƟ vely barely detectable in parental cells, were dramaƟ cally increased (up 
to 60-fold) in bortezomib-resistant cells (Figure 3A). This observaƟ on was confi rmed 
using 2 diﬀ erent anƟ bodies recognizing diﬀ erent epitopes within the β5 protein. This 
dramaƟ c increase in β5 expression was proporƟ onal to the gradually increasing con-
centraƟ ons of bortezomib during the stepwise selecƟ on. Notably, over a concentra-
Ɵ on range (up to 50 nM bortezomib) where bortezomib primarily inhibits chymot-
rypsin-like proteasome acƟ vity, β5 overexpression parallels the extent of bortezomib 
resistance (Figure 3B). Apart from Western blot analysis, we also explored whether 
β5 overexpression was associated with the 20S core parƟ cle of the proteasome by 
performing naƟ ve gel electrophoresis analysis. Results depicted in Figure 3C further 
demonstrate an increased expression of β5 in resistant cells compared with paren-
tal cells; but all of this increased expression was confi ned to the 20S proteasome 
complex rather than being present as unassembled “free” subunits. As a control, 
expression of subunit α7 remained unchanged, as did the overall proteolyƟ c acƟ vity 
in both parental and resistant cells using suc-LLVY-amc as a substrate (Figure 3C). 
This fi nding was further corroborated by gel fi ltraƟ on experiments (Figure 3D) that 
demonstrated that elevated expression of β5 was observed in bortezomib-resistant 
cells that eluted from the column solely as a high-molecular-weight fracƟ on of ap-
proximately 600 to 700 kDa protein, consistent with the 20S core parƟ cle’s molecular 
weight. In accord with data from Figure 3A, C, α7-subunit expression was largely 
unaltered between parental and bortezomib-resistant cells, although its presence 
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was not exclusively restricted to highmolecular-weight fracƟ ons, but also showed 
up in lower molecular weight fracƟ ons, possibly even as “free” subunits. Consistent 
with these experiments, immunohistochemical analysis (Figure S4) also confi rmed 
the colocalizaƟ on of β5 and α7 in THP1/BTZ cells.
In contrast to β5 protein levels, β5 mRNA levels in bortezomib resistant cells were 
only marginally increased at the highest selecƟ on dose (Figure 4A), suggesƟ ng that 
the inducƟ on of β5 protein most likely is eﬀ ectuated at the posƩ ranscripƟ onal level. 
As for the β5 transcript, β2 and β1 mRNA levels were only modestly elevated in cells 
with the highest bortezomib-resistance level (Figure 4A).
Figure 3: SelecƟ ve inducƟ on of proteasome β5-subunits in bortezomib-resistant cells. 
(A) Protein expression of proteasome β5-, β2-, and β1-subunits and α7-subunits in wild-type and borte-
zomib-resistant THP1 sublines. THP1/BTZ(-100) represents a subline of THP1/BTZ100 that was grown in the ab-
sence of bortezomib for 6 months. Note: 2 diﬀ erent sources of β5 anƟ bodies were used: Biomol (PW8895; 
Plymouth MeeƟ ng, PA) and 20S X from Novus Biologicals (LiƩ leton, CO), the laƩ er indicated by an asterisk 
(*). (B) InducƟ on of proteasome subunits β5, β2, and β1 in relaƟ on to resistance factors to bortezomib for 
the selected panel of bortezomib-resistant THP1 cells. Densitometry results are presented as the mean (± 
SD) of 4 separate experiments. (C) NaƟ ve gel electrophoresis of crude cell extracts of THP1/WT cells and 
THP1/BTZ100 cells subsequently analyzed for β5- and α7-subunit expression (leŌ  panels) and catalyƟ c acƟ v-
ity for the substrate Suc-LLVY-AMC (right panel). (D) Gel fi ltraƟ on of crude extracts of THP1/WT cells and 
THP1/BTZ100 cells via a high-performance liquid chromatography (HPLC)–linked Superdex 200 HR 10/30 
column (Supelco, Bellefonte, CA). Proteins were eluted by washing the column with 20 mM Tris-HCl, pH 7.5, 
5 mM ATP, and 120 mM NaCl at a fl ow rate of 0.4 mL/min. FracƟ ons were collected every minute and sub-
ject to Western blot analysis for β5 and α7. The column was calibrated with a mixture of purifi ed proteins 
in the MW range of 16.6 kDa to 669 kDa.
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Figure 4: Proteasome β5-, β2-, and β1-subunit mRNA levels and proteasome subunit–related catalyƟ c 
acƟ vity in wild-type and bortezomib-resistant cells.
(A) mRNAlevels for proteasome β5-, β2-, and β1-subunits in selected variants of bortezomib-resistant THP1 
cells relaƟ ve to THP1/WT cells. mRNA levels were quanƟ fi ed using _-glucuronidase (GUS) as reference 
gene and depicted relaƟ ve to THP1/WT cells. (B) Chymotrypsinlike, caspase-like, and trypsin-like protea-
somal acƟ viƟ es assayed with specifi c fl uorogenic pepƟ de substrates in cell extracts of THP1/WT, THP1/
BTZ30, THP1/BTZ100, and THP1/BTZ200 cells aŌ er a 4-day drug washout period (control) and aŌ er 24-hour 
incubaƟ on with 10 nM bortezomib (for THP/WT) and selecƟ ve concentraƟ ons of 30 nM, 100 nM, and 200 
nM bortezomib for the indicated bortezomib-resistant THP1 sublines. Controls for selecƟ ve inhibiƟ on of 
caspase-like acƟ vity and trypsin-like acƟ vity included Ac-APnLD (25 μM) and leupepƟ n (20 μM), respecƟ ve-
ly. All results represent the mean (± SD) of 3 independent experiments. (C) AcƟ vity labeling of consƟ tuƟ ve
and immunoproteasome β-subunits in intact THP1/WT and selected bortezomib-resistant THP/BTZ cells 
using bodipyFL-Ahx3L3VS aﬃ  nity probe.
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We next examined the possible role that these quanƟ taƟ ve alteraƟ ons in β5-subunit 
composiƟ on may bear on the various proteolyƟ c acƟ viƟ es of the proteasome. Pro-
teasomal proteolyƟ c acƟ viƟ es represented by chymotrypsin-like acƟ vity, caspase-like 
acƟ vity, and trypsin-like acƟ vity were measured using fl uorogenic pepƟ de substrates 
in cell extracts of parental cells incubated for 24 hours in the presence or absence of 
10 nM bortezomib. Bortezomib-resistant cells were tested aŌ er a 4-day drug-free pe-
riod (control), and aŌ er 24-hour incubaƟ on at their selecƟ ve bortezomib concentra-
Ɵ on (Figure 4B). AŌ er 4 days of incubaƟ on in drug-free medium, bortezomib-resist-
ant cells had a small (1.3- to 1.4-fold) increase in chymotrypsin-like acƟ vity compared 
with wild-type cells. Under bortezomib-selecƟ ve condiƟ ons (30, 100, or 200 nM), 
residual chymotrypsin-like acƟ vity was reduced to 8% to10% of drug-free controls, 
as observed for parental cells exposed to 10 nM bortezomib. AŌ er drug washout 
of bortezomib-resistant cells, caspase-like proteasome acƟ vity was signifi cantly in-
creased (1.8- to 2.3-fold; P < .001) over parental cells. In the presence of bortezomib, 
caspase-like acƟ vity was reduced to 26% to 35% of wild-type levels. Finally, basal 
trypsin-like acƟ vity was 1.4- to 1.7-fold (P < .01) increased in bortezomib-resistant 
cells compared with wild-type cells. In the presence of bortezomib, trypsinlike acƟ v-
ity was sƟ mulated by another 20% to 40% both in bortezomib-resistant cell lines and 
wild-type cells (Figure 4B). These results indicate that the qualitaƟ ve characterisƟ cs 
of proteasomal inhibiƟ on by bortezomib were retained in bortezomibresistant cells, 
whereas quanƟ taƟ vely, a marked up-regulaƟ on of β5-subunit protein did not lead to 
a β5-subunit–related increase in chymotrypsin-like proteasome acƟ vity.
Finally, probing of acƟ ve proteasome subunits was performed using the bodipyFL-
Ahx3L3VS aﬃ  nity labeling reagent (44). Labeling of consƟ tuƟ ve β5 and its immuno-
proteasome counterpart β5i was readily observed in parental THP1 cells (Figure 4C), 
but markedly inhibited at relaƟ vely low levels of bortezomib resistance in THP1/BTZ30 
cells. InteresƟ ngly, probing of acƟ ve β5 and β5i was partly restored in THP1 cells with 
higher levels of bortezomib resistance including THP1/BTZ50 and THP1/BTZ100 cells, 
thus underscoring the fact that proteasome acƟ vity is retained.
Stability of the bortezomib-resistance phenotype
To invesƟ gate the stability of the resistance phenotype and expression of β5-subunit 
in the absence of bortezomib, resistant cells were transferred to bortezomib-free 
medium for a period of 7 days and showed a gradual decline of β5 expression to 
40% of the original levels (Figure 5A); whereas, no substanƟ al alteraƟ ons were ob-
served in β5-subunit mRNA levels (Figure 5B). InteresƟ ngly, however, Figure 3A dem-
onstrated that β5-subunit expression was further reduced in THP1/BTZ(-100) cells that 
were cultured in bortezomib-free medium for 6 months, although they had retained 
a more than 35-fold resistance level for bortezomib (not shown). This prompted us 
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Figure 5: Dynamics of proteasome subunit expression in bortezomib-resistant cells aŌ er exposure and 
removal of bortezomib. 
(A) Eﬀ ect of 1- to 7-day removal of bortezomib-selecƟ ve pressure from THP1/BTZ100 cells on proteasome 
subunit β5 protein expression and (B) β5 proteasome subunit mRNA expression. Results are the means (± 
SD) of 3 separate experiments. (C) Protein expression of β1-,β2-, β5- and α/β-core proteasome subunits in 
THP1/WT cells, THP1/BTZ(-100) cells, and THP1/BTZ200 cells aŌ er 4-day bortezomib washout (control/0) and 
24-hour exposure to the indicated concentraƟ ons of bortezomib. (D) Protein expression of β1, β2, β5- and 
α/β-core proteasome subunits for THP1/WT cells,THP1/BTZ(-100) cells, and THP1/BTZ200 cells aŌ er a 4-day 
bortezomib washout period (control) and aŌ er 24-hour incubaƟ on with the indicated concentraƟ ons of 
bortezomib. Results of scanning of protein band intensiƟ es are presented as the mean ± SD of 3 separate 
experiments. (E) Eﬀ ect of short-term (0-24 hours) exposure of THP1/BTZ(-100) cells to 100 nM bortezomib on 
proteasome subunit β5 protein expression and (F) β5 proteasome subunit mRNA expression. Results are 
the means of duplicate experiments (E) and 3 separate experiments (± SD; F).
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to invesƟ gate whether β5-subunit expression could be rapidly reinduced upon bort-
ezomib reexposure. Indeed, when THP1/WT, THP1/BTZ(-100), and THP1/BTZ100 cells 
were exposed to a range of bortezomib concentraƟ ons (1-3 x IC50) for 24 hours, a 
marked and selecƟ ve inducƟ on of β5-subunit expression was noted for THP1/BTZ(-
100) cells and to a lesser extent for THP1/BTZ100 cells (Figure 5C,D). Fine-tuning the 
0- to 24-hour Ɵ me course of β5 inducƟ on revealed that within 8 to 16 hours aŌ er 
bortezomib exposure, β5-subunit expression was markedly induced in THP1/BTZ(-100) 
cells (Figure 5E) and was accompanied by a 2- to 3-fold inducƟ on of β5 mRNA levels 
(Figure 5F). CollecƟ vely, these results suggest that once bortezomib resistance has 
been provoked aŌ er chronic exposure, the drug resistance phenotype not only can 
remain dormant for long-term periods when cells are not exposed to bortezomib, 
but it would also be rapidly revived upon reexposure to bortezomib.
IdenƟ fi caƟ on of a mutaƟ on in the PSMB5 gene in THP1/BTZ cells
Given the stable and long-term retenƟ on of the bortezomibresistance phenotype, 
along with the dominant involvement of the β5-subunit, we explored whether a ge-
neƟ c alteraƟ on in the PSMB5 gene could have contributed to the onset of acquired 
resistance to bortezomib. To this end, we sequenced part of exon 2 of the PSMB5 
gene that encodes for the highly conserved binding pocket region for proteasome in-
hibitors within the β5 protein. In THP1 cells, selected for a very low level of acquired 
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Figure 6: Analysis of PSMB5 gene mutaƟ ons in bortezomib-resistant THP1 cells. 
Sequencing of PSMB5 gene exon 2 in THP1/WT cells and various BTZ-resistant sublines: THP1/BTZ7, THP1/
BTZ30, THP1/BTZ100, and THP1/BTZ(-100). Depicted is the single nucleoƟ de shiŌ  (G→A) at nucleoƟ de posiƟ on 
322 in THP1/BTZ30, THP1/BTZ100, and THP1/BTZ(-100) along with the corresponding change in a single amino 
acid subsƟ tuƟ on (Ala49Thr) within the mature PSMB5/β5 protein.
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resistance to bortezomib, that is, 7 nM (THP1/BTZ7), no geneƟ c alteraƟ ons could be 
observed (Figure 6). However, in THP1 cells displaying higher levels of bortezomib 
resistance including THP1/BTZ30 and THP1/BTZ100 cells, a single G to A nucleoƟ de shiŌ  
was idenƟ fi ed at posiƟ on 322 of the PSMB5 gene. In the mature and funcƟ onal β5-
subunit protein, this mutaƟ on introduces an Ala to Thr subsƟ tuƟ on at amino acid 49 
(Figure 6). We further established that the Ala49Thr mutaƟ on was retained in THP1/
BTZ(-100) cells (Figure 6). Based on the fact that Ala49 resides in the highly conserved 
substrate/inhibitor binding domain of the β5-subunit, this homozygous mutaƟ on is 
likely to contribute to the bortezomib-resistance phenotype.
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Figure 7: SiRNA-mediated silencing of proteasome β5-subunit inducƟ on restores bortezomib sensiƟ vity 
and induces apoptosis in bortezomib-resistant cells.
(A) β5-siRNA–induced silencing of β5-protein expression in THP1/BTZ(-100) and THP1/BTZ(200) cells aŌ er 24-
hour preincubaƟ on with transfecƟ on medium (DF2), control siRNA constructs (nontarget/GAPDH), and 
a β5-specifi c siRNA construct (transducƟ on eﬃ  ciency: > 85% based on siGlo+ cells by fl ow cytometry). 
AŌ er transfecƟ on, cells were incubated (24-48 hours) with the indicated concentraƟ ons of bortezomib. 
Protein expressions of α/β-core and β-acƟ n are shown as controls. A representaƟ ve picture of 3 separate 
experiments is depicted. (B) Bortezomib-induced apoptosis in THP1/WT, THP1/BTZ(-100), and THP1/BTZ100 
cells aŌ er siRNA-induced prevenƟ on of inducƟ on of β5-subunit expression as described in panel A. Bort-
ezomib exposure Ɵ me: 24 hours. Bortezomib concentraƟ ons used: 25 nM for THP1/WT and THP1/BTZ(-100) 
cells. Means of 4 separate experiments (± SD) are shown. *P < .01. (C) Bortezomib-induced cell growth 
inhibiƟ on of THP1/BTZ(-100)  cells aŌ er prevenƟ on of inducƟ on of β5-subunit expression by siRNA silencing 
as described in panel A and 24-hour exposure to 25 nM bortezomib. Means of 3 separate experiments (± 
SD) are shown. *P < .01.
CB
216
Chapter 10
SiRNA-dependent silencing of β5 inducƟ on in bortezomib-resistant 
cells reverses bortezomib sensiƟ vity and induces apoptosis
Finally, based on data in Figure 5, we determined whether prevenƟ on of β5-subunit 
inducƟ on would lead to restoraƟ on of bortezomib sensiƟ vity. To this end, the con-
sequences of siRNAbased silencing of β5 expression were explored in THP1/WT, 
THP1/BTZ(-100), and THP1/BTZ200 cells. In THP1/BTZ(-100) cells, the β5-siRNA–dependent 
prevenƟ on of β5-subunit up-regulaƟ on aŌ er bortezomib exposure (Figure 7A) was 
accompanied by both a signifi cantly higher fracƟ on of apoptoƟ c cells (Figure 7B) as 
well as increased bortezomib sensiƟ vity (Figure 7C). For THP1/BTZ200 cells with con-
sƟ tuƟ vely high levels of β5 expression (Figure 3A), β5 siRNA–dependent silencing 
also repressed β5 expression (Figure 7A), but not to a level that compromised bort-
ezomib resistance (results not shown). CollecƟ vely, these results further underscore 
the involvement of proteasome β5-subunit overexpression in conferring bortezomib 
resistance and provide a targeted strategy to reverse bortezomib resistance.
Discussion
This study provides several lines of evidence for the proteasome involvement, that of 
the β5-subunit in parƟ cular, in the acquisiƟ on of bortezomib resistance in THP1 cells: 
(1) a mutaƟ on in the PSMB5 gene involving an Ala49Thr subsƟ tuƟ on in the highly 
conserved substrate/inhibitor binding domain of the β5-subunit, (2) selecƟ ve over-
expression of the mutant β5-subunit protein paralleled bortezomib-resistance levels 
in THP1/BTZ cells, (3) rapid and marked inducƟ on of β5 in THP1/BTZ(-100) cells aŌ er 
exposure to bortezomib, (4) siRNA-guided silencing of β5-subunit gene expression 
restored bortezomib sensiƟ vity and induced apoptosis, and (5) bortezomib-resistant 
cells displayed marked crossresistance to other pepƟ de-based proteasome inhibi-
tors, in parƟ cular those that specifi cally target the β5-subunit. 
Crystallography data from yeast and mammalian proteasomes (45, 46) indicated 
that Ala49 is implicated in the eﬃ  cient binding of bortezomib in the substrate/inhibi-
tor binding pocket of the β5-subunit. Moreover, Ala49 is a highly conserved residue 
among many prokaryoƟ c and mammalian species. As such, subsƟ tuƟ on of Ala49 for 
Thr containing a neutral polar side chain is likely to have consequences for eﬃ  ciency 
of (reversible) binding of bortezomib and other pepƟ de-based proteasome inhibi-
tors. Prototypically this may be exemplifi ed by the 6-mer pepƟ de 4A6 that selecƟ vely 
targets β5 (but not subunits β1 and β2) for which up to more than 250-fold level 
of cross-resistance was observed in the bortezomib-resistant cells. The fi nding that 
217
Bortezomib resistance and mutant PSMB5 upregulaƟ on 
cross-resistance levels for ALLN, MG132, and MG262 were lower than the resistance 
factors for bortezomib may be consistent with the fact that these proteasome inhibi-
tors have addiƟ onal targets apart from β5, β2, and β1 proteasome subunits, for ex-
ample, lysosomal proteases, which may not be aﬀ ected in bortezomib-resistant cells 
(9, 15, 20, 44). The potenƟ al impact of Ala49 mutaƟ ons in conferring bortezomib 
resistance may be further supported by recent preliminary observaƟ ons by Lu et al 
(47) showing the same PSMB5 mutaƟ on in bortezomib-resistant human lymphoblas-
Ɵ c Jurkat T cells.
In keeping with the noƟ on of a prominent role of the β5 proteasome subunit in 
conferring high levels of resistance to bortezomib, other types of molecular mecha-
nisms previously reported to infl uence bortezomib acƟ vity did not seem to apply for 
bortezomib-resistant THP1 cells. No evidence for extensive metabolism (oxidaƟ ve 
deboronaƟ on) of bortezomib by cytochrome P450 reacƟ ons (48) could be obtained 
from gene array analysis of CytP450 enzymes. A putaƟ ve role for MDR proteins in 
bortezomib-resistant cells could be ruled out both by the lack of cross-resistance to 
prototypical MDR substrates (doxorubicin and mitoxantrone) and by the lack of up-
regulaƟ on of MDR proteins typically involved in drug resistance. Consistently, Mind-
erman et al (28) and our laboratory (R.O., R.J.S., G.J., unpublished observaƟ ons, April 
2008) showed that low levels (< 3-fold) of resistance to bortezomib were detected 
only in mammalian cells expressing high levels of Pgp, and not by other MDR drug 
eﬄ  ux transporters such as MRP1-6 or BCRP. In fact, none of these MDR transporters 
were found to be overexpressed in bortezomib-resistant THP1 cells. Furthermore, 
up-regulaƟ on of another proteolyƟ c system, tripepƟ dylpepƟ dase II, to compensate 
for proteasome inhibiƟ on by irreversible proteasome inhibitors (30-32), was ruled 
out based on the lack of crossresistance to the TPP II inhibitor, AAF-cmk (33). Finally, 
potenƟ al loss of bortezomib acƟ vity aŌ er short drug exposures due to consƟ tuƟ ve or 
transient inducƟ on of heat shock proteins (Hsp’s) (24, 49) was excluded in the pres-
ent chronic exposure model as judged from the lack of cross-resistance to the potent 
Hsp inhibitor geldanamycin (50) and unaltered hsp27 expression in bortezomib-re-
sistant cells (Figure S3).
Up-regulaƟ on of target enzymes is a common mode of resistance to several types of 
chemotherapeuƟ c drugs (51, 52). In this context, eﬀ ects on proteasomal β5-subunits 
as the primary target for bortezomib may not be unexpected. In fact, some recent 
studies revealed an overall inducƟ on of proteasome β-subunits (β5, β2, and β1) as 
an iniƟ al adapƟ ve response to low-dose bortezomib exposure (20, 21, 44). Results 
from the present study indicate that in cells with established acquired resistance 
to bortezomib aŌ er chronic exposure to stepwise increasing doses of bortezomib, 
up-regulaƟ on of a mutant β5 protein serves as a compensatory mechanism to re-
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tain suﬃ  cient chymotrypsin-like acƟ vity. An enhanced expression of 20S proteasome 
core parƟ cle-associated β5 in drugresistant cells (Figure 3C,D) may be consistent with 
this noƟ on. Also data from proteasome acƟ vity labeling experiments (Figure 4C) indi-
cate that at relaƟ vely low levels of bortezomib resistance (THP1/BTZ30) the bodipyFL-
Ahx3L3VS probe showed aƩ enuated binding/labeling to the mutant β5-subunit, but 
upon further upregulaƟ on of mutated protein in THP1/BTZ50 and THP1/BTZ100 cells, 
labeling with the probe can increase concomitantly. It is not readily clear whether the 
up-regulaƟ on of consƟ tuƟ ve β5 in bortezomib-resistant cells (Figure 3A,C,D) is ac-
companied by a concomitant decrease in immunoproteasome β5 expression as sug-
gested by gene array data (Figure S2). This status may be normalized to control levels 
in the absence of bortezomib, as illustrated for THP1/BTZ(-100) cells (Figure 3A), but 
rapidly restored upon rechallenging with bortezomib (Figure 5C). The up-regulaƟ on 
of β5 was most pronounced in cells exposed to bortezomib concentraƟ ons up to 50 
nM, a concentraƟ on range at which primarily β5-associated chymotrypsin-like pro-
teasome acƟ vity, and to a lesser extent also β1-associated caspase-like acƟ vity, will 
be essenƟ ally abolished. Consistently, beyond concentraƟ ons of 50 nM bortezomib, 
inducƟ on of β5 expression is leveling oﬀ , as from this point inhibiƟ on of proteasome 
subunit β2-associated trypsin-like acƟ vity will be iniƟ ated (16,17).
The present fi nding that the marked overexpression of β5 protein in bortezomib-re-
sistant cells is not paralleled by inducƟ on of β5 mRNA levels points to a posƩ ranscrip-
Ɵ onal regulatory mechanism. The nature of possible posƩ ranscripƟ onal eﬀ ects in 
bortezomib-resistant cells is presently unclear but may possibly include alteraƟ ons in 
proteasome homeostasis facilitated by an autoregulatory mechanism that mediates 
the diﬀ erenƟ al polyubiquiƟ naƟ on and degradaƟ on of mulƟ ple proteasome subunits, 
including β5 (53). Hence, impaired polyubiquiƟ naƟ on under bortezomib selecƟ ve 
pressure (Figure 1B) may diﬀ erenƟ ally aƩ enuate β5 degradaƟ on to yield a signifi cant 
increase in β5 protein levels.
Under bortezomib-selecƟ ve condiƟ ons, THP1/BTZ cells did not display any accumu-
laƟ on of ubiquiƟ nated proteins (Figure 1B) or inducƟ on of stress-induced proteins 
(Figure S3), prototypical for the acƟ on of proteasome inhibitors. Beyond the eﬀ ect 
of the mutant β5 protein, as well as its overexpression, it may be anƟ cipated that 
the up to 2-fold elevated bortezomib-sƟ mulated trypsin-like acƟ vity (Figure 4B) may 
compensate for the inhibiƟ on of chymotrypsin-like and caspase-like acƟ viƟ es by sus-
taining proteasome acƟ vity above criƟ cal catalyƟ c levels. Consequently, such a con-
diƟ on alone, or in combinaƟ on with acƟ viƟ es of deubiquiƟ naƟ ng enzymes (54), for 
example, Poh1 (55) as a possible candidate based on preliminary gene array studies 
(Figure S3), could also contribute to prevent the accumulaƟ on of toxic polyubiquiƟ -
nated proteins, which may otherwise trigger loss of mitochondrial membrane poten-
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Ɵ al and apoptosis.
We recently obtained evidence that a similar molecular basis of selecƟ ve β5 induc-
Ɵ on aŌ er chronic exposure to bortezomib as described herein for THP1 cells also 
applies for bortezomib-resistant variants of human T-lymphocyƟ c CCRF-CEM cells50 
(Figure S5). InteresƟ ngly, when human 8226 myeloma cells were exposed according 
to the same strategy, only moderate (≤ 5-fold) resistance levels were observed (56). 
These results suggest that the onset of bortezomib resistance may diﬀ er signifi cantly 
between hematologic tumor cell lineages. A possible lower propensity for mulƟ ple 
myeloma cells to acquire resistance to bortezomib may be consistent with the lack of 
detailed reports on this issue. Beyond this, in the case of mulƟ ple myeloma, host mi-
croenvironments may also play an important role in the eﬃ  cacy of proteasome tar-
geƟ ng (12). With the accumulaƟ ng knowledge of potenƟ al mechanisms of resistance 
to bortezomib, more direct screening for these parameters should be the subject of 
future clinically directed laboratory studies. Screening for PSMB5 gene mutaƟ ons in 
an isolated case of a bortezomib nonresponsive mulƟ ple myeloma paƟ ent did not 
provide evidence for mutaƟ ons (57). However, based on the present observaƟ on 
that PSMB5 gene mutaƟ ons may be provoked aŌ er exposure to clinically achievable 
concentraƟ ons of bortezomib in the range of 7 to 30 nM (Figure 6), screening for 
PSMB5 mutaƟ ons should be reconsidered. In the context of proteasome acƟ vity and 
proteasome subunit composiƟ on, the recent idenƟ fi caƟ on and validaƟ on of specifi c 
proteasome-targeted probes (44,58) may facilitate analyses on limited cell numbers.
It may be anƟ cipated that the molecular mechanism of resistance reported in the 
current study specifi cally applies for bortezomib or other proteasome inhibitors that 
selecƟ vely target the β5-subunit of the proteasome. With the emergence of second 
generaƟ on proteasome inhibitors targeƟ ng (ir)reversibly other proteasome subunits 
or mulƟ ple all β-subunits (13, 19, 59-61), it will be important to address whether 
they are able to circumvent bortezomib resistance, or that similar mechanisms of 
resistance are operaƟ ve as described herein for bortezomib. If so, this would warrant 
the design of strategies to prevent selecƟ ve up-regulaƟ on of specifi c proteasome 
subunits and thereby enhance the therapeuƟ c eﬃ  cacy of this novel class of thera-
peuƟ c agents.
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Figure S1: Expression of MulƟ drug Resistance transporters in bortezomib sensiƟ ve- and resistant THP1 
cells.  
Western blot analysis of MRP1-6, Pgp and BCRP in THP1/WT, THP/BTZ30 and THP1/BTZ200 cells. As posiƟ ve 
controls served drug-selected or transfected cell lines as described by Scheﬀ er et al (43). A representaƟ ve 
picture of 2 separate experiments is depicted.
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Figure S3:  Expression of selected resistance, apoptosis and cell cycle proteins in THP1/WT cells and 
Bortezomib-resistant cells. 
Western blot analysis of hsp27, hsp90, apoptosis inhibitor protein XIAP and p21 (cyclin dependent kinase 
inhibitor 1A) in THP/WT cells and bortezomib-resistant THP1 cells. Note: inducƟ on of p21 in THP1/BTZ500 
cells point to early growth inhibitory eﬀ ects of 500 nM bortezomib in these cells. A representaƟ ve picture 
of 2 separate experiments is shown.
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Figure S4:  Intracellular proteasome β5 and α7 subunit distribuƟ on in THP1/WT and THP1/BTZ200 cells.
Fluorescence microscopy of: (A)/(D); α7 proteasome subunits, (B)/E); β5 proteasome subunits and (C)/(F); 
merge of the α7 and β5 staining. Upper panels: THP1/WT cells; lower panels: THP1/BTZ200 cells.
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Figure S5: UpregulaƟ on of proteasome β5 subunit expression in bortezomib resistant CCRF-CEM cells.
Human CCRF-CEM cells of T cells origin were chronically exposed to stepwise increasing concentraƟ ons of 
bortezomib over a period of 6 months. Expression levels of proteasome subunit β5 and α7 are depicted for 
THP1/WT cells and two selected bortezomib resistant variants grown at 7 nM bortezomib (BTZ7) and 200 
nM bortezomib (BTZ200).  
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gene expression
4x up
2x up 
0
2x down
4 x down
N/A
Ratio Restant Cells / Wild Type Cells
BTZ30 BTZ100 BTZ-100 
Proteasome subunits (39 genes) (6 mo)    
Proteasome subunit, alpha type (PSMA1,2,3,4,6,7)
Proteasome subunit, alpha type, 5 (PSMA5)
Proteasome subunit, beta type, (PSMB1,4,10)
Proteasome subunit, beta type, 2 (PSMB2)
Proteasome subunit, beta type, 3 (PSMB3)
Proteasome subunit, beta type, 5 (PSMB5)
Proteasome subunit, beta type, 6 (PSMB6)
Proteasome subunit beta type 7 (PSMB7) ,  ,  
Proteasome subunit, beta type, 8 (PSMB8)
Proteasome subunit, beta type, 9 (PSMB9)
Proteasome 26S subunit, ATPase, 1 (PSMC1)
Proteasome 26S subunit, ATPase, 2 (PSMC2)
Proteasome 26S subunit, ATPase (PSMC3,5)
Proteasome 26S subunit, ATPase, 4 (PSMC4)
Proteasome 26S subunit, ATPase, 6 (PSMC6)
P t 26S b it ATP (PSMD1 5 7 8 9 10 12 13)ro easome  su un , non- ase, , , , , , , ,
Proteasome 26S subunit, non-ATPase, 2 (PSMD2)
Proteasome 26S subunit, non-ATPase, 4 (PSMD4)
Proteasome 26S subunit, non-ATPase, 11 (PSMD11)
26S proteasome-associated pad1 homolog (POH1) (PSMD14)
Proteasome activator subunit (PA28 alpha,beta,gamma;Ki)) (PSME1,2,3)
Proteasome inhibitor subunit 1 (PI31) (PSMF1)
Ubiquitin-conjugating enzymes (13 genes)
Ubiquitin activating enzyme E1-like protein (GSA7)
Ubiquitin-conjugating enzymes E2 (UBE2A,B,C,D1,E1,G2,H,I,M,N)
E3 ubiquitin ligase SMURF2 (SMURF2)
Ubiquitin protein ligase (UBE3B)
Deubiquitinating enzymes: Ubiquitin Specific Proteases (USP) (22 genes)
Ubiquitin specific proteases (USP1,3,4,6,7,8,9X,9Y,10,11,13,14,15,18,20,21,25,26,28,29)
Ubiquitin specific protease 2 (USP2)
Ubiquitin specific protease 5 (isopeptidase T) (USP5)
Deubiquitinating enzymes: Ubiquitin C-terminal hydrolases (UCH) (3 genes)
Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (UCHL1)
Ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase) (UCHL3)
Ubiquitin carboxyl-terminal hydrolase L5 (UCHL5)
Figure S2:  Micro array analysis for resistance- and proteasome related genes in bortezomib-resistant 
THP1 cells. 
RaƟ os of gene expression levels in  THP1/BTZ30, THP1/BTZ100 and THP1/BTZ(-100) cells relaƟ ve to THP1/WT 
cells are depicted for selected genes implicated in drug metabolism, resistance, apoptosis and cell cycle 
regulaƟ on, and compared with those in the ubiquiƟ n proteasome pathway. Experimental details are de-
scribed in the Materials & Methods secƟ on.
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gene expression
4x up
2x up
0
2x down
4 x down
N/A
Ratio Restant Cells / Wild Type Cells
BTZ30 BTZ100 BTZ-100 
Genes implicated in drug resistance and metabolism (101 genes) (6 mo)
ATP-Binding Cassette transporters (ABCA1-A9, A12, B1, B4, B7-B10, C1-C13)   
ATP-Binding Cassette transporters (ABCD1-D4, E1, F1, F2, G1, G2, G4, G5, G8)   
B-cell CLL/lymphoma 2 (BCL2)
BCL2-like 1 (BCL2L1)
Bl i h d l (BLMH)eomyc n y ro ase 
Breast cancer 1, early onset (BCRA1)
Breast cancer 2, early onset (BCRA2)
Catechol-O-methyltransferase (COMT)
Cellular retinoic acid binding protein 1 (CRABP1)
Cytochrome P450, family 1, subfamilies (CYP1A1,1A2,2B6,2C9,2D6,2E1,3A5)
Cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4)
Dihydrofolate reductase (DHFR)
E id l th f t t (EGFR)p erma  grow  ac or recep or 
ELK1, member of ETS oncogene family (ELK1)
Epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1)
Epoxide hydrolase 2, cytoplasmic (EPHX2)
V-erb-b2 erythroblastic leukemia viral oncogene homologs (ERBB2,3)
Excision repair cross-complementing rodent repair deficiency (ERCC3)
Estrogen receptors (ESR1,2)
Fibroblast growth factor 2 (basic) (FGF2)
V f FBJ i t i l h l (FOS)- os  mur ne os eosarcoma v ra  oncogene omo og 
Glycogen synthase kinase 3 alpha (GSK3A)
Glutathione S-transferase pi (GSTP1)
Hypoxia-inducible factor 1, alpha subunit (HIF1A)
Insulin-like growth factor receptors (IGF1R,2R)
Met proto-oncogene (hepatocyte growth factor receptor) (MET)
O-6-methylguanine-DNA methyltransferase (MGMT)
MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) (MLH1)
MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) (MSH2)
MutS homolog 3 (E. coli) (MSH3)
Major vault protein (MVP)
N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2)
NAD(P)H dehydrogenase, quinone 1 (NQO1)
Peroxisome proliferator-activated receptor (PARRdelta,gamma)
Peptidylprolyl isomerase A (cyclophilin A) (PPIA)
Retinoic acid receptor (RARalpha, beta,gamma)
Retinoblastoma 1 (including osteosarcoma) (RB1)
nuclear factor of kappa B (RELB)
Ribosomal protein L13a (RPL13A)
Retinoid X receptor, alpha (RXRA,B,G)
Superoxide dismutase 1 (SOD1)
Tumor necrosis factor receptor superfamily, member 11a (TNFRSF11A)
Topoisomerase (DNA) I (TOP1,2A,2B)
Tumor protein p53 (Li-Fraumeni syndrome) (TP53)
Thiopurine S-methyltransferase (TPMT)
Thymidylate synthetase (TYMS)
Xeroderma pigmentosum, complementation group A and C (XPA,C)
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gene expression
4x up
2x up
0
2x down
4 x down
N/A
Ratio Restant Cells / Wild Type Cells
BTZ30 BTZ100 BTZ-100 
Apoptosis (59 genes) (6 mo)
BCL2-antagonist of cell death (BAD)
BCL2-antagonist/killer 1 (BAK)
BCL2-associated X protein (BAX)
B-cell CLL/lymphoma 2 (BCL2)
BCL2-like 1 (BCL2L1)
BCL2-like 11 (apoptosis facilitator) (BCL2L11)
BH3 interacting domain death agonist (BID)
Baculoviral IAP repeat-containing (BIRC1-4)
Baculoviral IAP repeat-containing 5 (survivin) (BIRC5)
BCL2/adenovirus E1B 19kDa interacting protein 3-like (BNIP3L)
Caspases  (CASP1-10)
Conserved helix-loop-helix ubiquitous kinase (CHUK)
Cytochrome c, somatic (CYCS)
DNA fragmentation factor, 45kDa, alpha polypeptide (DFFA)
DNA fragmentation factor, (caspase-activated DNase) (DFFB)
Fas (TNFRSF6)-associated via death domain (FADD)
Fas (TNF receptor superfamily, member 6) (FAS)
Fas ligand (TNF superfamily, member 6) (FASLG)
Granzyme B (GZMB)
Helicase, lymphoid-specific (HELLS)
Harakiri, BCL2 interacting protein (contains only BH3 domain) (HRK)
Inhibitor of kappa B kinase (IKBKbeta,gamma)
Interferon regulatory factors (IRF1-7)
Jun oncogene (JUN)
Lymphotoxin alpha (TNF superfamily, member 1) (LTA)
Mitogen-activated protein kinase kinase 4 (MAP2K4)
Mitogen-activated protein kinase kinase kinase 1 (MAPK3K1)
Mitogen-activated protein kinase 10 (MAPK10)
Mdm2, double minute 2, p53 binding protein (mouse) (MDM2)
Nuclear factor of kappa B (p105) (NFKB1)
Nuclear factor of kappa B inhibitor alpha (NFKBIA)
Nuclear factor of kappa B inhibitor beta (NFKBIB)
Nuclear factor of kappa B inhibitor epsilon (NFKBIE)
Perforin 1 (pore forming protein) (PRF1)
Nuclear factor of kappa B, p65 (RELA)
Receptor (TNFRSF)-interacting serine-threonine kinase 1 (RIPK1)
Tumor necrosis factor (TNF superfamily member 2) (TNF)    ,   
Tumor necrosis factor receptor superfamily, member 10b (TNFRSF10B,1A,21)
Tumor necrosis factor receptor superfamily, member 1B (TNFRSF1B)
Pleckstrin homology domain containing, family G member 5 (PLEKHG5)
Tumor necrosis factor (ligand) superfamily, member 10 (TNFSF10)
Tumor protein p53 (Li-Fraumeni syndrome) (TP53)
Tumor protein p73 (TP73)
TNF receptor-associated factors (TRAF1-3)
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BTZ30 BTZ100 BTZ-100 
gene expression
4x up
2x up
0
2x down
4 x down
N/A
Cell Cycle (76 genes) (6 mo)
V-abl homomolog 1 (ABL1)
Ataxia telangiectasia mutated (ATM)
BUB1 budding uninhibited by benzimidazoles 1 (BUB1,3)
BUB1 budding uninhibited by benzimidazoles 1 beta (BUB1B)
Cyclins (CCN A1,A2,B1,B2,B3,D2, E1,E2, H)
Cyclin D3 (CCND3)
Congenital dyserythropoietic anemia, type I (CDAN1)
Cell division cycle 20 homolog (S. cerevisiae) (CDC20)
Cell division cycle 25 homolog A (S. pombe) (CDC25A)
Cell division cycle 25 homolog C (S. pombe) (CDC25C)
CDC45 cell division cycle 45-like (S. cerevisiae) (CDC45L)
Cell division cycle 6 homolog (S. cerevisiae) (CDC6)
Cell division cycle 7 homolog (S. cerevisiae) (CDC7)
Cadherin 1, type 1, E-cadherin (epithelial) (CDH1)
Cyclin-dependent kinase 2 (CDK2)
Cyclin-dependent kinase 4 (CDK4)
Cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A)
Cyclin-dependent kinase inhibitor 2 (CDKN2A,D)
CHK1 checkpoint homolog (S. pombe) (CHEK1)
CHK2 checkpoint homolog (S. pombe) (CHEK2)
Deltex 4 homolog (Drosophila) (DTX4)
E2F transcription factor 1 (E2F1)
E2F transcription factor 2 (E2F2)    
E2F transcription factor 3 (E2F3)
E2F transcription factor 4, p107/p130-binding (E2F4)
E2F transcription factor 5, p130-binding (E2F5)
E1A binding protein p300 (EP300)
Extra spindle pole bodies homolog 1 (S. cerevisiae) (ESPL1)
Growth arrest and DNA-damage-inducible, alpha (GADD45A)
Glycogen synthase kinase 3 beta (GSK3B)
Histone deacetylases (HDAC1-8)   
MAD1 mitotic arrest deficient-like  (yeast) (MAD1L1,2L1, 2L2)
Minichromosome maintenance complex components (MCM2,3,5,7)
Minichromosome maintenance complex component 6 (MCM6)
Mdm2, double minute 2, p53 binding protein (MDM2)
Myeloproliferative leukemia virus oncogene (MPL)
Origin recognition complex, subunit 1-like (yeast) (ORC1L,2L,3L,4L,5L,6L)
Proliferating cell nuclear antigen (PCNA)
Polo like kinase 1 (Drosophila) (PLK1)-     
Protein kinase, DNA-activated, catalytic polypeptide (PRKDC)
Protein tyrosine phosphatase, receptor type, A (PTPRA)
Pituitary tumor-transforming 1 (PRRG1)
Pituitary tumor-transforming 2 (PTTG2)
Retinoblastoma 1 (including osteosarcoma) (RB1)
Retinoblastoma-like 1 (p107) (RBL1)
S-phase kinase-associated protein 2 (p45) (SKP2)
SMAD f il b 4 (SMAD4) am y mem er  
Transcription factor Dp-1 (TFDP1)
Transforming growth factor, beta 1 (TGFB1)
Tumor protein p53 (Li-Fraumeni syndrome) (TP53)
WEE1 homolog (S. pombe) (WEE1)
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Abstract 
4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) was previously shown to 
be a cytotoxic pepƟ de with an unknown mode of acƟ on (De Jong et al, Cancer Res 
61, 2552-2557, 2001). Here we provide evidence that 4A6 elicits its pharmacologi-
cal acƟ vity both as a substrate and as a potent, selecƟ ve and reversible inhibitor 
of the proteasome β5 subunit (PSMB5) associated chymotrypsin-like acƟ vity of the 
26S proteasome. This conclusion is supported by the following lines of evidence: 
(a) Purifi ed proteasome preparaƟ ons facilitated cleavage of the 4A6 Nle-Glu pep-
Ɵ de bond, (b) The ability of 4A6 and related derivaƟ ves to inhibit chymotrypsin-like 
proteasome acƟ vity in a cell-based assay correlated with their IC50 for cell growth 
inhibiƟ on, (c) 4A6 (1-100 μM) inhibited chymotrypsin-like proteasome acƟ vity by 84-
93% when using cell extracts and fl uorogenic substrates, whereas no inhibiƟ on of 
caspase-like or trypsin-like proteasome acƟ viƟ es was observed, (d) 4A6 reversibly 
inhibited labeling of funcƟ onal β5 acƟ ve site nucleophiles with the aﬃ  nity probe 
BodipyFL-Ahx3L3VS, (e) human myelomonocyƟ c THP1 cells with acquired resistance 
to the proteasome inhibitor bortezomib due to a mutated PSMB5 gene were highly 
(up to 287-fold) cross-resistant to 4A6 and its related derivaƟ ves, and fi nally (f) expo-
sure to 4A6 provoked the accumulaƟ on of ubiquiƟ nated proteins and a marked up-
regulaƟ on of PSMB5 protein. Furthermore, 4A6 displayed diﬀ erenƟ al acƟ vity against 
various leukemia and breast cancer cell lines within the NCI60 panel of malignant 
cell lines. CollecƟ vely, these fi ndings idenƟ fy 4A6 as a novel, specifi c inhibitor of the 
chymotrypsin-like acƟ vity of the proteasome and thus warrant its exploraƟ on as a 
lead compound for drug development. 
IntroducƟ on
The central role that the ubiquiƟ n-proteasome system plays in intracellular protein 
degradaƟ on has been exploited as a potenƟ al therapeuƟ c target for the treatment 
of cancer and chronic infl ammatory diseases (1-7). The 26S-proteasome complex is 
made up of a 20S core unit, consisƟ ng of 4 stacked heptameric rings, which form 
an α7β7β7α7 complex, and is capped by two 19S regulatory units (8, 9). The 20S core 
unit harbors the proteasome’s catalyƟ c domain which is responsible for caspase-like, 
trypsin-like and chymotrypsin-like acƟ viƟ es, associated with the β1, β2 and β5 subu-
nit, respecƟ vely (10). Several types of proteasome inhibitors have been described 
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that reversibly or irreversibly inhibit proteasome acƟ vity by targeƟ ng one or more 
of these beta subunits (10-13). Bortezomib (Velcade®, PS341) is the fi rst proteasome 
inhibitor that was clinically approved and registered for the treatment of refractory 
mulƟ ple myeloma (4, 14). 
Bortezomib is a reversible and potent proteasome inhibitor (IC50: 3-5 nM) that pri-
marily targets the 5 subunit of the proteasome, although the 1 subunit and their 
immunoproteasome counterparts are also targeted (11, 15, 16). While bortezomib 
is clinically well tolerated (17), prolonged administraƟ on may result in neurotoxicity 
and drug resistance phenomena may emerge (11, 18-20). Thus alternaƟ ve protea-
some inhibitors are in demand (4, 6, 19, 21-23). 
The hexapepƟ de 4A6 (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) (24) was 
idenƟ fi ed from a pepƟ de library generated to idenƟ fy pepƟ de-based inhibitors of 
mulƟ drug resistance (MDR) transporters such as P-glycoprotein (Pgp/ABCB1) and 
MulƟ drug Resistance-associated Protein 1 (MRP1/ABCC1) (25). In recent years, sev-
eral types of pepƟ des (linear/cyclic, neutral/ hydrophobic) have been idenƟ fi ed for 
their interacƟ on with MDR eﬄ  ux transporters and their potenƟ al chemosensiƟ zing 
capacity; these include cyclosporin A, valinomycin, ALLN, dolastaƟ n 10, gramicidin 
D, pepstaƟ n A, leupepƟ n and Reversin 121 (26-33). Likewise, 4A6 was found to be 
a substrate for the MDR eﬄ  ux transporters Pgp and MRP1, but lacked the ability to 
reverse MDR-mediated drug resistance (24). In fact, 4A6 and related pepƟ des dis-
played potent cytotoxic eﬀ ects via an unknown mechanism (24). Here we explored 
the mode of acƟ on of 4A6 and hence provide evidence it exerts its cytotoxic acƟ vity 
by acƟ ng as a specifi c inhibitor of the chymotrypsin-like acƟ vity of the proteasome. 
This fi nding warrants the exploraƟ on of 4A6 as a lead compound for proteasome-
targeted drug development.
Materials and methods
Reagents 
Bortezomib (Pyrazylcarbonyl-Phe-Leu-boronate) was kindly provided by Millennium 
PharmaceuƟ cals (Cambridge, USA). The cytotoxic pepƟ des  4A6 (Ac-Thr(tBu)-His(Bzl)-
Thr(Bzl)-Nle-Glu(OtBu)-Gly-Bza) (monomer and dimer form) and 4E11 (Ac-Thr(OBzl)-
Glu(OtBu)-Glu(OBzl)-Asp(OtBu)-Glu(OtBu)-Gly-Bza) were synthesized as described 
previously (24). P121/Reversin (Boc-Asp(OBzl)-Lys-(Z)-OtBu) was kindly provided by 
Dr. B. Sarkadi (Budapest, Hungary). 
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Protease Inhibitor Cocktail (PIC) was obtained from Boehringer Mannheim (Ingelhe-
im, Germany). RPMI-1640 Ɵ ssue culture medium and fetal calf serum were obtained 
from Gibco Chem. Co (Grand Isl., NY, U.S.A). All fl uorogenic substrates (Suc-Leu-Leu-
Val-Tyr-amc, Ac-Arg-Leu-Arg-amc and Z-Leu-Leu-Glu-amc), the proteasome inhibi-
tors Ac-APnLD-H and leupepƟ n, and all proteasome subunit-related anƟ bodies (β1, 
β2, β5) were purchased from Biomol (Plymouth MeeƟ ng, PA, U.S.A.). AnƟ -ubiquiƟ n 
anƟ body (sc-8017) was purchased from Santa Cruz (USA). Ruthenium Red was ob-
tained from Sigma Chem Co (USA).
Synthesis of Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-OH
The tetramer (Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-OH) was synthesized by standard 
Fmoc-based solid phase pepƟ de synthesis on FmocNorLeu Sasrin resin. The Fmoc-
NorLeu resin was prepared by esterifi caƟ on of FmocNorLeu-OH (10 equivalents) with 
the unloaded resin using N,N’-diisopropylcarbodiimide (DIC, 10 equivalents) in DMF. 
The resin was deprotected with 1% trifl uoroaceƟ c acid (TFA) in methylenechloride 
for 2.5 h followed by precipitaƟ on of the pepƟ de with diethylether and HPLC purifi -
caƟ on (Waters 1525 EF HPLC system)
Cell culture
Human monocyƟ c/macrophage THP1 cells (ATTC, Manassas, USA) were cultured in 
RPMI-1640 medium supplemented with 5% fetal calf serum, 20 mM HEPES, 2 mM 
glutamine and 100 μg/ml penicillin/streptomycin at 5% CO2 and 37oC. Cell cultures 
were seeded at a density of 3·105 cells/ml and refreshed twice weekly.
Bortezomib-resistant THP1 cell lines were obtained by stepwise increasing extracel-
lular concentraƟ ons of bortezomib over a period of 6 months (34). In this study, bort-
ezomib-resistant THP1 variants used were grown in the presence of 50 nM (THP1/
BTZ50), 100 nM (THP1/BTZ100) and 200 nM bortezomib (THP1/BTZ200) (see Table 1). 
Some specifi c experiments also included THP1/BTZ100 cells that were cultured in the 
absence of bortezomib for 6 months (further designated as THP1/BTZ (-100) cells).
Mouse thymoma EL4 and human mulƟ ple myeloma H929 cells were cultured in 
RPMI-1640 medium supplemented with 8% fetal calf serum and 100 μg/ml penicil-
lin/ streptomycin at 5% CO2 and 37oC. 
4A6 cleavage assay
Proteasome was purifi ed from bovine liver as described previously (35). For digesƟ on 
assays, 1 μg proteasome was incubated with 1 μg 4A6 in 50 μl 50 mM Tris-HCl buﬀ er 
pH 8.5 at 45°C for 16 hours. Subsequently, the reacƟ on mixture was lyophilized and 
pepƟ des purifi ed using reversed-phase ZipTip®C18 Ɵ ps (Millipore). The purifi ed pep-
Ɵ de mixture was mixed in a 1:1 raƟ o with 10 mg/ml 2,5-dihydroxybenzoic acid (DHB, 
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Bruker Daltonik) matrix soluƟ on in 0.1% TFA and spoƩ ed on a MALDI (matrix assisted 
laser desorpƟ on/ ionizaƟ on) target plate. MALDI-TOF analysis was performed on an 
Autofl ex, linear MALDI-TOF-MS (Bruker Daltonik GmbH, Bremen, Germany). Spectra 
were analyzed with fl exAnalysis soŌ ware (Bruker Daltonik).
Growth inhibiƟ on assays 
EvaluaƟ on of drug sensiƟ vity was carried out as described before (36). Cells were 
seeded at an iniƟ al density of 1.25·105 cells/ml in individual wells of a 24-well plate 
containing up to 50 μl of drug soluƟ ons. InhibiƟ on of cell growth was determined 
aŌ er 72 hours incubaƟ on at 37oC by counƟ ng viable cells based on trypan blue ex-
clusion. The drug concentraƟ on required to inhibit cell growth by 50% compared to 
untreated controls was defi ned as the IC50. 
Western blot analysis (ubiquiƟ nated proteins/proteasome subunits) 
Western blot analysis to determine protein expression of (i) β1, β2 and β5 protea-
some subunits and (ii) the accumulaƟ on of ubiquiƟ nated proteins aŌ er 4A6 exposure 
was performed essenƟ ally as described previously (34, 36). Cells were harvested in 
the mid-log phase of growth and washed 3 Ɵ mes with ice-cold buﬀ ered saline pH 7.4. 
Total cell lysates of 5·106 cells were prepared by resuspending in 500 μl lysis buﬀ er 
containing: 50 mM Tris-HCl (pH 7.6), 5 mM dithiotreitol, 20 μl PIC (Protease Inhibitor 
Cocktail; 1 tablet/ml H2O), 20% glycerol and 0.5% NP-40. The suspension was soni-
cated (MSE sonicator, amplitude 7, for 3 x 5 seconds with 20 seconds Ɵ me intervals 
at 4oC) and centrifuged in an Eppendorf micro centrifuge (5 min, 12,000 rpm, 4oC). 
Protein content of the supernatant was determined by the Bio-Rad protein assay. 
20-30 Microgram of total cell lysates were fracƟ onated on a 10% polyacrylamide gel 
containing SDS and transferred onto a PVDF membrane. The membranes were pre-
incubated overnight at 4oC in blocking buﬀ er (5% Bio-Rad Blocker in TBS-T; 10 mM 
Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1% Tween-20) to prevent non-specifi c anƟ body bind-
ing. AŌ er blocking, the membranes were incubated for 1 hour at room temperature 
with primary anƟ bodies for proteasome subunit β1 (1:1000, PW8140), β2 (1:1000, 
PW8145) and β5 (1:1000, PW8895) or ubiquiƟ n (1:1000, Santa-Cruz, SC-8017). An 
anƟ body to α-tubulin was used (1:1000, Santa Cruz, sc-8035) to check and normalize 
for any loading diﬀ erences. AŌ er 3 washing steps with TBS-T, the membranes were 
incubated for 1 hour with HRP-labelled donkey-anƟ -rabbit (1:6000, Amersham, UK) 
or goat-anƟ -mouse (1:6000, Dako, Glostrup, Denmark) as secondary anƟ body. De-
tecƟ on of anƟ body binding was followed by chemoluminescence using Supersignal 
(Pierce Biotechnology, Rockford, USA) according to the manufacturers’ instrucƟ ons. 
Digital Image acquisiƟ on was performed using the Versadoc Imaging System (Biorad 
Lab., Veenendaal, The Netherlands). The signal intensity was determined densito-
metrically using QuanƟ ty One soŌ ware (Bio-Rad) and was expressed relaƟ ve to the 
236
Chapter 11
intensity of the α-tubulin signal.
Proteasome acƟ vity in cell lysates and intact cells
Chymotrypsin-like, trypsin-like and caspase-like proteolyƟ c acƟ viƟ es of the protea-
some were measured in freshly prepared cell lysates as described previously (15, 16, 
37). Five million untreated or bortezomib-exposed THP1 cells were washed 3 Ɵ mes 
with ice-cold PBS and pelleted by centrifugaƟ on (5 min, 12,000 RPM, 4oC). Cell pel-
lets were then resuspended in an ATP-containing lysis buﬀ er; 10mM Tris-HCl buﬀ er 
(pH 7.8) containing 5 mM ATP, 0.5 mM DTT and 5 mM MgCl2, and kept on ice for 
10 minutes. For complete lysis, cells were sonicated (MSE sonicator, amplitude 7, 
for 3 x 5 seconds with 20 seconds Ɵ me intervals at 4oC) followed by centrifugaƟ on 
(5 min, 12,000 RPM, 4oC) to remove cell debris. The supernatant was collected and 
protein concentraƟ on was determined using the Bio-Rad protein assay. Fluorogenic 
substrates to measure the chymotrypsin-like, trypsin-like and caspase-like acƟ vity 
were Suc-Leu-Leu-Val-Tyr-amc, Ac-Arg-Leu-Arg-amc and Z-Leu-Leu-Glu-amc, respec-
Ɵ vely, all at 100 μM fi nal concentraƟ ons. The substrates were incubated with 20 μg 
of total cell protein extract in the presence or absence of specifi c inhibitors (bort-
ezomib for chymotrypsin-like acƟ vity, Ac-APnLD-H for caspase-like acƟ vity and leu-
pepƟ n- for trypsin-like acƟ vity) in a total assay volume of 200 μl. The release of amc 
(7-amino-4-methyl-coumarin) was monitored online over a 2 hour Ɵ me period at 
37oC with 5 minute intervals. Fluorescence was measured on a Tecan SpectraFluor 
apparatus (Giessen, The Netherlands) using excitaƟ on and emission wavelengths of 
360 and 465 nm, respecƟ vely. ProteolyƟ c acƟ vity was calculated from the slopes of 
the linear porƟ on of the curves. All results were expressed as percentage relaƟ ve 
to untreated THP1/WT cells (100%). InhibiƟ on of chymotrypsin-like acƟ vity in intact 
cells was measured by the Proteasome-GloTM cell-based assay (Promega, Leiden, The 
Netherlands), using Suc-LLVY-aminoluciferin as a substrate, according to the manu-
facturer’s instrucƟ ons. 
Proteasome aﬃ  nity labeling 
Proteasome acƟ vity profi ling assays were performed as described (38, 39) using a 
close analog of the BodipyFL probe. Briefl y, mouse EL4 thymoma cells were incu-
bated at 37°C for 2 or 24 h with increasing concentraƟ ons of 4A6, followed by a 1 h 
chase with 500 nM probe. In other experiments, human H929 myeloma cells were 
incubated at 37°C with 1 μM 4A6 (2 h), 5 μM MG132 (1 h) or 20 nM bortezomib (1 
h) and subsequently probed with 500 nM probe (1 h), either directly or aŌ er a wash-
ing and recovery step. Cells were harvested and lysed for 30 min in NP40 lysis buﬀ er 
(50 mM Tris, pH 7.4, 150 mM NaCl, 1% NP40) at 4C. The Bradford assay was used 
to measure protein content. Proteins were denatured by boiling in reducing sample 
buﬀ er and analyzed by 12% SDS-PAGE using NuPAGE pre-cast gels (Invitrogen). Gels 
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were then scanned for fl uorescence emission using a ProXPRESS 2D Proteomic im-
aging system (Perkin Elmer). Images were analyzed using Totallab analysis soŌ ware 
(Nonlinear Dynamics, Newcastle upon Tyne, UK). Sypro staining served as a loading 
control.
Apoptosis assay 
InducƟ on of apoptosis was analyzed by fl ow cytometry using APOPTESTTM-FITC A700 
(VPS DiagnosƟ cs, Hoeven, the Netherlands) according to the instrucƟ ons of the 
manufacturer. In short, inducƟ on of apoptosis was determined aŌ er 24 hours drug 
exposure. One million cells were harvested and washed 3 Ɵ mes with ice-cold PBS. 
The cell pellet was incubated for 30 minutes with 7-Amino-acƟ nomycin D (7-AAD) 
on ice followed by incubaƟ on with Annexin-V according to the instrucƟ ons of the 
manufacturer. Annexin-V (early apoptosis) and 7-AAD (late apoptosis) staining was 
measured by fl ow cytometry (Beckton & Dickinson, FACScalibur) and analysed using 
FCSexpress V3 soŌ ware (Denovo soŌ ware, Thornhill, Canada).
NCI60 tumor cell line screening of 4A6 
The NCI 60 human tumor cell line screen was used to assess the acƟ vity profi le of 
4A6 against a panel of cell lines with various tumor backgrounds (40). ConcentraƟ ons 
of 4A6 inducing 50% growth inhibiƟ on (GI50) were determined aŌ er 48 hours drug 
exposure. 4A6 sensiƟ vity for each individual cell line is depicted relaƟ ve to the mean 
GI50 of the total cell line panel. 
StaƟ sƟ cs
StaƟ sƟ cal analysis was performed using Analysis of Variance between groups (ANO-
VA) in Graphpad prism. P values < 0.05 were considered to be staƟ sƟ cally signifi cant.
TABLE 1: Growth inhibitory eﬀ ects of cytotoxic pepƟ des on THP1 and bortezomib-resistant THP1 
cells
IC50 (μM) [Resistance Factor]
Drug THP1/WT THP1/BTZ50 THP1/BTZ100 THP1/BTZ-200
4A6 0.26 ± 0.06 [1] 44 117 287
4A6-dimer 0.80 ± 0.09 [1] >63* >63* >63*
4E11 3.9 ± 0.8 [1] >13* >13* >13*
CsA 3.8 ± 1.0 [1] 0.9 0.8 ND
Bortezomib# 0.0033 ± 0.0006 [1] 45 79 129
# Data from Oerlemans et al (34).
* Solubility of pepƟ de in medium is limited to a concentraƟ on of 50 μM. 
Results depicted are the mean of at least 3 separate experiments ± S.D.
ND: Not determined, CsA: cyclosporin A.
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Results
Cells with acquired resistance to pepƟ de-based proteasome inhibitor 
bortezomib are cross-resistant to the cytotoxic pepƟ des 4A6 and 4E11
Drug screening of human THP1 cell lines with resistance to the boronic dipepƟ de 
proteasome inhibitor bortezomib revealed cross-resistance to other known pepƟ de-
based proteasome inhibitors (e.g. ALLN, MG132), but surprisingly also for the linear 
cytotoxic hexapepƟ de 4A6, the laƩ er of which has an unknown mechanism of ac-
Ɵ on (34). To further explore the molecular basis of this observaƟ on, THP1 cells with 
various levels of bortezomib-resistance were screened for acƟ vity of 4A6, a dimer 
form of 4A6, another linear cytotoxic hexapepƟ de 4E11, and the cyclic cytotoxic de-
capepƟ de cyclosporin A (Table 1). Within this series of cytotoxic pepƟ des, 4A6 was 
the most potent inhibitor of THP1 cell growth (IC50: 0.26 μM), followed by a 3-fold 
lower potency for the 4A6 dimer and a 15-fold lower potency for 4E11 and cyclo-
sporine A (Table 1). These bortezomib-resistant cell lines displayed the highest lev-
els (up to 287-fold) of cross-resistance to 4A6 (Table1, Figure 1) and > 60-fold cross 
resistance to the 4A6-dimer. With respect to the pepƟ de 4E11, a consƟ tuƟ ve higher 
IC50 value compared to 4A6 (Table 1) along with limitaƟ ons in solubility of pepƟ des 
above concentraƟ ons of 50 μM, allowed for assessment of relaƟ vely low level (>13-
fold) of cross-resistance to 4E11. No cross-resistance of bortezomib-resistant cells 
Figure 1: Cross-resistance for 4A6 in bortezomib-resistant cells. 
Dose response curve for 4A6-induced growth inhibiƟ on of, solid bullets; wild type (WT) human myelo-
monocyƟ c THP1 cells and proteasome (bortezomib, BTZ)-resistance selected variants; open triangles; 
THP1/BTZ50, open squares; THP1/BTZ100 and open bullets; THP1/BTZ200, selected for growth in extracellular 
concentraƟ ons of 50 nM, 100 nM and 200 nM bortezomib, respecƟ vely. Results depicted are the mean of 
3 experiments ± S.D. 4A6 exposure Ɵ me: 72 hours. 
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was observed for cyclosporin A. CollecƟ vely, these results indicate that the pepƟ des 
4A6 and 4E11 share properƟ es with known inhibitors of the ubiquiƟ n-proteasome 
system, including bortezomib.
4A6 is a potent inhibitor of chymotrypsin-like proteasome acƟ vity
An intact cell-based luminogenic assay that monitors chymotrypsin-like proteasome 
acƟ vity was used to invesƟ gate whether the cytotoxic pepƟ des 4A6 and 4E11 could 
exert their cytotoxic eﬀ ect via inhibiƟ on of proteasome acƟ vity. Indeed, 4A6 dis-
played a marked inhibiƟ on of chymotrypsin-like proteasome acƟ vity (IC50: 0.21 ± 0.05 
μM) with a potency 28-fold lower than bortezomib (IC50: 0.0074 ± 0.002 μM (Figure 
2A). Likewise, the 4A6-dimer and 4E11 were found to inhibit chymotrypsin-like pro-
teasome acƟ vity, though with a lower potency than 4A6 (IC50: 0.49 ± 0.12 μM and 
2.4 ± 0.5 μM, respecƟ vely). A control pepƟ de Reversin 121, an inhibitor of the MDR 
transporter Pgp (27), had no eﬀ ect on proteasome acƟ vity (IC50: >> 25 μM). Hence, 
the ranking of proteasome acƟ vity inhibitory potencies (bortezomib > 4A6 > 4A6-
dimer > 4E11) Ɵ ghtly correlated with their ranking of potency to inhibit cell growth 
of THP1/WT cells (Table 1).
To address whether 4A6 is also capable of inhibiƟ ng one or both of the other prote-
ase acƟ viƟ es harbored by the proteasome, chymotrypsin-, caspase- and trypsin-like 
acƟ viƟ es were measured in THP1 cell extracts in the absence or presence of 4A6. 
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Figure 2: Proteasome acƟ vity assays.
(A) Potent inhibiƟ on of proteasome acƟ vity by the hexamer pepƟ de 4A6 Luminescent cell-based protea-
some assay measuring inhibiƟ on of chymotrypsin-like proteasome acƟ vity in intact THP1 cells aŌ er 1 hour 
exposure to bortezomib (closed bullets), the hexamer pepƟ de 4A6 (black squares), 4A6-dimer (open bul-
lets), the hexamer pepƟ de 4E11 (closed triangles) and, as control, the 3-mer pepƟ de P121/Reversin (open 
squares), a pepƟ de-based inhibitor of the MDR protein P-glycoprotein. Results represent the mean of 3 
experiments ± S.D. (B) InhibiƟ on of chymotrypsin-like but not caspase-like and trypsin-like proteasomal ac-
Ɵ vity by 4A6. Chymotrypsin-like, caspase-like and trypsin-like proteasomal acƟ viƟ es were measured with 
specifi c fl uorogenic pepƟ de substrates in cell extracts of THP1 cells aŌ er 1 hour exposure to 1μM (light grey 
bars), 10μM (dark gray bars) and 100 μM (black bars) of 4A6. Controls (striped bars) for selecƟ ve inhibiƟ on 
of chymotrypsin-like, caspase-like and trypsin-like acƟ vity included bortezomib (10 nM), Ac-APnLP (25 μM) 
and leupepƟ n (20 μM), respecƟ vely. AcƟ vity is presented as % relaƟ ve to control condiƟ on (white bars) and 
mean of 3 separate experiments ± S.D.
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Figure 3: 4A6 is a reversible inhibitor of proteasome subunit β5.
(A) EL4 cells were incubated with the indicated concentraƟ ons of 4A6 for 2 hours or 24 hours and then 
probed with a proteasome aﬃ  nity probe as described in the Materials & Methods secƟ on. (B) H929 cells 
were incubated with 1 μM 4A6 (2h), 20 nM bortezomib (1h) or 5 μM MG132 (1 h). Subsequently, cells were 
either probed directly with the aﬃ  nity probe (0’) or resuspended in fresh medium without inhibitor and leŌ  
to recover for the indicated Ɵ mes. As a control, non-treated cells were probed directly. A representaƟ ve 
of 2 separate experiments is shown. (C) MALDI spectrum of 4A6 (m/z 1080.6) (D) MALDI spectrum of 4A6 
aŌ er proteasomal digesƟ on, showing the appearance one major cleavage product at m/z 749.5, which 
corresponds to Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-OH.
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Consistent with results shown in Figure 1A, 4A6 elicited potent inhibitory eﬀ ects on 
chymotrypsin-like proteasome acƟ vity, but had no inhibitory eﬀ ect on caspase- and 
trypsin-like acƟ vity over a wide concentraƟ on range of 1-100 μM (Figure 2B). These 
results demonstrate that 4A6 is a potent and selecƟ ve inhibitor of chymotrypsin-like 
proteasome acƟ vity. 
4A6 is a reversible inhibitor of chymotrypsin-like proteasome acƟ vity 
AcƟ vity probing of consƟ tuƟ ve and immunoproteasome β-subunits in EL4 cells that 
were pre-exposed to 4A6 for 2-24 hours revealed a marked and specifi c inhibiƟ on of 
the β5 subunit with half maximal inhibiƟ on at 4A6 concentraƟ ons between 0.1 and 
0.5 μM and complete inhibiƟ on at concentraƟ ons > 5 μM (Figure 3A). We next as-
sessed whether this inhibiƟ on of β5-subunit probing could be recovered aŌ er with-
drawal of 4A6. Data shown in Figure 3B illustrate that 4A6 is a reversible inhibitor of 
β5-subunit acƟ vity as iniƟ al recovery of acƟ vity probed could be observed already 
aŌ er 15 minutes of 4A6 withdrawal and almost complete recovery aŌ er 2 hours of 
4A6 withdrawal. For comparison, the proteasome inhibitor MG132 blocked acƟ v-
ity probing of all β-subunits, with a recovery 2 hours aŌ er drug withdrawal (Figure 
3B). Bortezomib dominantly inhibited β5-subunit probing but aﬃ  nity labeling was 
fully recovered within 2 hours aŌ er drug withdrawal (Figure 3B). We fi nally explored 
whether 4A6 remained intact as a pepƟ de or could be subject to proteolyƟ c cleavage 
when exposed to purifi ed proteasomes. Comparison of mass spectra of the intact 
pepƟ de (Figure 3C) and the pepƟ de aŌ er proteasomal digesƟ on (Figure 3D) shows 
that next to 4A6 (m/z 1080.6), one main addiƟ onal peak appeared aŌ er digesƟ on at 
m/z 749.5, corresponding to the 4-mer pepƟ de Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-OH. 
A smaller peak appeared at m/z 934.6, corresponding to 5-mer pepƟ de Ac-Thr(tBu)-
His(Bzl)-Thr(Bzl)-Nle-Glu(OtBu)-OH. This indicates that 4A6 is predominantly cleaved 
at the P4-P5 posiƟ on and to a lesser extent at the P5-P6 posiƟ on. The main 4A6 pro-
teasomal cleavage product, Ac-Thr(tBu)-His(Bzl)-Thr(Bzl)-Nle-OH was synthesized, 
but did not show a proteasome inhibitory eﬀ ect or cell growth inhibitory potenƟ al 
(data not shown). Hence, these results suggest that 4A6 is a dual substrate and re-
versible inhibitor of proteasome subunit β5. 
Cellular exposure to 4A6 induces accumulaƟ on of ubiquiƟ nated 
proteins and apoptosis but displays properƟ es disƟ nct of bortezomib 
One hallmark of proteasome inhibiƟ on is the accumulaƟ on of ubiquiƟ nated proteins, 
which are toxic to cells and induce apoptosis (41-43). Exposure of THP1/WT cells 
to 4A6 and 4E11 for 24 hours resulted, just as for the known proteasome inhibi-
tor bortezomib, in a marked accumulaƟ on of ubiquiƟ nated proteins, illustrated by a 
characterisƟ c smear on a Western blot probed with an anƟ -ubiquiƟ n anƟ body (Fig-
ure 4A). In contrast, the same concentraƟ ons of 4A6 and 4E11 did not provoke any 
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accumulaƟ on of ubiquiƟ nated proteins in bortezomib-resistant cells. Consistent with 
these observaƟ ons was the eﬃ  cient inducƟ on of apoptosis by 4A6 in parental THP1/
WT cells but none by 4A6 (over a concentraƟ on range of 0-25 μM) in THP1/BTZ200 
cells (Figure 4B and C). For comparison, the anƟ -cancer drug and topoisomerase II 
inhibitor etoposide (VP16) was equally eﬀ ecƟ ve in inducing apoptosis in THP1/WT 
and THP1/BTZ200 cells (not shown).
To explore whether 4A6 shares properƟ es with the known proteasome inhibitor 
bortezomib, we invesƟ gated the ability of 4A6 to mimic a reported feature of bort-
ezomib, the disregulaƟ on of intracellular calcium homeostasis that triggers caspase 
acƟ vaƟ on and apoptosis (44). This process could be counteracted by inhibitors of the 
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Figure 4: 4A6-induced accumulaƟ on of ubiquiƟ nated proteins and inducƟ on of apoptosis in THP1/WT 
cells but not in bortezomib-resistant cells.
(A) AccumulaƟ on of ubiquiƟ nated proteins in THP1/WT cells and bortezomib-resistant THP1/BTZ200 cells 
aŌ er 24 hours exposure to the indicated concentraƟ ons of bortezomib and 4A6. THP1/BTZ200 cells were 
allowed a 4 days drug washout period (control) before exposure to bortezomib or 4A6. (B) InducƟ on of 
apoptosis (Annexin-V posiƟ ve cells) in THP1/WT cells (closed bullets) and THP1/BTZ200 cells (open bullets) 
aŌ er 24 hours exposure to a concentraƟ on range of 4A6. (C) A representaƟ ve fl ow-cytometric picture 
of apoptosis inducƟ on (Annexin-V/7-AAD staining) following 24 hours incubaƟ on of THP1/WT cells and 
THP1/BTZ200 cells with 25 μM 4A6. (D) Ruthenium Red protects from bortezomib-induced but not from 
4A6-induced cell growth inhibiƟ on. THP1 cells were incubated for 72 hours with a concentraƟ on range 
of bortezomib or 4A6 in the absence (-) or presence (+) of 25 μM Ruthenium Red. The raƟ o of IC50 values 
for bortezomib and 4A6 of cells in the presence versus the absence of Ruthenium Red is depicted as fold 
protecƟ on. Mean of 3 separate experiments ± S.D.
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mitochondrial calcium uniporter (e.g. Ruthenium Red), thereby providing a protec-
Ɵ ve eﬀ ect against bortezomib (44). While a marked abrogaƟ on of bortezomib acƟ vity 
could be obtained by Ruthenium Red, no eﬀ ect of this compound was observed with 
respect to 4A6 acƟ vity (Figure 4D). These results suggest that 4A6 has no apparent 
impact on mitochondrial calcium homeostasis.
4A6 provokes proteasome β5 subunit inducƟ on 
Given the specifi c targeƟ ng of 4A6 of the β5 subunit of the proteasome, we explored 
whether exposure to 4A6 had an eﬀ ect on the expression of the β5 subunit as com-
pared to the other catalyƟ c subunits β1 and β2. To this end, THP1/WT cells and the 
bortezomib-resistant cell lines THP1/BTZ100 and THP1/BTZ(-100) , the laƩ er a subline 
of THP1/BTZ100 that was grown in the absence of bortezomib for 6 months, were 
exposed to a concentraƟ on range of 4A6 (0.1-10 μM) for 24 hours (Figure 5A). No 
signifi cant eﬀ ects of 4A6 exposure were observed regarding expression of the β1 and 
β2 proteasome subunits. In contrast, a dose-dependent increase in proteasome β5 
subunit expression was noted for both THP1/WT cells with relaƟ vely low basal levels 
of β5 expression and the two bortezomib-resistant cell lines, including THP1/BTZ(-100) 
cells that retained a level of cross-resistance to 4A6 similar as THP1/BTZ100 cells (Fig-
ure 5A). Densitometric analysis showed a 3-5 fold increase in β5 subunit inducƟ on in 
Figure 5: 4A6 provokes inducƟ on of proteasome β5 subunit expression. 
(A) Protein expression of β1, β2 and β5 proteasome subunits in THP1/WT cells, the bortezomib resistant 
cell line THP1/BTZ100 grown in the presence of 100 nM bortezomib, and THP1/BTZ(-100) cells, a subline of 
THP1/BTZ100 that was grown in the absence of bortezomib for 6 months. Before incubaƟ ons with 4A6, 
THP1/BTZ100 cells were allowed a 4 days bortezomib washout period (control/0), aŌ er which cells were 
exposed for 24 hours exposure to the indicated concentraƟ ons of 4A6. Expression of α-tubulin served as a 
loading control. (B) Results of scanning of protein band intensiƟ es of (A) are presented as mean ± S.D of 3 
separate experiments. 
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all three cell lines at 10 μM 4A6 exposure as compared to drug-free controls (Figure 
5B). This result implies that inducƟ on of proteasome β5 subunit expression consƟ -
tutes a rapid adapƟ ve response upon targeƟ ng of this subunit by the inhibitor 4A6.
4A6 vs bortezomib acƟ vity against NCI60 panel of tumor cell lines
In order to assess whether or not 4A6 and bortezomib have overlapping cytotoxic 
acƟ viƟ es against specifi c tumor cell types, a side by side comparison of their acƟ v-
ity profi le was made using the NCI panel of 60 diﬀ erent tumor cell lines (40). Based 
on mean log10GI50 concentraƟ ons obtained aŌ er 2 days of drug exposure, bortezo-
mib was 2-3 orders of magnitude more potent than 4A6. InteresƟ ngly, both drugs 
showed an overlap with respect to sensiƟ vity for a panel of leukemia, breast cancer, 
melanoma, and to some extent colon cancer cells (Figure 6). 4A6 proved rather inac-
Ɵ ve towards a panel of renal cancer cells and lung cancer cells. Moreover, cells with 
high levels of expression of the mulƟ drug eﬄ  ux transporter p-glycoprotein (Pgp), 
including HCT-15, ACHN, UO-31 and NCI/ADR-RES (45), displayed marked resistance 
to 4A6, but not as much to bortezomib. COMPARE analysis of GI50 values for 4A6 vs 
bortezomib for the NCI-panel of 60 cell lines showed a correlaƟ on coeﬃ  cient (r) of 
0.37. These results demonstrate that 4A6 has an overlapping acƟ vity profi le with 
bortezomib against the NCI60 panel of cell lines; however, 4A6 acƟ vity is compro-
mised by the presence of an MDR phenotype.
Discussion
Here we report that the cytotoxic hexameric pepƟ de 4A6 elicits its pharmacologi-
cal acƟ vity as a selecƟ ve and reversible inhibitor of chymotrypsin-like proteasome 
acƟ vity. The specifi c 4A6 targeƟ ng of the chymotrypsin-like proteasome acƟ vity was 
further corroborated by inducƟ on of proteasome β5 subunit expression and marked 
cross-resistance to 4A6 in cells resistant to bortezomib, a known proteasome inhibi-
tor that preferenƟ ally targets β5 subunits (16).
Most pepƟ de-based proteasome inhibitors contain tri- or tetrapepƟ de moieƟ es that 
dock into one or more of the proteasome acƟ ve site pockets (46-48). However, pep-
Ɵ des extended with N-terminally linked spacers and specifi c caps can also retain their 
proteasome inhibitory potenƟ al (38, 49). Notwithstanding this fact, 4A6, as well as 
another hexameric pepƟ de (4E11) revealed a moƟ f and mode of acƟ on diﬀ erent 
from known pepƟ de-based proteasome inhibitors. The linear hydrophobic nature 
of 4A6 likely facilitates its interacƟ ons with the β5-subunit of the proteasome that 
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preferenƟ ally cleaves aŌ er hydrophobic amino acid residues (8, 10). To this end, we 
explored whether the interacƟ on of 4A6 with the proteasome just involves steric oc-
clusion of the β5 acƟ ve site or whether 4A6 serves as a substrate for cleavage by the 
proteasome. Consistent with this noƟ on may be the fact that the dimer form of 4A6, 
which contains the same amino acid sequence as 4A6 and is therefore also likely to 
be cleaved by the proteasome, is almost equally eﬀ ecƟ ve in inhibiƟ ng β5-associated 
proteasome acƟ vity (Figure 2A and Table 1). In this context, it is important to note 
that replacement of Thr(Bzl) at P3 by Lys(Z) or Ala in 4A6 abolished the cytotoxic 
eﬀ ect by 4A6 (24), suggesƟ ng that this residue is essenƟ al for eﬀ ecƟ ve proteasome 
binding and inhibiƟ on. 
The marked level of cross-resistance to 4A6 of cells resistant to the proteasome in-
hibitor bortezomib (Table 1 and Figure 1) is indicaƟ ve that 4A6 and bortezomib do 
share a common mode of interacƟ on with the β5 acƟ ve site. In fact, recent studies 
from our laboratory revealed that the molecular basis of bortezomib resistance in 
these cells involved a mutaƟ on in the PSMB5 gene that introduced an amino acid 
Figure 6: Profi le of acƟ vity of bortezomib vs 4A6 against the NCI-panel of 60 malignant cell lines. 
Data are based on 48 hours drug exposure and presented as log GI50 for each individual cell line and as GI50 
relaƟ ve to the mean GI50 of all cell lines tested. 
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change (Ala → Thr) at posiƟ on 49 of the PSMB5 protein (34). Since the Ala49 posiƟ on 
resides in the bortezomib binding pocket of PSMB5 and is involved in the interacƟ on 
with bortezomib (47, 48, 50), the Ala49Thr mutaƟ on may underlie loss of bortezo-
mib binding and acquisiƟ on of bortezomib resistance (34). The even higher levels of 
cross-resistance to 4A6 than resistance levels to bortezomib suggest that Ala49 is 
even more criƟ cal in binding 4A6 than bortezomib. In this context, it was interest-
ing to note that exposure of bortezomib-resistant cells to 4A6 provoked a marked 
upregulaƟ on of mutated PSMB5 protein (Figure 5), presumably as a compensatory 
mechanism to counteract loss of proteasome acƟ vity due to inhibiƟ on by 4A6.
Even though the indicated PSMB5 mutaƟ on may be the dominant factor in the 4A6 
resistant phenotype, it was previously reported that cellular extrusion via the MDR 
eﬄ  ux transporters Pgp (ABCB1) and MRP1 (ABCC1) could also confer resistance to 
4A6 (24). This was further illustrated in the acƟ vity profi le of 4A6 in the NCI60 panel 
of cell lines where cells with a consistent MDR phenotype (mainly Pgp) were mark-
edly less sensiƟ ve to 4A6 (Figure 6). In contrast, such an MDR phenotype had rela-
Ɵ vely lesser implicaƟ ons for the acƟ vity of bortezomib. The presence of the boron 
group in bortezomib most likely abolishes the ability of this compound to serve as 
a profi cient substrate for MDR transporters as compared to other small pepƟ des 
(51). Although Figure 6 demonstrated an overlap in acƟ viƟ es against some tumor 
types (leukemia/breast cancer), the current study indicates (Figure 4D) that at least 
one mode of acƟ on of 4A6 was disƟ nct from bortezomib by not inducing apoptosis/
growth inhibiƟ on via dysregulaƟ on of mitochondrial calcium homeostasis (44). Con-
sistent with this study we showed that inhibiƟ on of the mitochondrial uniporter with 
ruthenium red abrogated the growth inhibitory eﬀ ects of bortezomib, but had no 
eﬀ ect on 4A6 acƟ vity. 
In conclusion, this study reported on 2 novel hexameric pepƟ de-based proteasome 
inhibitors with several properƟ es disƟ nct from currently idenƟ fi ed proteasome in-
hibitors, including bortezomib. One of these pepƟ des, 4A6, may serve as a lead com-
pound for drug development by further opƟ mizaƟ on its selecƟ ve proteasome β5 
subunit targeƟ ng against leukemia and breast cancer cells. The noƟ on that 4A6 is 
a potenƟ al Pgp and MRP1 substrate may on the one hand compromise some of its 
acƟ vity against tumor cell expressing this drug eﬄ  ux transporter, on the other hand 
it may underlie a diﬀ erent, possibly more favorable toxicity profi le than bortezomib.
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ConƟ nuing treatment of chronic paƟ ents is oŌ en accompanied by the development 
of drug resistance, which then hampers the long term eﬃ  cacy of therapeuƟ c drugs. 
The issue of drug resistance has been well recognized for cancer chemotherapeu-
Ɵ c drugs (1), anƟ bioƟ cs (2) and anƟ -viral drugs (3). However, also in auto-immune 
diseases like rheumatoid arthriƟ s (RA) drug resistance is an important and clinical 
relevant problem as reduced eﬃ  cacy of convenƟ onal chemical disease modifying 
anƟ -rheumaƟ c drugs (DMARDs) is oŌ en observed aŌ er prolonged treatment or even 
already at therapy onset (4, 5). In general, drug resistance can be caused by mulƟ -
ple molecular mechanisms (6); in this thesis we focused on DMARD resistance as-
sociated with drug eﬄ  ux transporters belonging to the ABC transporter family, also 
referred to as mulƟ drug (MDR) transporters. Along with invesƟ gaƟ ng the potenƟ al 
contribuƟ on of selected ABC transporters in resistance to chemical DMARDs, we also 
explored novel experimental therapeuƟ c strategies that may bypass MDR-associated 
resistance. Of note, resistance to biological DMARDs has also been observed, in par-
Ɵ cular via an anƟ body response to biologicals, e.g. infl iximab and adalimumab (7). 
This type of immune-mediated resistance mechanisms is not further discussed in 
this thesis.
MDR transporters and DMARD resistance 
The ABC drug eﬄ  ux transporters consƟ tute a family of 49 proteins, of which we fo-
cussed on those members that are known to confer resistance to specifi c types of 
drugs used in cancer chemotherapy and/or known for exhibiƟ ng anƟ -infl ammatory 
properƟ es (6, 8-10). Specifi cally, ABC/MDR drug eﬄ  ux transporters that were evalu-
ated included P-glycoprotein (P-gp, ABCB1), MulƟ drug Resistance Associated Protein 
1-5 (MRP1-5, ABCC1-5) and Breast Cancer Resistance Protein (BCRP, ABCG2). 
In the fi rst part of this thesis we uƟ lized in vitro model systems of human cell lines rep-
resentaƟ ve of immune cells implicated in the pathophysiology of RA; T cells (model: 
CCRF-CEM cells) and monocyƟ c-macrophage cells (model: THP1 cells). Furthermore, 
we selected two DMARDs, chloroquine (CHQ) and sulphasalazine (SSZ), for which 
clinically a relaƟ vely rapid onset of loss of eﬃ  cacy has been reported (5, 11). In vitro 
resistance to these DMARDs was provoked by cellular exposure to stepwise increas-
ing concentraƟ ons of drugs, mimicking dose escalaƟ ons given to paƟ ents in a clinical 
seƫ  ng. Together, the in vitro studies provided informaƟ on on several issues; (a) Ɵ me 
frame of resistance development, (b) molecular mechanism of resistance, (c) cross-
resistance profi les to other DMARDs, (d) potenƟ al resistance reversal strategies, (e) 
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drug-drug interacƟ ons, and (f) potenƟ al side eﬀ ects.
In vitro chloroquine resistance
Acquired resistance to chloroquine (CHQ) was provoked in two variants of human 
CEM cells of T cell origin. Independently, in both cell lines, upregulaƟ on of the MDR 
transporter MRP1 provides the molecular basis for up to a 5-fold level of CHQ re-
sistance over a Ɵ me-frame of 6 months (12). Although CHQ-resistant cells retained 
their sensiƟ vity to other DMARDs (e.g. methotrexate and sulphasalazine), most strik-
ingly these cells had also acquired a high level of cross-resistance, unrelated to MRP1 
inducƟ on, to the glucocorƟ coids (GC) predisone and dexamethasone. Currently, it 
is understood that GC can exert their anƟ -infl ammatory acƟ on by genomic mecha-
nisms (interacƟ on of GC/GC-receptor complex with GC-responsive elements on the 
DNA) as well as nongenomic mechanisms (13). The laƩ er may involve cross-talk be-
tween the GC-receptor and several signalling pathways such as the Mitogen-AcƟ -
vated Protein Kinases (MAPKs) ERK, JNK and p38, and also cAMP-dependent PKA 
(14, 15) [see Figure 1]. Given the noƟ on that CHQ can inhibit MAPK signaling (16), 
this could provide a mechanisƟ c basis for the observaƟ on of collateral GC-resistance 
in CHQ-resistant CEM cells. Intriguingly, it was observed that the GC-resistance in 
CHQ-resistant CEM cells could be transiently reversed by increasing intracellular 
cAMP levels, suggesƟ ng that a cAMP-dependent protein kinase A (PKA) acƟ vaƟ on 
mechanism plays a role in the GC-resistant phenotype. Consistent with this hypoth-
esis were comparaƟ ve micro-array data for CHQ-sensiƟ ve and resistant CEM cells 
(unpublished observaƟ ons) showing that a cAMP-dependent pathway was disrupted 
in GC-resistant CEM cells as mRNA expression levels of selected genes that are typi-
cally diﬀ erenƟ ally regulated by cAMP were markedly increased; e.g. -globin mRNA 
(100-fold) (17) and adrenomedullin mRNA (40-fold) (18, 19). In depth mechanisƟ c 
studies by Ji et al (20) and Garza et al (15) demonstrated that a GC-resistant phe-
notype was characterized by acƟ vaƟ on of ERK and JNK while p38 MAPK and PKA 
acƟ vity was suppressed. cAMP could revert GC-resistance by iniƟ aƟ ng a cascade of 
events including acƟ vaƟ on of PKA and p38 MAPK, which promotes phosphorylaƟ on 
of GR at serine 211 and drives GR-mediated transcripƟ on of the pro-apoptoƟ c bcl2 
family member Bim, which iniƟ ates inducƟ on of apoptosis (GC-sensiƟ vity). It will be 
worthwhile to establish whether similar types of processes underlie the reversible 
dynamics of GC-resistance to GC-sensiƟ vity in CHQ-resistant CEM cells aŌ er cAMP 
inducƟ on by forskolin. 
Obviously, if in vitro data for development of GC-resistance aŌ er long term CHQ ex-
posure would also be confi rmed in a clinical seƫ  ng, this would argue against the 
combinaƟ on of these DMARD drugs.
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In vitro sulphasalazine resistance
Independent of in vitro studies by Van der Heijden et al (21, 22) with human CEM 
cells of T cell origin, we observed (chapter 5) upregulaƟ on of the MDR transporter 
BCRP/ABCG2 in human monocyƟ c/macrophage THP1 and U937 cells when chronical-
ly exposed to the DMARD sulphasalazine (SSZ). These iniƟ al recogniƟ ons that BCRP 
can serve as a drug eﬄ  ux transporter for SSZ has iniƟ ated spin oﬀ  studies revealing 
that BCRP expressed in intesƟ nal Ɵ ssue (9, 23) is an important modulator of SSZ-
bioavailability and plasma levels. This is parƟ cularly illustrated in BCRP knock out 
mice, which showed > 100-fold higher plasma levels of SSZ than their BCRP profi cient 
counterparts (24). Moreover, in human individuals, single nucleoƟ de polymorphisms 
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Figure 1: Mechanism of acƟ on and resistance to glucocorƟ coids; involvement of glucocorƟ coid receptor 
and signaling pathways. 
GlucocorƟ coids (GC) elicit genomic and non-genomic eﬀ ects. The laƩ er can be mediated via binding to a 
membrane-associated glucocorƟ coid receptor (mGR), or non-specifi cally at high GC concentraƟ ons. Fol-
lowing diﬀ usion, GC may be extruded from cells by the MDR transporter Pgp to confer GC-resistance. GC 
bound to cytoplasmic GR is translocated to the nucleus where it binds to GRE, non-GRE, kB or AP1 sites to 
induce or inhibit transcripƟ on of specifi c infl ammatory regulatory proteins. GR exist as a and b isoforms 
aŌ er alternaƟ ve splicing of the GR gene. Each GRα and GRβ mRNA produces at least 8 addiƟ onal isoforms 
by alternaƟ ve translaƟ on iniƟ aƟ on. GRα and GRβ proteins are subject to mulƟ ple post-translaƟ onal modi-
fi caƟ ons (e.g. phosphorylaƟ on, ubiquiƟ naƟ on and nitraƟ on) aﬀ ecƟ ng binding eﬃ  ciencies to DNA binding 
sites. cAMP acƟ vaƟ on of PKAII will inhibit the Akt pro-survival pathway and will promote enhanced GC-
dependent apoptosis aŌ er acƟ vaƟ on of (CHQ-inhibited) p38 MAPK and inducƟ on of Bim. Further details 
are described in the text. AbbreviaƟ ons: cAMP; cyclic adenosine monophosphate, Bim; Bcl-2-interacƟ ng 
mediator of cell death, PKA; protein kinase A, Pgp; P-glycoprotein. This fi gure is a composiƟ on based on 
data described in refs (Ji et al, (20); Barnes and Adcock, (122), BuƩ gereit et al, (13), Lu and Cidlowski, (43)). 
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within the BPRP gene can give rise to diﬀ erenƟ al SSZ disposiƟ ons as illustrated by the 
noƟ on that subjects harbouring the BCRP 34GG/421CA genotype had a 2.4-fold high-
er SSZ area under the concentraƟ on-Ɵ me curve as compared to subjects with the 
BCRP 34GG/421CC genotype (25). InteresƟ ngly, Shukla et al (26) reported that non-
toxic doses of curcumin, a naturally occurring polyphenolic compound, could inhibit 
intesƟ nal BCRP acƟ vity and increase SSZ absorpƟ on by 2-2.5 fold. Since polyphenolic 
compounds are common consƟ tuents of many dietary products and fl uids, these 
could be responsible for variabiliƟ es in SSZ-absorpƟ on and plasma levels in RA pa-
Ɵ ents taking this DMARD. 
The outcome of the in vitro studies also revealed a potenƟ ally important mechanism 
of drug interacƟ ons of SSZ with the folate antagonist methotrexate (MTX). Consist-
ent with earlier studies by Jansen et al (27) also SSZ-resistant THP1 and U937 cells 
displayed resistance to MTX when combined with SSZ, the molecular basis for which 
being the potent inhibiƟ on by SSZ of the Reduced Folate Carrier (RFC), the dominant 
cellular entry route for MTX in most immune cells (28) [see Figure 2A]. Along with 
this mechanism, of further interest were recent observaƟ ons that SSZ, at clinically 
Figure 2: (A) Sulphasalazine inhibits RFC-mediated uptake of natural folates and folate antagonists, includ-
ing MTX. Cell entry of folates and MTX in most immune-eﬀ ector cells is mediated by the reduced folate 
carrier (RFC). InhibiƟ on of folate uptake may lead to intracellular folate depleƟ on unless other factors that 
regulate folate homeostasis in immune cells, i.e. intracellular retenƟ on due to polyglutamylaƟ on (via the 
enzyme FPGS), or reduced cellular extrusion by the MDR transporters BCRP and MRP1-5 compensate for 
this eﬀ ect. (B) SSZ inhibits intesƟ nal folate and MTX uptake via proton-coupled folate transporter (PCFT). 
PCFT funcƟ ons opƟ mally at a luminal pH of 5.5. InhibiƟ on of PCFT acƟ vity by SSZ aﬀ ects folate homeostasis 
in the enterocyte , which is further dependent on the luminal extrusion via BCRP (localized at the apical 
membrane) and  transport to the liver via MRP1,3 (localized at the basolateral membrane).  Note; SSZ is 
also a substrate for extrusion via BCRP. AbbreviaƟ ons: FA: folate, RFC; reduced folate carrier, FPGS; Folyl-
polyglutamate synthetase, PCFT; Proton-coupled folate transporter, MRP; mulƟ drug resistance associated 
protein, BCRP; breast cancer resistance protein, MTX; methotrexate. 
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achievable concentraƟ ons, also appeared to be a potent inhibitor of the proton-cou-
pled folate transporter (PCFT), which facilitates intesƟ nal uptake of natural folates 
and several folate antagonists like MTX (29-33) [see Figure 2B]. So conceivably, both 
SSZ-PCFT and SSZ-RFC interacƟ ons might not only negaƟ vely infl uence absorpƟ on of 
MTX, they could also convey diminished intracellular folate levels being responsible 
for subclinical folate defi ciencies that have been reported for RA paƟ ents under SSZ 
therapy (34) and may also be reminiscent of hereditary folate malabsorpƟ on disease 
caused by specifi c loss of funcƟ on mutaƟ ons in the PCFT gene (35). Despite potenƟ al 
antagonisƟ c SSZ-MTX drug interacƟ ons and apparent lack of clear addiƟ ve or syner-
gisƟ c eﬀ ects of this drug combinaƟ on in RA treatment (36, 37), there may be room 
for improved eﬃ  cacy of the SSZ+MTX combinaƟ on for RA paƟ ents with a subopƟ mal 
response to SSZ alone (38-40). MechanisƟ cally such an improved eﬃ  cacy in this sub-
group of paƟ ents could possibly be explained by an SSZ-induced eﬀ ect of reducing 
intracellular folate status (27), under which condiƟ on MTX faces less compeƟ Ɵ on for 
polyglutamylaƟ on or target enzyme inhibiƟ on and can thus be more eﬀ ecƟ ve. Obvi-
ously, this hypothesis would require experimental confi rmaƟ on.
Another interesƟ ng feature that emerged from the in vitro studies was the acquisi-
Ɵ on of glucocorƟ coid (GC) sensiƟ vity in SSZ-adapted THP1 and U937 cells over GC-
resistant parental cells by upregulaƟ on of glucocorƟ coid receptor  (GR) expres-
sion. TradiƟ onally, it has been well accepted that mulƟ ple parameters can determine 
GC-sensiƟ vity or GC-resistance, among others GR expression levels, raƟ os of GR 
isoforms (GR over GR), altered binding aﬃ  niƟ es of GR and cellular extrusion by 
the drug eﬄ  ux transporter P-glycoprotein (41). However, more recent studies have 
introduced another level of complexity in the role of GR in conferring GC-sensiƟ vity 
and GC-resistance. It has been reported that the single GR gene is subject to dif-
ferenƟ al splicing that can yield 8 isoforms of GR and GR (see also Fig 1), of which 
each can be subject to diﬀ erenƟ al post-translaƟ onal modifi caƟ ons including phos-
phorylaƟ on, ubiquiƟ naƟ on and/or sumoylaƟ on, which aﬀ ect receptor funcƟ oning 
(42). Moreover, alternaƟ ve translaƟ on iniƟ aƟ on gives rise to unique Ɵ ssue distribu-
Ɵ on profi les of GRs which underlie Ɵ ssue-specifi c GC-sensiƟ vity/resistance profi les 
(43). Finally, beyond the role of cytoplasmic GRs in transducing genomic acƟ viƟ es 
to elicit an anƟ -infl ammatory response, there is also evidence that membrane-as-
sociated GRs can be involved in non-genomic acƟ viƟ es. In parƟ cular, GCs bound to 
membrane-associated GRs could possibly funcƟ on as regulators/inhibitors of signal 
transducƟ on pathways downstream of T cell receptor acƟ vaƟ on (44). It sƟ ll remains 
to be established whether any of these novel mechanisms of acƟ on of GCs and GRs 
could be involved in the in vitro GC-sensiƟ zing eﬀ ect of SSZ for THP1 and U937 cells. 
Although cauƟ on should be made in translaƟ ng the in vitro data to a clinical seƫ  ng, 
SSZ + MTX and prednisolone forms the basis of the eﬀ ecƟ ve COBRA combinaƟ on 
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therapy for RA paƟ ents (45, 46). Conceptually, it will be interest if in vitro studies 
with SSZ-adapted cells could provide further insight into the molecular basis of the 
eﬃ  cacy of the COBRA combinaƟ on therapy. 
MDR in clinical samples 
Following in vitro studies, our studies on MDR-related DMARD resistance were ex-
tended to clinical samples from RA paƟ ents, including peripheral blood lymphocytes 
and monocyte-derived macrophages (chapter 6) as well as synovial Ɵ ssue (chapter 
7). 
From these studies we aimed to draw conclusions regarding the following quesƟ ons: 
(a) are specifi c MDR transporters diﬀ erenƟ ally expressed in immune cells from RA 
paƟ ents vs those of healthy controls, (b) does DMARD treatment infl uence MDR ex-
pression levels, and (c) is a diminished DMARD response in any way associated with 
specifi c MDR transporter(s) overexpression? Given the cross-secƟ onal design of our 
study we were not able to acquire a full assessment of a dynamic profi le of develop-
ment of DMARD resistance in conjuncƟ on with an eventual upregulaƟ on of MDR 
transporters, for this purpose a longitudinal study is warranted.
With respect to peripheral blood cells, our studies corroborate those of others (47-
51) revealing basal expression levels and funcƟ onal acƟ viƟ es of several MDR trans-
porters. Notably, MDR protein and mRNA levels were widely distributed and present 
in T cells (Pgp; MRPs), monocytes (Pgp, MRPs), dendriƟ c cells (Pgp, MRPs, BCRP) 
and macrophages (MRPs, BCRP) of both RA paƟ ents and healthy controls. A concise 
overview of immune cells, their MDR transporter expression and potenƟ al DMARD 
substrates for these transporters is summarized in Table 1.
Of interest, increased levels of MRP1 (PBLs), MRP3 and BCRP (macrophages) were 
found in RA paƟ ents compared to healthy controls. Furthermore, increased P-gp 
funcƟ onal acƟ vity in CD3+ cells was associated with receiving DMARD treatment and 
also expression of other MDR transporters were modestly increased but not to a 
staƟ sƟ cally signifi cant level.  Together our data from peripheral blood cells as well as 
synovial Ɵ ssue from RA paƟ ents support the view that MDR transporter expression 
in immune cells from RA paƟ ents is an infl ammaƟ on-related phenomenon and not 
as much merely a DMARD-induced process. 
In any event, regardless as to whether MDR inducƟ on is an infl ammaƟ on- or DMARD-
induced eﬀ ect, in both scenarios extrusion of DMARDs via specifi c MDR transport-
ers can contribute to a diminished clinical acƟ vity when the DMARDs of use are 
substrates for one or more specifi c MDR transporters. The apparent lack of marked 
DMARD-induced overexpression of specifi c MDR transporters is opposite to what has 
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been observed in cancer paƟ ents treated with chemotherapy (1). A likely explanaƟ on 
is that cancer paƟ ents are oŌ en administered considerably higher doses of therapeu-
Ɵ c drugs than RA paƟ ents, which could then provoke a drug-induced upregulaƟ on of 
specifi c MDR transporters. Most RA paƟ ents used in our study used low dose MTX 
(7.5-30 mg/week), while high dose MTX for treatment of (childhood) leukemia may 
include dosages of up to 2-3 g/m2. In case a MTX-induced upregulaƟ on of MDR trans-
porters would have been anƟ cipated, these may have included MRP1-5 or BCRP, 
which have MTX as one of their preferred substrates. Rather, the most frequently up-
regulated expression and funcƟ onal acƟ vity was monitored for P-glycoprotein, which 
does not have hydrophilic drugs like MTX among its substrates (28). Hence, increased 
expression of Pgp on CD3+ cells seems more indicaƟ ve for higher disease acƟ vity 
and is not an important factor in failure to MTX therapy. In fact, Agarwal et al (52) 
reached the same conclusion based on a small study with 18 DMARD-naïve and 10 
DMARD-refractory RA paƟ ents; at baseline Pgp-acƟ vity was higher in lymphocytes 
of RA paƟ ents than for healthy controls and aŌ er 4 months MTX treatment expres-
sion of Pgp correlated with disease acƟ vity and not with refractoriness to therapy 
with MTX. In earlier studies examining lymphocyte MRP1 funcƟ onal acƟ vity, Hider 
Table 1: Overview of MDR transporter expression in diﬀ erent immune cells and their known DMARD 
substrates.
MDR Transporter Blood Cell type DMARD substrates
Pgp (ABCB1)
T-cells, ATC, B-cells, IDC, MDC, Macrophages, 
erythrocytes, granulocytes, monocytes, stem 
cells, NK cells, granulocytes
chloroquine, 
glucocorƟ coids
MRP1 (ABCC1)
Stem cells, T-cells, NK-cells, LC, IDC, MDC, 
monocytes, erythrocytes macrophages, 
platelets
methotrexate, chloroquine
MRP2 (ABCC2) T-cells, NK-cells methotrexate
MRP3 (ABCC3) T-cells, LC, IDC methotrexate
MRP4 (ABCC4) Stem cells, platelets, LC, IDC, MDC, macrophages, methotrexate, azathioprin
MRP5 (ABCC5) T-cells, IDC, macrophages, erythrocytes methotrexate, azathioprin
MRP6 (ABCC6) IDC unknown
MRP7 (ABCC10) unknown unknown
MRP8 (ABCC11) unknown methotrexate
MRP9 (ABCC12) unknown unknown
BCRP (ABCG2) Stem cells, Macrophages, LC, IDC, MDC methotrexate, lefl unomide, sulphasalazine
AbbreviaƟ ons: NK-cells, natural killer cells; LC, Langerhans Cell; IDC, Immature dendriƟ c cell; MDC, 
Mature dendriƟ c cell. For references, see chapter 2.
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et al (53) also noted a higher baseline MRP1 expression in RA paƟ ents over healthy 
controls, which was reduced upon response to MTX treatment in conjuncƟ on with a 
reducƟ on of disease acƟ vity. InteresƟ ngly, our studies also revealed abundant BCRP 
expression on macrophages in the inƟ mal lining layer and the synovial sublining of 
synovial biopsies from RA paƟ ent even prior to receiving MTX or lefl unomide thera-
py. Together, these observaƟ ons point to the fact that infl ammatory condiƟ ons can 
convert a marked eﬀ ect on expression levels of several MDR transporters. There is 
indeed evidence that pro-infl ammatory cytokines and stress signals and can regulate 
MDR gene expression (54, 55). Obviously in RA, elevated levels of circulaƟ ng or local 
pro-infl ammatory cytokines may provide environmental condiƟ ons for upregulaƟ on 
of MDR transporters. With respect to BCRP, its expression can also be induced under 
hypoxic condiƟ ons by the acƟ on of the transcripƟ on factor HIF1 (56). Since RA syn-
ovium consƟ tutes a hypoxic environment, this may have contributed to upregulaƟ on 
of BCRP separate of a possible drug-induced process. Given the noƟ on that there is 
considerable macrophage heterogeneity in RA synovium (57), it would be of interest 
to explore a possible relaƟ onship between BCRP expression and dynamics of reten-
Ɵ on at sites of infl ammaƟ on and response to selected DMARDs.
The fact that basal levels of MDR transporters may fl uctuate under various infl am-
matory and stress condiƟ ons further underscores a potenƟ al physiological role they 
may harbor in controlling an adapƟ ve response to these processes (reviewed in 
detail in Chapter 2). This is parƟ cularly indicated in MDR knock-out animal studies, 
most of which demonstrate a reduced infl ammatory response to toxic agents, stress 
or infl ammatory triggers (58-61). In fact, the crucial role of several MDR transporter 
in immunological processes is now clearly established, e.g. Pgp, MRP1 and MRP4 
in dendriƟ c cell diﬀ erenƟ aƟ on and migraƟ on (61), Pgp in T-cell acƟ vaƟ on (62) and 
BCRP in stem cell side populaƟ ons (63). These physiological funcƟ ons of several MDR 
transporters may warrant cauƟ on when considering strategies of improving DMARD 
therapy by blocking the pharmacological funcƟ on of these transporters by impairing 
their DMARD extrusion. From an auto-immune disease perspecƟ ve it may be benefi -
cial to suppress immune eﬀ ector funcƟ ons by blocking of MDR transporters, but too 
much suppression may compromise basal immune funcƟ ons, resulƟ ng in adverse 
events. Thus far, strategies of blocking MDR transporters (mainly Pgp) to improve 
anƟ cancer therapy eﬃ  cacy were rather disappoinƟ ng due to unfavourable pharma-
cological properƟ es of the inhibitors, toxicity of the inhibitors or pharmacokineƟ c 
interacƟ ons (1, 64, 65). These observaƟ ons may cast doubt whether similar types of 
strategies of blocking MDR transporters to improve DMARD eﬃ  cacy would be eﬀ ec-
Ɵ ve when concomitant immunosuppressive eﬀ ects are unpredictable.
Future direcƟ ons for MDR studies in RA may also include analysis of polymorphic 
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variants in relaƟ on to DMARD response. In this context, there are a few studies that 
incorporated single nucleoƟ de polymorphic (SNP) variants of Pgp in assessment of 
MTX response for RA paƟ ents (66, 67), but since MTX is not a substrate for Pgp, it 
would make more sense to evaluate polymorphic variants of MRP1-5 (68) or BCRP 
(25, 69) for a putaƟ ve contribuƟ on in MTX response as these transporters have MTX 
among one of their substrates for cellular extrusion. Beyond further analysis of a role 
of MDR transporters in DMARD eﬃ  cacy, it is important to note that the number of 
MDR transporters included in our current studies only represent a fracƟ on (20%) of 
the 49 members of the ABC family of drug transporters. Of note, recently funcƟ ons 
of some of the other members of the ABC transporter family have been idenƟ fi ed 
that could be of direct and indirect relevance for the pathophysiological processes 
associated with RA. Specifi cally, it could be of interest to explore whether diﬀ erenƟ al 
expression or funcƟ on of ABC transporters such as ABCG1, ABCG5 and ABCA1, being 
involved in cholesterol and lipid transport in macrophages (70, 71), could play a role 
in cardiovascular comorbidity events frequently observed in RA paƟ ents (46, 72).
New experimental drugs
The paragraphs above described the potenƟ al role of MDR transporters in conferring 
DMARD resistance and discussed the pros and cons of MDR blockers to overcome re-
sistance. One other logical strategy to overcome MDR-related loss of DMARD eﬃ  cacy 
is to design and idenƟ fy experimental drugs that are not or poor substrates for MDR 
transporters. This type of drugs may include second generaƟ on of currently applied 
DMARDs, e.g. analogues of the anchor drug in RA, methotrexate. In fact, we recently 
idenƟ fi ed a novel folate antagonist structure, BGC945, that due to its L-glutamate-
D-glutamate side chain is not a substrate for MDR transporters like MRP1-5 or BCRP 
that have MTX among its substrates (73).
Another category of experimental drugs that was evaluated in this thesis included in-
hibitors of the ubiquiƟ n-proteasome. This pathway is responsible for the degradaƟ on 
of the major bulk of intracellular proteins including short-lived proteins, cell-cycle 
regulatory proteins and misfolded/denatured proteins (74-76). Two diﬀ erent types 
of proteasomes can be disƟ nguished; consƟ tuƟ ve proteasomes and immunoprotea-
somes (77). The laƩ er are dominantly acƟ ve in immune cells (monocytes, B cells, 
T cells, dendriƟ c cells) upon exposure to interferon-. Immunoproteasomes serve 
the generaƟ on of T cells epitopes and presentaƟ on of anƟ genic pepƟ des for pres-
entaƟ on by MHC class I molecules (78-80). Proteasome inhibitors represent a novel 
generaƟ on of targeted drugs, of which bortezomib is its main representaƟ ve receiv-
ing considerable aƩ enƟ on for its rapid registraƟ on and successful applicaƟ on in the 
treatment of therapy-refractory mulƟ ple myeloma and mantle cell lymphoma (81, 
82). From a rheumatology therapeuƟ c perspecƟ ve the proteasome has also received 
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aƩ enƟ on as a potenƟ al target (83-86), among others for reasons that the protea-
some mediates the breakdown of IB, the natural inhibitor of the acƟ vaƟ on of the 
transcripƟ on factor NFB that drives the transcripƟ on of pro-infl ammatory cytokines 
such as TNF (87). Indeed, our data described in chapter 9 demonstrated that bort-
ezomib was capable of suppressing the release of NFB-inducible proinfl ammatory 
cytokines by acƟ vated T cells from RA paƟ ents. Recently, bortezomib also displayed 
potent therapeuƟ c eﬃ  cacy in a murine model with collagen-induced arthriƟ s (88) as 
well as in a murine model with lupus-like disease (89). In the laƩ er study, bortezomib 
depleted plasma cells producing anƟ bodies to double-stranded DNA, ameliorated 
glomerulonephriƟ s and conferred prolonged survival of mice with lupus-like disease. 
Finally, a recent study revealed that a specifi c immunoproteasome inhibitor, PR957, 
could block cytokine producƟ on and suppressed the progression of collagen-induced 
arthriƟ s in mice (90). Together, in vitro, ex vivo and animal model studies indicate 
that (immuno)proteasome inhibitors deserve further evaluaƟ ons for future clinical 
applicaƟ on as anƟ -arthriƟ c drugs. 
Due to the chronic nature of their disease, arthriƟ c paƟ ents normally face long term 
administraƟ on of chemical or biological DMARDs. Since for proteasome inhibitors it 
was not readily clear what long term eﬀ ects on immune cells would be, or whether 
it would be accompanied with the onset of resistance to these types of drugs, we set 
out to explore this issue in an vitro model system of monocyƟ c/macrophage THP1 
by mimicking gradual dose escalaƟ ons with exposure to stepwise increasing concen-
traƟ ons of bortezomib. Recently, also other research groups have iniƟ ated similar 
approaches by in vitro adaptaƟ on of haematological cell line models (T cells, my-
eloma cells, myelomonocyƟ c cells) to bortezomib. Data emerging from the majority 
of these studies revealed a consensus profi le that acquired resistance to bortezomib 
is oŌ en associated with alteraƟ ons at the level of the proteasome as a target (91-95), 
but also a consƟ tuƟ vely high NFkB acƟ vity and inability to undergo apoptosis were 
reported as contribuƟ ng factors in resistance (96, 97). Importantly, the contribuƟ on 
of MDR transporters in bortezomib resistance seems rather limited (94, 98). At low 
levels of bortezomib resistance (2-5-fold IC50 concentraƟ ons), immediate responses 
included increased expression of proteasome subunit 5, being the primary target 
of bortezomib, as well as the two other subunits 2 and 1 harboring proteolyƟ c 
acƟ vity (92, 93, 95). InteresƟ ngly, TNF was capable to interfere in this proteasome 
subunit upregulaƟ on and potenƟ ate bortezomib acƟ vity (99). Conceivably, elevated 
expression of 5 subunits may be uƟ lized for de novo proteasome assembly to com-
pensate for the inhibitory eﬀ ects of bortezomib.  At higher selecƟ ve concentraƟ ons 
of bortezomib (> 30 nM and > 10-fold IC50) also markedly higher levels of resistance 
could be observed as a result of a mutaƟ on in the PSMB5 gene encoding for the 
5 subunit. In bortezomib-resistant monocyƟ c/macrophage THP1 cells this mutaƟ on 
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introduced an amino acid subsƟ tuƟ on (Ala49Thr) in the highly conserved substrate 
binding pocket of the 5 subunit of the proteasome. Recently, other Ala49Thr and Al-
a49Val subsƟ tuƟ ons were idenƟ fi ed independently in at least 3 other bortezomib-re-
sistant haematological cell lines (100-103), suggesƟ ng that Ala49 may be considered 
as a hot spot for mutaƟ ons in the PSMB5 gene through which acquired resistance for 
bortezomib may be facilitated. As a further follow up, we have recently also idenƟ -
fi ed (101) 2 other mutaƟ ons in the PSMB5 gene leading to amino acid subsƟ tuƟ ons 
at Cys52Phe and Thr21Ala in cell lines selected at moderately high levels of bort-
ezomib (30 nM) and 1 mutaƟ on leading to a an amino acid subsƟ tuƟ on at Met45Ile 
in THP1 cells selected at very high concentraƟ ons of bortezomib (500 nM) (104). As 
an overview, Figure 3 demonstrates the importance of Ala49, Thr21 and Met45 in 
the proteasome 5 subunit binding pocket for bortezomib based on crystallographic 
data from yeast 20S proteasome (105).
Together, we showed (see chapter 9) on the one hand that the proteasome inhibitor 
bortezomib elicits potenƟ al anƟ -rheumaƟ c eﬀ ects by suppressing the release of pro-
infl ammatory cytokines and bypasses an MDR phenotype. On the other hand, how-
ever, also development of resistance to bortezomib can occur by the introducƟ on of 
mutaƟ ons in the PSMB5 gene encoding for the proteasome 5 subunit. Future stud-
ies should further explore PSMB5 mutaƟ ons could also be a common mechanism of 
bortezomib resistance in a clinical therapeuƟ c seƫ  ng and thus a cause of bortezomib 
refractoriness. The bortezomib resistant cell lines may also serve as a valuable tool 
Figure 3: (A) The ubiquiƟ n proteasome pathway. The 26S proteasome is an ATP-dependent protease com-
plex comprised of a 20S catalyƟ c core (organized into four stacked rings of seven subunits each, i.e. α, β, 
β, α) and two 19S regulatory caps. 19S caps are responsible for recogniƟ on of ubiquiƟ nylated proteins (lid) 
and also contain ATPase acƟ vity (base) required for linearizaƟ on of large proteins facilitaƟ ng their entry in 
the catalyƟ c core. Three β-subunits (β1, β2, β5) are responsible for the diﬀ erent enzymaƟ c acƟ viƟ es of the 
proteasome and are diﬀ erenƟ ally inhibited by small molecule inhibitors such as bortezomib. (B) Stereore-
presentaƟ on of bortezomib binding in the β5 binding pocket of yeast 20S proteasome. Bortezomib forms a 
reversible pseudocovalent bond formaƟ on with the hydroxyl group of Thr1 in the β5 acƟ ve site. Hydrogen 
bonds of bortezomib with Thr 21, Ala49, Gly47 and Met45 are depicted as orange dashes binds and water 
as red dots. From B.S. Moore et al, (106). 
A B
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to invesƟ gate the impact of bortezomib resistance on; (a) pro-infl ammatory cytokine 
release profi les, (b) protein degradaƟ on, pepƟ de processing and anƟ gen presenta-
Ɵ on as well as other funcƟ onal properƟ es of immune cells, and (c) evaluaƟ on of ra-
Ɵ onally designed proteasome inhibitors that may overcome bortezomib-resistance.
It has been a persisƟ ng challenge to design specifi c and selecƟ ve proteasome inhibi-
tors with opƟ mal eﬃ  cacy and minimal toxicity in either anƟ -cancer or anƟ -arthriƟ c 
therapies (107). Extended crystallographic knowledge of the proteasome may be 
helpful for drug development purposes (78). At this moment novel second generaƟ on 
of proteasome inhibitors are in diﬀ erent stages of preclinical and clinical evaluaƟ on. 
These novel proteasome inhibitors may harbor properƟ es disƟ nct of bortezomib by 
being irreversible inhibitors of the proteasome or by diﬀ erenƟ al targeƟ ng of one or 
more of the three proteolyƟ cally acƟ ve -subunits of the proteasome (108, 109). 
Also the availability of orally acƟ ve proteasome inhibitors (110-112) will be a step 
forward for their clinical administraƟ on. Our studies revealed that a cytotoxic hexam-
eric pepƟ de 4A6 was a potent and selecƟ ve inhibitor of the proteasome 5 subunit. 
This pepƟ de may serve as a lead for other raƟ onally designed pepƟ des, which may 
be devoid of the property of being potenƟ al substrates for the MDR transporters Pgp 
and MRP1 (113).
Should proteasome inhibitors already be eligible for clinical evaluaƟ on as experi-
mental RA treatment for instance aŌ er failure to chemical and biological DMARDs? 
ObjecƟ vely, despite promising results of considerable eﬃ  cacy in animal models of 
arthriƟ s, there are sƟ ll a number of issues that need further consideraƟ on. One is 
that bortezomib-induced neuropathy has been observed as a toxic side eﬀ ect in pa-
Ɵ ents with mulƟ ple myeloma (114). This may be less of an issue when lower dosages 
of bortezomib would be eﬀ ecƟ ve as an anƟ -arthriƟ c agent or when second genera-
Ɵ on of proteasome inhibitor may be devoid of neurotoxic side eﬀ ects. Furthermore, 
cauƟ on may be indicated when RA paƟ ent with cardiac co-morbidiƟ es as long term 
treatment with bortezomib may aﬀ ect cardiac myocyte funcƟ on (115). Again, it is not 
clear whether dose reducƟ on of bortezomib or second generaƟ on of proteasome 
inhibitors would face the same eﬀ ect. It should also be considered that consƟ tuƟ ve 
proteasome acƟ vity, but not as much immunoproteasome acƟ vity in immune cells 
decreases with aging (116, 117) or can be inhibited by several dietary products (118). 
It is not readily clear how this would infl uence treatment eﬃ  cacy or toxicity with 
bortezomib or second generaƟ on proteasome inhibitors. Finally, it is well established 
that proteasomes can emerge in circulaƟ on and be a marker of disease acƟ vity in 
auto-immune diseases (119, 120). Moreover, several proteasome subunits were re-
cently idenƟ fi ed as auto-anƟ gens eliciƟ ng autoimmune reacƟ vity (121). How protea-
some inhibitor therapy would infl uence circulaƟ ng proteasomes and/or autoimmune 
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reacƟ vity is an issue that deserve further exploraƟ on. 
In conclusion, proteasome inhibitors harbour potenƟ ally interesƟ ng properƟ es to 
elicit anƟ -arthriƟ c eﬀ ects as was illustrated in preclinical and animal model systems. 
Whether the onset of resistance to proteasome inhibitors would be clinically rel-
evant when RA paƟ ents should be treated with these drugs, is presently unknown. 
Data from in vitro studies, however, may be helpful in idenƟ fying various modes of 
resistance and assist in the design of strategies to bypass it. 
General conclusion
Altogether, by virtue of their chemical structure or mode of acƟ on, the majority of 
contemporary and experimental chemical or biological drugs used in RA, cancer and 
infecƟ ous disease treatment will impose a stress/toxic response to many cell types in 
our body, which will subsequently provoke a defence response. It will remain a chal-
lenge to idenƟ fy the various defence mechanisms for each type of drug in relaƟ on to 
its mechanism of acƟ on at clinically relevant drug concentraƟ ons. As such, avoiding 
that natural defence mechanisms turn into clinical resistance mechanisms will be 
ulƟ mate goal to opƟ mize treatment eﬃ  cacy of paƟ ents with autoimmune diseases in 
general and RA paƟ ents in parƟ cular. 
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Chapter 13
Summary
Rheumatoid arthriƟ s (RA) is a chronic infl ammatory disease, which, in the Nether-
lands, aﬀ ects approximately 1% of the populaƟ on. The disease is mainly character-
ized by infl ammaƟ on of the joints which become swollen and painful. The chronic 
infl ammaƟ on will eventually be destrucƟ ve to the carƟ lage and bone of the joints, 
leading to serious disability, immobility, reducƟ on of quality of life and reducƟ on 
of life expectancy. Furthermore, due to the high prevalence of RA and the chronic 
burden of the disease, RA also has a major socio-economic impact due to substanƟ al 
health care costs and because of its impact on work ability (or capacity). Therefore, 
current strategies for RA treatment include rapid and aggressive intervenƟ ons with 
classical and biological disease modifying anƟ -rheumaƟ c drugs aiming for prolonged 
suppression of the disease and ideally achieving complete remission. In this context, 
worldwide eﬀ orts are now going on to explore, design and evaluate novel treatment 
opƟ ons for RA, taking advantage of the cumulaƟ ve knowledge of the pathophysiol-
ogy of RA.  
Although the exact cause of RA remains unknown, several risk factors have been 
clearly linked to the onset of RA (Chapter 1). It is assumed that a combinaƟ on of a cer-
tain geneƟ c background and external events can iniƟ ate an autoimmune response. 
In an autoimmune disease seƫ  ng, the immune system is deregulated and cannot 
make an adequate disƟ ncƟ on between self and non-self. For rheumatoid arthriƟ s 
it is believed that the immune system recognizes a certain component in the joint, 
possibly carƟ lage, as a foreign and dangerous substance that needs to be eliminated. 
The process of eliminaƟ on is regulated by the infl ammatory response executed by 
the immune system. For this process, the immune system can recruit several types 
of immune-eﬀ ector cells, including: (a) dendriƟ c cells (involved in anƟ gen processing 
and presentaƟ on), T cells (involved in cellular defense by specifi c killing of infected 
cells), B cells (can diﬀ erenƟ ate to anƟ body producing plasma cells) and monocytes/ 
macrophages (involved in phagocytosis and digesƟ on of cellular debris and patho-
gens).  In a complex manner all cells of the immune system communicate with each 
other by the secreƟ on of specifi c hormonal-like signals, which are called chemokines 
and cytokines. Within this advanced and complex communicaƟ on network, the cyto-
kine Tumor Necrosis Factor α (TNFα) is considered to be a dominant mediator of the 
infl ammatory response. In RA it is now generally accepted that immune-eﬀ ector cells 
(macrophages, dendriƟ c cells, T-lymphocytes and B-lymphocytes) together with an 
unbalanced secreƟ on of pro-infl ammatory cytokines such as TNFα are essenƟ al for 
the onset as well as the maintenance of the disease. Therefore most treatment op-
Ɵ ons for RA are currently focused on the control of the infl ammatory response and 
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prevenƟ on of bone lesions by either eliminaƟ ng infl ammatory cells or by interfering 
in the cytokine/chemokine communicaƟ on network. 
Classical and biological disease modifying anƟ -rheumaƟ c drugs (DMARDs) are com-
monly prescribed to paƟ ents with RA. These molecules/anƟ bodies are able to damp-
en the infl ammaƟ on and they are even capable of inducing temporary remissions 
of the disease in a number of paƟ ents. However, since these drugs are unable to 
cure the disease, they require chronic administraƟ on to sustain clinical benefi t. Un-
fortunately, for many RA paƟ ents therapeuƟ c benefi ts of DMARDs are temporary, 
as DMARDs will oŌ en gradually lose their eﬃ  cacy aŌ er several months or years of 
chronic use. This process is also known as acquired resistance to therapeuƟ c drugs. 
In a small number of paƟ ents, lack of eﬃ  cacy may already be observed at treatment 
iniƟ aƟ on, which is referred to as primary or inherent resistance to DMARDs. Howev-
er, usually treatment failure to DMARDs occurs aŌ er a period of adequate treatment 
response, referred to as secondary failure. AddiƟ onal disƟ ncƟ ons can be made when 
resistance to DMARDs includes only one class of DMARDs (e.g. folic acid analogues) 
or when it involves mulƟ ple DMARDs that are chemically and funcƟ onally unrelated. 
In the laƩ er case, this is referred to as a mulƟ drug-resistant phenotype. Important 
quesƟ ons are how paƟ ents acquire resistance to DMARDs and what is/are the under-
lying mechanism(s) of resistance. In this thesis we focused on one important mech-
anism which concerns the involvement of mulƟ -drug resistance (MDR) drug eﬄ  ux 
transporters. MDR proteins belong to the family of energy (Adenosine Triphosphate, 
ATP)-driven ATP-binding casseƩ e (ABC) transporters, which may pump a wide range 
of diﬀ erent compounds out of cells. There is now accumulaƟ ng evidence that several 
DMARDs are substrates of disƟ nct MDR proteins and thereby cause a diminished 
eﬃ  cacy of DMARDs. Specifi cally, we set out to address two main goals in this thesis:
1. To defi ne the role of drug eﬄ  ux transporters in conferring resistance/loss of ef-
fi cacy to DMARDs in immune-competent cells implicated in the pathophysiology 
of RA.
2. To explore the eﬃ  cacy of some novel experimental targeted drugs with the po-
tency to overcome DMARD resistance, taking into account that they may them-
selves also be subject to the development of resistance. 
Chapter 1 provides an overview of the pathophysiological aspects of RA and sum-
marizes current treatment modaliƟ es for this disease. Furthermore, the potenƟ al 
role of drug eﬄ  ux transporters in conferring resistance to DMARDs is described. Fi-
nally, the introducƟ on discusses new experimental therapeuƟ c opƟ ons for RA, such 
as proteasome inhibitors, a new class of small molecule drugs with potenƟ al anƟ -
infl ammatory properƟ es. 
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In Chapter 2 we reviewed the current state of the literature concerning MDR trans-
porters and their relaƟ on to the immune system. It is recognized that MDR transport-
ers are present on most immune-eﬀ ector cells (T-cells, B-cells, monocytes/macro-
phages, dendriƟ c cells), including those that play a role in RA pathophysiology. Apart 
from a possible pharmacological funcƟ on in conferring drug resistance by extruding 
therapeuƟ c drugs including DMARDs, several MDR transporters also fulfi l important 
immuno-regulatory funcƟ ons by facilitaƟ ng the transport of compounds that serve 
as mediators of infl ammaƟ on (e.g. leucotrienes) and/or are involved in cell diﬀ eren-
Ɵ aƟ on and maturaƟ on. This dual funcƟ on of MDR transporters and the implicaƟ ons 
for autoimmune disorders as well as for cancer is extensively discussed. Conceivably, 
interference of physiological MDR funcƟ on in autoimmune diseases by specifi c MDR 
blockers may aƩ enuate the aberrant immune response in RA paƟ ents however, in 
immune-compromised cancer paƟ ents, MDR blocking may elicit an adverse eﬀ ect.
Though not being the most potent DMARD, the anƟ malarial (hydroxy) chloroquine 
(CHQ) has a modest but established place in RA treatment, also because it is easy 
to combine it with other DMARDs. In RA clinical pracƟ ce, however, CHQ is among 
the DMARDs of which a relaƟ vely rapid loss of eﬃ  cacy has been reported upon pro-
longed administraƟ on. The mechanisƟ c basis for this is largely unknown. In Chapter 
3 we mimicked the development of resistance mechanism to CHQ by in vitro expo-
sure of a human T-cell line to a stepwise increasing concentraƟ on of CHQ. Following 
this procedure, cells acquired a 3-4 fold level of resistance to CHQ over a period 
of 5 months. ExaminaƟ on of the mechanism of resistance revealed the overexpres-
sion of mulƟ drug resistance-associated protein 1 (MRP1). The role of this drug eﬄ  ux 
transporter was further confi rmed by the fact that blocking of MRP1 reversed CHQ 
sensiƟ vity. CHQ-resistant T-cells remained fully sensiƟ ve to other DMARDs, including 
methotrexate (MTX), lefl unomide, cyclosporine A and sulphasalazine. Rather strik-
ingly, CHQ-resistant cells were highly resistant (> 1,000-fold) to the glucocorƟ coids 
(GCs) dexamethasone and prednisolone due to a disturbed cyclic-AMP dependent 
protein kinase A signaling pathway. Consistently, transient acƟ vaƟ on of cAMP-de-
pendent protein kinase A sensiƟ zed cells for GCs.  Finally, CHQ-resistant T cells dem-
onstrated a markedly impaired capacity to release the pro-infl ammatory cytokine 
TNF- and the chemokine IL-8, suggesƟ ng that CHQ-resistance in this model T cell 
line does not necessarily compromise its anƟ -infl ammatory eﬀ ects.  
Inherent or acquired resistance to glucocorƟ coids (GCs) is a well recognized problem 
in the treatment of infl ammatory diseases and it limits the opƟ mal eﬃ  cacy of GCs. In 
addiƟ on, increase of dosage could be necessary but will lead to an increase incidence 
of substanƟ al adverse events. As shown in chapter 3, resistance to CHQ was associ-
ated with a marked cross-resistance to GCs. However, in Chapter 4 we reported an 
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opposite phenomenon, namely that prolonged exposure of two primary GC-resistant 
human monocyƟ c/macrophage cell lines could be sensiƟ zed for GCs aŌ er prolonged 
exposure to another DMARD; sulphasalazine (SSZ). Recovery of GC-sensiƟ vity in 
SSZ-exposed cells was conveyed via GC-induced apoptoƟ c cell death, together with 
inhibiƟ on of NFkB acƟ vaƟ on. GC-sensiƟ vity was also greatly improved by the fact 
that in SSZ-exposed cells, the expression of the GC receptor  protein was markedly 
increased, probably by increased stabilizaƟ on of GR protein. These results deserve 
further experimental elaboraƟ on to disclose potenƟ al mechanisms of clinical acƟ vity 
of the triple DMARD combinaƟ on therapy of methotrexate, sulphasalazine and pred-
nisolone as part of the COBRA treatment protocol for RA paƟ ents.  
DMARD combinaƟ ons are quite common in RA treatment protocols. For one type 
of DMARD combinaƟ on, i.e. MTX + SSZ, confl icƟ ng results have been reported: ei-
ther this combinaƟ on has an addiƟ ve/synergisƟ c or an antagonisƟ c eﬀ ect over either 
DMARD alone. In Chapter 5 we examined whether possible drug interacƟ ons infl u-
ence the eﬃ  cacy of the MTX + SSZ combinaƟ on against an in vitro model of human 
monocyƟ c/macrophage cells. Indeed, two types of negaƟ ve interacƟ ons of SSZ with 
MTX were observed. First, SSZ was shown to be a potent and non-compeƟ Ɵ ve in-
hibitor of the reduced folate carrier (RFC), the main cellular uptake route for MTX. 
Secondly, long term SSZ exposure provoked a marked upregulaƟ on of the mulƟ drug 
resistance transporter ABCG2 (BCRP). Since this drug eﬄ  ux transporter has MTX 
among its extrudable substrates, this may contribute to a diminished eﬃ  cacy of MTX. 
Altogether, these observaƟ ons have relevant implicaƟ ons for the opƟ mal use and 
adverse eﬀ ects of MTX+SSZ combinaƟ ons in RA treatment. Considering the laƩ er, 
SSZ-RFC interacƟ ons may not only hamper cellular MTX uptake, it may also impair 
cellular uptake of natural folate cofactors, possibly leading to a subclinical causing 
folate defi ciency. These results also plead for giving folate supplementaƟ on and for 
spacing administraƟ on of sulfasalazine and MTX over Ɵ me, anƟ cipaƟ ng that the in-
hibitory eﬀ ects of SSZ on RFC-dependent MTX uptake are only transient.
In vitro studies have clearly established that MDR proteins can facilitate resistance to 
several DMARDs. Data demonstraƟ ng a role of MDR transporters in clinical DMARD 
resistance are scarce. Most clinical studies regarding this subject were focused on 
the P-glycoprotein, the fi rst idenƟ fi ed MDR transporter, but the possible contribu-
Ɵ on of other MDR transporters received liƩ le aƩ enƟ on. Therefore, in Chapter 6, 
we evaluated the expression profi le and funcƟ onal acƟ viƟ es of selected MDR trans-
porters (P-gp, BCRP and MRP1 to 9) on immune-eﬀ ector cells of RA paƟ ents in re-
laƟ on to clinical DMARD responsiveness and DMARD refractoriness. For this study 
peripheral blood lymphocytes (PBLs) and monocyte-derived macrophages (MDM) 
were obtained from RA paƟ ents (including DMARD-naive and DMARD-(non) respon-
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sive paƟ ents) and healthy controls. By using diﬀ erent techniques, such as real-Ɵ me 
PCR, immunohistochemistry and fl ow cytometry we were able to examine the pres-
ence and funcƟ onal acƟ vity of MDR transporters. We demonstrated that many MDR 
transporters are expressed on peripheral blood lymphocytes and monocyte-derived 
macrophages from both RA paƟ ents and healthy controls. However, increased mRNA 
levels of MRP1 (2.5-fold), MRP4 (1.6-fold) and MRP7 (1.9-fold) were observed only 
in peripheral blood lymphocytes of RA paƟ ents. In monocyte-derived macrophages 
we detected signifi cantly increased levels of BCRP protein (2.4-fold) and BCRP mRNA 
(2.8-fold), whereas P-gp protein expression correlated with disease acƟ vity. In T-lym-
phocytes, the acƟ vity of P-gp was found to be signifi cantly increased in RA paƟ ents 
treated with DMARDs when compared to DMARD therapy-naive paƟ ents. To assess 
whether any of the MDR transporters was associated with DMARD therapy failure, 
only MRP2 and MRP4 mRNA levels were found to be increased in DMARD non-re-
sponders when compared to DMARD-responders. CollecƟ vely, this study suggests 
that upregulaƟ on of specifi c MDR drug eﬄ  ux transporters on immune-competent 
cells of RA paƟ ents is more a refl ecƟ on of disease acƟ vity rather than a DMARD-
induced phenomenon. However, in both scenarios, elevated MDR expression can 
contribute to an aƩ enuated DMARD response in RA paƟ ents. As follow up of this 
cross-secƟ onal study, it will be of interest to further explore expression profi ling of 
MDR transporters on immune-eﬀ ector cells of RA paƟ ents in a longitudinal study of 
DMARD use and emergence of loss of eﬃ  cacy. 
Besides analysis of MDR transporter expression on peripheral blood cells (chapter 
6), we also extended our studies to infl amed synovial Ɵ ssue from RA paƟ ents. Chap-
ter 7 reports on the immunohistochemical analysis of expression levels of the MDR 
transporters P-gp, MRP1-5, MRP8, MRP9 and BCRP on infl ammatory cells in synovial 
Ɵ ssue of RA paƟ ents with acƟ ve disease before and aŌ er 4 months of treatment with 
MTX (7.5-15 mg/week) or lefl unomide (20mg/day). Results were compared with 
non-infl amed synovial Ɵ ssue from orthopedic paƟ ents. In all RA synovial biopsies, 
both prior to treatment and aŌ er 4 months of MTX treatment, abundant expression 
of BCRP was observed on macrophages in the inƟ mal lining layer as well as on macro-
phages and endothelial cells in the synovial sublining. StaƟ sƟ cal analysis showed that 
there was a trend towards more abundant BCRP expression at higher disease acƟ vity. 
Furthermore, median BCRP expression was 4-8 fold higher for MTX-non-responders 
when compared to MTX-responders. The same trend was observed for RA paƟ ents 
treated with lefl unomide: a 2.5-fold higher BCRP expression was observed in synovial 
biopsies from ‘lefl unomide-failures’ when compared to biopsies from paƟ ents with 
a good response on lefl unomide. Moderate expression of MRP1 was observed in 
T-cell areas of some synovial biopsies, whereas expression of P-gp, MRP2-5, MRP8 
and MRP9 were below the immunohistochemical detecƟ on levels. In control synovial 
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Ɵ ssue, along with very low levels of infi ltrated macrophages, only a few BCRP posi-
Ɵ ve cells were observed, while staining for the other MDR-proteins was negaƟ ve. 
Since we found posiƟ ve staining on macrophages in all RA synovial biopsies prior to 
therapeuƟ c intervenƟ ons, expression of BCRP seems to be an infl ammaƟ on-depen-
dent phenomenon rather than a drug-induced eﬀ ect associated with the onset of 
resistance. Notwithstanding this fact, since MTX, lefl unomide and sulphasalazine are 
established substrates for BCRP, this transporter may contribute to a reduced thera-
peuƟ c eﬀ ect of these DMARDs.
A controversial issue that remains is that MDR transporters could be directly or in-
directly be involved in the cellular secreƟ on of infl ammaƟ on-associated chemokines 
and cytokines. There is ample evidence that MDR transporters can extrude small 
molecule compounds and pepƟ des with molecular weight < 1kD, but whether this 
also holds for higher molecular weight chemokines (up to 8 kD) or cytokines (up to 20 
kD) is not completely clear. In Chapter 8 we invesƟ gated whether MDR transporters 
MRP1-5, P-gp or BCRP are involved in the secreƟ on of chemokines CCL20, MCP1 and 
IL-8 and cytokine TNFα. Cell lines with or without overexpression of one of the MDR 
transporters were acƟ vated with the phorbol ester PMA and the calcium ionophore 
ionomycin to sƟ mulate producƟ on of chemokines and cytokines. By using specifi c 
blockers of MDR transporters we examined whether this had an eﬀ ect on chemo-
kine and cytokine secreƟ on when compared to the condiƟ on without MDR blockade. 
The results indicated no robust diﬀ erences in CCL20, MCP1, IL-8 and TNFα secreƟ on 
between acƟ vated parent cell lines without MDR expression and counterparts with 
overexpression of MRP2, 3, 4, 5 and BCRP or aŌ er blocking of these transporters. 
InteresƟ ngly, CCL20 secreƟ on was reduced aŌ er blocking of MRP1 or P-gp, however, 
this showed variability among diﬀ erent cell lines. One other interesƟ ng point was 
that P-gp showed the capability to extrude the acƟ vator of chemokine/cytokine pro-
ducƟ on, PMA, which may support the conclusion that MDR transporters do not di-
rectly extrude higher molecular weight chemokines and cytokines, but that they can 
have an indirect eﬀ ect on suppression of chemokine/cytokine secreƟ on by extruding 
small molecule acƟ vators of this process. 
New experimental drugs with novel mechanisms of acƟ on could be uƟ lized to bypass 
MDR-associated DMARD resistance. One such class of novel experimental drugs is 
proteasome inhibitors which interfere in protein degradaƟ on processes. The pro-
teasome has a crucial role in the acƟ vaƟ on of the transcripƟ on factor NFB, which 
drives the transcripƟ on of several pro-infl ammatory cytokines such as TNF and IL-
1. It does so by facilitaƟ ng the breakdown of IBα protein, the natural inhibitor of 
NFB. Thus, proteasome inhibitors may harbor the capacity to block IB protein 
breakdown, block NFB acƟ vaƟ on and elicit an anƟ -infl ammatory eﬀ ect by suppress-
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ing pro-infl ammatory cytokine producƟ on. In Chapter 9 we evaluated the potenƟ al 
anƟ -infl ammatory properƟ es of bortezomib, a boron-containing dipepƟ de-based 
proteasome inhibitor, which is currently registered for the treatment of hematologi-
cal malignancies. Indeed, we observed that bortezomib conveyed a rapid and potent 
inhibiƟ on of TNFα producƟ on by acƟ vated T-cells from RA paƟ ents. This inhibitory 
potency was also demonstrated in T cells from DMARD non-responsive RA paƟ ents. 
Along with a reducƟ on in TNFα release, bortezomib had addiƟ onal delayed eﬀ ects 
of inhibiƟ ng T-cell acƟ vaƟ on by CD3/CD28 and, aŌ er > 48 hours exposure, a marked 
inducƟ on of apoptosis of peripheral blood lymphocytes of RA paƟ ents. 
Despite the promising anƟ -infl ammatory eﬀ ect of bortezomib, it is not clear what the 
long term eﬃ  cacy and toxicity of this drug will be during chronic administraƟ on as 
anƟ cipated for RA paƟ ents. Furthermore, it is also not clear whether long term bort-
ezomib exposure will provoke the onset of resistance to this drug. To obtain more 
insight into the possible development of acquired resistance to bortezomib and the 
idenƟ fi caƟ on of the molecular basis of resistance, we set out to expose in vitro hu-
man monocyƟ c/macrophage THP1 cells to stepwise increasing extracellular concen-
traƟ ons of bortezomib from 2.5 nM to 200 nM (Chapter 10). Indeed, by this protocol, 
high levels of bortezomib resistance (45-129 fold compared to parental cells) could 
be provoked. ExaminaƟ on of the molecular mechanism of bortezomib-resistance in 
these cells revealed two major fi ndings; (1) a mutaƟ on in the PSMB5 gene encoding 
for the proteasome β5 subunit protein of the 26S proteasome, being the primary tar-
get of bortezomib. This mutaƟ on resulted in an amino acid subsƟ tuƟ on at posiƟ on 49 
of the 5 subunit protein from alanine to threonine (Ala49Thr). This amino acid posi-
Ɵ on is known to be criƟ cal for bortezomib docking in the acƟ ve site of the 5 subunit. 
(2) A marked and selecƟ ve overexpression (up to 60-fold) was observed of PSMB5 
protein but not of the other two catalyƟ cally acƟ ve proteasome subunits PSMB6 
and PSMB7, or of one of the non-catalyƟ c  subunits of the proteasome, PSMA7. In 
addiƟ on, the bortezomib-resistant cells also displayed high levels of cross-resistance 
to other 5 subunit-targeted cytotoxic pepƟ des, including 4A6, MG132, MG262 and 
ALLN, but they retained full sensiƟ vity to a broad spectrum of chemotherapeuƟ c 
drugs as well as to all DMARDs. Bortezomib sensiƟ vity in bortezomib-resistant cells 
could be restored by siRNA-mediated silencing of PSMB5 gene expression prevenƟ ng 
the upregulaƟ on of 5 subunit protein. Altogether, these studies demonstrate that 
drug resistance phenomena should also be considered for proteasome inhibitors as 
novel experimental drugs.  
Bortezomib is the fi rst prototypical proteasome inhibitor that entered into the clinic. 
ConƟ nuous research being done to design, idenƟ fy and evaluate second generaƟ on 
of proteasome inhibitors that may have superior properƟ es over bortezomib with 
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regard to irreversible binding vs reversible binding, the targeƟ ng of other catalyƟ -
cally acƟ ve proteasome subunits, or the capability to bypass bortezomib resistance. 
In Chapter 11 we reported on a cytotoxic pepƟ de, 4A6, with an unknown mechanism 
of acƟ on. Based on cross-resistance profi ling for bortezomib resistant cells it was 
suggested that 4A6 could be a proteasome inhibitor. More detailed characterizaƟ on 
revealed that 4A6 is a potent and reversible inhibitor of the proteasome β5 subunit. 
4A6 displayed diﬀ erenƟ al acƟ vity against various leukemia and breast cancer cell 
lines, but its acƟ vity may be limited by the fact that it is a substrate for cellular ex-
trusion by the MDR transporters P-gp and MRP1. SƟ ll, 4A6 may be considered as a 
lead compound for further drug development of novel proteasome inhibitors that 
lack MDR substrate aﬃ  nity and elicit anƟ -infl ammatory properƟ es in an RA clinical 
treatment seƫ  ng. 
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Key points of the thesis 
Preclinical/in vitro laboratory studies: 
• Acquired resistance to the DMARD chloroquine is mediated by drug eﬄ  ux via 
upregulated expression of mulƟ drug resistance-associated protein 1 (MRP1).
• Chloroquine resistance is accompanied by a marked cross-resistance to gluco-
corƟ coids related to suppression of the cyclic-AMP protein kinase A signalling 
pathway.
• Sulphasalazine and methotrexate are prone to drug interacƟ ons based on the 
fact that sulphasalazine is a potent inhibitor of cellular uptake of methotrexate 
via the reduced folate carrier. Consequently, this interacƟ on may limit addiƟ ve/
synergisƟ c eﬀ ects of this DMARD combinaƟ on.
• Chronic exposure to sulphasalazine sensiƟ zes immune-eﬀ ector cell lines for glu-
cocorƟ coids.
• MulƟ drug resistance (MDR) drug eﬄ  ux transporters may be indirectly involved 
in the secreƟ on of chemokines and cytokines by mediaƟ ng the extrusion of 
(small molecule) acƟ vators of this process.
• Acquired resistance to the proteasome inhibitor bortezomib is conferred by an 
Ala49Thr mutaƟ on in the highly conserved bortezomib-binding pocket of the 
proteasome 5-subunit (PSMB5) protein.
Clinically-directed laboratory studies: 
• MulƟ drug resistance transporters are well known for their pharmacological role 
in conferring drug resistance; however, their physiological role in immune-eﬀ ec-
tor cells may be equally important for opƟ mal immune-funcƟ on. 
• Upregulated expression of specifi c MDR drug eﬄ  ux transporters in peripheral 
blood cells seems primarily a disease-acƟ vity associated phenomenon rather 
than a DMARD-induced eﬀ ect. 
• The MDR transporter BCRP is highly expressed on synovial Ɵ ssue macrophages 
and may be responsible for an aƩ enuated response to the DMARDs methotrex-
ate, lefl unomide and sulphasalazine, all three being substrates for BCRP.
• The proteasome inhibitor bortezomib is highly eﬀ ecƟ ve in suppressing pro-in-
fl ammatory cytokine release by acƟ vated T cells from RA paƟ ents.
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Reumatoïde artriƟ s (RA) is een chronische ontstekingsziekte die in Nederland onge-
veer 1% van de bevolking treŌ . De ziekte wordt vooral gekenmerkt door een ontste-
king van de gewrichten met zwelling, roodheid en pijn van de aangedane gewrichten 
tot gevolg. Uiteindelijk zal de chronische ontsteking de gewrichten aantasten en lei-
den tot ernsƟ ge invaliditeit, immobiliteit, vermindering van de kwaliteit van leven en 
van levensverwachƟ ng. Omdat RA een veel voorkomende chronische aandoening is, 
heeŌ  de ziekte ook grote sociaal-economische gevolgen met hoge kosten voor de ge-
zondheidszorg. De hedendaagse behandeling van RA bestaat uit snelle en agressieve 
intervenƟ es met chemische en biologische disease modifying anƟ -rheumaƟ c drugs 
(DMARDs). Door gebruik van deze geneesmiddelen wordt een langdurige onderdruk-
king van de ziekte nagestreefd en idealiter volledige remissie, genezing is echter nog 
niet mogelijk. Om deze reden worden er wereldwijd conƟ nu inspanningen geleverd 
om de achtergrond van het ziekteproces te onderzoeken en met deze kennis nieuwe 
therapieën voor de behandeling van RA te ontdekken en te evalueren. 
Hoewel de precieze oorzaak van RA nog niet is opgehelderd, is het wel duidelijk dat 
er meerdere risicofactoren gekoppeld zijn aan het ontstaan van RA (hoofdstuk 1). 
Algemeen wordt aangenomen dat een combinaƟ e van een bepaalde gevoeligheid in 
geneƟ sche achtergrond en externe gebeurtenissen (bijvoorbeeld trauma of infecƟ es) 
kunnen leiden tot een auto-immuun reacƟ e. Bij een auto-immuunziekte is het im-
muunsysteem ontregeld waardoor het bij het reguleren van een afweerreacƟ e niet 
voldoende onderscheid kan maken tussen lichaamsvreemde of lichaamseigen com-
ponenten. Bij RA wordt op dit moment verondersteld dat het immuunsysteem een 
component in de gewrichten, mogelijk kraakbeen, herkent als een potenƟ eel gevaar 
dat afgeweerd moet worden. Dit afweerproces uit zich door een ontstekingsreacƟ e 
waarbij het immuunsysteem betrokken is. Het immuunsysteem heeŌ  een scale aan 
celtypes dat hierbij een rol kan pelen ; bijvoorbeeld: dendriƟ sche cellen (betrokken 
bij de verwerking en presentaƟ e van anƟ genen), T-cellen (onder meer betrokken bij 
de cellulaire afweer door geïnfecteerde cellen op te ruimen), B-cellen (producƟ e van 
anƟ lichamen na diﬀ erenƟ aƟ e tot plasmacel ) en monocyten/macrofagen (betrokken 
bij de fagocytose en verwerken van restanten van cellen en pathogenen). De cellen 
van het immuunsysteem zijn door de uitscheiding van specifi eke hormonaalachƟ ge 
signaalstoﬀ en, chemokines en cytokines genaamd, in staat om met elkaar te commu-
niceren. Het type signaalstoﬀ en dat door de verschillende cellen wordt uitgescheiden 
is bepalend voor de soort afweerreacƟ e die in het lichaam plaatsvindt. Binnen het 
geavanceerde en complexe communicaƟ enetwerk van de ontstekingsreacƟ e wordt 
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het cytokine Tumor Necrosis Factor α (TNFα) beschouwd als een dominante speler. 
Bij RA wordt nu algemeen aangenomen dat immuun-eﬀ ector cellen (macrofagen, 
dendriƟ sche cellen, T-lymfocyten en B-lymfocyten), samen met een ontregelde uit-
scheiding van ontstekingsgerelateerde cytokines zoals TNFα, van essenƟ eel belang 
zijn voor het ontstaan en de instandhouding van de ziekte. Daarom is het merendeel 
van de huidige behandelingen gericht op het onder controle brengen en houden van 
de ontstekingsreacƟ e en prevenƟ e van schade aan boƩ en, hetzij door de uitschake-
ling van ontstekingscellen, dan wel door ingrijpen in het cytokine/chemokine com-
municaƟ enetwerk. 
Klassieke (en biologische) DMARDs worden voorgeschreven aan paƟ ënten met RA. 
Deze kleine moleculen/anƟ lichamen kunnen de ontsteking temperen en zijn zelfs 
in staat om in een deel van de paƟ ënten Ɵ jdelijk remissie te induceren. Echter, om-
dat deze medicijnen niet in staat zijn om de ziekte te genezen, is chronische toedie-
ning noodzakelijk om klinische vooruitgang te behouden. Helaas zijn voor veel RA 
paƟ ënten de therapeuƟ sche voordelen van DMARDs slechts Ɵ jdelijk. Vaak verliezen 
DMARDs na chronisch gebruik van een aantal maanden of jaren geleidelijk hun werk-
zaamheid. Dit proces wordt ook wel verworven resistenƟ e genoemd. Bij een klein 
deel van de paƟ ënten kan het gebrek aan werkzaamheid al worden waargenomen 
bij aanvang van de behandeling, dit wordt ook wel primaire of inherente resistenƟ e 
genoemd. Echter, in de meeste gevallen treedt DMARD-resistenƟ e op na een peri-
ode van een iniƟ ële goede respons op de therapie. Een extra onderscheid kan nog 
worden gemaakt tussen resistenƟ e die slechts één klasse DMARDs omvat (bijv. foli-
umzuur analoga) dan wel juist meerdere DMARDs omvat die chemisch en funcƟ o-
neel van elkaar verschillen. In het laatste geval spreekt men ook van een mulƟ drug-
resistent fenotype. Belangrijke vragen zijn hoe paƟ ënten resistenƟ e tegen DMARDs 
ontwikkelen en wat de onderliggende mechanismen hierbij zijn. Een belangrijk me-
chanisme waar we ons in dit proefschriŌ  op gericht hebben, is de betrokkenheid 
van mulƟ -drug resistenƟ e (MDR) pompen (transporters). MDR pompen zijn eiwiƩ en 
die behoren tot de familie van energie (ATP) aĬ ankelijke ABC-transporteiwiƩ en, die 
een breed scala aan verschillende stoﬀ en uit cellen kunnen pompen. Er zijn steeds 
meer aanwijzingen dat verschillende DMARDs substraten zijn voor afzonderlijke 
MDR eiwiƩ en. Hierdoor kan de aanwezigheid van deze pompen tot een verminderde 
werkzaamheid van DMARDs leiden. Op basis van deze achtergrond, hebben we be-
sloten om de volgende twee doelstellingen in dit proefschriŌ  verder te onderzoeken: 
1) Het bepalen van de rol van drug transporters in de ontwikke-
ling van resistenƟ e/verlies van werkzaamheid van DMARDs bij im-
muuncellen die een belangrijke rol spelen in de pathofysiologie van RA. 
2) Het onderzoeken van de werkzaamheid van enkele nieuwe specifi eke geneesmid-
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delen die de potenƟ e hebben om DMARD-resistenƟ e te omzeilen, hierbij rekening 
houdend dat ook tegen deze nieuwe geneesmiddelen resistenƟ eontwikkeling kan 
optreden. 
Hoofdstuk 1 geeŌ  een overzicht van de pathofysiologische aspecten en de huidige 
behandelingsmethoden van RA. Daarnaast wordt de potenƟ ële rol van drug trans-
porteiwiƩ en in het ontstaan van resistenƟ e tegen DMARDs beschreven. Tot slot wor-
den nieuwe experimentele therapeuƟ sche opƟ es voor RA besproken. De aandacht 
richt zich hierbij vooral op proteasoomremmers, een nieuwe klasse van doelgerichte 
geneesmiddelen met mogelijke ontstekingsremmende eigenschappen.
In hoofdstuk 2 wordt een overzicht gegeven van de huidige stand van de literatuur 
met betrekking tot de relaƟ e van MDR transportereiwiƩ en en het immuunsysteem. 
Deze gegevens onderkennen dat MDR transportereiwiƩ en aanwezig zijn op de 
meeste immuun-gerelateerde cellen (T-cellen, B-cellen, monocyten/macrofagen en 
dendriƟ sche cellen), met inbegrip van degenen die een rol spelen bij RA. Naast een 
mogelijke farmacologische rol in het ontstaan van resistenƟ e tegen geneesmiddelen 
zoals DMARDs, vervullen diverse MDR transporteiwiƩ en ook belangrijke immuun-
regulerende funcƟ es door het transport van moleculen die fungeren als ontstekings-
factoren (bijv. leucotrienen) en/of betrokken zijn bij diﬀ erenƟ aƟ e en uitrijping van 
immuuncellen. Deze dubbele funcƟ e van MDR transporteiwiƩ en en de gevolgen 
voor zowel paƟ ënten met auto-immuunziekten als met kanker, worden in dit hoofd-
stuk uitgebreid besproken. Hieruit komen aanwijzingen naar voren dat het blokke-
ren van de fysiologische funcƟ e van MDR transporteiwiƩ en mogelijk de abnormale 
immuunrespons bij RA paƟ ënten kan afremmen, hetgeen een voordelig eﬀ ect zou 
sorteren. Echter, voor kankerpaƟ ënten, bij wie het immuunsysteem vaak verzwakt is, 
kan het blokkeren van MDR transporteiwiƩ en juist een negaƟ ef eﬀ ect hebben door 
een verdere onderdrukking van het immuunsysteem. 
Het anƟ malaria geneesmiddel en tevens DMARD (hydroxy) chloroquine (CHQ) heeŌ  
een bescheiden maar vaste plaats binnen de behandeling van RA, mede door het 
gemak waarmee dit middel te combineren is met andere DMARDs. Echter, uit de 
klinische prakƟ jk blijkt dat CHQ één van de DMARD’s is waarvoor een relaƟ ef snel 
verlies van werkzaamheid is gemeld na langdurige toediening. Het mechanisme hier-
achter is grotendeels onbekend. In hoofdstuk 3 hebben wij de ontwikkeling van CHQ 
resistenƟ e nagebootst door een menselijke T-cellijn in-vitro bloot te stellen aan een 
stapsgewijs toenemende concentraƟ e van CHQ. Door deze methode verkregen we na 
een periode van 5 maanden cellen die 3 tot 4 maal resistenter waren voor CHQ. Uit 
onderzoek naar het resistenƟ emechanisme bleek er in de CHQ-resistente cellen een 
verhoogde expressie van het mulƟ drug resistenƟ e-geassocieerde transportereiwit 1 
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(MRP1) aanwezig te zijn. De rol van deze drugtransporter werd verder bevesƟ gd door 
het blokkeren van MRP1 waarmee de CHQ gevoeligheid hersteld kon worden. CHQ-
resistente T-cellen bleven wel volledig gevoelig voor andere DMARDs, waaronder 
methotrexaat (MTX), lefl unomide, cyclosporine A en sulfasalazine. Zeer opvallend 
was het feit dat CHQ-resistente cellen ook in hoge mate resistent (> 1.000-voudig) 
bleken voor de glucocorƟ coïden (GCs) dexamethason en prednisolon tengevolge van 
een verstoorde cyclisch AMP-aĬ ankelijke proteïne kinase A signaaltransducƟ e route. 
In overeenstemming hiermee bleek dat een Ɵ jdelijke acƟ vaƟ e van cAMP-aĬ ankelijke 
proteïne kinase A de gevoeligheid voor GCs te kunnen herstellen. Ten sloƩ e bleken 
CHQ-resistente T-cellen ook een opvallende verstoorde capaciteit te hebben om het 
pro-infl ammatoire cytokine TNF- en het chemokine IL-8 uit te scheiden. Dit wijst 
erop dat CHQ-resistenƟ e in dit T-cellijn model niet noodzakelijkerwijs de anƟ -infl am-
matoire eﬀ ecten van CHQ compromiƩ eert.
Inherente of verworven resistenƟ e tegen glucocorƟ coïden (GCs) is een erkend pro-
bleem in de behandeling van (chronisch) infl ammatoire aandoeningen en beperkt 
hiermee hun opƟ male werkzaamheid. Zoals weergegeven in hoofdstuk 3, was re-
sistenƟ e tegen CHQ geassocieerd met een duidelijke kruis-resistenƟ e tegen GCs. In 
hoofdstuk 4 rapporteren we over een tegenovergesteld verschijnsel. Na langdurige 
blootstelling aan de DMARD sulfasalazine (SSZ) werden twee primair GC-resistente 
humane monocytaire/macrofaag cellijnen gevoelig voor GCs. Herstel van de GC-ge-
voeligheid in deze aan SSZ blootgestelde cellen werd verkregen via GC-geïnduceerde 
apoptoƟ sche celdood samen met remming van NFkB acƟ vering. GC-gevoeligheid 
was ook sterk verbeterd door een aanzienlijke verhoging van het glucocorƟ coïd re-
ceptor  eiwit in SSZ-blootgestelde cellen, waarschijnlijk door een betere stabilise-
ring van het GR eiwit. Deze resultaten verdienen verder experimenteel onderzoek 
om potenƟ ële mechanismen te onderzoeken die de klinische acƟ viteit van DMARD-
combinaƟ etherapie met methotrexaat, sulfasalazine en prednisolon als onderdeel 
van de COBRA-protocol voor de behandeling van RA paƟ ënten kunnen verklaren. 
De combinaƟ e van DMARDs is tegenwoordig gangbaar in veel behandelprotocollen 
voor RA. Voor een bepaald type DMARD combinaƟ e, t.w. MTX + SSZ, zijn echter te-
genstrijdige resultaten gerapporteerd. Hierdoor is het onduidelijk of deze combinaƟ e 
een addiƟ ef/synergeƟ sch eﬀ ect of een antagonisƟ sch eﬀ ect sorteert ten opzichte van 
iedere DMARD afzonderlijk. In hoofdstuk 5 onderzochten wij of mogelijke genees-
middelinteracƟ es van invloed zijn op de werkzaamheid van het MTX + SSZ combina-
Ɵ e in een in vitro model van menselijke monocytaire/macrofagen cellen. Er konden 
twee vormen van negaƟ eve interacƟ es van SSZ met MTX worden waargenomen. Ten 
eerste bleek SSZ een krachƟ ge en niet-compeƟ Ɵ eve remmer van de gereduceerde 
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folaat transporter (RFC) te zijn. Dit is de belangrijkste route voor cellulaire opname 
van MTX. Ten tweede bleek langdurige blootstelling van SSZ een duidelijke verhoog-
de expressie te induceren van het mulƟ drug transporteiwit ABCG2 (BCRP). Omdat 
BCRP in staat is MTX uit een cel te transporteren, kan een verhoogde expressie van 
BCRP bijdragen aan een verminderde werkzaamheid van MTX. Samen hebben deze 
bevindingen relevante gevolgen voor het opƟ male gebruik van MTX + SSZ combina-
Ɵ es voor de behandeling van RA. Indien we dit laatste in ogenschouw nemen, kun-
nen SSZ-RFC interacƟ es niet alleen de cellulaire opname van MTX belemmeren maar 
mogelijk ook leiden tot een tekort aan natuurlijke folaten in de cel. Deze resultaten 
pleiten dan ook voor het geven van folaat suppleƟ e en gespreide toediening van SSZ 
en MTX Ɵ jdens behandeling, rekeninghoudend met het gegeven dat de remmende 
eﬀ ecten van SSZ op RFC-aĬ ankelijke MTX opname van voorbijgaande aard zijn. 
In vitro studies hebben duidelijk aangetoond dat MDR transporters betrokken kun-
nen zijn bij resistenƟ e tegen verschillende DMARDs. Klinische gegevens waaruit 
blijkt dat MDR transporters een rol spelen in DMARD resistenƟ e zijn echter schaars. 
De beperkte klinische studies over dit onderwerp waren voornamelijk gericht op P-
glycoproteïne (P-gp), de eerste geïdenƟ fi ceerde MDR transporter. De mogelijke bij-
drage van andere MDR transporters heeŌ  nog weinig aandacht gekregen. Daarom 
hebben wij in hoofdstuk 6 het expressie profi el en funcƟ onele acƟ viteit van gese-
lecteerde MDR transporters (P-gp, BCRP en MRP1-9) op immuun-gerelateerde cel-
len van RA paƟ ënten geëvalueerd in relaƟ e tot de klinische respons op DMARDs. 
Voor dit onderzoek werden perifere bloed lymfocyten (PBLs) en van monocyt aŅ om-
sƟ ge macrofagen (MDM) verkregen van 52 RA paƟ ënten (inclusief DMARD-naïeve 
en DMARD-(non) responsieve paƟ ënten) en 19 gezonde vrijwilligers. Met behulp 
van verschillende technieken zoals real-Ɵ me PCR, immunohistochemie en fl ow cy-
tometrie waren we in staat om de aanwezigheid en de funcƟ onele acƟ viteit van 
bovengenoemde MDR transporters te bepalen. Wij toonden aan dat verschillende 
MDR transporters aanwezig zijn op perifere bloed lymfocyten en MDM bij zowel 
RA-paƟ ënten als gezonde controles. In perifere bloed lymfocyten van RA paƟ ënten 
werden verhoogde mRNA niveaus van MRP1 (2.5-voudig), MRP4 (1.6-voudig) en 
MRP7 (1.9-voudig) waargenomen. In van monocyten aŅ omsƟ ge macrofagen wer-
den aanzienlijk verhoogde niveaus van het BCRP eiwit (2.4-voudig) en BCRP mRNA 
(2.8-voudig) waargenomen, terwijl P-gp eiwit expressie correleerde met de ziekte-
acƟ viteit. In T-lymfocyten van RA paƟ ënten die werden behandeld met DMARDs 
bleek de acƟ viteit van P-gp signifi cant (1.7-voudig) te zijn verhoogd ten opzichte van 
DMARD-naïeve paƟ ënten. Daarnaast bleken alleen MRP2 en MRP4 mRNA niveaus te 
zijn gestegen in DMARD non-responders in vergelijking met DMARD-responders. De 
resultaten van deze studie suggereren dat een verhoging van specifi eke MDR trans-
porters op immuun-gerelateerde cellen van RA paƟ ënten eerder een weerspiegeling 
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is van de ziekte acƟ viteit dan dat er van een DMARD-geïnduceerd fenomeen sprake 
is. In beide scenario’s echter, kan een toename in de expressie van MDR transporters 
bijdragen tot een verminderde DMARD respons bij RA paƟ ënten. Naar aanleiding van 
deze cross-secƟ onele studie is vervolg onderzoek in een vorm van een longitudinale 
studie noodzakelijk om het belang van MDR transporters in het ontstaan van het 
verlies van werkzaamheid van DMARDs verder te bepalen. 
Naast de analyse van MDR transporter expressie op perifere bloedcellen (hoofdstuk 
6), hebben we ook het ontstoken synoviale weefsel van RA paƟ ënten nader bestu-
deerd. Hoofdstuk 7 beschrijŌ  de immunohistochemische analyse van de expressie-
niveaus van de MDR transporters P-gp, MRP1-5, MRP8, MRP9 en BCRP op infl am-
matoire cellen in synoviaal weefsel. Dit weefsel was aŅ omsƟ g van RA paƟ ënten met 
een acƟ eve ziekte voorafgaand en na 4 maanden behandeling met MTX (7.5-15 mg /
week) of lefl unomide (20mg/day). Resultaten werden vergeleken met niet-ontstoken 
synoviaal weefsel aŅ omsƟ g van orthopedische paƟ ënten. In alle RA synoviale biop-
ten, zowel voorafgaand en na 4 maanden MTX behandeling, werd een verhoogde 
expressie van BCRP waargenomen op macrofagen in de inƟ male laag evenals op ma-
crofagen en endotheelcellen in de synoviale sublining. StaƟ sƟ sche analyse toonde 
een trend aan van een verhoogde BCRP expressie naar mate de ziekte-acƟ viteit ho-
ger was (gedefi nieerd door de ziekte-acƟ viteit score gebaseerd op 28 gewrichten/
DAS28). Bovendien was de mediane BCRP expressie 4 tot 8 keer hoger voor paƟ ën-
ten die niet reageerden op MTX in vergelijking met paƟ ënten die wel op MTX rea-
geerden. Een vergelijkbare trend werd waargenomen voor RA paƟ ënten die behan-
deld werden met lefl unomide: BCRP expressie was 2.5 maal verhoogd in synoviale 
biopsieën aŅ omsƟ g van ‘lefl unomide-falers’ ten opzichte van paƟ ënten met een 
goede respons op lefl unomide. Een lage expressie van MRP1 werd waargenomen op 
T-cellen van sommige synoviale biopten, terwijl expressie van P-gp, MRP2-5, MRP8 
en MRP9 onder de immunohistochemische detecƟ eniveaus bleven. In controle sy-
noviale weefsel werden slechts kleine aantallen geïnfi ltreerde macrofagen waarge-
nomen waarvan een nog kleiner deel posƟ ef werd bevonden voor BCRP. De kleuring 
van de overige MDR-eiwiƩ en was negaƟ ef. Omdat macrofagen van alle RA synoviale 
biopten al voor de start van de therapeuƟ sche intervenƟ e een posiƟ eve aankleuring 
lieten zien, lijkt de expressie van BCRP eerder een ontstekingsaĬ ankelijk verschijnsel 
te zijn dan een geneesmiddel-geïnduceerd eﬀ ect geassocieerd met het ontstaan van 
resistenƟ e. Ongeacht dit gegeven, kan BCRP toch een bijdrage leveren aan een ver-
minderde eﬀ ecƟ viteit van MTX, lefl unomide and sulfasalazine omdat deze DMARDs 
bewezen substraten zijn voor BCRP. 
De directe of indirecte betrokkenheid van MDR transporters in de cellulaire secre-
Ɵ e van onstekings gerelateerde chemokines en cytokines blijŌ  een controversieel 
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onderwerp. Er zijn voldoende aanwijzingen dat MDR transporters laag-moleculaire 
verbindingen en pepƟ den met een molecuulgewicht <1kD kunnen transporteren. Of 
dit ook geldt voor chemokines en cytokines met hogere molecuulgewichten van res-
pecƟ evelijk tot 8 kD en tot 20 kD, is nog onduidelijk. In hoofdstuk 8 onderzochten 
we of MDR transporters MRP1-5, P-gp en BCRP betrokken zijn bij de secreƟ e van de 
chemokines CCL20, MCP1 en IL-8 en het cytokine TNFα. Hiertoe werden cellijnen 
met en zonder overexpressie van een specifi eke MDR transporter gesƟ muleerd met 
de forbolester PMA en de calcium ionofoor ionomycine om de cellen aan te zeƩ en 
tot de producƟ e van chemokines en cytokines. Met behulp van specifi eke blokkers 
voor de MDR transporters onderzochten wij of de chemokine en cytokine secreƟ e 
veranderde ten opzicht van de condiƟ e zonder blokkade. De resultaten lieten geen 
robuuste verschillen zien in CCL20, MCP1, IL-8 en TNFα secreƟ e tussen geacƟ veer-
de cellijnen zonder specfi eke MDR expressie en overeenkomsƟ ge cellijnen met een 
overexpressie van MRP2, 3, 4, 5 of BCRP. Ook het blokkeren van de transporters liet 
geen eenduidige eﬀ ecten zien. Een interessante observaƟ e was wel de verlaagde 
secreƟ e van CCL20 na blokkering van MRP1 of P-gp. Echter, de resultaten waren sterk 
variabel tussen de verschillende cellijnen. Een laatste interessante bevinding was dat 
de acƟ vator van chemokine/cytokine producƟ e, PMA, door P-gp uitgescheiden kon 
worden. Dit kan een ondersteuning zijn van de conclusie dat MDR transporters niet 
via een directe weg moleculen met een hoger molecuulgewicht transporteren maar 
eerder via een indirecte weg door transport van laag-moleculaire acƟ vator molecu-
len die chemokine/cytokine secreƟ e induceren. 
Experimentele geneesmiddelen met nieuwe werkingsmechanismen kunnen mogelijk 
worden gebruikt om de MDR-geassocieerde DMARD resistenƟ e te omzeilen. Protea-
soomremmers is een nieuwe klasse van experimentele geneesmiddelen die ingrijpt 
in het proces van de gecontroleerde aĩ raak van eiwiƩ en. Het proteasoom speelt 
daarnaast ook een cruciale rol in de acƟ vaƟ e van de transcripƟ e factor NFB door 
het aĩ reken van het IBα eiwit, de natuurlijke remmer van NFB. GeacƟ veerd NFB 
iniƟ eert de transcripƟ e van verschillende pro-infl ammatoire cytokines zoals TNF 
en IL-1. Proteasoomremmers bieden de mogelijkheid om de aĩ raak van het IBα 
eiwit te blokkeren, NFB acƟ vaƟ e te blokkeren en een ontstekingsremmend eﬀ ect te 
bewerkstelligen door het onderdrukken van de producƟ e van pro-infl ammatoire cy-
tokines. In hoofdstuk 9 hebben we de potenƟ ële anƟ -infl ammatoire eigenschappen 
geëvalueerd van bortezomib, een boron-bevaƩ ende dipepƟ de proteasoomremmer. 
Bortezomib is momenteel geregistreerd voor de behandeling van enkele hematolo-
gische maligniteiten. Conform de verwachƟ ng konden we aantonen dat bortezomib 
een snelle en krachƟ ge remming van TNFα producƟ e gaf in geacƟ veerde T-cellen 
van RA paƟ ënten. Dit remmende eﬀ ect werd ook aangetoond in T-cellen aŅ omsƟ g 
van RA paƟ ënten die niet meer reageerden op DMARD behandelingen. Naast een 
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verlaging van TNFα secreƟ e, vertoonde bortezomib aanvullende eﬀ ecten door het 
remmen van CD3/CD28 geïnduceerde T-cel acƟ vaƟ e en, na > 48 uur blootstelling, 
een sterke inducƟ e van geprogrammeerde celdood (apoptose) van perifere bloed 
lymfocyten van RA paƟ ënten. 
Ondanks de veelbelovende anƟ -infl ammatoire werking van bortezomib is het on-
duidelijk wat de lange termijn werkzaamheid van dit middel zal zijn bij chronische 
toediening zoals naar verwachƟ ng noodzakelijk is voor de behandeling van RA pa-
Ɵ ënten. Bovendien is het onduidelijk of langdurige blootstelling aan bortezomib 
gepaard zal gaan met de ontwikkeling van resistenƟ e tegen dit geneesmiddel. Om 
meer inzicht te verkrijgen in de mogelijke verworven resistenƟ e voor bortezomib 
en de idenƟ fi caƟ e van de moleculaire basis hiervan hebben we in hoofdstuk 10 hu-
mane monocyt/macrofaag THP1 cellen in vitro bloot gesteld aan een stapsgewijze 
toenemende concentraƟ e van bortezomib (oplopend van 2.5 nM tot 200 nM). Bij 
selecƟ e op deze laatste concentraƟ e bleken cellen 129-maal minder gevoelig te zijn 
voor bortezomib dan de oorspronkelijke cellen. Onderzoek naar het moleculaire me-
chanisme van bortezomib-resistenƟ e in deze cellen resulteerde in twee belangrijke 
bevindingen: (1) een mutaƟ e in het PSMB5 gen coderend voor het proteasoom β5 
subunit eiwit van het 26S proteasoom, de primaire target van bortezomib. Deze mu-
taƟ e heeŌ  geresulteerd in een vervanging van het aminozuur alanine door threonine 
op posiƟ e 49 (Ala49Thr) van het 5-subunit eiwit. Deze posiƟ e speelt een cruciale rol 
in de binding van bortezomib in het acƟ eve centrum van de 5 subunit van het pro-
teasoom. (2) Een markante en selecƟ eve overexpressie (tot 60 maal) van het PSMB5 
eiwit werd waargenomen, maar niet van de twee andere katalyƟ sch acƟ eve protea-
soom subunits PSMB6 en PSMB7 of van een van de niet-katalyƟ sche -subunits van 
het proteasoom, PSMA7. Daarnaast vertoonden bortezomib-resistente cellen een 
hoge mate van kruisresistenƟ e tegen andere 5-subunit gerichte cytotoxische pepƟ -
den, waaronder 4A6, MG132, MG262 en ALLN. Volledige gevoeligheid bleef wel be-
houden voor alle DMARDs en een breed spectrum van anƟ kankergeneesmiddelen. 
Bortezomib gevoeligheid in bortezomib-resistente cellen kon worden hersteld door 
siRNA-gemedieerde onderdrukking van PSMB5 genexpressie waarmee de opregu-
laƟ e van het 5 subunit eiwit voorkomen kon worden. Concluderend toonde deze 
studie aan dat er met resistenƟ e ontwikkeling rekening moet worden gehouden bij 
een eventuele toekomsƟ ge toepassing van proteasoomremmers als nieuwe experi-
mentele medicaƟ e bij RA behandeling. 
Bortezomib is de eerste klinisch beschikbare proteasoomremmer. Doorlopend onder-
zoek richt zich op het ontwerpen, idenƟ fi ceren en evalueren van tweede generaƟ e 
proteasoomremmers. Deze nieuwe proteasoomremmers beschikken mogelijk over 
superieure eigenschappen ten opzichte van bortezomib. De nieuwe generaƟ e pro-
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teasoomremmers kan een irreversibele remming van het proteasoom bewerkstel-
ligen daar waar bortezomib een reversibele proteasoomremmer is. Daarnaast kun-
nen nieuwe generaƟ e proteasoomremmers aangrijpen op andere katalyƟ sch acƟ eve 
proteasoom subunits en daarmee de mogelijkheid bieden om bortezomib resistenƟ e 
te omzeilen. In hoofdstuk 11 beschrijven we een cytotoxisch pepƟ de, 4A6, met een 
onbekend werkingsmechanisme. Omdat bortezomib-resistente cellen een markante 
kruisresistenƟ e bleken te vertonen voor 4A6, was dit een aanwijzing dat 4A6 mogelijk 
een proteasoomremmer zou kunnen zijn. Na uitgebreidere karakterisering bleek in-
derdaad dat 4A6 een krachƟ ge, selecƟ eve en reversibele remmer van het proteasoom 
β5 subunit is. Daarnaast vertoonde 4A6 diﬀ erenƟ ële acƟ viteit tegen diverse leukemi-
sche en borstkanker cellijnen. Een nadeel is echter dat de acƟ viteit van 4A6 beperkt 
kan worden door het feit dat het een substraat is voor de MDR transporters P-gp en 
MRP1. DesalnieƩ emin mag 4A6 worden beschouwd als een prototype experimen-
teel geneesmiddel om door te ontwikkelen tot een nieuwe proteasoomremmer zon-
der aﬃ  niteit voor MDR transporters maar met een onstekingsremmende werking die 
op de lange termijn voor therapeuƟ sche doeleinden geschikt gemaakt kan worden.
Kernpunten van het proefschriŌ  
Preklinisch / in-vitro laboratorium studies:
• Verworven resistenƟ e tegen de DMARD chloroquine wordt is gemedieerd door 
een verhoogde cellulaire uitscheiding van deze DMARD, veroorzaakt door een 
verhoogde expressie van MRP1 (mulƟ drug resistenƟ e-geassocieerd eiwit 1).
• Chloroquine resistenƟ e gaat gepaard met een markante kruisresistenƟ e tegen 
glucocorƟ coïden, veroorzaakt door de onderdrukking van de cyclisch AMP-pro-
teïne kinase A signaaltransducƟ eroute.
• Sulfasalazine en methotrexaat kunnen geneesmiddelinteracƟ es vertonen door-
dat sulfasalazine een krachƟ ge remmer is van de cellulaire opname van me-
thotrexaat via de gereduceerde folaat carrier. Hierdoor kunnen addiƟ eve/syner-
gisƟ sche eﬀ ecten van deze DMARD combinaƟ e beperkt worden.
• Chronische blootstelling aan sulfasalazine induceert gevoeligheid van immuun-
eﬀ ector cellijnen voor glucocorƟ coïden.
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• MulƟ drug resistenƟ e transporters kunnen indirect betrokken zijn bij de secreƟ e 
van chemokines en cytokines door middel van de uitscheiding van (kleine) acƟ -
vator moleculen die bij dit proces betrokken zijn. 
• Verworven resistenƟ e tegen de proteasoom remmer bortezomib wordt veroor-
zaakt door een Ala49Thr mutaƟ e in het sterk geconserveerde bortezomib-bin-
dende gebied van het proteasoom 5-subunit (PSMB5) eiwit.
Klinisch-gericht laboratoriumonderzoek:
• MulƟ drug resistenƟ e transporters zijn bekend met betrekking tot hun farma-
cologische rol in het veroorzaken van resistenƟ e tegen geneesmiddelen. Hun 
fysiologische rol in immuun- gerelateerde cellen kan als even belangrijk worden 
beschouwd voor een opƟ maal funcƟ oneren van het immuunsysteem immuun-
funcƟ e. 
• Verhoogde expressie van specifi eke mulƟ drug resistenƟ e transporters in peri-
fere bloedcellen en synoviale macrofagen lijkt eerder een ziekte-acƟ viteit gere-
lateerd verschijnsel te zijn dan een DMARD-geïnduceerde eﬀ ect.
• De MDR transporter BCRP komt markant tot expressie op macrofagen in het sy-
noviale weefsel en kan verantwoordelijk zijn voor een verminderde eﬀ ecƟ viteit 
van de DMARDs methotrexaat, lefl unomide en sulfasalazine, alle drie substraten 
van BCRP.
• De proteasoomremmer bortezomib is zeer eﬀ ecƟ ef in het onderdrukken van de 
secreƟ e van ontstekingsƟ mulerende cytokines door geacƟ veerde T-cellen van 
RA paƟ ënten.
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Dankwoord
Eindelijk, daar ligt het dan. 5 jaar onderzoek gebundeld in een handzaam formaat. 
Trots ben ik, maar zeker ook opgelucht. Uiteindelijk vergeet je alle hordes die hebt 
moeten nemen om hier te komen. Maar toch moet ik eerlijk bekennen dat de weg 
naar dit resultaat is niet alƟ jd eenvoudig is geweest. Op het moment dat je start met 
je promoƟ e kan niemand je voorspellen hoe het zal verlopen. Zelf had ik ook nooit 
kunnen bedenken hoe het exact zou gaan lopen. Uiteindelijk heb ik zelf ervaren dat 
je als promovendus in grote mate zelf verantwoordelijk bent voor het succesvol vol-
brengen van het onderzoek. Toch is dit niet genoeg. Ook heb ik ervaren dat de men-
sen om je heen uiteindelijk de sleutel zijn tot een succesvolle promoƟ e. De Ɵ jden van 
individuele wetenschap bestaan niet meer. Goed wetenschappelijk onderzoek bereik 
je pas door samenwerking. Dit hoofdstuk geeŌ  mij de gelegenheid om iedereen te 
bedanken waarmee ik de afgelopen jaren gewerkt heb. Een ding staat voor mij vast, 
zonder jullie was het nooit gelukt!
Allereerst wil ik mijn copromotor dr. Gerrit Jansen bedanken. Beste Gerrit, een paar 
regels is eigenlijk te beperkt om jou te bedanken. Het merendeel van dit resultaat 
heb ik uiteindelijk aan jou te danken. Voor mij ben je de belangrijkste persoon ge-
weest. Vanaf het eerste moment dat je mij de kans gaf om stage bij je te lopen tot 
aan dit moment heb je mij weten te moƟ veren en te sƟ muleren. Je onuitpuƩ elijke 
bron van opƟ misme en (wetenschappelijk) enthousiasme en creaƟ viteit waren voor 
mij van groot belang. Nooit zal ik vergeten hoe jij alƟ jd weer een posiƟ eve draai wist 
te geven aan resultaten die ik regelrecht de prullenbak in wilde gooien. Ook was je 
nooit bang om hierdoor een andere weg in te slaan en risico’s te nemen. Ik weet 
zeker dat je passie voor het onderzoek en je persoonlijkheid een aantal bijzondere 
arƟ kelen heeŌ  voortgebracht. Voor dit alles ben ik je dan ook erg dankbaar. 
Daarnaast wil ik professor Dijkmans (promotor), professor Scheper (promotor) en 
professor Lems (copromotor) bedanken. 
Beste Ben. Zeer hartelijk dank voor je open en enthousiaste begeleiding. Vanaf mijn 
stage bij de VU tot op dit moment heb je het MDR onderzoek binnen de afdeling 
alƟ jd volledig gesteund. Het onderzoek heeŌ  zich de afgelopen jaren enorm ontwik-
keld wat tot mooie publicaƟ es heeŌ  geleid. Dankzij je klinische blik bleef de paƟ ënt 
een centrale rol binnen het onderzoek spelen. Het geloof in het onderzoek en de ma-
nier waarop je dit uiƩ e en ondersteunde heeŌ  mij erg weten te moƟ veren. Ook toen 
ik besloot een andere weg in te slaan heb je ook hier volledige steun voor gegeven. 
Bedankt voor je waardevolle bijdrage.
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Beste Rik, hierbij wil ik ook jou bedanken voor je enthousiaste en goede begeleiding. 
Dankzij je experƟ se op het gebied van mulƟ drug resistenƟ e, je creaƟ viteit maar ook 
je kriƟ sche blik op zaken waren we in staat om het onderzoek in goede banen te 
houden. Dankzij de ondersteuning van jouw groep heeŌ  het MDR onderzoek bin-
nen de Reumatologie zich enorm ontwikkeld. Nooit zal ik je advies vergeten om mijn 
proefschriŌ  zo snel mogelijk af te ronden, “anders kon het wel eens lang gaan duren”. 
Hier heb ik nog regelmaƟ g aan terug moeten denken....
Willem, je klinische blik en wetenschappelijke insteek heeŌ  het onderzoek de vorm 
gegeven die het nodig had. Door je verbondenheid met de kliniek waren we in staat 
om een brug te bouwen tussen het lab en de kliniek. Dankzij deze brug konden we de 
juiste paƟ ënten voor het MDR onderzoek includeren en succesvol onderzoek doen. 
Hartelijk dank hier voor.
Mijn dank gaat ook uit naar de leescommissie/promoƟ e-commissie, bestaande uit 
prof.dr. L.A. Aarden, prof.dr. Y.G. Assaraf, dr. T.D. de Gruijl, prof.dr. G.J. Ossenkoppele, 
prof.dr. G.J. Peters, prof.dr. R.E. Toes en prof.dr. C.L. Verweij. Hartelijk dank voor het 
beoordelen van het manuscript. 
Beste Joost. Speciale dank voor jou. Ten eerste omdat je mijn paranimf wilde zijn, 
ondanks de enorme drukke Ɵ jden die je doormaakt door je specialisaƟ e (wanneer 
ben je nu echt niet meer die “simpele dokter”?) en het ouderschap. Ik heb je alƟ jd 
een bijzondere collega gevonden, iemand waarmee je alles kon delen. Jij was ook 
een van de weinigen die een vergelijkbaar onderzoek deed en wist waarom dingen 
gingen zoals ze gingen. Voor de vormgeving van mijn proefschriŌ  heb ik dankbaar 
gebruik gemaakt van jouw proefschriŌ , ik hoop dat je dit niet erg vindt. Zoals je zelf al 
in je dankwoord aangaf zal ook ik onze trip naar de V.S. nooit vergeten. Het was een 
bijzondere ervaring die ik niet had willen missen! Ik vond het erg jammer dat jij op 
een gegeven moment het lab moest verlaten om je specialisaƟ e ergens anders voort 
te zeƩ en. Toch was je alƟ jd bereikbaar voor wetenschappelijk en medisch advies. Ik 
wens jou (en Inge) heel veel geluk toe.
Natuurlijk wil ik ook al mijn andere collega’s van de afdeling Reumatologie bedan-
ken. Mirjam en Ernst, hartelijk dank voor de mooie momenten met jullie. De Eular in 
Barcelona was een van die bijzondere momenten. Marijn, Danielle, Debby, Mignon, 
Henny, Marleen, Mike en Vokko, allemaal hartelijk dank voor de mooie Ɵ jd! Ondanks 
mijn verhuizing naar het CCA hielden de dagelijkse lunches toch stand, wat ik heel 
belangrijk vond! Kabir, hartelijk dank voor je enthousiaste inzet Ɵ jdens je stage. Ik 
wens jullie allemaal heel veel succes met het afronden van eventuele promoƟ es en 
verdere carrière.
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Ook wil ik alle andere reumatologen, arts-assistenten, arts-onderzoekers en andere 
mensen van het VU Medisch Centrum, het Slotervaartziekenhuis en het Jan van Bree-
men InsƟ tuut bedanken voor alle hulp. Zonder Natalja Basoski, Irene BulƟ nk, Irene 
van der Horst, Conny van der Laken, Marita Nabibux, JulieƩ e de Ree, Dirkjan van 
Schaardenburg, Annemarie Schilder, KirsƟ  Steen, FrankƟ en Turkstra, Elleke Verkerke 
en Alexandre Voskuyl was het nooit gelukt om voldoende paƟ ënten en vrijwilligers te 
includeren in de studie. Speciale dank gaat uit naar Michelien Kolﬀ  en Ewa Platek, zij 
stonden alƟ jd klaar voor het bepalen van de ziekte-acƟ viteit bij de paƟ ënten in onze 
studie. Zonder secretariële ondersteuning is een promovendus nergens; Marjo, het 
was fi jn om met je samen te werken. Ook dank voor je bereidheid om regelmaƟ g als 
vrijwilliger op te treden. Beste Ida en Noortje, hartelijk dank voor jullie ondersteu-
ning Ɵ jdens de laatste fase van mijn promoƟ e. 
Om mijn onderzoek mogelijk te maken heb ik vanaf het begin sterk moeten leunen 
op de kennis en technische mogelijkheden van andere afdelingen. Al deze mensen 
wil ik daarom heel erg bedanken voor de openharƟ ge samenwerking. 
Bij de afdeling Pathologie o.l.v. prof. dr. G.A. Meijer was alle kennis over MDR trans-
porters aanwezig. George, voor mij blijf je de expert op het gebied van MDR anƟ li-
chamen. Je was alƟ jd bereid om te helpen en advies te geven, ook al kwam ik op het 
laatste moment nog even binnen vallen. Hiervoor mijn dank. Rieneke, heel erg be-
dankt voor de preƫ  ge samenwerking. Je gaat het volgens mij nog erg ver schoppen 
in de wetenschap. Heel veel succes met je carrière en misschien komen we elkaar 
nog wel eens tegen bij een fesƟ val. Beste Wouter, bedankt en heel succes met het af-
ronden van je promoƟ e. Tanja, Antoinet, Anneke en Jelle: hartelijk dank voor de pret-
Ɵ ge samenwerking. Pepijn, heel veel succes met je carrière en misschien bezoeken 
we nog wel eens een feest samen. Speciale herinneringen gaan uit naar Mariska de 
Jong. Ondanks de korte Ɵ jd dat ik met haar kon samenwerken heeŌ  haar overlijden 
een grote indruk bij me achtergelaten. Hoofdstuk 11 van dit proefschriŌ  is aan haar 
opgedragen ter nagedachtenis. 
Ook wil ik de mensen op het lab van de afdeling Oncologie o.l.v. prof. dr. G.J. Peters 
bedanken. Beste Frits, bedankt dat ik alƟ jd zonder problemen gebruik mocht maken 
van alle faciliteiten en kennis van je afdeling. Simone, Jan-Hendrik, Henk, Adrie, Irene 
en Eveline, bedankt voor de preƫ  ge samenwerking. Kees en Auke, bedankt voor al 
jullie ondersteuning bij de RT-PCR. Mariëlle, jij ook bedankt voor de leuke gesprek-
ken op het lab en ik hoop dat je het naar je zin hebt bij je “nieuwe” werkgever. Chiel, 
ondanks dat je al een hele Ɵ jd weg bent bij de VU heb ik alƟ jd genoten van de mo-
menten dat jij op het lab aanwezig was. Dear Clara, thank you for all your help in the 
lab and the confocal experiments. Beste Ietje, wat had het westernbloƩ en zonder jou 
moeten zijn? Het was alƟ jd erg gezellig om met je samen te werken en voor mij blijf 
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je de koningin van de Westernblot met het beste recept! 
Van de afdeling Kinder-oncologie/hematologie o.l.v. prof. dr. G.J.L. Kaspers, wil ik Jac-
queline, Ina, Josefi en en Petra bedanken. Bedankt voor al jullie hulp bij de micro-ar-
rays. Niels, hartelijk dank voor de fi jne samenwerking. Mede dankzij jouw inspanning 
hebben we Blood kunnen halen. Heel veel succes met je carrière in de geneeskunde! 
Van het lab van afdeling Dermatologie o.l.v. dr. S. Gibbs bedank ik Sander voor al zijn 
hulp bij het opzeƩ en van de ELISA assays voor de chemokine experimenten. 
Ook wil ik Dr. Huib Ovaa en Celia Berkers (SecƟ e Cellulaire Biochemie, NKI, Amster-
dam) bedanken voor hun experƟ se op het gebied van proteasomen. Dank aan profes-
sor Paul-Peter Tak (SecƟ e Klinische Immunologie & Reumatologie, AMC, Amsterdam) 
door wie we gebruik konden maken van een panel synoviale biopten.  Dear professor 
Yehuda Assaraf (Haifa, Israel), thank you for your enthusiasƟ c discussions during your 
visits in Amsterdam. I will never forget your quote “A celebraƟ on of genes” and your 
feedback on all manuscripts. Dear professor Manohar Ratnam (Laboratory for Can-
cer Biology at the Medical University of Toledo, Ohio, USA) and all colleagues, thank 
you for giving me the opportunity to visit your lab. I really enjoyed my stay, it was an 
unforgeƩ able experience. Dr. Jean-Pierre Gillet (University of Namur, Belgium), thank 
you for your help with the ABC transporter micro-array experiments during our stay 
in Namur.
Bijzondere dank aan alle paƟ ënten en vrijwilligers die hebben deelgenomen aan het 
onderzoek. Zonder deze mensen was het niet mogelijk geweest om de juiste gege-
vens te verzamelen. Het Reumafonds en V-ICI wil ik hartelijk danken voor hun fi nan-
ciële ondersteuning van het onderzoek. 
Beste Przemek, hartelijk dank voor je hulp bij het drukken van mijn proefschriŌ . 
Ook dank aan al mijn collega’s bij Lundbeck B.V. voor hun interesse in mijn onder-
zoek. Speciale dank gaat uit naar Herben en Mariken. Ik ben jullie enorm dankbaar 
voor het vertrouwen dat jullie in mij hebben gehad. 
Mijn proefschriŌ  heb ik op opgedragen aan mijn ouders. Pa en Ma, hartelijk dank 
voor de onvolwaardige steun die jullie mij gegeven hebben. Zonder jullie support 
was dit resultaat nooit haalbaar geweest. Ook dank aan mijn broers Rob (ja, mijn 
scripƟ e is eindelijk af) en Remi, hun aanhang, mijn vrienden en mijn schoonfamilie 
voor hun steun en interesse in mijn onderzoek. 
Beste Patrick, speciale dank voor jou. Zonder enige twijfel wilde je meteen als pa-
ranimf optreden Ɵ jdens mijn promoƟ e. Ik vind het bijzonder dat je als een van mijn 
beste vrienden deze rol wilt vervullen. 
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Lieve Femke. Met mijn dank aan jou sluit ik dit hoofdstuk, mijn proefschriŌ  en een 
belangrijk deel van ons leven samen af. Dankzij je enthousiasme en realiteitszin was 
ik in staat om alles in het goede spoor te houden. Heel erg bedankt voor alle liefde 
en steun die je mij de afgelopen jaren hebt gegeven.
The End   
Ruud
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